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Abstract 
 
Cancer is a disease in which cellular control over growth and differentiation has been lost. 
Targeted therapies for the treatment of cancer are becoming an increasing area of focus 
within the pharmaceutical industry and academia, due to the increasing understanding of the 
biology behind tumourgenesis.  
 
There are 518 protein kinases within the human genome and they play a significant role 
within cellular signalling. Aberrant signalling of kinases can contribute to the development of 
cancer, and inhibition of kinase targets can result in either a cytostatic or cytotoxic effort. 
Kinases have a discrete ATP-binding domain, which presents an ideal target for small-
molecule inhibitors. mTOR (mammalian target of rapamycin) is a serine/threonine protein 
kinase, which forms two complexes, mTORC1 and mTORC2, as part of the PI 3-K/Akt 
pathway, a growth/survival pathway which has aberrant signalling in a number of cancers.  
 
 
 
The development of ATP-competitive inhibitors of mTOR has been based on a series of 2,6-
diaminosubstituted pyrimidines, with modest activity against mTOR, as exemplified by 
NU6027 and NU6227 originally designed as CDK2 inhibitors. Structure-activity 
relationships for inhibition of mTOR have been explored. The 4-substituent was either 
modified to a smaller alkoxy group or completely removed, giving reduced activity. At the 5-
position compounds with other substituents were then synthesised. Modifications of the 2- 
and 6-amino groups were also investigated. The pyrimidine heterocycle was also replaced 
with two pyridine regioisomers. None of the synthesised compounds showed improved 
mTOR inhibitory activity over NU6227 and NU6027. 
 
The tumour suppressor p53 is activated as a response to DNA-damage, oncogene activation 
and cellular stress. Once activated p53 acts as a transcription initiator, inducing the 
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transcription of a number of genes, including those involved in halting the cell cycle, 
repairing DNA-damage and initiating apoptosis. A further transcriptional target of p53 is 
MDM2, a negative regulator of p53. Inhibitors of the MDM2-p53 interaction have been 
reported including the isoindolinones e.g. NCL-00008406. 
 
Structure-activity relationships (SAR) studies for the identification of replacement of the 4-
nitro group showed that a 4-ethynyl substituent had a similar level of potency, along with the 
4-bromo, 3-fluoro substituents. SARs around the isoindolinone A-ring identified the 6-tert-
butyl substituent as equipotent to the parent. Synthesis of an oxetane derivative such as NCL-
00018327 has demonstrated that replacing the cyclopropyl group with a 3,3-oxetane 
substituent either maintained or improved activity against MDM2.  
 
Synthetic efforts have identified highly potent, low nanomolar, isoindolinone-based inhibitors 
of the MDM2-p53 protein-protein interaction. Optimal substituents for the benzyl group have 
been identified, avoiding the use of a  nitro group which is toxic within drugs.  Synthesis of 
an oxetane derivative has been shown to be either equi- or more potent than cyclopropyl 
derivatives, and this modification is predicted to improved the aqueous solubility by reducing 
the clogP. Synthesis of a tert-butyl analogues using an alternative synthetic route has 
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developed the SAR around the A-ring and resulted in an improved synthetic scheme. 
Purification of a range of MDM2 mutant proteins has identified a crystallisable form of 
MDM2 and the recently solved crystal structure of an isoindolinone bound to MDM2 should 
guide further improvements to potency and aid the incorporation of groups to improve 
physical properties. 
 
Cancer is a disease in which control over cellular growth is deregulated. Synthetic efforts 
have been directed toward the development of two targeted anti-cancer agents; the kinase 
mTOR and the protein-protein interaction MDM2/p53. 2,6-diaminopyrimidine were 
identified as most inhibitors of mTOR, but demonstrated a flat SAR and no increase in 
potency was observed. Isoindolinones have been identified as a valuable scaffold to inhibit 
the protein-protein interaction and have demonstrated excellent potencies.  
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mTOR  Mammalian target of Rapamycin 
mTORC1 mTOR complex 1 
mTORC2 mTOR complex 2 
mp  Melting point  
N.D  Not determined 
PE  Petroleum ether (b.p 40-60 
o
C) 
PIKK  Phosphatidylinositiol 3-kinase related kinase 
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RE  Responsive elements 
Rf  Retardation factor 
Rt  Retention time 
RNA  Ribose nucleic acid 
RT  room temperature 
s  singlet 
SAR  Structure activity relationships 
sat.  saturated 
Ser   Serine 
t  triplet 
Thr  Threonine 
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1. Cancer: An Introduction 
 
Cancer is a disease in which cellular control over growth and replication has been lost. There 
are around 200 different types of cancer,
1
 each characterised by significant changes within 
the genome. 298, 000 new cases of cancer are diagnosed each year within the UK, with 
around 54 % of cases being breast, lung, large bowel or prostate cancer. The 20 most 
common cancers by incident in 2007 are shown below (Figure 1). 
 
Figure 1 The twenty commonest cancers by incident in 2007 (Taken from reference 1) 
 
Cancer is predominantly a disease of older people, with 75% of cases reported in 2007 being 
in the over sixties age group, and 76% of cancer deaths being in the over sixty fives age 
group. 
1
 Traditionally cancer has been treated by surgery, with radiation therapy emerging at 
the end of the 19
th
 century with the discovery of X-rays.
2
 However, for metastasised tumours 
and haematological cancers a more system wide approach is needed. The development of 
chemotherapeutic agents began with the observation that cytotoxic agents killed rapidly 
proliferating cells.
2
 The challenge lies in selectively killing cancer cells over normal cells and 
ensuring complete elimination of the tumour cell.
2
  Novel anti-cancer agents are constantly 
being developed, assisted by the increasing understanding of the biology of tumour cells. 
 
The tumourgenesis process can be considered a Darwinian process, in which a build up of 
mutations confers a growth advantage over normal cells. Mutations within the genome lead 
either to the activation of oncogenes or the inactivation of tumour suppressors.
3
 The 
combination of the two allows cells to continue reproducing without restraint, despite the 
1.  Cancer: An Introduction 
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presence of DNA damage. Hanahan and Weinberg identified six ‘hallmarks of cancer’ which 
can be used to describe the behaviour of nearly all cancer cells,
3
 allowing the cell to 
overcome the regulatory pathways within the cell to prevent cancer. The six hallmarks of 
cancer are 
 Self sufficiency to growth signals 
 Insensitivity to antigrowth signals 
 Evasion of apoptosis 
 Limitless replicative potential 
 Angiogenesis 
 Tissue invasion and metastases 
In a normal cell growth signals are required before progressing through the cell cycle. 
However, within tumour cells the growth signals, which are transmitted via transmembrane 
receptors, are not required for growth. The tyrosine receptor kinases are overexpressed in a 
number of cancers, leading to cancer cells being hyper-sensitive to ambient levels of growth 
signals. Structural modifications to the receptors may lead to growth signal independent 
signalling, as well as mutations within the downstream signalling proteins. Growth signalling 
pathways are deregulated in a high number of cancers, allowing the continuing growth of 
tumours.
3
 
 
Alongside the self sufficiency to growth signals, cancer cells must also be insensitive to anti-
growth signals. Within a normal cell, the cell is maintained in a quiescent state by both 
soluble growth inhibitors and immobilised inhibitors on the surface of neighbouring cells. For 
tumourgenesis to occur cancer cells must evade these signals.
3
 
 
These two ‘hallmarks of cancer’ allow cells to grow in an uncontrolled manner. However, for 
a tumour to develop, cells must also avoid death. A resistance to apoptosis is a hallmark of all 
tumour cells, commonly (~ 50%) this resistance is acquired via a mutation of p53,
3
 a tumour 
suppressor, which normally cells detects DNA-damage and can initiate programmed cell 
death. 
 
A further fundamental difference between ‘normal’ cells and tumour cells is a limitless 
replicative ability. Normal cells cannot replicate endlessly, even in the presence of growth 
signals, replication can only occur for 60-70 rounds of mitosis.
3
 Telomeres are repeating units 
1.  Cancer: An Introduction 
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of six base pairs at the ends of chromosomes. At each round of replication some of the 
telomeres are lost, and will eventually be completely degraded. This can result in 
chromosome fusion, which results in cell death. However, within nearly all tumour cells 
telomere maintenance is observed, in 85-90% upregulation of telomerase activity, which adds 
base pairs, giving an endless replicative ability.
3
 
 
To support continuing growth angiogenesis must occur. To supply sufficient nutrients and 
oxygen, cells must lie within 100 µm of capillary blood vessels. Within normal cells 
angiogenesis is a tightly controlled process, but for tumours to progress, the development of 
these blood vessels must occur at an early to mid point in tumour formation.
3
 
 
The final ‘hallmark of cancer’ described by Hanahan and Weinberg, is the ability to invade 
local tissue and metastasise to distant sites. The process of metastasis occurs within most 
human cancer, with tumour cells seeking a location where growth is not limited by space or a 
lack of nutrients. Metastasise are thought to cause 90% of cancer deaths.
3
 
 
A further publication from Hanahan and Weinberg describes further characteristics which 
enable the development of tumours.
4
 The enabling characteristics are 
 Deregulation of cellular energetics 
 Genome instability and mutations 
 Avoiding immune destruction 
 Tumour-promoting inflammation 
Deregulation of cellular energetics allows continuous growth and proliferation.
4
 Genome 
instability and mutations will be discussed in greater detail shortly. Avoiding immune 
destruction is also crucial for tumour development. Cells and tissue are continuously 
monitored by the immune system, which can recognise and eliminate emerging tumours. 
Those which survive must avoid detection by the immune system. Immunocompromised 
mice are more prone to carcinogen derived tumours than immunocompetent mice.
4
 The 
fourth enabling characteristic is tumour-promoting inflammation. Inflammation can 
contribute towards the development of tumours, by supplying bioactive molecules to the 
tumour such as growth factors, survival factors and proangiogentic factors such as 
extracellular matrix modifying enzymes which allows angiogenesis and metastases to occur.
4
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Luo et al suggest that the key to developing new treatments lies with identifying critical 
signalling pathways, and members of signalling pathways within tumour cells whose 
inhibition results in ‘system failure’.5 Luo et al have identified a further set of ‘hallmarks’ 
which whilst not uniquely found in cancer cells, must be tolerated for cancer cells to survive. 
They term these the ‘stress phenotype’.5 
 
The first of the stress phenotypes is high levels of DNA-damage. Tumours have high levels 
of genetic instability, partially due the loss of telomeres, allowing fusion of unprotected 
chromosomes, partially due to mutation within the DNA repair and DNA stress response 
pathway, which allows the cancer cells to survive, but also allows for accumulation of DNA 
damage.
5
 
 
The fusion of chromosomes can lead to translocation and amplification of genes. This in turn 
can lead to the second stress phenotype – proteotoxic stress, the stress caused by the 
misfolded proteins. Translocated genes and anuploidy can alter the stoichiometry of protein 
complexes within cells, leading to a build up of unfolded proteins which aggregating within 
cells.
5
 
 
Further ‘stress phenotypes’ include: mitotic stress, in which the shift in chromosome 
distribution within cancer cells leads to rapid evolution; metabolic stress, where tumour cell 
get their energy from glycolysis; and oxidative stress, where higher levels of reactive oxygen 
species are generated by oncogenic signalling, which in turn damages DNA, leading to 
further transformation.
5
 
 
These stress phenotypes contribute further to the difference between cancer cells and normal 
cells which can be exploited in developing selective anti-cancer chemotherapeutic agents. 
Luo et al have characterised cancer cells as having oncogenic and non-oncogene addiction.
5
 
Oncogene addiction is the reliance of tumour cells on oncogenes to drive the tumourgenesis 
process, whereas non-oncogenic addiction is the reliance on genes which are not mutated, but 
are necessary for maintaining the tumour cell. The non-oncogene addiction includes genes 
which allow the tumour cells to cope with the cellular stress caused by the ‘stress oncogene’.5 
 
There are two approaches which can be taken to exploit the difference between cancer and 
normal cells. The first is ‘stress sensitisation’, where vital proteins within the stress support 
1.  Cancer: An Introduction 
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pathway are inhibited and the cell is sensitised to cellular stress, which should induce cell 
death. The second approach is stress overload in which the existing stress is intensified, to 
overwhelm the stress support pathways, which should also lead to cell death.
5
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2. mTOR: An Anti-Cancer Target 
 
2.1 Protein Kinases and Protein Kinase Inhibitors 
 
Protein kinases transfer the terminal (γ) phosphate group of adenosine triphosphate (ATP) to 
the hydroxyl groups of amino acid side-chains within proteins (Figure 2). This process 
activates proteins, usually by inducing a change in conformation. There are three classes of 
protein kinase: serine/threonine kinases, tyrosine kinases and dual kinases. The 
phosphorylation process can be reversed through the activity of phosphatases, resulting in 
free hydroxyl groups and orthophosphate (Pi). Without the activity of phosphatases, 
phosphorylation would essentially be irreversible as it is a highly favourable process, the 
hydrolysis of ATP to ADP has ΔG of -50.2 kCal/mol.6 
 
Figure 2 
 
There are 518 protein kinases within the human genome.
7
 All 518 share a highly conserved 
catalytic domain, alike in both sequence and structure.
7
 The ATP-binding site lies in a deep 
cleft between the C- and N-terminal lobes,
8
 and consists of: a  hydrophobic pocket, which 
binds the purine of ATP; a hinge region, which connect the C- and N- lobes; a P loop, which 
acts as ceiling to the pocket and the activation loop.
8
 The activation loop can undergo 
significant conformational changes as a result of its phosphorylation state. When 
phosphorylated (the ‘active’ form) the activation loop moves to close up a hydrophobic 
pocket adjacent to the ATP-binding site which is present in the unphosphorylated 
configuration (inactive), also known as the ‘DFG out’ configuration.8 The aspartate of the 
DFG binds two Mg
2+
 ions, which co-ordinate to the three phosphate groups of ATP on 
binding.
9
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Protein kinases play a vital role within the cell, with virtually every cellular process governed 
by a cascade of phosphorylation.
10
 Disregulation of kinase is observed in a number of 
diseases, including cancer, immunological, neurological, metabolic and infectious disease.
10
 
Since the success of imatanib (1) (Gleevec) protein kinases have become a major focus of 
anti-cancer drug discovery efforts, with compounds targeting 30 different kinases reaching 
the level of phase I clinical trials.
10
 
 
The majority of kinase inhibitors target the ATP binding site. The compounds, usually 
heterocycles, form one to three hydrogen bonds with the hinge region, mimicking those 
formed by ATP.
10
 Inhibitors may also bind to other regions around the adenine binding site 
including the hydrophobic pockets I and II, the ribose binding region and phosphate binding 
region.
11
 Selectivity can be gained from these regions, but generally not from the adenine 
binding residues.
11
 ATP-competitive inhibitors are also known as type I kinase inhibitors.
11
 
As this class of  inhibitors target the ATP-binding site the structure should be highly 
conserved and not alter significantly due to mutation, as mutation may not be tolerated for 
ATP-binding and lead to a lack of function.
7
 
 
Figure 3 Representation of ATP-competitive binding site (Taken from reference 11) 
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Type II kinase inhibitors occupy a hydrophobic pocket adjacent to the ATP-binding site. This 
hydrophobic pocket is not present when the kinase is in its active form, instead it occupies a 
pocket formed when the activation loop is in the ‘DFG’ out configuration.11 Inactive 
conformation inhibitors occupy the hydrophobic pocket created by the inactive configuration 
via a hydrophobic ‘tail’ but also usually have a ‘head’ group which can interact with the 
adenine binding site. Inhibitors which bind to the inactive conformation are sometimes 
known as allosteric inhibitors,
11
 however, this term has also been applied to inhibitors such as 
rapamycin, which bind at a distant site and do not interact with the ATP-binding site.
10
 
 
Figure 4 Representation of the allosteric binding site (Taken from reference 11) 
 
Accessing the ‘DFG’ out conformation may allow greater selectivity for kinase inhibitors as 
residues exposed within the inactive conformation hydrophobic pocket are less conserved.
11
 
Inhibitors which bind to the inactive conformation may also have a greater cellular potency, 
as ATP has a lower affinity for inactive conformation kinases.
11
 Imatinib (1) binds to the 
inactive conformation and locks the kinase in an inactive conformation, thus ensuring that the 
aspartate (from the ‘DFG’) cannot co-ordinate to the magnesium ion in the catalytic site.7 
 
There are two further classes of kinase inhibitors. Class III refers to the previously discussed 
‘allosteric’ inhibitors which bind at a distant site, far removed from the ATP-binding site 
(rather than adjacent like type II inhibitors).
10
 These inhibitors usually bind in a unique 
manner, and use an individual mechanism to inhibit kinase activity.
10
 By avoiding the highly 
conserved ATP-binding site the type III inhibitors are usually highly selective. Rapamycin, a 
potent and highly selective inhibitor of mTORC1, acts in this manner. 
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Type IV are covalent kinase inhibitors. These form an irreversible covalent bond with the 
active site, usually by reacting with a cysteine residue in a Micheal-type reaction.
10
 Type IV 
inhibitors usually consist of a group which bind to the ATP-binding site, thus targeting the 
molecule, which can then react with the nucleophilic residue.  
 
Selectivity of a kinase inhibitor is particularly important, especially during early development 
of a new class of kinase inhibitor. A selective kinase inhibitor should be less toxic and will 
make target validation simplier,
8
 with closely related kinases most likely to share sensitivity 
to a particular inhibitor.
12
 A single residue within the ATP-binding site can control the 
sensitivity of a kinase to a particular inhibitor. This residue, known as the gatekeeper residue, 
controls access to the hydrophobic pocket.  Kinases with a larger residue at this site have a 
greater range of resistance to kinase inhibitors.
12
 The gatekeeper residue does not affect 
binding of ATP as the hydrophobic pocket it controls access to is not exploited by ATP.
7
 
Mutation of the gate keeper residue is a common mechanism of developing resistance to 
inhibitors,
10
 and as this area in not exploited by ATP, the kinase is still functional. Kinase 
inhibitors which can tolerate a variety of residues at this point can avoid this loss of 
efficiancy.
10
 Zuccotto et al have demonstrated the influence of the gatekeeper residue on 
access to the hydrophobic pocket by comparing the crystal structure of CDK2 (Phe 
gatekeeper) and bRAF (Thr gatekeeper). The bRAF crystal structure has a larger hydrophobic 
pocket accessible to a small molecule, in comparison to the CDK2 inhibitor (Figure 5).
13
 
 
Figure 5 Comparison of the CDK2 and bRAF kinase domain, with differing gatekeeper 
residues (Taken from reference 13) 
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With the emergence of rationally-targeted agents,
8
 kinase inhibitors have been increasingly 
important. Alongside this, sophisticated techniques for designing of new inhibitors have been 
developed, aided by NMR and protein crystallography.
8
  High-throughput screening has 
helped identify starting points for a number of drug discovery programmes and this has now 
been joined by fragment-based screening to identify new starting points. 
 
2.2 Phosphatidylinositiol 3-kinase Lipids (PI 3-K) 
  
Phosphatidylinositiol lipids are comprised of an inositol ring with a phosphatidic acid group 
attached via the 1’-OH group. The inositol group can be phosphorylated by ATP at all 
positions around the ring apart from the 2’ and 6’ position by lipid kinases, with the position 
and combination of phosphorylation effecting function.
14
 Phosphatidylinositol 3-kinases (PI 
3-K) phosphorylate the membrane bound inositol ring at the 3-position.
14
 There are multiple 
isoforms of PI 3-K, which can be divided into 3 distinct classes, which share a homologous 
core catalytic domain.
14
 
 
Figure 6 Phosphorylation of the inositol ring at the 3-position (Taken from reference 6) 
 
Class I consists of a heterodimer made up of ~110 kDa catalytic subunit known as p110 and a 
regulatory or adaptor subunit. The preferred substrate of class I is phosphatidylinositol (4, 5) 
biphosphate (PtdIns (4,5) P2) giving phosphatidylinositol (3,4,5) triphosphate (PtdIns (3,4,5) 
P3).
14-15
 The activity of class I PI 3-K is reversed by the lipid phosphatise Pten (phosphatase 
and tensin homologue deleted on chromosome 10).
16
 
 
Class I can be further divided into class IA and class IB. Class IA consists of one of three 
isoforms of p110, either α, β or δ and an adaptor protein, one of the isoforms of p85, α, β or γ. 
p110 isoforms α and β are ubiquitously spread throughout cells, however p110δ is far less 
common, mostly found within leukocytes. The adaptor protein p85 has two Src-homology 2 
(SH2) domains which bind to phosphorylated tyrosine kinase receptors, allowing the PI 3-K 
to relocate from the cytoplasm to the membrane where the phosphatidylinositol lipids are 
2. mTOR: An Anti-Cancer Target 
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located.
14-15
 Stimulation of almost every receptor induces activation of class IA.
14
 The 
strengths and extent of these signals differs between signals, with insulin and PDGF 
signalling strongly, whilst EGFR has much weaker signalling.
15
 Class IA is also activated by 
Ras though the mechanism of this process is unclear.
15-16
 
 
PtdIns (3,4,5) P3 product of class I activity acts as a secondary messenger recruiting a number 
of  proteins to the membrane.
16
 These proteins are recruited via a domain known as the 
pleckstrin homology (PH), a structurally conserved area of around 100 amino acids
15
 which 
bind inositol lipids with high affinity.
14
  
 
Class IB has only one isoform of p110, the γ isoform and an adaptor protein of p101 kDa, 
which has no sequence homology to any other known protein. Class IB is activated by 
heterotrimeric G-protein coupled receptors.
14
  
 
Figure 7 (Taken from reference 15) 
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Class II is larger than either classes I and III with a molecular mass of larger than 170 kDa, 
due to an extra C2 domain, which can bind to phospholipids. In vitro class II prefer PtdIns as 
substrate. Mammals have 3 class II isoforms - α, β and γ, with α and β found ubiquitously and 
γ primarily found in the liver.14 Class II is found at the cell membrane unlike class I which is 
found in the cytoplasm under resting conditions.
15
 The effect of class II signalling is unclear. 
 
Class III is a homology of yeast vesicular protein sorting protein Vsp34p. In vitro class III 
only acts on PtdIns and is not stimulated by cell signalling. Class III is found in complex with 
p150, a Ser/Thr protein kinase – which targets class III to the membrane.14 In yeast Vsp34p 
has a role within protein trafficking to the vacuole and within mammals the role is thought to 
be similar, moving proteins to the lysosome.
15
  
 
2.3 Phosphatidylinositol 3-kinase-like Kinases 
 
The phosphatidylionsitol 3-kinase-like kinases (PIKK) are a family of serine/threonine 
protein kinases. As the name suggests, they share significant sequence similarity (20-25%)
17
 
to a family of lipid kinases, the phosphatidylinositol 3-kinases, rather than other 
serine/threonine protein kinases. PIKK family members are large, with molecular masses 
ranging from 280 kDa to 470 kDa.
17
 
 
There are six members of the PIKK family: mammalian target of rapamycin (mTOR), DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), ataxia-telangiectasia mutated (ATM), 
ataxia- and Rad 3-related (ATR), suppressor of morphogenesis in genitalia (SMG-1) and 
transformation/transcription domain-associated protein (TRRAP).
18
 
 
The PIKK family have a range of diverse functions. mTOR controls cellular growth in a 
nutrient and amino acid sensitive manner. DNA-PK plays a role within non-homologous end-
joining as a response to DNA double strand breaks. ATM and ATR act within the signalling 
pathway as a response to genome damage. ATM acts chiefly within the signalling of double 
strand breaks and ATR with other types of DNA-damage, such as that caused by UV light.
17
 
SMG-1 is involved in the monitoring of RNA known as ‘nonsense mediated mRNA decay’ 
(NMD)
19
 which recognises and eliminates mRNA species which code for non-functional or 
harmful residues.
17
 TRRAP acts as a transcriptional co-activator, however, TRRAP does not 
behave as a kinase, instead functioning as a ‘scaffold’ recruiting histone acetyl transferases.17 
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The kinase domain of PIKKs (apart from TRRAP) contains the residues vital for ATP 
binding seen in other ‘traditional’ kinases, the DXXXXN and the DFG motif. This lack of the  
kinase motif results in TRRAP being catalytically inactive.
17
 Of the catalytically active 
PIKKs four out of five demonstrate a preference for the phosphorylation of Ser/Thr residues 
followed by a glutamine residue, known as S/T Q directed kinases. However, the fifth, 
mTOR shows no such preference for this particular motif, and as yet no mTOR motif for 
phosphorylation has been identified.
17
 It has been proposed that the difference in 
phosphorylation site preference lies in the role of the kinase, all catalytically active PIKK 
enzymes which preferentially phosphorylate the S/T Q motif function within genome 
monitoring and repair, whereas mTOR does not, perhaps ensuring that mTOR does not 
interfere with genome stability.
19
 
 
The catalytic domain of the PIKKs is flanked on either side by domains known as FAT 
(FRAP-ATM-TRRAP) and FAT-C,
18
 which are always found in combination.
17
 The FAT 
domain lies on the N-terminal side of the catalytic domain and is made up of around 500 
residues, however the function of the FAT domain is unclear.
18
 The FAT-C domain lies 
towards C-terminus of PIKK enzymes, it is a highly conserved region of around 30 amino 
acids. It has been shown to be critical for catalytic activity and mutagenesis experiments have 
demonstrated the importance of the conserved hydrophobic residues. It has been proposed 
that this region plays an important role within protein-protein interactions.
18
 
 
The PIKK family also share a further structure motif known as HEAT (Huntington, 
Elogation factor 3, Alpha-regulatory subunit of protein phosphatise 2A and Tor1) repeats.
19
 
The PIKK enzymes can have as many as 40-54 HEAT repeats,
19
 with each HEAT repeat 
made up of a pair of interacting anti-parallel helices linked by a flexible intraunit loop. Each 
helix is made up of 10-20 residues, with the intraloop made up of 5-8 residues.
20
 Between 63-
83% of the non-kinase domain of  ATM, ATR and mTOR has identified as forming HEAT 
repeats and can form a superhelical structure.
20
 The HEAT repeats have been identified in all 
PIKK family members
19-22
 and are thought to function within forming macromolecules. 
 
Within the FAT domain on mTOR lies an area known as the FKBP12·rapamycin binding 
(FRB) domain.
18
 The FRB lies adjacent to the catalytic domain, and binds to the mTOR 
inhibitor rapamycin·FKBP12 complex (to be discussed in greater detail in chapter 2.5). The ~ 
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110 residue region
23
 forms four helices, a pair of HEAT repeats, one of which is unique to 
mTOR.
20
 
 
 
Figure 8 Structure of the PIKK with domains highlights 
 
2.4 Mammalian Target of Rapamycin 
 
2.4.1 mTOR Complex 1 and 2 
 
The serine/threonine protein kinase mammalian target of rapamycin (mTOR) forms two 
complexes, both of which function within the PI 3-K/Akt growth/survival pathway. mTOR 
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complex 1, also known as mTORC1, is the rapamycin sensitive complex and co-ordinates 
growth signals and the availability of nutrients and cellular energy, to induce protein 
synthesis. It is made up of mTOR protein, raptor, mLST8, deptor and PRAS40.
24
 Both deptor 
and PRAS40 (proline-rich Akt substrate of 40 kDa)
25
 inhibit the catalytic activity of 
mTORC1, which is relieved on cellular signalling and will be discussed in more detail in 
Chapter 2.4.2,
24
 mLST8 (lethal with sec13 protein 8) helps to activate mTORC1 by 
stabilising the mTOR/raptor interaction,
25
 and although it associates with the kinase domain 
of mTORC1, it does not interact with substrates.
26
 Raptor is a 150 kDa protein, with a highly 
conserved N-terminal domain, it has three HEAT domains and seven WD40 domains, which 
are important for protein-protein interactions.
26
 Raptor acts as a scaffold, recruiting and 
interacting with mTORC1 substrates.
27
 Disruption of either mTOR or raptor genes results in 
embryonic lethality, with death at around 5.5-6.5 days.
28
  
 
mTORC1 signalling is implicated in a number of cancers, due to its role within protein 
synthesis and its function within the PI 3-K pathway, which commonly has aberrant 
signalling within cancer. This includes mutant or over expressed PIK3CA, which is the gene 
coding for the PI 3-K p110 α subunit, mutation or amplification of Akt or loss of the tumour 
suppressor Pten.
29
 
 
Yip et al have determined the 3D structure of mTORC1 by cyroelectron microscopy.
30
 
mTORC1 was observed to form a dimer of two mTORC1 units with a cavity within the 
complex, the function of which is unclear. Antibody labelling identified location of PRAS40 
and mLST8 binding. Incubating with rapamycin, a macrolide inhibitor of mTORC1 (see 
chapter 2.5) significantly reduced the levels of mTORC1, suggesting that rapamycin acts by 
destabilising the complex. This effect was not observed on treatment with the ATP-
competitive inhibitor Torin1 (16).
30
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Figure 9 Cryo EM reconstruction of mTORC1(Taken from reference 30) 
 
Figure 10 Cyro EM demonstrating dimer, with raptor (in gold) N and C terminus, kinase 
domain (purple star), binding site for PRAS40 and mLST8 and interface with raptor (black 
lines) (Taken from reference 30)  
 
mTORC2 is the rapamycin and nutrient insensitive mTOR complex.
27
 mTORC2 is made up 
of mTOR protein, rictor, mLST8, protor, deptor and mSIN1 (also known as mitogen-
activated-protein-kinase-associated protein 1).
24, 31
 Rictor is the rapamycin insensitive 
companion of mTOR and protor the protein observed with rictor.
27
 Interaction of mTOR with 
either raptor or rictor is mutually exclusive, complexes either contain raptor or rictor.
32
 Rictor 
knockouts result in embryonic lethality slightly later at ~ 10.5 days. Interestingly, mSIN1 
knockout also results in embryonic lethality after 10.5 days, indicating that mSIN1 is only 
necessary for mTORC2 function but not mTORC1.
28
 Each complex has a distinct cellular 
function, though both lie within the PI 3-K/Akt pathway and there are several interactions 
between both mTOR substrates and activators at various points within the pathway.  
 
2. mTOR: An Anti-Cancer Target 
26 
 
Guertin et al have observed that loss of the tumour suppressor Pten is associated with prostate 
cancer, and that mTORC2 activity is required in development of the tumour.
33
 Pten-deficient 
cell-line PC-3C requires rictor to form tumours with nude mice and transforms prostate 
epithelial cells in vivo.
33
 In adenocarcinoma driven by loss of Pten, loss of rictor impairs 
development of tumours, but has little effect on normal prostate tissue.
24
  
 
Figure 11 
 
2.4.2 The Function of mTORC1 and 2 Within the PI 3-K/Akt Pathway 
 
As a response to the binding of growth signals to tyrosine receptor kinases PI 3-Kα is 
activated. PI 3-Kα is comprised of a p110α and p85 subunits and phosphorylates membrane 
bound PtdIns(4,5)P2 to PtdIns(3,4,5)P3.
14
 The phosphorylation of PtdIns(4,5)P2 to 
PtdIns(3,4,5)P3 can be reversed by the activity of the phosphatase and tumour suppressor 
Pten (phosphatase and tensin homolog deleted on chromosome ten).
34
 PtdIns(3,4,5)P3 is a 
secondary messenger and recruits a number of proteins via their pleckstrin homology domain, 
a conserved domain of approximately 100 residues, which binds PtdIns(3,4,5)P3 with high 
affinitiy.
14, 28
  Recruited proteins included Akt and PDK1. mTORC2 is also recruited via the 
pleckstrin homology domain of mSIN1.
35
 Mutation or upregulation of the PI3KCA gene 
coding for p110α or loss of Pten either through mutation or deletion can result in an aberrant 
signalling of the PI 3-K/Akt pathway. PI3KCA mutation is common and is observed within a 
number of cancers including ovarian, colorectal, breast, gastric, brain and cervical whilst Pten 
inactivation is observed in glioblastomas, endometrial, and prostate cancers, amongst 
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others.
29
 Mutations or amplifications of Akt have also been observed in cancers, including 
breast, ovarian, glioblastoma and pancreatic.
29
 
 
 
Figure 12 A simplified PI 3-K/Akt pathway 
 
The exact mode of mTORC2 activation is unclear. mTORC2 can be stimulated on exposure 
to serum, in particular serum containing insulin and insulin-like growth factor 1, suggesting 
that mTORC2 is activated by the PI 3-K pathway.
36
 Both mTORC2 and rictor are 
phosphorylated multiple times. Rictor phosphorylation at Thr1135 has been demonstrated to 
be sensitive to both rapamycin treatment, growth factors and levels of amino acids, which 
indicates that Thr1135 is phosphorylated downstream of mTORC1. An in vitro kinase assay 
indicated that rictor Thr1135 was phosphorylated by S6K, which is one of the target proteins 
of mTORC1.
37
 The TSC1/2 complex, which has previously been thought to act purely as an 
upstream suppressor of mTORC1 activity (discussed below) has been proposed to act as a 
positive regulatory of mTORC2 activity. Inactivated TSC1/2 reduces mTORC2 activity, but 
inactivated Rheb, which is a target of TSC1/2 activity has no effect.
37
 However the full 
mechanism of mTORC2 activation has yet to be deduced. 
 
In addition to mTORC2 playing a part within actin polymerisation and cell spreading via 
PKCα and Rho,38 its crucial role within the PI 3-K pathway is phosphorylation of Akt at 
Ser473.
25
 This site lies within the C-terminus and is vital for full activation of Akt.
27
 Akt is 
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also phosphorylated by PDK1 at Thr308, but phosphorylation at Ser473 is sufficient to ensure 
that some kinase targets of Akt can be phosphorylated, including the TSC1/2 complex. Full 
phosphorylation of Akt is required before other targets such as FOXO1/3 can be 
phosphorylated.
27
 Akt controls the cell-cycle by regulating the FOXO protein, cyclin D1, p27 
and GSK3. Akt also regulates MDM2, caspase-9, IKKα and Bad, controlling apoptosis. Akt 
phosphorylation of MDM2 induces translocation of MDM2 into the nucleus where it can 
inhibit the anti-apoptopic activity of p53.
24
 mTORC2 has also been proposed to 
phosphorylate SK61, a target protein of mTORC1, which belongs to the same family as 
Akt.
38
 
 
Phosphorylation and activation of Akt can either control cell survival or in aberrant signalling 
potentially drive tumourgenesis by increasing cell growth, proliferation and migration, as 
well as the shift to glycolytic metabolism.
28
 Akt phosphorylates TSC2 of the TSC1/2 
heterodimeric complex at Ser939 and Thr1462.
26
 TSC1 (also known as hamartin) is a 130 
kDa protein and TSC2 (also known as tuberin) a 200 kDa protein, which without Akt 
signalling form a stable heterodimer.
26, 38
 When forming a stable heterodimer the TSC 
complex acts as a GTPase activating protein (GAP). TSC1/2 activates Rheb (Ras homolog 
enriched in brain) to convert bound GTP to the inactive GDP bound form.
25
 On 
phosphorylation by Akt the heterodimer dissociates, inactivating the GAP activity of 
TSC1/2.
25
 The Ras/MAPK pathway can also phosphorylate TSC1/2 complex through the 
kinase activity of Rsk.
25
 
 
Figure 13 
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As protein synthesis is both an energy-rich and nutrient-rich pathway protein synthesis must 
be halted in times of nutrient and/or energy starvation. The energy-sensing AMP-dependent 
protein kinase (AMPK), which is activated by phosphorylation at Thr172 and Thr1227 by 
LKB1, phosphorylates TSC2 at Ser1345 and Ser1227, which activates the TSC1/2 
complex.
25, 35
 AMPK is activated as a response to a change in AMP:ATP ratio.
25
 LKB1 also 
phosphorylates raptor at Ser792 and Ser722, promoting 14-3-3 protein binding and 
inactivating mTORC1.
25
 The tumour suppressor p53 also acts via AMPK. On sensing DNA-
damage p53 upregulates the transcription of AMPK, preventing continued cell growth in the 
face on DNA-damage.
35
 AMPK can also phosphorylate p53 at Ser15,
24
 stabilising p53 
allowing increased levels of transcription of p53 cellular targets and halting the cell cycle 
whilst the cell is in energy-starvation conditions. 
 
Hypoxia is also proposed to influence the PI 3-K/Akt pathway through the TSC1/2 complex. 
On phosphorylation, TSC2 is proposed to binds 14-3-3 proteins. As a response to hypoxia 
HIF (hypoxia inducible factor) is stabilised, inducing the expression of a number of genes, 
including those associated with angiogenesis, and Redd1 and 2. Redd1 can complete with 
TSC2 for binding with 14-3-3 proteins, relieving the inhibition of the TSC1/2 complex.
25
 
TSC1/2 can then act as a GAP, resulting in mTORC1 remaining inactive. 
 
Destabilisation of the TSC1/2 complex results in loss of GAP-activity ensuing that Rheb 
existing as its active GTP-bound form. Rheb interacts with mTORC1, through a poorly 
understood mechanism, activating mTOR.
23
 As Rheb is selective for mTORC1, it is thought 
that the protein may interact with raptor, rather than the mTOR protein itself.
28
 Bai et al 
proposes that Rheb activation of mTORC1 is due to its interaction with FKBP38.
39
 FKBP38 
is related to FKBP12, a protein which, when bound to rapamycin, can inhibit mTORC1 (see 
Chapter 2.5). FKBP38 binds to the FRB domain of mTOR (but only mTOR in mTORC1) and 
inhibits the kinase activity of mTORC1. Bai et al propose that GTP-bound Rheb interacts 
with FKBP38, which disrupts FKBP38 binding with mTORC1, relieving its inhibitory 
activity.
39
 
  
Cellular nutrient levels have also been demonstrated to influence mTORC1 signalling. The 
strongest link between mTOR and nutrients is the Rag family of small GTPases.
35
 The Rag 
family forms a heterodimer composed of either Rag A or B and Rag C or D. In the inactive 
state either Rag A or B is bound to GDP and RAG C or D is bound to GTP. However, in the 
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presence of amino acids the nucleotide binding switches through an unknown mechanism, to 
the active form.
24, 35
 The RAG heterodimer can then interact with raptor and induces the 
translocation of mTORC1 to the surface of endosomes and lysosomes, where it can interact 
with Rheb.
35
 Interestingly, it has been shown that withdrawal of Leu has similar effect to 
starvation of a range of amino acids. The amino acid levels may be detected by a mechanism 
reliant on leucine levels.
25
 
 
PRAS40 is an inhibitory member of the mTORC1 complex that has been proposed to bind to 
the kinase domain of mTOR, preventing kinase activity.
28
 On Akt activation PRAS40 is 
phosphorylated by Akt at Thr246, targeting PRAS40 to 14-3-3 binding, which relieves the 
inhibitory activity of PRAS40 on mTORC1 by sequestering PRAS40.
25, 28
 However, this may 
not be the full picture for PRAS40, as it also has a TOF sequence (discussed in more detail 
below), which suggests that it could be a substrate of mTORC1.
28
 
 
After activation mTORC1 can phosphorylate a number of target proteins involved in protein 
synthesis. mTORC1 targets are thought to have a TOF (target of TOR) motif, which consists 
of five amino acids – a phenylalanine, followed by two hydrophobic amino acid, then two 
acidic residues. This TOF motif is thought to be important for target protein to interact with 
raptor.
25
 
 
The two best described targets of mTORC1 kinase activity are the p70 S6 kinase 1 (S6K1) 
and eukaryotic initiation factor 4E-binding protein 1 (4E BP1).
25
 Phosphorylation of 4E BP1 
causes it to dissociate from eukaryotic initiation factor 4E (eIF4E). Without phosphorylation 
4E BP1 is bound to eIF4E, inhibiting the translational initiation activity eIF4E.
26
 eIF4E binds 
and recognises the cap, which contains a 7-methyl guanosine moiety,
40
 at the 5’ end of 
mRNA and mediates transcription of the mRNA.
25-26
 4E BP1 is phosphorylated at numerous 
sites including Thr37, Thr46, Ser65, Thr70, Ser83, Ser101 and Ser112.
26
 Of these four are 
linked to mTOR kinase activity: Thr37, Thr46, Ser65 and Thr70, with Ser65 and Thr70 lying 
close to the eIF4E binding site.
32
  
 
After repression of eIF4E is relieved it can form the initiation complex with proteins 
including eIF4G, allowing translation of mRNA with highly structured 5’-UTRs 
(untranslated regions).
38
 The complex also contains eIF4F (which binds to the mRNA 5’ 
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cap), eIF4A (an ATP-dependent helicase which unwinds mRNA secondary structure) and 
eIF4B which enhances eIF4A activity.
33, 35, 41
 
 
Figure 14 
 
Phosphorylation of S6K1 at Thr389 in the linker region of S6K1 and Ser371 activates S6K1 
as a kinase.
25-26
 S6K1 phosphorylates S6, the function of which is unclear. S6 was thought to 
increase transcription of mRNA with a TOP (tract of pyrimidine) mRNA, which is common 
within RNA coding for ribosomes and other regulators within the protein translation 
process.
26
 However, later evidence did not support this theory.
38
 Ribosome biogenesis is 
controlled through the activity of S6K1, which induces the translational activity of RNA 
polymerase I, resulted in transcription of ribosome proteins.
35
 S6K phosphorylates a member 
of the initiation complex (mentioned above) eIF4B, as well as PDCD4 (phosphorylation-
dependent degradation of programmed cell death 4) which blocks association of eIF4A to the 
complex.
33
 S6K can also phosphorylate a number of other targets, including mTORC2. S6K1 
is also involved in a negative feedback loop, once activated it can phosphorylate and degrade 
IRS-1 at Ser302, suppressing its activity, including the activation of PI 3-K.
25, 28
 
 
mTORC1 is also linked to autophagy, the process in which cells degrade damaged, redundant 
or dangerous proteins, providing substrates during low nutrient availability.
35
 mTORC1 
regulates autophagy, inhibiting it at nutrient-rich conditions.
25
 In yeast, Atg1 plays a vital role 
in the inducement of autophagy. When forming a complex with Atg13 and Atg17, Atg1 
functions as a kinase inducing autophagy. TORC1 phosphorylates Atg13, destabilising the 
complex and inhibiting Atg1.
42
 In humans, the homolog of Alg1 is Ulk1 and 2, and Ulk1 is 
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known to function in autophagy. mTORC1 interacts with Ulk1/Atg13/FIP200 (homolog of 
Atg17) complex and phosphorylate Ulk1 and Atg13.
42
 
 
The PI 3-K/Akt pathway has wide-reaching consequences for cellular growth and survival. 
Aberrant signalling within this pathway has been associated with a wide-range of cancers. As 
mTOR (both within mTORC1 and 2) is rarely mutated it presents an attractive medicinal 
chemistry target within cancer. The macrolide rapamycin was the first inhibitor of mTORC1, 
but also contributed to the discovery of mTOR (hence the name target of rapamycin) and is 
discussed in chapter 2.5, however, the development of ATP-competitive inhibitors of mTOR, 
which inhibit both complexes, has becoming an area of wide-ranging focus. 
 
2.5 Rapamycin and ‘Rapalogs’ 
 
Rapamycin (2) is a macrolide produced by the bacteria Streptomyces hygroscopius.
34
 
Discovered during the 1970’s in a soil sample from Easter Island (Rapa Nui)34  rapamycin 
was originally developed by Ayerst as an anti-fungal against Candida albicans, 
Crytotococcus neoforms and Aspergillus fumigates,
43
 however, development was stopped on 
the discovery of potent immunosuppressive activity.
34
 The deducing of the mechanism of 
action of rapamycin led to an increase in interest leading to the approval of rapamycin in 
1997 as an anti-rejection agent.
34
 Rapamycin is commonly used in combination with 
cyclosporine to prevent renal graft rejection.
43
 However, studies at the NCI also observed 
anti-tumour activity within both in vivo and in vitro studies. 
 
Figure 15 
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Rapamycin activity is derived from its activity as a potent (low and sub-nanomolar)
44
 and 
highly selective allosteric inhibitor of mTORC1. Rapamycin interacts with the immunophilin 
FK506-binding protein (FKBP12).
43
 The rapamycin·FKBP12 complex then interacts with 
mTORC1 via the FKBP12 rapamycin binding (FRB) domain, inhibiting the catalytic activity 
of mTORC1. The FRB domain is a 11 kDa region is adjacent to the PIKK domain, and the 
formation of the tertiary complex forms a ‘sandwich’ like structure.34 The mechanism by 
which rapamycin inhibits mTORC1 catalytic activity is unclear, the rapamycin·FKBP12 
complex has been proposed to act as a physical obstruction between the mTOR catalytic 
domain and its substrates. The formation of this complex also appears to destabilise the 
interaction between mTOR and raptor, despite raptor binding further than 1000 residues away 
from the FRB domain.
38
 The resulting loss of the mTOR raptor complex may contribute to 
the loss of mTOR catalytic activity as the mTOR/raptor complex is required for catalytic 
activity.  
 
Figure 16 Structure of mTOR FRB, rapamycin and FKBP12 tertiary complex (Taken from 
reference 34) 
 
Rapamycin is a highly selective molecule, inhibiting only one of the two mTOR complexes. 
It has been proposed that rictor or a further component of the mTORC2 complex can prevent 
binding of rapamycin·FKBP12, either by physically blocking the FRB domain or by 
allosterically altering the FRB binding site on rictor binding.
38
 However, long term treatment 
with rapamycin decreases levels of mTORC2, which in approximately 20% of cell lines is 
sufficient to reduce Akt phosphorylation.
31
 It has been proposed that this is due to the 
inactivation of mTORC1 by rapamycin, which the cell then compensates for by forming more 
mTORC1, leaving insufficient mTOR protein available to form mTORC2.
23
 Guerin et al also 
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proposed that rapamycin·FKBP12 can bind to recently synthesised mTOR protein, 
preventing the formation of mTORC2.
33
  
 
Rapamycin is a white solid that is soluble in organic solvent; however it is insoluble in 
aqueous solutions.
43
 Rapamycin can only be given via oral administration; it has rapid 
absorption with peak concentration reached at 2 h. However, bioavailability of rapamycin is 
low (only around 15 %) and can vary greatly between patients.
45
 Intestinal CYP450 3A 
enzymes and P-glycoproteins can influence absorption of rapamycin.
45
 
 
To improve the pharmacokinetic properties of rapamycin a series of semi-synthetic 
derivatives have been developed. All are very structurally similar to rapamycin, with 
modifications only at the C40 position, an area not involved in either binding to FKP12 and 
mTOR.
45
 Four ‘rapalogs’ have so far been developed – Temsirolimus (3) (or CCI-779 from 
Wyeth),
34, 44
 Everolimus (4) (RAD001 from Novartis),
34, 44
 Deforolimus (5) (or 
Ridaforolimus) (AP23573 from Ariad)
34, 44
 and Zotarolimus (6) (ABT-578 from Abbott).
46
 
All ‘rapalogs’ act via the same mode of action as rapamycin.45 
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Figure 17 
 
Temsirolimus (3) was the earliest analogue of rapamycin. It is a water-soluble ester analogue 
of rapamycin
34
 and acts as a prodrug form of rapamycin.
45
 It is rapidly hydrolysed, with 
intravenous administration rapamycin can be detected as quickly as 15 min with peak 
concentration between 0.5 h and 2 h.
45
 Temsirolimus was licensed by the FDA in 2007 for 
use in the treatment of renal cell carcinoma and can be used as either an oral or intravenous 
administration.
45
 
 
Everolimus (4) is a hydroxyl ethyl ether analogue of rapamycin. It has immunosuppressive 
activity, can be used in a synergistic manner with cyclosporine and was approved in Europe 
for its immunosuppressant activity.
45
 In vitro everolimus has immunosuppressive activity 
three times lower than of rapamycin, however in vivo activity is comparable, due to the 
improved pharmacokinetics.
43
 Everolimus also has anti-cancer activity and was licensed in 
the US for treatment of kidney cancer in 2009.
47
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Deforolimus (5) is a phosphinate analogue of rapamycin.
34
 Deforolimus is the newest 
addition to the series of rapamycin analogues.
45
 It is stable in organic solutions and aqueous 
solution at a range of pH. Deforolimus is also stable in both plasma and blood, indicating that 
5 does not act as a prodrug in vivo.
43
 Deforolimus  had activity against a range of cell lines in 
vitro
43
 and is currently in phase III clinical trials.
48
  
 
Zotarolimus (6) is a rapamycin analogue designed to be used as a drug to elute from coronary 
stents to prevent restenosis.
46
 It replaces the C40 hydroxyl group with a tetrazole moiety.
44
  
 
Rapamycin and its analogues are well tolerated and share similar side-effects.
45
 However, 
identification of the correct subset of patients who will benefit from rapamycin or rapalog 
treatment is vital as within trials less than 10% of patients responded.
34
  Rapamycin treatment 
can trigger an S6K1 dependant negative feedback loop which leads to increased signalling 
from IRS1/2, leading to increased activation of Akt, as well as MEK-ERK signalling.
23, 33
 
This reduces the usefulness of rapamycin and rapalogs as a treatment for cancer. Rapamycin 
and rapalogs have been found to be useful in mantle cell lymphoma, renal cell carcinomas 
and endometrial cancer, a small number of cancers, given that aberrant signalling within the 
PI 3-K/Akt pathway is very common.
49
 However, it is thought that an ATP-competitive 
inhibitor of mTOR, which should in theory target equally both complexes of mTOR, will 
avoid this issue by targeting the pathway at two points, leading to a more pronounced effect 
on cellular growth and survival. An ATP-competitive inhibitor will also be useful as 
mTORC2 has been implicated in some cancers.
33
 
2.6 mTOR Inhibitors Targeting the Kinase Domain 
 
The PI 3-K/Akt pathway is a key cellular pathway regulating cellular proliferation and 
growth, survival and protein synthesis.
29
 The significance of this pathway within cancer lies 
within frequent mutation, such as mutation or amplification of the PIK3CA gene, which is 
mutated in around 15% of tumours, making it the most commonly mutated kinase within the 
human genome.
29
 In view of the frequency with which the PI 3-K/AKT pathway has aberrant 
signalling in cancers, it is thought that targeting this pathway could have a wide range of 
therapeutic uses.  There is a wide range of evidence validating kinases within this signalling 
cascade as therapeutic targets.
29
 Applying Luo et al’s theory of oncogene and non-oncogene 
addiction,
5
 a number of tumours are ‘addicted’ to the PI 3-K/Akt pathway. Targeting this 
2. mTOR: An Anti-Cancer Target 
37 
 
pathway on which the tumour is ‘addicted’ should selectively target tumour cells over normal 
cells. Crucially, mTOR itself, which is a key component of this pathway, is rarely mutated,
34
 
making mTOR a non-oncogene addiction. This can prove beneficial for the purpose of drug 
discovery as the tumour relies on this kinase for continual growth and replication but 
genetically mTOR is stable and unlikely to mutate, leading to small-molecule inhibitors 
becoming ineffective. For these reasons, mTOR has become an increasingly popular target 
within both academic and pharmaceutical drug discovery. 
 
An early inhibitor of both complexes of mTOR was the natural product Wortmannin (7), 
which inhibits mTOR with an IC50 of 40 nM.
50
 Wortmannin is a pan PI 3-K and PIKK 
inhibitor, which binds in the ATP-binding site and then covalently modifies the protein, 
through a reaction with a Lys residue (Lys833 in PI 3-Kγ)51 and the C-21 position of 
Wortmannin in a Michael-type reaction.
52
 Wortmannin is unstable in solution, but has some 
uses as probe compound.
51
 
 
 
Scheme 1 Mechanism of covalent attack by the PI 3-K on Wortmannin 
 
 The first example of an ATP-competitive inhibitor of mTOR is the pan PI 3-K and PIKK 
ATP-competitive inhibitor LY294002 (8). The compound, developed by Lilly, inhibits 
mTOR with an IC50 of 5 µM.
53
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The compound PI-103 was synthesised as part of a programme to develop isoform selective 
inhibitors of PI 3-K but was also found to have off-target activity including inhibition of 
mTOR.
54-55
 PI-103 inhibits mTORC1 89% at 0.50 µM, but has greater activity against PI 3-K 
with an IC50 of 2, 3 and 3 nM against α, β and γ isoforms respectively.
56
 PI-103 also inhibits 
the PIKK family member DNA-PK, with an IC50 of 14 nM.
56
 PI-103 demonstrated a rapid 
effect, with phosphorylation of Akt at both Ser473 (mTORC2 site) and Thr308 (PDK1 site) 
inhibited within 15 min of treatment.
56
 PI-103 also showed activity with human tumour 
xenografts with upregulation of the PI 3-K pathway.
56
 However, PI-103 has a poor metabolic 
profile, with greater than 70% metabolism after 30 min incubation with human microsomes 
which combined with the ‘dirty’ inhibition profile of PI-103 would be undesirable as a drug. 
 
 Stauffer et al have demonstrated that the imidazo[4,5-c] scaffold is a privileged scaffold for 
the development of ATP-competitive kinase inhibitors.
57
 From this series two dual PI 3-
K/mTOR inhibitors have been developed, NVP-BEZ235 (10) and NVP-BBD130 (11), are 
both potent and stable, orally administered agents.
58
 NVP-BEZ235 has IC50s of 4, 75, 7, 5 nM 
against PI 3-K isoforms α, β, δ and γ respectively. 10 also inhibits mTOR with an IC50 of 20.7 
nM within a KLISA assay and in vitro has an IC50 of 6.5 nM measuring reduction of 
phosphorylation of S6 at Ser235.
59
 NVP-BBD130 has IC50s of 72, 2340, 201 and 382 nM 
again PI 3-K isoforms α, β, δ and γ respectively, and an IC50 against mTOR of 7.7 nM 
determined by measuring phospho S6.
58
 By measuring autophosphorylation of DNA-PK on 
treatment with NVP-BEZ235, inhibition of DNA-PK was observed, though only at high 
concentrations of NVP-BEZ235.
59
  
 
Docking of NVP-BEZ235 into a PI 3-Kγ-based 3-D homology model of PI 3-Kα kinase 
domain demonstrated that 10 forms three H-bonds with the protein. The core quinoline 
nitrogen forms one H-bond with PI 3-Kα Val851, the quinoline substituent nitrogen forms a 
hydrogen bond with the backbone of Asp933 and the nitrile nitrogen interacts with the side-
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chain of Ser774.
59
 Hydrophobic interactions with Met772, Tyr836 and Met922 also 
contribute to binding.
59
 Homology modelling with mTOR suggests similar binding, including 
replication of the H-bond to the Ser2165 (mTOR numbering) side chain.
59
  
 
 
 
Treatment of Pten-null cell-lines PC3M and U87MG with 10 demonstrated a dose-dependent 
effect on cell-proliferation, with a GI50 of 10-12 nM.
59
 NVP-BEZ235 has a cytostatic effect, 
inducing growth arrest at G1 due to downregulation of cyclin D1. However 10 can increase 
the efficiency of anticancer drugs, such as temozolomide in combination.
59
 Treatment of 
tumour-bearing mice with both NVP-BEZ235 and NVP-BBD130 reduced 
neovascularisation, without effecting pre-existing vessels.
58
 Both NVP-BEZ235 and NVP-
BBD130 have a good pharmacological profile, with high and prolonged cellular exposure.
58
 
Treatment of PC3M with a 50 mg/kg dose of NVP-BEZ235 resulted in a plasma Cmax of 1.68 
µM at 0.5 h and a C24 of 0.03 µM. Within the tumour tissue a Cmax of 2.05 nM was observed 
after 1 h, which after 24 h was decreased to 0.23 nM. NVP-BEZ235 is currently in phase I/II 
clinical trials in solid tumours.
49
    
 
During synthetic efforts to develop dual tyrosine and PI 3-K inhibitors a number of mTOR 
inhibitors were developed.
60
 PP242 and PP30 share a pyrazolopyrimidine scaffold and inhibit 
mTOR with an IC50 of 0.008 and 0.080 µM respectively.
60-61
 PP242 also demonstrates a 
minimum of 10-fold selectivity over all isoforms of PI 3-K,
61
 and  in a screen against 219 
protein kinases at a concentration 100-fold above that of the mTOR IC50, only demonstrated 
at 90% inhibition of one kinase and three at 75%.
60
 Due to the selectivity of PP242 and PP30 
over PI 3-Kα, the functions of mTOR within the PI 3-K/Akt can be explored and the different 
response to mTOR kinase domain inhibition and rapamycin can be explored.
61
 PP242 was 
shown to have a dose-dependent inhibition of proliferation, and inhibited phosphorylation of 
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4E BP1 at Thr36, Thr45 and Ser65 to a greater extent than rapamycin, suggesting that some 
functions of mTORC1 are insensitive to rapamycin treatment.
61
 
 
 
Development of the Torin series of inhibitors has resulted in a highly potent mTOR inhibitor. 
During SAR exploration of 6-(pyridin-3-yl)-N-(3-(trifluoromethyl)phenyl)quinolin-4-amine 
(14) it was observed that compound 10 contained a cyclic urea moiety which constrains 
substituents in the ideal conformation for biological activity. Luo et al decided to incorporate 
a six-membered lactam to hold the trifluoromethyl substituted aniline in the optimal position 
which after further optimisation, and addition of an acetyl substituted piperizine gave 
compound (15), which was observed to improve biological activity against mTOR from 5 
µM to 5.4 nM.
62
  Compound 15 was then docked into an mTOR homology model based on 
the crystal structure of PI 3-Kγ. It was proposed that compound 15 forms a hydrogen bond 
between the quinoline nitrogen and Val2240 in the hinge, with the quinoline substituent 
positioning in an inner hydrophobic pocket consisting of Glu2190, Leu2192, Asp2195, 
Tyr2225, Asp2357, Phe2358, Gly2359 and Asp2360 and the substituent quinoline nitrogen is 
proposed to form a hydrogen bond with Tyr2225 side-chain. The phenyl piperizine 
substituent positioned below a loop consisting of residues 2183-2187 and the acyl carbonyl 
carbon is thought to form a hydrogen bond with the amine of Lys2186.
62
 Optimisation of the 
acyl substituent to a propyl amide increased activity to an IC50 of 0.29 nM against mTOR, 
and a cellular IC50 of 2 nM, this compound was named Torin1 (16) and subjected to further 
biochemical analysis.
62
  
 
Torin1 has 800-fold selectivity over PI 3-K and is highly selective over other PIKK enzymes 
with the exception of DNA-PK. Within  LanthaScreen analysis 16 has an IC50 against mTOR 
of 4.32 nM and against DNA-PK of 6.34 nM, however, within a radiometric kinase assay 
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against DNA-PK it has a IC50 of approximately 1 µM.
62
 Both human and mice microsome 
stability studies revealed a half-life of 4 min, and in vitro studies demonstrated a half-life of 
0.5 h, which is proposed to be due to high first-pass metabolism. Intraperitoneal dosing 
resulted in suppression of phosphorylation at Akt Ser473 for 2-3 h and phosphorylation of S6 
(an indirect target of mTORC1 activity) was inhibited for 6 h in the lungs and 10 h within the 
lungs.
62
 A U87MG xenograft model, which is a Pten-null glioblastoma cell line, 
demonstrated 99% inhibition of growth inhibition after 10-days dosing, but growth returned 
after cessation of treatment, suggesting Torin1 is cytostatic.
62
 
 
Due to the pharmacokinetic problems, poor water solubility and low oral bioavailability of 
Torin1 further synthetic efforts were directed towards identification of a further compound 
with improved properties.
63
 It was proposed that by reducing the molecular mass of 16 a 
more water-soluble compound could be developed, which would potentially reduce the sites 
for metabolism.
63
 Removal of the piperizine moiety, and replacement of the substituent 
quinoline groups with amino-substituted pyridine resulted in compound 17 Torin2. Torin2 
has an EC50 of 0.25 nM and is estimated to be 10-fold more potent that Torin1. Torin2 also 
maintains 800-fold selectivity over PI 3-K.
63
 17 is predicted to bind in a similar mode to 
compound 15, with the hinge hydrogen bond maintained. The pyridine nitrogen forms a 
hydrogen bond to Tyr2225. The pyridine amino substituent forms two hydrogen bonds with 
Asp2195 and Asp2357.  
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Torin2 displayed improved pharmacodynamics over Torin1, with over 95% inhibition of 
phosphorylation of S6K Thr389 and Akt Thr308 after 6 h in lung and liver tissue. 17 also has 
a t1/2 of 11.7 min in liver microsomes and on intravenous and oral dosing in mice had a t1/2 of 
less than 2 h. Torin2 has improved oral bioavailability of 51%.
63
 LanthaScreen assay analysis 
of Torin2 has an IC50 of 2.81 nM (against mTOR) and 0.5 nM (against DNA-PK), though 
kinase assay activity of 17 against DNA-PK has not been reported. 
 
Development of Torin1 has also supported the findings of Feldman et al who demonstrated 
that ATP-competitive inhibitors of mTOR inhibited a greater range of mTORC1 
phosphorylations than rapamycin.
61
 Treatment of MEFs (mouse embryonic fibroblasts) with 
Torin1 reducing protein synthesis by 50%.
64
 
 
KuDOS pharmaceuticals published two series of ATP-competitive inhibitors of mTOR in 
2009.
65-66
 The first series is based on either a pyrimidine or triazine scaffold, optimisation 
gave compound 18, with an IC50 of 0.023 µM, and selectivity over PI 3-Kα, with an IC50 > 10 
µM. However, this series shown disappointing cellular activity, which was possibly due to 
poor cell permeability.
66
 The second series was based on pyridopyrimidine scaffold, with 
optimisation leading to compound 19.
65
 Compound 19 (also known as Ku-0063794) has an 
IC50 of 0.016 µM. Cell-line U87MG was treated with 19 for 2 h and inhibition of 
phosphorylation of S6 at Ser235 and Akt Ser473 was measured with IC50s of 0.10 and 0.15 
µM observed for these targets respectively. Treatment of the T47D breast cancer cell line 
with 19 resulted in a GI50 of 0.35 µM.
65
 On treatment of 76 protein kinases with 1µM of 19, 
no significant inhibition was observed and at 10 µM only one kinase showed any significant 
degree of inhibition, the MAPK kinase-1, with 55% inhibition at 10 µM. This panel also 
included PI 3-Kα and β.67  
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As with previous compounds Ku-0063794 has a greater effect on 4E BP1 phosphorylation 
than rapamycin and induces G1 growth arrest. Treatment of HEK-293 (human embryonic 
kidney) cells with 19 resulted in almost complete loss of S6K activity, resulting in a decrease 
of phospho-S6. This effect was rapid, with maximal inhibition observed within 10 min. 
Inhibition of Akt phosphorylation at Ser473 was also observed, with a knock-on decrease in 
Akt target phosphorylations.
67
 Garcia-Martinez et al also proposes that Ku-0063794 is more 
selective than PP242. At 1 µM 22 out 76 kinases were inhibited by PP242 at > 50%, and 46 
out of 76 were inhibiting at > 50% at a concentration of 10 µM, unlike Ku-0063794, which 
only inhibits one other kinase > 50% at 10 µM.
67
 
 
Further development resulted in AZD8055 (20), a potent, selective and orally available ATP-
competitive inhibitor of mTOR.
68
 AZD8055, is currently in phase I/II clinical trials for solid 
tumours, including hepatocellular carcinoma.
49
 20 has an IC50 of 0.13 nM against truncated 
mTOR, and 0.8 nM against mTOR extracted from HeLa cells. A range of ATP 
concentrations resulted in a linear IC50, indicating 20 is ATP-competitive, and has a Ki of 1.3 
nM. Counterscreening against class I and II PI 3-K, DNA-PK and ATM, demonstrated a 
1000-fold selectivity for mTOR and a panel of 260 other kinases demonstrated no significant 
activity at 10 µM.
49
 In MDA-MB-468 cells an IC50 of 24 nM and 27 nM was calculated for 
phosphorylation of Akt Ser473 and S6 Ser235.
49
 Xenograft studies with U87-MG bearing 
mice observed that after a 10 mg/kg oral dose phosphorylation of Akt at Ser473 had 
decreased to 5% of control level after 20 min, and inhibition of phosphorylation was greater 
than 50% for at least 8 h. Phosphorylation of S6 at Ser235 was decreased to 21% of control 
level after 20 min, though after 8 h 63% of control level of phosphorylation was observed.
49
 
 
One of the most potent and selective mTOR inhibitors has been developed by Wyeth 
Pharmaceuticals, who have published a number of articles on the development of ATP-
competitive inhibitors of mTOR.
69-76
 The Wyeth compounds e.g. 21-23 contain a 
pyrazolopyrimidine core, where potency was achieved with morpholine, piperidine and 
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aromatic substituents,
72
 but replacement of the morpholine moiety with a bridged morpholine 
groups in the 4–position achieved selectivity over PI 3-Kα.76 Docking of this series of 
compounds into an mTOR homology model, based on the crystal structure of PI 3-Kγ 
suggested that the morpholine group forms a hydrogen bond with a hinge residue Val2240 
backbone NH. The pocket the morpholine groups occupy is defined by Tyr867 and Cys885 
(PI 3-Kγ numbering), which limits the size of the substituent, tolerates an ethyl bridged 
morpholine, but not a dimethyl morpholine. Within mTOR, the bridged morpholine 
derivative can still interact with Val2240, however, within PI 3-K, this interaction cannot 
occur, resulting in a loss of PI 3-K activity. A single change in amino acid is thought to be the 
grounds for this selectivity. mTOR has a smaller Leu residue, which tolerates the bridged 
morpholine group, whilst PI 3-K has a Phe residue, which creates a smaller pocket, ensuring 
the bridged morpholine is not tolerated.
71, 76
 
 
WYE-132 (24)
70
 is the most potent and selective compound developed in this study, with an 
mTOR IC50 of 0.21 nM and PI 3-Kα IC50 of 1180 nM, giving 5619 fold selectivity.
69
 23 has 
high selectivity over ATR, with an IC50 of >10000 nM and hSMG1 (IC50 = 1250 nM) and in 
a panel of 230 protein kinases was largely inactive.
70
 24 also has a LNCap cellular assay IC50 
of 2 nM and was shown to have metabolic stability with a half life of greater than 30 min in 
murine microsomes and 26 min in human microsomes.
69
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The selectivity of WYE-132 was tested using biomarkers in a nude mouse MDA361 
xenograft model. Treatment with WYE-132 showed complete inhibition of phosphorylation 
at the mTORC1 biomarker S6K Thr389, sustained suppression of the mTORC2 biomarker 
Akt Ser 473 and complete inhibition of the downstream biomarker S6 Ser 240/244 for 8 h at 
a dose of 25 mg/kg. No phosphorylation was observed at the PI 3-K biomarker Akt Thr308, 
demonstrating the selectivity of this compound.
69
 Within the nude mouse model a dose of 25 
mg/kg resulted in complete inhibition of growth of the tumour but with no significant weight 
loss within the mice.
69
 WYE-132 has been demonstrated to induce a G1 arrest, and like other 
compounds has been demonstrated to fully inhibit 4E BP1, unlike the rapalog CCl-779.
70
 
Treatment of an oral 5 mg/kg dose of 24 in a MDA361 tumour resulted in a growth delay in a 
dose-dependent manner, and within MDA361, BT474, LNCap and H1975 cell-lines, which 
all have both PI 3-K/mTOR and Her-2 hyperactivation, a significant apoptopic response was 
observed.
70
 
 
Wyeth also published on an alternative series of mTOR inhibitors which replace the 
pyrazolopyrmidine core with a thienopyrimidine core e.g. 25 (IC50 = 0.7 nM).
77
 Potency in 
this series of compound is good, as is selectivity, but cellular potency is slightly lower than in 
the pyrazolopyrimidine series.
77
 Further work identified a dimorpholine substituted triazine 
moiety as having activity against mTOR.
78
 Incorporation of bridged morpholines was shown 
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to increase selectivity for mTOR over PI 3-Kα, and side chains at 4-position of the 
ureidophenyl type of previous molecules such as 24 increased potency.
78
 Unfortunately, the 
bridged morpholine groups were seen to be the primary site of metabolism of these 
compounds.
79
 Synthetic efforts were then directed towards identification of alternative groups 
for the 2- and 6-position, that maintains potency and selectivity over PI 3-Kα, as well as 
identification of the optimal position of the 4-position.
79-80
 The optimal replacement for the 
bridged morpholine groups were found to be either a tetrahydropyran group or a (R)-3-
methylmorpholine.
80
  For the 4-position substituent, a basic group was found to improve 
cellular activity, though selectivity was reduced in comparison with previous analogues (e.g. 
24), a range of compounds were synthesised, including 26 with an IC50 of 0.2 nM, 27 with an 
IC50 of 0.7 nM and 28 with an IC50 of 0.7 nM.
80
 
 
27 has the poorest selectivity over PI 3-Kα, only 131-fold, with both 26 and 28 having at least 
400-fold selectivity for mTOR over PI 3-Kα. The highest cellular IC50 were observed for 27 
with values < 0.8 nM in both LNCaP and MDA468 cell-lines.
80
 
 
Along with these series of selective ATP-competitive inhibitors of mTOR, Wyeth have also 
published a number of dual PI 3-K/mTOR inhibitors, including PKI-402 (29).
81
 These dual PI 
3-K/mTOR inhibitors have a triazolopyridimidine core and have a morpholine group on the 
4-position of the pyrimidine. The structure of PKI-402 is show below. PKI-402 has an IC50 of 
1.4, 9.2 and 1.7 nM for PI 3-Kα, γ and mTOR respectively and an IC50 of 8 nM in MDA-361 
cell lines. Compound 29 was also shown to induce cleaved PARP enzymes, a marker of 
apoptosis.
81
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 Sutherlin et al have also developed a dual mTOR/PI 3-K inhibitor. GNE-493 (30) is an 
orally available inhibitor and has good selectivity over other kinases.
82
 Compound 30 has an 
IC50 of 3.4 and 30 nM for PI 3-Kα and mTOR respectively and in nude mice has a half life of 
3.6 h.
82
 GNE-493 was also shown to be 0.5-2 more potent within PC3 and MCF7 cell lines 
than a PI 3-K inhibitors alone.
82
 
 
The dual PI 3-K/mTOR inhibitor GSK2126458 (30), is currently in phase I clinical trials for 
solid tumours or lymphomas.
49
 30 was originally developed as a potent PI 3-K inhibitor and 
has a PI 3-Kα IC50 of 0.04 nM, but is also active against other isoforms of PI 3-K. 30 was 
also found to have both mTOR and DNA-PK activity, with a Ki of 0.18 and 0.3 nM against 
mTORC1 and mTORC2 respectively, and a DNA-PK of 0.28 nM.
83
 GSK2126458 was 
crystallised with PI 3-Kγ, which demonstrates that the pyridyl nitrogen forms a H-bond with 
a conserved water molecule, the sulphonamide interacts with Lys833, the difluorophenyl 
group sits within a hydrophobic pocket and the quinoline nitrogen forms a hydrogen bond to 
Val882 within the hinge.
83
 
 
In cellular assays, 30 induces G1 arrest and in vivo has good oral bioavailability and low 
clearance. Monitoring of pharmacodynamic response indicated that a single dose of 300 
µg/mL resulted in a decrease in phosphorylation of Akt for 10 h, with a return to control 
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levels after 24 h. Within a BT474 xenograft model treatment with 30 resulted in dose-
dependent decrease in tumour growth. 
 
D’Angelo et al have described the synthesis of a series of benzothiazole-based dual PI 3-
K/mTOR inhibitors.
84
 Compound 31 has an IC50 against mTOR of 2.0 nM and a Ki against PI 
3-Kα of 1.2 nM, though 31 also inhibits PI 3-Kβ, γ and δ with an Ki < 5 nM, DNA-PK with 
an IC50 of 3 nM and hVsp34 with a Ki of 31 nM.
84
 
 
Crystallisation of 31 with PI 3-Kγ identified that the N-acetylbenzothiazole forms two 
hydrogen bonds with Val882 backbone, and a hydrogen bond with Tyr867 and Asp841 via a 
water molecule to the pyridine ring nitrogen.
84
 31 displayed stability to both human liver 
microsome and rat liver microsomes of greater than 50 (µL/min)/mg, and in vivo, after 
intravenous administration had clearance of 0.007 (L/h)/kg and a half life of 19 h. Given 
orally to rats, 31 has an oral bioavailability of 103%.
84
 Pharmacodynamic analysis of 31 
identified a dose dependant decrease in the phosphorylation of Akt Ser473, and significant 
inhibition was observed for 24 h after dosing. 
 
However, further investigation revealed that in vivo compound 31 is metabolised to the 
deacetylated compound.
85
 To avoid this two approaches were taken.  In the first, the N-acetyl 
amino benzothiazole moiety was replaced with a range of 6,6-heterocycles, which negated 
the requirement for the acetamide moiety of compound 31.
85
 The second approach replaced 
the benzothiazole moiety with a range of 6,5-bicyclic heterocycles, with the aim of 
identifying a more stable acetamide moity.
86
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The N-acetyl 2-aminobenzothiazole moiety forms two key hydrogen bonds with Val882 
backbone, the benzothiazole nitrogen interactions with Val882 NH and the amino hydrogen 
atom interacts with the carbonyl of Val882.
85
 It is these interactions which any 6,6 
heterocycle must reproduce to maintain activity. It was also postulated that substitution from 
either the 3- or 4-position of a 6,6-hetrocycle could probe the ribose pocket and lead to a 
further increase in potency.
85
 After synthesis of a range of heterocycles a quinoline was found 
to maintain potency comparable to the N-acetyl 2-aminobenzothiazole analogue. Substitution 
with a morpholine group at the 4-position of the quinoline ring which lead to a further 
increase in potency, gave 32, with an IC50 against PI 3-Kα of 0.6 nM, and in vitro activity of 
4.6 nM against PI 3-Kα and 3.9 nM against mTOR. Compound 32 is also active against all 
isoforms of PI 3-K, hVsp34 and DNA-PK.
85
 
 
X-ray crystallography of compound 32 bound in PI 3-K γ active site revealed that the 
quinoline nitrogen forms a hydrogen bond with Val882 backbone NH, the hydrogen bond 
formed between the pyridyl nitrogen Asp841 and Tyr867 in compound 31 is maintained, 
though the morpholine ring points out towards solvent, rather than toward the ribose pocket 
as predicted.
85
 32 has good metabolic stability in both rat liver microsomes and human liver 
microsomes, in vivo clearance was good (0.17 L/kg/h) and good bioavailability (92%).
85
 In 
vivo pharmacodynamic modelling demonstrated that after 3 h, a 3 mg/kg dose resulted in 
97% inhibition of Akt Ser473 phosphorylation. In a Pten-null U-87 MG glioblastoma model 
oral dosing of 10 mg/kg daily reduced growth to 28% of control.
85
 
 
Design of alternative 5,6-heterocycles to replace the benzothiazole moiety identified 
imidazopyridazines as having good potency. Compound 33 has a Ki of 1.4 nM against PI 3-
Kα (with activity also observed against other isoforms), an IC50 of 0.4 nM against mTOR and 
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an IC50 of 13 nM for the phosphorylation of Akt within U87 MG.
86
 Incubation with 
hepatocytes and microsomes revealed the acetyl group of compound 33 was stable, with only 
trace amounts of deacetylation observed.
86
 In vivo 33 had low clearance 0.04 L/h/kg and an 
oral bioavailability of 46%.  A xenograft model with U87 MG, demonstrated that 3mg/kg 
once a day dosing resulted in tumour stasis. 
 
The mTORC1/2 inhibitor OSI027 is currently in phase I clinical trials for solid tumours and 
lymphomas. The structure of OSI027 has not currently been revealed, but synthetic efforts 
directed towards the discovery of OSI027 have recently been published. Crew et al describe 
the optimisation of a series of imidazo[1,5-a]-pyrazine compounds.
87
 Several other inhibitors 
of mTOR are currently in clinical trials but the structure of these compounds has not been 
disclosed. These include XL765, a dual mTOR (IC50 = 157 nM) and PI 3-Kα (IC50 = 39 nM) 
inhibitor in phase I clinical trials for solid tumours, non-small-cell lung cancer and malignant 
glioma and phase I/II for breast cancer, and GDC0980 a further dual inhibitor with an IC50 of 
17.3 nM (against mTOR) and 4.8 nM (against PI 3-Kα). GDC0980 is currently in phase I 
trials for non-Hodgkin’s lymphomas and solid tumours. An mTOR selective inhibitor 
currently in phase I trials is INK128, with an IC50 against mTOR of 1 nM.
49
 
 
All ATP-competitive inhibitors of mTOR are either selective for mTOR or dual PI 3-
K/mTOR inhibitors. Whether an mTOR selective inhibitor or a dual PI 3-K/mTOR will be 
optimal has yet to be established. Inhibition of both mTORC1 and mTORC2 is well tolerated 
within adult tissue. During mouse models of leukaemia with PP242, only a mild effect was 
observed on normal lymphocytes. However, selective mTOR inhibitors can potentially suffer 
from problems due to the S6K negative feedback loop. Lack of mTORC1 signalling results in 
continued signalling from IRS-1, which results in the conversion of PtdIns (4,5) P2 to PtdIns 
(3,4,5) P3 recruiting PDK1. As PDK1 phosphorylation is not inhibited by selective mTOR 
inhibitor, loss of mTORC1 signalling results in PDK1 phosphorylation of Akt, which if a 
suboptimal dose of an mTOR selective inhibitor is used, can result in full Akt activation.
35
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Rodrik-Outmezguine et al have observed that treatment of a number of cell lines with 
AZ8055 resulted in inhibition of phosphorylation of Akt Ser473, S6K and 4E BP1 for greater 
than 24 h.
88
 Inhibition of Akt Thr308 was also observed, although after 4 h phosphorylation 
levels began to return to baseline levels, as well as the phosphorylation levels of Akt targets 
including PRAS40 and FOXO1/3, inhibition of Akt Thr308 is only temporary. Treatment of 
PP242 was also observed to have the same effect, and this effect was identified as being due 
to reactivation of Akt as a result of AZ8055 and PP242 activation of PI 3-K. However, 
cotreatment with either an Akt inhibitor or an HER kinase inhibitor, the phosphorylation of 
PRAS40 and FOXO1/3 was not observed. In cells treated with both a Akt inhibitor and 
AZ8055 an increase in the level of apoptopic cells was observed, as well as an increase in 
levels of cleaved PARP and caspase-3.
88
 
 
A PI 3-K/Akt inhibitor would avoid the activation of Akt but may prove more toxic to normal 
cells. In studies with PI-103, a toxic effect on normal lymphocytes was also observed,
35
 
however, this could be due to the slightly promiscuous profile of PI-103. The current clinical 
trials should illuminate which class of inhibitor is optimal for tumours addicted to the PI 3-
K/Akt pathway. 
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3.1 Inhibitors of Protein-protein Interaction 
 
Inhibiton of protein-protein interactions is an important area within medicinal chemistry. 
Protein-protein interactions control a number of cellular processes including mammalian 
immune response, recognition between cells, signal transduction and transcription. These 
interactions are not random but the result of the particular structures of each protein 
involved.
89
 
 
The development of small molecule protein-protein inhibitors faces a number of challenges. 
Unlike enzymes, where the active site is small and frequently shielded from solvent,
90
 
protein-protein interactions occur over large areas (750 -1500Å on each protein)
89
 and are 
relatively flat. Interactions can also occur over non-adjacent binding domains.
90
  Small-
molecules require pockets into which they can bind.  In enzymes, small molecules can exploit 
the active site. However, with protein-protein interactions identifying a small pocket may be 
more difficult.
89
 For some protein-protein interactions, although the area of the interaction 
may be large, the binding may be due to a small number of high affinity interactions between 
a small number of residues and any disruption of the binding could result in a biochemical 
effect.
89
 These areas of high affinity residues are known as a ‘hot spots’, and were identified 
in 1995
91
 by Wells and Clackson using mutagenesis studies.
92
 These studies involved a 
process known as alanine scanning, in which residues at the face of the protein-protein 
interaction are mutated to alanine, to identify the individual contribution to the binding 
energy of each residue.
93
 This analysis identified that residues contributed unevenly to the 
binding interaction, with some labelled ‘hot spots’ strongly contributing to the binding 
interaction. To be defined as a ‘hot spot’ a residue must cause an increase in free binding 
energy of 8.37 kJ/mol on mutation to an alanine.
93
 The average number of ‘hot spots’ at the 
face of a protein-protein interaction is 9.5%.
93
   They are usually hydrophobic regions with 
buried charged regions. ‘Hot spots’ are complementary to each other, with residues on one 
protein fitting into a pocket on the other protein.
91
 
 
Therapeutic proteins and antibodies have shown success in inhibiting extracellular protein-
protein interactions, however, as these are not usually cell permeable or orally bioavailable 
there is a need for small-molecules to disrupt cellular protein-protein interaction.
94
 To 
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develop inhibitors of the protein-protein interaction compounds must mimic protein surfaces, 
such as α-helices and β-sheets, and are known as surface mimetics or proteomimics.91 These 
challenges ensure not all protein-protein interactions are druggable, and attempts to develop 
small molecules to inhibit interactions are very dependent on the unique structure of each 
protein; those with ‘hot-spots’ are most likely to be druggable. Each protein-protein 
interaction must be carefully chosen before beginning development.
95
 Blundell et al proposed 
that interactions between one rigid component, and one more flexible component, which only 
forms a secondary structure on binding to the partner, may prove to be the most druggable 
protein-protein interactions.
96
 The p53 MDM2 protein-protein interaction is an example of a 
protein-protein interaction of this type and is discussed in more detail in chapter 3.2. The use 
of peptides may aid the identification of druggable protein-protein interactions. If a small 
fragment of peptide from one of proteins is able to bind to the second this suggests a suitable 
pocket exists for the targeting of small molecules.
94
 
 
 The ‘rules’ for designing small molecule inhibitors of protein-protein may be different to 
typical enzyme inhibitors. Ligand efficiency may be much lower as the binding region is a 
large hydrophobic region. Abbott’s compound ABT-263 (33) fails Lipinski’s criteria, with a 
molecular mass of well over 500 Da but is orally available and has good cellular activity.
95
 
There is currently only one non-natural protein-protein inhibitor on the market.
95
 Maraviroc 
(34) is an anti-HIV agent developed by Pfizer;
97
 however, this molecule does obey Lipinski’s 
rule.
95
 Maraviroc is a chemokine co-receptor 5 antagonist, antagonism of CCR5 (a GPCR)
98
 
by Maraviroc inhibits HIV binding, preventing virus entry into the cell.
97
 Targeting protein-
protein interactions are becoming an increasing area of interest within drug discovery with 
the emergence of new techniques for drug discovery. 
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3.2 p53, MDM2 and MDMX 
 
p53 is a tumour suppressor that was simultaneously discovered in 1979 by a number of 
groups. Named after its apparent mass of 53 kDa, p53 acts as a tumour suppressor through its 
ability to act as a transcription factor and instigator of apoptosis.
99
 p53 acts as the cells’ 
regulator of growth arrest, cell cycle senescence and apoptosis as a response to cellular stress. 
Under stress conditions, cellular levels of p53 rapidly increase to prevent proliferation of cells 
containing damaged DNA.
100
 It is highly conserved throughout, over both vertebrates and 
invertebrates, underlining its crucial cellular function.
101
 The importance of p53 as a tumour 
suppressor is underlined by one in two cancers carrying a mutation of p53, and remaining 
cancers negate p53 by inactivation of associated pathways.
102
  
 
 
Figure 19 Structure of p53 
 
The tumour suppressor p53 is a 393-residue protein, consisting of a number of domains (see 
Fig 19) including a transactivational domain, an unfolded acidic region which acts as a 
promiscuous binding site for proteins such as MDM2 and p300/CBP (which are discussed in 
more detail later). A short section of this domain (residues 15-29) is able to form an α-helix 
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on binding to MDM2.
102
 The DNA-binding domain is a structured region which interacts 
with DNA in a sequence specific manner.
102
 It interacts with both the minor and the major 
groove of DNA, the minor groove via two loops which contain a Zn
2+
, co-ordinated to 
His179, Cys176, Cys238 and Cys242 and the major via loop-sheet-helix motif.
102
 
 
Although p53 is a monomer under low concentrations, under stressed conditions it can form a 
tetramer. p53 is transcriptionally active as a tetramer, monomeric p53 can bind to DNA but 
its affinity is 10-100 times lower than that of tetrameric p53.
103
 The tetramer is made up of 
four identical p53 chains – 393 residues in length.102 The tetramer is formed by residues 325-
356, which form the tetramization domain. The quaternary structure is made up of a dimer of 
dimers, with each monomer consisting of a short β-strand (residues 326-335) and an α-helix 
(335-355) linked by Gly334.
103
 The monomer forms a V shape, with hydrophobic residues 
Ile332, Phe338 and Phe341 forming an hydrophobic cluster at the hinge of the V structure.
103
  
Two monomers interact via β-sheets, forming an anti-parallel double strand, with the two 
helices forming a double helical bundle.
103
 The anti-parallel β-sheet has eight backbond H-
bonds. The two dimers interact through the α-helices,103 forming a four-helix bundle.102 The 
tetramer is stabilised by hydrophobic interactions.
102
 The formation of tetramers also aids 
accumulation of p53 within the nucleus. The leucine-rich nuclear export signal located 
between residues 340-351 is on the monomer surface but is hidden when the tetramer is 
formed. For nuclear export to occur the tetramer must dissociate.
102-103
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Figure 20 Tetramer of p53 – each colour represents a monomer unit (Taken from reference 
102) 
 
Murine double minute gene 2 (MDM2) is a 90 kDa protein, with human MDM2 containing 
491 amino acids.
104
 MDM2 was first discovered in mouse chromosomes from abnormal 
chromosomes known as double minutes, and a human homolog was later discovered.
105-106
 In 
1992, MDM2 was discovered to interact with p53, blocking the biological activity of p53. 
MDM2 achieves this by firstly blocking the transactivation domain of p53 and secondly 
acting as a p53 specific E3 ubiquitin ligase.
107
 The E3 ubiquitin ligase activity of MDM2 
catalyses the ubiquitylation of p53, which in turn labels the protein for degradation by 
proteasomes. MDM2 is one of the target genes of p53 transcriptional activity and as MDM2 
inhibits and marks p53 for degradation, these two proteins are locked in a negative feedback 
loop.
99
 The negative feedback mechanism allows p53 to be kept at low cellular concentration 
under unstressed conditions. When the stress pathway is activated, p53 is stabilised and 
cellular concentrations increase. As a response, MDM2 levels are also increased, which will 
bring the level of p53 back down to its previous low concentrations after the stress signalling 
has been removed. MDM2 has a number of different domains which are shown below.  
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Figure 21 Structure of MDM2 
 
The proteins MDM2 and p53 interact via a hydrophobic region on MDM2, which lies 
towards the amino terminus of MDM2. The hydrophobic region forms a deep cleft made up 
of residues 19-102.
104
 These residues form two structurally similar sections which fold to 
form a pocket lined by 14 highly conserved hydrophobic and aromatic amino acids. Residues 
Gly58, Glu68, Val75 and Cys77 are important for p53 binding, as MDM2 with mutations at 
any of these sites does not interact with p53.
100
 p53 interacts with this region through an 
amphipathic α-helix found within the amino terminal domain, the area also responsible for 
p53 transcription abilities. The α-helix is formed by 15 amino acids, those crucial for binding 
are residues 18-26, whilst Thr18 is thought important in stabilising the α-helix. Phe19, Trp23 
and Leu26 of p53 insert into the cleft formed by MDM2.
100, 108
 The strength of the interaction 
between these two proteins is thought to have an  IC50 of between 60 -700 nM (dependent on 
length of the p53 peptide used) but the interactions are predominantly hydrophobic, with only 
3 H-bonds thought to be formed; the most deeply buried being formed with Trp23 on p53.
100
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Figure 22 The MDM2 protein (in grey) with the p53 amino acids which interact with this 
region shown in yellow (Taken from reference 108) 
 
Figure 23 p53 amino acids as space-filling models demonstrating that p53 is complementary 
to MDM2 (Taken from reference 108) 
 
In unstressed cells p53 is a very unstable protein with a half life of 5-30 minutes as a result of 
being constantly degraded by MDM2, and is therefore found in low cellular concentrations 
under normal conditions. As a response to DNA damage, hypoxia, telomere shortening or 
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oncogene activation p53 is stabilized via the blocking of p53 degradation.
100
 MDM2 inhibits 
p53 activity in two ways. The first is by physically blocking the domain p53 uses for 
transcriptional activation. p53 requires L22 and W23 for transcriptional activity but these 
amino acid residues are found within α helix through which p53 and MDM2 interact.104 The 
second approach by which MDM2 deactivates p53 is through its E3 ligase activity.  
 
The protein MDM2 has both self and p53 ligase activity, due to its highly conserved C-
terminal RING finger domain.
100
 The RING domain (Really Interesting New Gene) has a 
C2H2C4 motif, which chelates Zn
2+
, important for ligase activity.
101
 Modification of proteins 
by ubiquitin conjugation is a cellular mechanism which marks proteins for degradation by 
protease.
100
 MDM2 monoubiquitinates lysine residues, predominantly within the C-terminal 
domain of p53, by transferring ubiquitin from E2 conjugating enzymes.
101
 When the MDM2-
p53 complex is in a further complex with p300/CREB binding protein,
100
 which acts as a 
scaffold, p53 can then be polyubiquitinated. It is the polyubiquitination which marks p53 for 
degradation by cellular proteases.
100
 Before the proteasome can degrade p53, it must be 
exported from the nucleus into the cytoplasm of the cell. The exact mechanism of this export 
is unclear, but the MDM2 mediated ubiquitination is thought to be important. The 
ubiquitination of one or more lysines residues within a group of six lysines found between 
residues 370-386 at the C-terminal of p53 is thought to be a vital requirement.
109
 The nuclear 
export of p53 also requires the p53 C-terminal nuclear export signal (NES), found at residues 
345 to 355.
109
 Nie et al propose that the ubiquitination of the lysine residues is vital as it 
induces a conformational change which can then activate or expose the NES, resulting in p53 
nuclear export.
109
  
 
The relationship between p53 and MDM2 was further complicated by the discovery in 1996 
of MDMX (also known as MDM4). MDM2 and MDMX are descended from a common 
ancestor gene and share significant sequence similarity.
101
 The N-terminal domain of MDMX 
has highest sequence similarity with MDM2 (53.6%).
110
  MDMX can also bind to the N-
terminal of p53, therefore also blocking the translational activity of p53. However, the Leu54 
(of MDM2) is replaced by a methionine in MDMX, resulting in a smaller binding site.
111
 The 
central domain of MDMX has 41.9% sequence similarity and the C-terminal domain has 
51.3% sequence similarity,
110
 but MDMX does not have the E3 ligase activity of MDM2.
99
 
Instead MDMX acts to stabilise and increase the ligase activity of MDM2. In vivo, MDM2 is 
not particularly stable, and by formation of a heterodimer with MDMX through the RING 
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domain on both proteins, MDM2 is stabilised. MDMX is in turn labelled with ubiquitin by 
MDM2 and marked for degradation.
104, 111
 
 
Due to the role of p53 as a tumour suppressor, the interaction between p53, MDM2 and 
MDMX is important within cancer. p53 is either lost or mutated in either 50% of cancers
112
 
with MDM2 amplified in around 7% of all cancers.
113
 However, within some cancer types 
this figure rises. Within brain tumours or nervous system cancers (including astrocytomas, 
oligodendriomas, glioblastomas, gliosarcomas, medulloblastomas, ependymomas and 
neuroblastomas) the figure rises to 10.4%, within HCC it rises to 44.4%, within soft tissue 
tumours 30.9% and in Hodgkins disease to 66.7%.
114
 However, these two mutations rarely 
happen simultaneously. In most tumours with amplified levels of MDM2, the cell has 
retained wild type p53, but because of the high levels of MDM2, the protein is rapidly 
degraded, allowing the cell to replicate unrestricted. If the MDM2 function was restricted, the 
p53 could function normally, placing the cell into senescence or beginning a programme of 
apoptosis. This makes the MDM2 a highly attractive target for the development of new anti-
cancer therapeutics within medicinal chemistry.  
 
3.3 p53 Cellular Function 
 
The tumour suppressor p53 is activated as a response to genotoxic stress or oncogenic 
activation through two distinct pathways. These two pathways act to release p53 from the 
inhibitory activity of MDM2, allowing p53 to act as a transcriptional initiator. Through this, 
the cell cycle is halted allowing either cellular repair or apoptosis if the damage cannot be 
repaired.  
 
The first pathway is activated as a response to genotoxic stress.  The genotoxic stress includes 
irradiation, x-rays, ultraviolet radiation, ionising radiation (IR), cytotoxic chemotherapeutic 
drugs and carcinogens.
115
 The signal from genotoxic stress is transmitted to p53 through a 
pathway of ‘stress kinases’.100 As a response to IR and double strand breaks,116 ataxia 
telanglectasia mutated (ATM)
117
 kinase is activated. ATM phosphorylates p53 at serine 15 as 
well as MDM2 at Ser395. ATM also acts on the checkpoint kinase CHK2, phosphorylating 
CHK2 at threonine 68. This activates CHK2 allowing the DNA-damage signal to be 
amplified, resulting in the phosphorylation of a number of targets including p53 at serine 20 
as well as other sites within p53.
116, 118
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In the case of DNA-damage caused by UV radiation, single strand breaks and bulky lesions, 
ATR is activated.
116, 119
 ATR can also phosphorylate Ser15,
116
 as well as activating CHK1. 
Activation of CHK1 results in the phosphorylation of p53 at Ser20. Therefore whether 
activated by DNA-damage resulting in single strand breaks or double strand breaks, p53 will 
be phosphorylated at both sites Ser15 and Ser20. 
 
p53 can be further phosphorylated by other kinases including DNA-PK.
120
 One crucial site of 
phosphorylation is Thr18 by CK1. Phosphorylation at Ser15, Ser20 and Thr18 of p53 and 
sites on MDM2 are thought to destabilise the interaction between p53 and MDM2. Ser15, 
Ser20 and Thr18 lie on the α-helix which interacts with MDM2 – Thr18 is especially 
important as it can destabilise the α-helix – altering its structure.114 Phosphorylation of 
MDM2 at a site close to the RING domain by ATM or an ATM-dependant kinase also acts to 
switch the MDM2 ligase activity from p53 to MDM2/MDMX, leading to increased 
accumulation of p53.
101
 
 
Phosphorylation at multiple sites destabilises the interaction between p53 and MDM2, 
releasing p53 from the inhibitory activity of MDM2. This results in the increase in the half-
life of p53 and its accumulation in the nucleus. In addition, p53 can also be stabilised as a 
response to oncogene activation. 
 
Acute renal failure (ARF) is the result of the alternative transcription of the gene for the 
inhibitor of cyclin dependent kinase 4a.
121
 ARF (p14
ARF
 in humans)
115
 is a tumour suppressor 
and is activated by oncogenes including Ras.
100
 It acts by sequestering MDM2,
115
 physically 
releasing p53 from its interaction. ARF inhibits the E3 ligase activity of MDM2 by binding to 
the RING finger domain of MDM2,
100
 stabilising the cellular level of p53. Over the process 
of the development of a tumour, the boundary between these two methods of p53 activation 
can blur.  Continuous replicative cycles as a result of oncogene activation results in 
replicative stress. The resulting DNA damage will activate the stress kinase cascade.  
 
After p53 has been freed from the inhibitory activity of MDM2, it can then undertake its 
transcriptional activity. p53 acts as a transcription initiator, initiating the transcription of a 
large number of genes. p53 can undergo a range of post-translational modifications including 
phosphorylation, acetylation, methylation, ubiquitination, sumoylation and neddylation.
122
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The degree of modification can control which genes are translated and the level of 
translation.
122
 Phosphorylation of p53 increases the affinity for transcriptional co-activators, 
including histone acetyl transferases (HATs) p300 and CREB binding protein (CRB).
114
 
These HATs acetylate p53 at sites within the carboxyl terminal of p53, sites which are 
usually ubiquitinated, therefore contributing to the further stabilisation of p53 as well as 
increasing the site specificity of p53.
123
 p53 and p300 can then form a DNA-binding 
complex. 
 
The C-terminal of p53 interacts with DNA through a 26 amino acid sequence.
124
 The 26 
amino acid sequence contains nine basic residues which interact with DNA/RNA. Residues 
K120, S241, R273, A276 and R283 interact with the phosphate backbone in the major 
groove; residues K120, C277, R283 form H-bonds with DNA-bases and R248 interacts with 
the minor groove, forming multiple H-bonds. p53 binds with DNA in a sequence specific 
manner.
124
 p53 binds to areas of DNA known as responsive elements (REs).
123
 The RE 
sequence consists of RRRCWWGYYY and 0-21 spacer and RRRCWWGYYY where R = 
purine W = A or T and Y = pyrimidine.
124
 Genes whose transcription is initiated by p53 have 
a RE within the DNA close to or within the gene. p53 binding to one of these RE either 
activates or represses transcription.
123
 p53 binds to RE and for genes whose transcription is 
activated by p53 will recruit general transcription proteins through protein-protein 
interaction.
123
 However, for genes which are repressed by its binding, p53 either blocks the 
gene through overlap of the binding site, by squelching of the transcriptional activator or by 
recruiting p53 histone deacetylases. Proteins whose transcription is inhibited by p53 includes 
Bcl-2,
123
 an anti-apoptotic protein which will be discussed later. 
 
The transcription of number of proteins is initiated by p53. These proteins include those 
responsible for initiating apoptosis, preventing angiogenesis, growth arrest and DNA 
repair.
125
 A few examples of p53 target genes and the cellular processes they are involved in 
are listed below. 
 PUMA – Apoptosis 
 DRAM – Autophagy 
 p21 – Cell cycle arrest 
 R2 – DNA repair 
 LIF – Embryo Implantation 
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 TSP1 – Inhibition of Angiogenesis 
 TIGAR – Inhibition of ROS/survival 
 ICAM-1 – Innate immunity 
 SCO2 – Metabolism 
 MDM2 – p53 Regulation 
 PAI-1 – Senescence126 
 
Some of these translation targets will be discussed in more detail. p21, which acts to prevent 
cell cycle progression by inhibiting cyclin E and CDK2, is required for progression from G1 
to S phase.
116
 The expression of p21 is induced by very low cellular levels of p53. This 
allows a temporary pause of the cell cycle as a response to mild DNA damage or stress, 
allowing the issue to be resolved and the cell to survive.
126
  
 
Two further proteins also play a vital role in halting the cell cycle and DNA-repair. GADD45 
(Growth Arrest DNA Damage) is proposed to have a role in halting the cell cycle at the G1 to 
S phase transition – possible through an interaction with p21.127 Better understood is the role 
of GADD45 in G2 to M arrest. GADD45 can interact with the Cdc2 (also known as 
CDK1)/cyclin B complex, causing it to dissociate. As the CDK1/cyclin B complex induces 
the G2 to M transition, this dissociation halts the cell-cycle before it enters mitosis.
127
 G2 
arrest is also instigated by the 14-3-3 protein, a further transcriptional target of p53 which 
acts in two ways. 14-3-3 acts upstream of cyclin B/Cdc2, preventing activation, which is 
required for the G2/M transition.
128
 CHK1 and 2 phosphorylate Cdc25, and phospho-Cdc25 
can then bind to 14-3-3. The 14-3-3 sequesters Cdc25 in the cytoplasm, preventing activation 
of Cdc2 (by dephosphorylation). The phospho-Cdc2 binds to 14-3-3σ (one member of the 14-
3-3 family), which also anchors it in the nucleus, preventing the inducement of the G2 to M 
transition.
122
 The halting of the cell cycle allows repair of DNA damage or the stress-
signalling to abate. GADD45 is also implicated in DNA damage repair. GADD45 interacts 
with PCNA, a protein which is involved in the nucleotide excision repair pathway.
127
 
However, if this DNA damage cannot be repaired, the cell commits to apoptosis, 
programmed cell death, to prevent the continuing proliferation of damaged genetic material. 
 
There are two major routes to apoptosis, the intrinsic and extrinsic pathway.
115
 p53 plays a 
role within both of these pathways, as well as a family of proteins called the Bcl-2 (B 
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lymphoma 2) family. The Bcl-2 family contain both pro and anti-apoptotic members. The 
anti-apoptotic members block apoptosis and include Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1 
whilst the pro-apoptosis members block inhibitors of apoptosis. The proapoptotic members 
can be divided further into two subfamilies: the BAX family compromising of BAX, BAK 
and BOK and the BH3-only subfamily compromising of BID, BIM, BAD, BIK, BMF, 
PUMA, NOVA; and HRK. Both the intrinsic and extrinsic pathways result in the activation 
of proteases known as caspases, but via a differing route. The extrinsic pathway is also 
known as the death receptor pathway whilst the intrinsic pathway is also known as the 
mitochondrial pathway.
115
 
 
The extrinsic pathway is activated by members of the tumour necrosis factor (TNF) including 
TNFα, FAS/CD95 ligand and APO2 ligand. These activate death receptors including 
TNF/NGF receptor family
115
 resulting in activation of the cell surface receptor FAS. This 
interacts with FADD protein (Fas associated death domain) forming the complex DISC 
(death-inducing signalling complex). The complex activates caspase 3 and caspase 7 which in 
turn results in apoptosis.
115
 p53 initiates the transcription of a number of proteins within this 
pathway.
115
 
 
The intrinsic pathway results in the release of cytochrome c from the mitochondria into the 
cytoplasm through the activity of the Bcl-2 family.
115
 Bcl-2 is found within the outer 
membrane of the mitochondria and is thought to safeguard the integrity of the mitochondrial 
membrane, but other anti-apoptosis members such as Bcl-XL and BCL-W only associate 
with the mitochondria after a cytotoxic event.
129
 The anti-apoptopic proteins are found in 
complex with the BAX family proteins BAX and BAK under unstressed condition. Both are 
both activated by BID, a member of the BH3 only family. As BID is, in turn, activated by 
TNFα and FAS ligand, a link is formed between the extrinsic and the intrinsic pathway.115  
 
Bcl-associated protein (BAX)
121
 is found within the cytoplasm under normal conditions in 
complex with anti-apoptopic conditions,
115
 however, as a result of apoptotic signalling it is 
replaced in this complex by BAD and other BH3 only members which inhibit the BH3-only 
proteins by binding to them. The anti-apoptopic proteins include proteins PUMA and NOXA 
which are translated as a result of p53 activity.
129,115
 BAX then changes conformation and is 
incorporated into the outer membrane of mitochondria.
129
 Unlike BAX, BAK (Bcl- 
homologous antagonist-killer)
121
 is always found within the mitochondrial membrane but 
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during apoptosis changes conformation.
129
 Both BAX and BAK are responsible for making 
the membrane of the mitochondria permeable, forming channels which allows the efflux of 
cytochrome c.
121
 
 
Figure 24 Cellular changes after an apoptotic event 
 
Once cytochrome c is released from the mitochondria it binds to Apaf-1 (Apoptotic protease 
activating factor 1) forming apoptosome.
115
 Apoptosome acts on procaspase 9, resulting in its 
activation which in turn activates caspase 3 and 7, these in turn activate other caspases 
beginning what is known as a ‘caspase cascade’ resulting in cell death.115 Caspases (Cysteine 
aspartic acid proteases) are selective proteases.  There are 14 caspases, which organize all 
steps of apoptosis.
115
 They are found within the cell as inactive precursors, which are known 
as procaspases and are activated during apoptosis. The caspases act to break down cellular 
molecules and DNA, condense chromatin and result in the changes of an apoptotic cell.
130
 
 
A further aspect of the apoptosis pathway directly links p53 to apoptosis. During apoptosis a 
small portion of the free p53 migrates to the membrane of the mitochondria.
121
 p53 then 
interacts with Bcl-XL, freeing Bax from its complex with Bcl-XL. This results in Bax 
releasing cytochrome c from the mitochondria. 
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3.4 Drug-like Inhibitors of the MDM2-p53 Protein-protein Interaction 
 
The tumour suppressor p53 protects the integrity of the genome and prevents the 
development of tumours. In 7% of all tumours the cell retains wild type functional p53 but is 
essentially p53-null due to an over expression of MDM2.
113
 The highest frequency of 
amplification occurs in soft-tissue cancer, osteosarcomas and oesophageal carcinomas.
113
 
Therefore, small drug-like molecules which inhibit the protein-protein interaction between 
p53 and MDM2 are an attractive target for the treatment of cancer. The interaction between 
MDM2 and p53 is an ideal target for the development of small molecule inhibitors. The area 
of interaction is relatively small, calculated to be 660Å
2
 surface area on MDM2 and 809Å
2
 
surface area on p53, and forms a ‘hot spot’, an area of intense interaction formed by an α-
helices of p53 and a hydrophobic cleft on MDM2 (discussed in chapter 3.2).
113
 
 
 
Figure 25 X-ray Structure of MDM2 with p53 bound, crucial residues for the interaction are 
shown in purple 
 
Inhibition of the protein-protein interaction was first demonstrated by the use of peptides 
such as the 12mer peptide (Ac-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH2) 
that demonstrated an IC50 of 0.3 µM.
113
 Introduction of unnatural amino acids further 
increased potency, by inducing the correct conformation before binding to the MDM2 pocket. 
Experimentation with unnatural amino acids also identified that the replacement of 
tryptophan (which mimics Trp23) with 6-chlorotryptophan fills a small hydrophobic cavity 
unfilled by the wild type p53, thus leading to a 60-fold increase in potency between the two 
comparable peptides.
113
 However, peptides are not appropriate for use as drugs and extensive 
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medicinal chemistry efforts have resulted in a number of small-molecule inhibitors of the 
p53/MDM2 interaction. 
 
3.4.1. Nutlins 
 
One of the first series of potent, small molecule inhibitors of the MDM2 p53 protein-protein 
interaction were the Nutlins, developed by scientists at Hoffman la Roche.
131
 A screen of a 
diverse library of chemicals identified a class of cis-imidazolines as lead compounds for the 
inhibition of the MDM2 p53 interaction. These compounds, named Nutlins (for the Nutley 
inhibitors) (35-37) have activity within the range of IC50 100-300 nM range.
131
 
 
Figure 26 
 
The IC50 values for the compounds were identified as 0.26 µM and 0.14 µM for Nutlin-1 and 
-2 respectively, with these two compounds tested as a racemic mixture. Nutlin-3 was 
separated into its two enantiomers using chiral HPLC. The IC50 for these two enantiomers 
initially arbitrarily named Nutlin-3a (37) and Nutlin-3b were 0.09 µM and 13.6 µM 
respectively.
131-132
 
 
The crystal structure of Nutlin-2 bound to human MDM2 shows that it closely mimics the 
interaction of p53 and MDM2. The cis-imidazoline scaffold mimics the α-helix backbone of 
p53. One bromophenyl group sits in the pocket occupied by Trp23 of p53; the second 
bromophenyl group sits in the Leu26 pocket, and the ethyl ether side chain points towards the 
Phe19 pocket.
131
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Figure 27 Nutlin 2 bound to MDM2 PBD code 1RV1 (Taken from reference 102) 
 
The as Nutlins target the MDM2 p53 interaction stabilising p53, treatment of cells with these 
compounds should result in an increase in levels of p53, MDM2 and p21 (as both MDM2 and 
p21 are transcriptional targets of p53). However, this effect should only be observed in cells 
with wild type p53 and not those with mutated or deleted copies of the gene. Nutlin-1 was 
tested against human cancer cell lines with wild type p53 (colon cancer cell lines HCT116 
and RKO) and also cell lines with inactive p53 (SW480 (colon), MDA-MB-435 (breast) and 
PC3 (prostate)) to act as a negative control. HCT116 was treated with Nutlin-1 for 8h. A dose 
dependent increase in levels of p53, MDM2 and p21 was observed. SW480 was treated under 
similar conditions and whilst basal levels of p53 were observed, no increase in MDM2 or p21 
was observed.
131
 To ensure that the HCT116 response was a post-translational response to 
treatment with the Nutlin, the gene expression of both p53 and p21 was monitored. Treatment 
with Nutlin-1 had no effect on p53 expression but p21 increased in a dose-dependent manner, 
suggesting that the Nutlins were acting purely by inhibiting the MDM2 p53 protein-protein 
interaction to upregulated p53 cellular levels.
131
 
 
A recent patent has been published from the Nutlin series suggesting increase in activity and 
an improvement in the physical properties of the series.
133
 The Nutlin analogue RG7112 (38) 
is currently in clinical trials. The hydrogen atoms in the imidazolidine ring of the early Nutlin 
compounds have been replaced by methyl groups and the piperazine ring has a further N-
propyl methyl sulfone group. This additional change may possibly be forming further H-bond 
interaction between the sulfone oxygen atoms and Tyr67 and Asn72.
134
  
3. MDM2/p53: An Anti-Cancer Target 
69 
 
 
 
3.4.2. Spirooxindoles 
 
A series of spirooxindoles are also potent small molecule inhibitors of the MDM2 p53 
protein-protein interaction. Crystal structures of the MDM2 p53 interaction showed that the 
indole side chain of Trp23 from the p53 peptide forms a hydrogen bond with a carbonyl of 
the MDM2 protein backbone.
135
 
 
Ding et al then identified compounds which could imitate this interaction. Oxindoles were 
found to mimic this interaction and a screen of natural products was undertaken to identify 
compounds which contained this motif. A number of alkaloids were identified, including 
spirotryprostatin A and Alstonisine, and although these did not inhibit the protein-protein 
interaction the spiro (oxindole-3,3’-pyrolidone) motif was used as a starting point.135 The 
spiro pyrrolidine ring provides a rigid scaffold from which group to mimic the Phe19 and 
Leu26 can be added. Molecules were designed using the docking program GOLD by altering 
the R
1
, R
2
 and R
3
 around the ring. This process, followed by further optimisation resulted in 
compound 39, which has a Ki of 86 nM in a fluorescence polarisation assay.
135
 
 
Figure 28 Spirooxindoles core, following optimisation gave 39  
3. MDM2/p53: An Anti-Cancer Target 
70 
 
 
To test the cell activity of the spirooxindoles series the compounds were tested against 
LNCaP human prostate cancer cells, which have wild type p53. Compound 39 had an IC50 of 
0.83 µM. The compounds were also shown to be selective for cell lines with wild type p53 
and for cancer cells. Treatment of normal human prostate epithelial cell, with wild type p53, 
had an IC50 of 10.5 µM.
135
 
 
Although the preliminary compounds showed good potency, comparison with the p53 
inhibitory peptides suggested that additional interactions may be accessible to gain additional 
activity. X-ray crystallography identified a fourth interaction between MDM2 and Leu22 of 
p53.
136
 The 5’ carbonyl of  39 is predicted to lie within 2 Å of the position of carbonyl 
backbone of Leu22 in p53, suggesting that expanding the compound from the 5’ carbonyl 
may pick up further interaction with MDM2. As Leu22 is partially solvent exposed the 
additional functionalities may also act to improve solubility. Ding et al used the docking 
program GOLD to predict that the N, N-dimethylamine group of 39 can be replaced with 2-
morpholin-4-yl-ethylamine group.
136
 The oxygen within the morpholine was proposed to lie 
close to the positively charged amine of Lys90 of MDM2. The resulting compound has a Ki 
of 13 nM.
136
 
 
Further optimisation of the m-chlorophenyl ring resulted in incorporation of a fluorine in the 
2-position. Combination of the two changes resulted in the development of MI-63 (40) with a 
Ki of 3 nM. Compound 40 has four chiral centres, and as binding to MDM2 is stereospecific, 
identification of the most active stereoisomer (shown below) is important.  A further isomer 
with the opposite stereochemistry has a Ki of 4 µM.
136
 
 
 
Figure 29 The structure of MI-63 (40) 
 
Other protein-protein interactions have a similar binding interaction to MDM2-p53 i.e one 
partner forms an α-helix which fits into a complementary pocket on the other partner.136 This 
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manner of binding is seen for the Bcl-2/Bcl-XL anti-apoptotic proteins with a pro-apoptotic 
protein such as BID, BAD, or BAX, and was studied to see if compound 40 inhibits this 
binding. No significant inhibition was observed at concentrations up to 50 µM, suggesting 
that the spirooxindoles are selective for the MDM2-p53 interaction. Compound 40 was also 
tested to ensure that it was only active in cells with wild type p53, which supports the 
believed mode of action, as well as minimally toxic to normal cells.
136
 
 
Although compound 40 is a potent inhibitor of the MDM2-p53 protein-protein interaction it 
has a poor pharmacokinetic profile and modest oral availability. MI-63 is therefore not a 
good drug candidate. The morpholine group is partially solvent exposed so there is no 
selectivity for the functionality at this position, and therefore the substituent was altered 
without loss of activity. Replacement with either a methylpiperazinyl or a methyl-piperadinyl 
group resulted in a Ki of 1.5 and 20 nM respectively.
137
 Both the N-methyl-piperazinyl and N-
methyl-piperadinyl substitutions resulted in improved pharmacokinetic profile but the 
maximum concentration within the plasma and the area under the curve remained low.
137
 The 
morpholine, methylpiperadine and methylpiperazine are all protonated and positively charged 
at physiological pH, contributing to the low bioavailability. The synthesis of a butyl-1,2-diol 
group improved the Ki to 0.6 nM, and also improved pharmacokinetics, as well as higher 
concentration within the plasma and improved area under the curve. The compound (41), 
known as MI-147, became the new lead compound.
137
 A further compound, MI-219 (42) was 
also synthesised, without the fluorine atom on the phenyl ring, instead it lies on the oxindole 
ring. MI-219 has an IC50 of 162 nM, but in cellular assays is only slightly less growth 
inhibitory in SJSA-1 and HCT-116 cell lines than MI-147.
137
 MI-219 has improved oral 
bioavailabilty than MI-147 (from 21% to 65%) and a 25 mg/kg oral dose achieve a Cmax of 
3751 ng/mL and an area under the curve of 7677 h·mg/L.
137
  
 
Figure 30  
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SJSA-1 cell lines, with wild type p53 MDM2 amplified, were treated with compound 41. A 
dose dependent activation of p53 was observed, with increasing levels of MDM2 and p21. 
Compound 41 also induces a dose dependent increase in BAX, PUMA, and NOVA.
137
 A two 
day treatment of SJSA-1 cell line with 1.25 µM dose of compound 41 resulted in cell death in 
50% of cells. Compound 41 was confirmed to be acting in a p53-dependant manner as 
minimal effects were seen on a SAOS-2 cell line which has deleted p53. In xenograft models 
animals were treated with either 41 alone or 41 in combination with irinotecan and was 
growth inhibitory. Compound 41 is potentially the most potent, orally available, cell 
permeable, specific inhibitor of the MDM2 p53 protein-protein interaction.
137
  
 
3.4.3. 1,4-Benzodiazepine-2,5-diones 
 
From a screen of MDM2 binding of 338, 000 compounds designed using directed diversity 
software, 1216 compounds were selected for further investigation by Grasberger et al.
138
 
From these 1216, 116 compounds had a benzodiazepinedione core. The benzodiazepinedione 
compounds have two chiral centres and were screened as a mixture of four stereoisomers, 
with the most active compounds used as a guide for further elaboration of this scaffold. 
Separation of the most active pair of enantiomers revealed the active compound to be the (S, 
S) diastereoisomer.
138
 
 
The benzodiazepinediones were screened using a novel affinity-based assay named 
‘Thermofluor’. The assay uses fluorescent dye to monitor the unfolding of protein on heating. 
Compounds which bind to the MDM2 protein increase the thermal stability of the protein and 
will increase the temperature at which the protein unfolds. The value was quantified by 
change in the mid-point transition temperature. The initial 116 benzodiazepinedione 
compounds had a change in the midpoint transition temperature of 1.0 - 4.9 
o
C,
138
 with any 
hit being a compound with a change of greater than three times the standard deviation. The 
change in stability of the MDM2 protein over a range of concentrations allowed a 
dissociation constant (Kd) to be calculated.
139
  
 
Further characterisation of the hits was under taken using a fluorescence polarisation (FP) 
assay. This assay used fluorescein-labelled p53 peptide which undergoes excitation at 485 nm 
and emits at 530 nm. On the binding of a compound to the MDM2, the p53 peptide will be 
3. MDM2/p53: An Anti-Cancer Target 
73 
 
displaced and the polarisation will be altered. This change was expressed as a percentage 
with respect to the p53 control.
139
 
 
Figure 31  
 
Optimisation around the benzodiazepinedione ring resulted in compound 42, with a Kd of 67 
nM and an IC50 of 420 nM.
139
 Incorporation of an ortho amino group on the benzylic ring 
improved the IC50 value for the compound but reduced cellular potency, probably due to the 
compound behaving as a zwitterion.
140
 The amino group is thought to form a hydrogen bond 
with Val93 on MDM2,
140
 and can be replaced with a hydroxyl group which can form a 
similar H-bond. A methyl group on the benzylic carbon maintains good potency in the R-
enantiomer, with a 3-fold increase in potency.
141
 
 
Figure 32 Structure of compounds 43, 44, 45 and 46 
 
Groups on the 1-amino position are relatively solvent exposed, and were therefore varied to 
improve water solubility. A valeric acid group (43), whilst increasing solubility and potency 
can form a zwitterion which resulted in poorer cell activity when compared to a morpholin-4-
ylethyl group (44), a 2-(2-methoxyethoxy)ethyl (45) and 1-methyl-4-proplylpiperazine (46), 
although these compounds had somewhat reduced potency.
140
 This series are amongst the 
most potent inhibitors of the MDM2 p53 protein-protein interaction published. The 
benzodiazepinedione scaffold acts as an α-helix mimic to orientate the aromatic groups into 
the correct positions to interact with MDM2.
142
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3.4.4. Chromenotriazolopyrimidines 
 
A further class of inhibitors of the MDM2/p53 protein-protein interaction has been published 
by Allen et al.
143
 From a high-throughput screen of 1.4 million compounds, compound 47 
(shown below) was identified as binding to MDM2. Compound 47 was initially tested as a 
racemic mixture of syn and anti diastereoisomers and had an IC50 of 3.88 µM.
143
 On chiral 
separation the active compound was shown to be the syn 6R, 7S configuration (48) with an 
IC50 of 1.23 µM.
143
 
 
Figure 33  
 
Compound 48 was cocrystallised with MDM2. The crystal structure shows the C7 
bromophenyl group occupies the Leu26 pocket, forming a weak π-stacking interaction with 
His96 which lies 4.0-4.9Å away. The C6 bromophenyl group lies within the Trp23 pocket 
and the aromatic ring of the chromenone lies within the Phe19 pocket.
143
 
 
 
Figure 34 
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However, compound 48 has a number of problems as a lead structure. It has a high molecular 
weight (536.22 Da), although the ligand efficiency is comparable with other protein-protein 
inhibitors. The isomers of compound 47 are poorly soluble in DMSO and at room 
temperature solutions of enantiomerically pure syn diastereoisomers racemise to the anti 
configuration.
143
 The racemisation only occurs at the 6-position and is thought to proceed via 
the mechanism shown below. 
 
Scheme 2 
 
To prevent racemisation the N11 position was methylated (49), preventing formation of the 
enamine, the intermediate in the racemisation process. N-methylation increases stability in 
solution, and improved organic solubility. Crucially, N-methylation maintained good potency 
with an IC50 of 1.17 µM.
143
 
 
The N-methylated compound was then used as a starting point for further development. In an 
attempt to reduce the molecular mass the dibromo motif was replaced by either difluoro 
which was not tolerated, or dichloro which was equipotent, IC50 = 1.21 µM for 89 Da 
reduction in molecular mass. The Trp23 pocket was probed by a series of larger substituents 
on the C6 aryl group. Of these, the linear groups with some π-character maintained some 
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activity, with the nitrile analogue the most active at 2.08 µM. These substitutents are thought 
to interact with aromatic residues Phe86 and Phe91 of MDM2.
143
  
 
Synthetic efforts were directed at optimising the substituents for the Leu26 pocket 
demonstrated that the fluorophenyl analogue was better tolerated as the C6 substituent, 
however, no improvements in potency were observed.
143
 The aromatic ring of the 
chromenone was then probed. In the C1 position a methoxy group was shown to be 
favourable, with a 3.9-fold increase in potency observced for the racemic mixture. The 6R,7S 
enantiomer of the methoxy compound (50) has an IC50 of 0.20 µM. The improvement in 
potency is thought to be due to the twist induced in the molecule due to clashes between the 
methoxy group and the N11 methyl group. This induces an improved in the position of the 
two bromophenyl groups within the Trp23 and Leu26 pockets.
143
 
 
At the C2 position of the chromenone a methyl substituent improved potency 2-fold, with an 
IC50 of 0.44 µM (0.39 µM for the 6R,7S enantiomer (51)).
143
 The crystal structure of 51 
showed a small pocket which could be probed by a small group, as demonstrated by tolerance 
for an ethyl group. No further increase in potency was observed by substitution at either the 
C3 or C4 position around the ring. However, addition of the C1 methoxy group and C2 
methyl group failed to have an additive effect with an IC50 3.94 µM.
143
 
 
Biochemical analysis demonstrated that the chromenotriazolopyrimidines are cell permeable, 
though the level varied between different compounds. Treatment of HCT116 cells with 51 
showed a dose-dependent increase in p21 mRNA although not in p53 knockout cells 
indicating chromenotrizolopyrimidines acts via MDM2 inhibition.
143
 However, compound 49 
has high clearance (2.4 L/h/kg) and an oral bioavailability of only 23%. On incubating with 
rat liver microsomes less than 5% remained after 30 min and on intraveneous administration 
significant levels of des-methyl enantiomers were detectable within the plasma.
144
 Oxidative 
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N-demethylation and isomerisation were thought to occur, resulting in the formation of the 
inactive enantiomers therefore a more metabolically stable substituent was required.  
 
A series of N-alkyl carboxylic acid were synthesised. Of these the N-pentyl carboxylic acid 
analogue (52) was shown to maintain good potency with an IC50 of 0.76 µM for the racemic 
mixture and 0.35 µM for the (6R,7S) enantiomer. 52 showed low in vivo clearance and 
modest oral bioavailability of 54%.
144
 
 
Figure 35 
 
3.4.5. Imidazoindoles 
 
Imidazoindole scaffold for MDM2-p53 inhibition was discovered simultaneously by a 
number of groups including Novartis and Popwicz et al.
145
 The imidazoindole scaffold is also 
the only scaffold to also have MDMX inhibitory activity. The imidazoindole scaffold 
compromises an imidazole ring with a phenyl substituent at the 4-position, a 2-carboxy-6-
chloroindole substituent at the 5-position and a 4-chlorobenzyl substituent at position 1.
146
 
 
 Novartis 101(WW298) (53) has an IC50 of 0.19 µM against MDM2 and 19.7 µM against 
MDMX.
145
 The indole group of WW298 sits within the Trp23 pocket with the indole N 
forming an H-bond to Leu54 of MDM2. However, in the Trp23 pocket of MDMX binding of 
WW298 induces an energetically unfavourable change in conformation.
145-146
 The phenyl 
ring occupies the Phe19 pocket, orientated perpendicular to the ring of Phe19 and the Leu26 
pocket is filled by the chlorobenzyl group.
146
 Within the MDMX crystal structure the N,N-
dimethylaminopropyl moiety folds over the Phe19 pocket, shielding the pocket from solvent 
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and providing addition hydrophobic interactions.
146
 However, the crystal structure of WW298 
with MDM2 is not currently available to confirm whether this occurs with MDM2. The N,N-
dimethylaminopropyl pyrrolidine moiety also improves the water solubility of WW298. 
 
Figure 36 
 
Compound  54 (WK23) developed by Popwicz et al
145
 is essentially the core of WW298. It 
lacks the dimethylamino pyyrolidine moiety, instead replacing the amide linker with a 
carboxylic acid group. WK23 has significantly lower activity, with an IC50 of 1.71 µM. A 
crystal structure of WK23 bound to MDM2 demonstrates that it binds in a similar manner to 
WW298 (Figure 37).
145
  
 
Figure 37 WK23 bound to MDM2 (PDB 3LBK) 
 
To date no MDM2 p53 protein-protein inhibitor has been approved for clinical use. R7112 
(38) from Hoffman – La Roche is undergoing clinical evaluation, and R7112 is currently in 
phase I trials for haematological neoplasm (from May 2008 to March 2012)
134
 and advanced 
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solid tumours (from December 2007 to November 2011)
134
 and is an orally available 
compound.
132
 A Johnson and Johnson MDM2 inhibitor with a non-p53 mechanism 
JNJ00676910 underwent clinical trials from November 2006 to February 2010 for 
advanced/refractory solid tumours. However, no results have been published and there is 
currently no evidence of this compound going forward into phase II trials.
134
 AT-219 is 
undergoing late preclinical development. It is an optimised member of the spirooxindoles 
family of compounds.
132
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4. The Development of ATP-competitive Inhibitors of mTOR 
 
4.1 Pyrimidines as mTOR Inhibitors 
 
A high-throughput screen of pyrimidine-based compounds carried out by KuDOS 
Pharmaceuticals identified a number of O
4
-substituted pyrimidines as having inhibitory 
activity against mTOR. Three series were identified and are shown below.
147-151
 The 
compounds were originally synthesised within a CDK2 project of the NICR drug discovery 
laboratories and all compounds had exhibited some degree of activity against this target. The 
structures of compounds and their inhibitory activity against both mTOR and CDK2 are 
shown below (Table 1). 
 
Table 1 
Compound Series X R 
Kinase Inhibition (IC50 µM) 
mTOR CDK2 
55 A H H >50 >50 
56 A NO H 2.6 2.2 
57 A CHO H 3.1 6.2 
58 A NO2 H 1.5 8.3 
59 A CN H 1.5 62 
60 A NO COMe >50 28 
61 A NO COEt 11 ~100 
62 B NO - 2.0 27 
63 C NO SO2NH2 4.7 0.001 
64 C NO OH 3.1 0.016 
 
In the O
4
-cyclohexylmethoxy series substituents are required at the 5-position for activity 
against both mTOR and CDK2. Modest activity is observed for those compounds bearing 
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electron withdrawing, H-bond accepting substituents at the 5-position. However, with the 
exception of compound 59 no selectivity for mTOR is observed. For the acyl analogues the 
propionyl derivative (61) shows significant selectivity for mTOR, in contrast to the acetyl and 
unsubstituted derivatives (60) and (56), although the latter is much more potent against 
mTOR than 61. 
 
Compound 62 shows that a benzyl substituent is tolerated for mTOR activity but not for 
CDK2. The N
2
-anilino series also maintains good potency against mTOR. However, these 
compounds are highly selective for CDK2 over mTOR, suggesting that pursuing compounds 
of this type would be unwise. The most promising starting points from the HTS were 
NU6027 (56) and NU6227 (59) that showed the best potency for mTOR and offered the 
possibility of selectivity over CDK2. 
 
Figure 38 
 
The CDK2 inhibitory activity of compounds 55-64 has been described previously.
147-151
 All 
maintain a crucial triplet of hydrogen bonds with the CDK2 protein, forming a donor-
acceptor-donor motif. The 5-nitroso-6-aminopyrimidines were found to form a pseudo-cycle 
between the nitroso group and one proton on the 6-amino group (Figure 39) and therefore act 
as a purine-mimetic.
149
 Detailed structure-activity relationships have been deduced for CDK2 
inhibition by 2,6-diamino-4-alkoxypyrimidines and so synthetic efforts were first directed 
towards generating a SAR for mTOR inhibition. This is particularly important given the lack 
of an available crystal structure of the ATP-binding site of mTOR. A detailed understanding 
of the SAR should aid the development of a potent inhibitor, but also aid in the separation of 
mTOR inhibitory activity from that of CDK2. 
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Figure 39 
 
4.2 Synthesis of NU6027 and NU6227 
 
As a prelude to further studies, compounds NU6227 and NU6027 were prepared using the 
described synthetic route.
152
 The first step in both synthetic schemes requires generation of 
cyclohexylmethoxide formed by heating sodium in cyclohexylmethanol. On addition of 4-
chloro-2,6-diaminopyrimidine (65)  the 4-chloro group is displaced by the 
cyclohexylmethoxide to generate 4-(cyclohexylmethoxy)pyrimidine-2,6-diamine (55). The 
reaction utilises the electron-deficient nature of pyrimidines to facilitate an SNAr addition-
elimination reaction displacing the chloride with the alkoxide. 
 
Scheme 3 Reagents and conditions; a) Na, cyclohexylmethanol, 90 min, 180 
o
C, 20%;         
b) NaNO2(aq), AcOH(aq), 40 min, 80 
o
C, 86% 
 
The 5-nitroso substituent was installed by nitrosation with sodium nitrite in aqueous acetic 
acid at 80 
o
C in 86% yield. The electron-donating nature of the substituents on the pyrimidine 
counteracts the electron deficient nature of the pyrimidine ring, allowing electrophilic 
substitution to occur at the activated 5-position of the pyrimidine under mild conditions. 
 
The synthetic route to NU6227 is shown below (Scheme 4). Bromination at the 5-position 
was achieved using N-bromosuccinimide in acetic acid at 60 
o
C in 80% yield. Previously the 
nitrile moiety had been incorporated using CuCN after protection of the amino groups.
152
 
Protection of the amino groups by acetylation prevents chelation to the copper but may also 
have activated the ring, by reducing the electron-donating nature of the amino groups. 
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Protection of the amino groups was achieved in a 53% yield using a 1:1 mixture of acetic 
acid and acetic anhydride.  Incorporation of the nitrile group was achieved using CuCN in 
DMF for 5 h. Ethylenediamine was then added to chelate the remaining copper, allowing it to 
be removed on aqueous work-up, but also as a useful side reaction resulted in the removal of 
the acetyl protecting groups, giving the desired final compound in 70% yield. 
 
Scheme 4 Reagent and conditions; a) NBS, AcOH, 1 h, 60 
o
C, 80%; b) AcOH, Ac2O, 
overnight, reflux, 53%; c) i. CuCN, DMF, 5 h, reflux; ii. Ethylenediamine, overnight, 70%  
 
4.3 Modifications to the O
4
-Position of NU6227 
 
4.3.1. Synthesis of O
4
-Alkyl Substituted Analogues of NU6227 
 
To develop the O
4
 structure activity relationship a series of O
4
-alkyl analogues were 
synthesised. The 5-cyano analogue has some selectivity for mTOR over CDK2 and as a 
number of 5-nitroso analogues had previously been synthesised, the substitution at the 5-
position was fixed as the nitrile group. A range of substituents was selected covering alkyl 
and cycloalkyl groups, all smaller than a cyclohexylmethyl group. 
 
 
Figure 40 
 
The desired compounds were synthesised using a similar synthetic route to that of NU6227 
(Scheme 5). Previous work suggested that whilst the 5-nitroso substituted compounds were 
sufficiently electron deficient to allow incorporation of a 4-methoxy substituent, followed by 
displacement with the desired 4-substituent (Scheme 6), this does not occur with 5-nitrile 
analogues.
153
 As a result the O
4
-substituent must be incorporated in the first step of the 
synthetic scheme. Consequently, five linear syntheses were undertaken, rather than one 
divergent route. 
4. The Development of ATP-competitive Inhibitors of mTOR 
 
84 
 
 
Scheme 5 Reagents and conditions; a) Na, ROH, 20 min – 5 h, 98-160 oC; b) NBS, AcOH, 
15–60 min, RT-60 oC; c) AcOH, Ac2O, reflux, 17-48 h; d) i. CuCN, DMF, 2-7 h, 120 
o
C; ii. 
Ethylenediamine, overnight 
 
Scheme 6 Reagents and conditions: a) Na, MeOH, 1 h, 50 
o
C, 96%; b) NaNO2(aq), AcOH(aq), 
20 min, 80 
o
C, 84% c) Morpholine, 10 min 120 
o
C, 76% 
154
 
 
Each sodium alkoxide was generated from sodium in the neat alcohol with conventional 
heating, followed by the addition of 4-chloro-2,6-diaminopyrimidine (65).  However, a 
search of the literature suggested that microwave heating may also be appropriate for the 
SNAr reaction,
155
 and a slight improvement was achieved in this way (Table 2).  For alcohols 
that did not react readily with sodium, microwave heating proved impractical as the metal 
cannot remain in the reaction mixture when heating in the microwave. 
 
Scheme 7 Reagents and conditions; a) Na, isopropanol 
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Table 2 
Heating type Temperature (
o
C) Time Yield (%) 
Conventional 125 14 h 55 
Microwave 160 20 min 67 
 
Bromination was achieved in an analogous manner to NU6227 (59) using N-
bromosuccinimide. However, for the isopropyl, sec-butyl and isobutyl analogues the reaction 
required less vigorous conditions. The desired products were obtained in 15 min at room 
temperature in good yields (58% for the isopropyl analogue, 72% for the sec-butyl analogue 
and 86% for the isobutyl analogue). Indeed, heating the isopropyl, sec-butyl and isobutyl 
analogues gave only poor yields (~ 20%).   
 
Acetylation of the amino groups was achieved using a 1:1 mixture of acetic acid and acetic 
anhydride, though further addition of acetic anhydride and longer reaction times were 
required to increase conversion to the product, compared to those required for the 
cyclohexylmethyl compound (67). Displacement of the bromo substituent was achieved using 
CuCN in DMF. It was found that reducing the temperature to 120 
o
C (from 160 
o
C) gave 
cleaner conversion to the product. Reaction conditions are summarised below. 
 
Scheme 8 Reagents and conditions; a) i. CuCN, DMF ii. Ethylenediamine 
Table 3 Conditions and yields for conversion to nitrile product  
Number O
4
-substituent 
Temperature 
(
o
C) 
Reaction time 
(h) 
Yield (%) 
81 Ethyl 160 3.5 75 
82 Isopropyl 120 2 25 
83 sec-butyl 120 6 61 
84 isobutyl 120 7 30 
85 cyclopropylmethyl 120 4 82 
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Compounds 82 and 85 required additional purification by semi-preparative HPLC before 
achieving appropriate purity for biological testing. The impurity was likely to be bromo-
substituted compound 74, which is generated from remaining starting material on addition of 
ethylenediamine. To try and avoid this problem, further equivalents of CuCN were added to 
try to ensure complete conversion of 74 to 75, but this approach was not successful. 
 
4.3.2. 4-Unsubstituted Analogues of NU6227  
 
Previously a number of 4-substituted pyrimidines had been prepared (see chapter 4.3.1 and  
Payne
154
). The synthesis of the unsubstituted analogues was explored to expand the SAR. 
Compound 86 maintains all substituents found in NU6227, other than the 4-position 
substituent. The analogous 5-nitroso analogue cannot be prepared as the nitrosation reaction 
requires a highly activated pyrimidine ring, and nitrosations without either the 4-alkoxy or 6-
amino groups have previously proved impossible.
153
 Feuer et al suggest that the reaction 
occurs via initial nitrosation on the amino group, followed by a rearrangement to give the 5-
nitroso compound, a variation of the Fischer-Hepp reaction.
156
  
 
Scheme 9 Reagents and conditions; a) p-methoxybenzylamine, DMF, 3 h, 100 
o
C, 91%; b) 
TFA, DCM, 18 h, reflux, 77% 
 
The synthesis of compound 88 is possible from bromo compound 87. Displacement of the 2-
bromo substituent was achieved employing para-methoxybenzylamine, which was used as a 
convenient source of the amino group. A number of methods of deprotection of the amine 
groups was then attempted. The deprotection was first attempted using 2,3-dichloro-5,6-
dicyanobenzoquinone (DDQ) (89) in DCM. The use of the oxidant DDQ requires a 2-
electron transfer from the electron rich methoxybenzyl group to the DDQ via a charge 
transfer complex (Scheme 10).
157
 However, treatment of compound 88 with DDQ failed to 
remove the PMB group. Hydrogenation using 10% Pd/C in acidic methanol also failed to 
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remove the PMB group. Finally 88 was treated with 70% TFA in DCM at reflux overnight to 
give 86 in a 77% yield.  
Scheme 10 
 
4.4 Structure-Activity-Relationships Around the Amino Groups 
 
4.4.1. Synthesis of Pyrimidine Derivatives Lacking a 2-Amino Group 
 
The three hydrogen bonds formed by the 2,6-diamino groups and the N
1
 of the pyrimidine 
ring has been shown to be essential for CDK2 inhibitory activity.
149
 A 2-unsubstituted 
analogue of NU6227 and NU6027 would establish whether this is also true for mTOR 
inhibitory activity. If mTOR inhibitory activity does not require the 2-amino group, mTOR 
inhibitory activity could be separated from CDK2 activity and the 2-position may provide an 
interesting position for further substitution. 
 
Luo et al generated a series of 6-aminosubstituted-4-chloropyrimidines from 4,6-
dichloropyrimidine using microwave heating.
158
 para-Methoxybenzylamine can be used as a 
convenient source of the amino group, and due to the electron-rich nature of the p-
methoxybenzyl group, it can be easily removed, leaving the desired amino group in place. 
Compound 91 was formed by treating 4,6-dichloropyrimidine with para-
methoxybenzylamine, in the presence of Hünig’s base in isopropanol, in 83% yield. Despite 
the dichloro-motif no formation of the di-amino compound was observed. Only 0.9 eq of the 
p-methoxybenzylamine was used and the pyrimidine ring is deactivated toward SNAr 
reactions after the first displacement. 
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Scheme 11 Reagents and conditions; a) p-methoxybenzylamine, DIPEA, isopropanol, 20 
min, 120 
o
C, 83%; b) Na, cyclohexylmethanol, 180 
o
C, 30 min, 76% or NaH, 
cyclohexylmethanol, THF, 18 min, 120 
o
C, 72%; c) NBS, AcOH, 1 h, 69%; d) i. CuCN, 
DMF, 3 days, 120 
o
C; ii. Ethylenediamine, 3 days, 28%; d) TFA, DCM, 18 h, reflux, 50% 
 
Two alternative reaction conditions were developed for the formation of compound 92. The 
first reaction uses the published methodology, i.e. sodium in neat cyclohexylmethanol with 
conventional heating, giving 92 in 76% yield. The second uses microwave heating. Previous 
work had suggested that formation of O
4
-alkoxy derivatives with microwave heating is 
feasible, though impractical for derivatives where formation of the sodium alkoxide requires 
heating. A series of O
4
-benzyl derivatives were also synthesised using microwave heating 
from sodium hydride and the appropriate benzyl derivative in THF.
153
 Therefore, this 
methodology was also applied to the formation of compound 92 in 72% yield.  
 
Bromination of 93 was achieved with NBS in AcOH using the conditions previously 
optimised for the formation of the O
4
-alkyl derivatives (81-85). Slightly longer reaction times 
were required, as the lack of the 2-amino group results in a less-activated ring towards 
electrophilic aromatic substitution. The nitrile group was incorporated using CuCN in DMF 
at 120 
o
C to give 94. The PMB group was removed from compound 94 using 30% TFA in 
DCM at reflux to give compound 95 in 50% yield. 
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Scheme 12 Reagents and conditions; a) p-methoxybenzylamine, DIPEA, isopropanol, 20 
min, 120 
o
C, 83%; b) Na, cyclohexylmethanol, 180 
o
C, 30 min, 76% or NaH, cyclohexyl 
methanol, THF, 18 min, 120 
o
C, 72%; c) NaNO2(aq), AcOH(aq), 1 h, 80 
o
C, 79%; d) TFA, 60 
o
C, 1 h 
 
A similar synthetic route to scheme 11 was developed for the synthesis of the 2-unsubstituted 
analogue of NU6027 (56) (Scheme 12).  Compound 96 was synthesised from compound 
92using sodium nitrite in aqueous acetic acid in an analogous reaction to the synthesis of 
NU6027. Deprotection of the PMB group was attempted using neat TFA, a reaction which 
had previously been successful for more electron-rich pyrimidine systems.
159
 However, 
multiple products were observed by TLC and the major component was only isolated in poor 
yield (Scheme 12). The 
1
H NMR spectrum of the isolated compound was initially thought to 
correspond to that of the expected product 97. However, mass spectrometry showed an m/z of 
208, which corresponded to a chemical formula of C11H16N2O2, presumed to be 6-
hydroxypyrimidine 98 (Scheme 13). 
 
Scheme 13 Reagent and conditions; a) TFA, 1 h, 60 
o
C 
 
Compound 98 can be formed via a diazonium reaction; thus the reaction of TFA with the 5-
nitroso group of 96 liberates nitrous acid forming the diazonium intermediate. Reaction with 
water will produce the 6-hydroxy compound 98.  
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In light of the above results a milder deprotection of the PMB group was attempted (Table 4). 
Oxidative conditions were attempted including CAN, both in a buffered reaction with sodium 
tetraborate/ borax buffer, in an analogous reaction to Marko et al,
160
 and in a dual phase 
reaction as described by Fürstner et al.
161
 The ‘dual phase’ reaction was achieved using a 
mixture of chloroform and water, with either 1,2-dimethoxyethane or camphorsulfonic acid 
as phase-transfer agent to aid the reaction (Table 4).  
 
Table 4  
Reagents Conditions Observations 
TFA 0 
o
C 
Pyrimidinone compound 
observed after 15 min 
1.5 eq TFA in DCM 0 
o
C 
Slow conversion to 
pyrimidinone compound 
DDQ RT No reaction 
CAN, aqueous acetonitrile RT Loss of nitroso group 
CAN, buffered solution RT, pH 8 Mixture of products 
CAN, dual phase conditions, DME RT No reaction 
CAN, dual phase conditions, DME 
(5% of solvent total) 
RT, vigorous stirring No reaction 
CAN, dual phase conditions, DME 
and camphorsulfonic acid 
RT, vigorous stirring No reaction 
 
The failure of the PMB route required an alternative approach to compound 97. As the 
nitroso group had proved especially sensitive, it was decided to remove the para-
methoxybenzyl group before nitrosation.  
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Scheme 14 Proposed reagents and conditions; a) 4-methoxybenzylamine, DIPEA, 
isopropanol, 83 min, 120 
o
C, 83%; b) sodium, cyclohexylmethanol, 30 min, 160 
o
C, 76%; c) 
trifluoroacetic acid, DCM, 24 h, reflux 87%; d) NaNO2 (aq), AcOH(aq), 80 
o
C  
 
Aminopyrimidine 99 was prepared from PMB protected 92 (prepared as discussed for 
Scheme 11) using 30% TFA in DCM at reflux overnight in good yield. Attempts to nitrosate 
99 using the previous conditions failed, instead forming pyrimidinone 98. The failure of the 
reaction may be explained by the lack of activation of amino pyrimidine 99 relative to the 
diamine 56. Alternative conditions were then investigated. Previous work had identified 
nitrosation conditions appropriate for electron-deficient pyrimidines.
159
 Compound 99 was 
treated with sodium nitrite in trifluoroethanol with stoichiometric equivalents of TFA at 
reflux. This reaction proceeded at a slower rate than previous nitrosation reactions and a 
small percentage of the 5-nitroso 97 was observed by LCMS, but the predominant observed 
product was compound 98.   
 
Marchal et al used isoamyl nitrite in DMSO as nitrosating reagent on a series of alkoxy, 
amino pyrimidines.
162
 However, for the example which correlates with the desired  
ecompound, (4-methoxy-6-aminopyrimidine) they also observed failure of the nitrosation. 
Instead, they isolated the pyrimidinone formed by diazotation and hydrolysis.
162
 The result 
obtained by Marchel et al demonstrated that the nitrosation cannot be performed with a free 
amino group in place. The nitrosating agent always forms nitrous acid, and without an 
activating group para- to the 5-position, this preferentially forms the diazonium ion instead of 
nitrosating the pyrimidine ring.  
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It was proposed that an alternative protecting group, which is removed under different 
conditions to PMB, may allow access to compound 97, therefore, the synthesis of 97 via an 
allyl protected amino group was attempted. The SNAr reaction on 4-6-dichloropyridimidine 
with allylamine proceeded cleanly at room temperature for 24 h, with good conversion to 
give 100. The second displacement of the chloro from the pyrimidine heterocycle with 
cyclohexylmethoxide was undertaken as previously with NaH, cyclohexylmethanol in THF 
and microwave irradiation at 120 
o
C. However, conversion to the product was incomplete, 
and using medium pressure column chromatography separation of the starting material and 
product was not possible. Increasing the time of heating from 15 min to 20 min resulted in 
total conversion to the product. Compound 101 was then nitrosated using standard conditions, 
in a 66% yield.  
 
Scheme 15 Proposed reagents and conditions; a) allylamine, Et3N, THF, 24 h, 98%; b) 
cyclohexylmethanol, NaH, THF, 20 min, 120 
o
C, 75%; c) NaNO2(aq), acetic acid(aq), 75 min, 
80 
o
C, 66%;  d) deprotection  
 
Deprotection of the allyl group to give the free amine group and the desired 5-nitroso 97 was 
then required. The deallylation was initially attempted using Wilkinson’s catalyst and 
DABCO. These conditions isomerize the allyl double bond, allowing extraction using 
DABCO as a nucleophile.
163
 Allyl 102 was treated with Wilkinson’s catalyst and DABCO in 
refluxing ethanol. However, the allyl group remained in place but the nitroso group had been 
removed giving allyl 101. 
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Scheme 16 Reagent and Conditions; a) DABCO, Rh(PPh3)3Cl, EtOH, 80 
o
C, 4 h 
 
Ueda et al used palladium triphenylphosphine and N,N-barbituric acid to remove allyl groups 
during the total synthesis of (+)-haplophytine.
164
 Treatment of 102 with Pd(PPh3)4, 1,3-
dimethylbarbituric acid in refluxing DCM failed to remove the allyl group. However, 
replacing the DCM with the higher boiling ethanol resulted in the generation of a number of 
products. 
1
H NMR identified these two products as 101 and 99, one lacking the 5-nitroso 
group 101 and the other lacking the 5-nitroso and the allyl group 99. 
 
Figure 41 
 
Karpf et al removed allyl groups in their azide free synthesis of oseltamivir using 10% 
palladium on carbon and ethanolamine in ethanol.
165
 However, under these conditions, the 
nitroso group was rapidly removed. In view of these unsuccessful results and time-constraints 
it was decided to discontinue work on the synthesis of 97. 
 
4.4.2. Synthesis of 6-Hydroxylamino Pyrimidines 
  
The high-throughput screen which identified pyrimidine-based compounds as having mTOR 
inhibitory activity also identified a number of 6-amino acyl derivatives with mTOR inhibitory 
activity e.g. 60 and 61. A range of acyl and carbamates derivatives were therefore 
synthesised.  These derivatives may be unstable under assay conditions, and HPLC 
monitoring showed decomposition over time.
154
 A more stable substituent was required to 
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probe the region around the 6-amino position, such as the methyl (103) and the benzyl (104) 
aminoxy analogues. 
 
Figure 42 
 
Too et al proposed that with electron-withdrawing methoxy or benzyloxy groups on the 6-
amino groups an alternative tautomer may be observed, whereby the amino tautomer (105) 
interconverts with the imino tautomer (106), which would disrupt the triplet of hydrogen 
bonds to the protein.
166
  However, with the 5-nitroso group forming a hydrogen bond to the 6-
amino proton the equilibrium may favour the desired tautomeric form. 
 
The synthetic route to access compounds 103 and 104 is shown below. 
  
Scheme 17 Proposed reagents and conditions; a) R = Me methylamine hydrochloride, 
DIPEA, DMSO, 16 h, 130 
o
C, 52%; R = Bn O-benzylhydroxylamine, DIPEA, DMSO, 6 h, 
130 
o
C, 66%; b) Na, cyclohexylmethanol; c) NaNO2(aq), AcOH(aq) 
  
Too et al prepared aminooxy-substituted purines by treating chloro-substituted purines with 
10 equivalents of the appropriate alkyl substituted hydroxylamines in the presence of Hünig’s 
base.
166
 To avoid using such a large excess of reagent, conditions were adapted from the 
synthesis of compound 91 to synthesise 109. However, multiple products were formed. 
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Therefore, optimisation of this reaction was undertaken.  The conditions  and results are 
summarised below. 
 
Table 5 Results and conditions for the synthesis of 109 
Solvent Heating type 
Equivalents of          
O-benzyl 
hydroxylamine 
Temperature 
(
o
C) 
Time Yield 
Isopropanol microwave 1 140 75 min 27 % 
n-Butanol microwave 1 160 90 min 39% 
Trifluoro-
ethanol 
microwave 1 170 - 0% 
DMSO microwave 1 170 40 min 29% 
DMSO microwave 1 180 15 min 17% 
DMSO microwave 1 170 30 min 29% 
DMSO conventional 1 130 8 h 42% 
DMSO conventional 1.5 130 6 h 66% 
 
Conventional heating for longer times at a low temperature was shown to be higher yielding, 
along with increasing the equivalents of O-benzylhydroxylamines. These conditions were 
then applied to the synthesis of compound 108, though the reaction time was slightly longer 
for the methyl compound and slightly lower yielding (52%). However, on attempting 
formation of cyclohexylmethoxy compound 111, the sensitive nature of hydroxylamine 109 
again proved problematic. Treatment of compound 109 with either sodium in 
cyclohexylmethanol or sodium hydride with cyclohexylmethanol in THF at 120 
o
C with both 
microwave and conventional heating resulted in decomposition of the starting material and 
the formation of by-products. Under similar conditions the analogous methyl compound was 
also seen to decompose. Multiple products may be formed as a result of nucleophiles 
attacking the benzyl and methyl group. Therefore, incorporation of the hydroxylamine 
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functionality at a later step may be advantageous. An alternative synthetic route was devised 
which reversed the order of substitution. The synthetic route is shown below (Scheme 18). 
 
Scheme 18 Proposed reagents and conditions; a) Na, Cyclohexylmethanol, 20 min, 100 
o
C, 
62%; b) R = Me, methoxyamine hydrochloride, DIPEA, DMSO, 130 
o
C; R = Bn, O-
benzylhydroxylamine, DIPEA, DMSO, 130 
o
C; c) NaNO2(aq), AcOH(aq) 
 
Conventional introduction of the cyclohexylmethoxide group (180 
o
C, Na) resulted in 
disubstitution forming 113. Optimisation of this reaction was therefore undertaken. Optimal 
conditions were found to 0.9 eq. of sodium at 100 
o
C, resulting in the formation of compound 
112 in a 62% yield. However, attempts to incorporate the amino-oxy functionality proved 
unsuccessful. In view of their instablity it was decided to discontinue work on these 
compounds. 
 
Table 6 
Equivalents of sodium Temperature (
o
C) Product 
Excess 180 113 
Excess 120 113 
0.9 100 112 
 
Unfortunately, modification to either of the amino groups proved either unsuccessful, or 
abolished activity. Alternative areas of the molecule were then addressed to develop further 
the SAR. 
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4.4 Modifications to the 5-Position 
 
Potent compounds identified from the high throughput screen all maintained an electron-
withdrawing substituent capable of accepting a hydrogen-bond at the 5-position. Compounds 
bearing electron-withdrawing substituents, which cannot form hydrogen bonds, have also 
been synthesised, including the acetylene derivative shown below, but this modification 
resulted in a loss of biological activity against mTOR. 
 
Figure 43 
 
To examine further the structure-activity relationships around the 5-position a series of 
analogues was therefore designed. Compound 117, which introduces a CH2 unit between the 
aromatic ring and the nitrile group, was synthesised. Hockova et al alkylated at the 5-position 
by treating 2,6-diaminopyrimidinone with bromoacetonitrile in the presence of base.
167
 Using 
this synthetic route compound 117 was synthesised in an unoptimised yield of 9% (Scheme 
19).  
 
Scheme 19 Reagents and conditions; a) bromoacetonitrile, NaHCO3, DMF, 4 days, 9%; b) 
(bromomethyl)cyclohexane, K2CO3, DMF, 15 h, 100 
o
C, 22%  
 
Formation of the desired final compound requires alkylation of the pyrimidine oxygen. The 
attempted conditions are shown below (Table 7). The alkylation reaction with 
(bromomethyl)cyclohexane proved successful, although purification of compound 117 
proved difficult, requiring multiple rounds of medium pressure chromatography, followed by 
recrystallisation giving compound 117 in 22% yield. 
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Table 7 
Reagents Conditions Yield (%) 
DEAD, PPh3, 
Cyclohexylmethanol, THF 
RT No reaction 
DEAD, PPh3, 
Cyclohexylmethanol, DMF 
RT No reaction 
DIAD, PPh3, 
Cyclohexylmethanol, DNF 
100 
o
C No reaction 
(Bromomethyl)cyclohexyl, 
K2CO3, DMF 
100 
o
C 22 
 
 Both the N-alkylated product and O-alkylated product are possible results of this reaction. 
The 
13
C NMR spectrum of the major product suggested O-alkylation. The predicted values 
for the methylene carbon adjacent to either the pyrimidine N or the exocyclic O are 44 or 72 
ppm respectively. The observed value for the methylene carbon was 70.3 ppm, suggesting 
that the desired O-alkylated compound has been formed. Unlike the compounds where the 
nitrile group is directly attached to the aromatic ring, which have a strong absorption peak in 
the IR at around 2000 cm
-1
, compound 117 had a weak CN absorption, as expected for an 
alkyl nitrile as this is known to be a weaker absorption. 
 
Compound 118 extends the nitrile further from the 5-position and retains a hydrogen bond 
acceptor at a similar position to that of the nitroso group in NU6027. 
 
 
Figure 44 
 
Quiroga et al cyanoacetylated a series of pyrimidinone compounds by forming a mixed 
anhydride from cyanoacetic acid and acetic anhydride. Pyrimidinones  are required starting 
materials, as the use of pyrimidines as the starting material resulted in acylation at the 
exocyclic amino group.
168
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Scheme 20 Reagents and conditions; a) Ac2O, NCCH2CO2H, 80 
o
C; b) (bromomethyl) 
cyclohexane, K2CO3, DMF, 15 h, 100 
o
C 
 
Scheme 21 
 
The mixed anhydride was formed from acetic anhydride and cyanoacetic acid at 80 
o
C. 
Pyrimidinone (115) was then added to the reaction mixture to form compound 119. As the 
cyano-substituted portion of the acetic anhydride is more electron-deficient, attack from the 
pyrimidinone ring should occur on this moiety. However, the crude product obtained from 
this reaction proved to be very insoluble, and no purification or NMR analysis was possible. 
Therefore the synthesis of this molecule was delayed until the biological results of compound 
117 were obtained. Subsequently, as 117 showed a loss of activity, no further synthetic 
efforts were directed towards 118. 
 
It has been proposed that the biological potency of derivatives with electron-withdrawing 
groups at the 5-position is due to the acidification the two amino protons, leading to the 
formation of stronger hydrogen bonds with the protein. A fluorine group at the 5-position of 
the pyrimidine ring would also act to acidify the 2-amino protons. The 5-fluoropyrimidine 
derivative 119 might identify whether the 5-substituent is required to act as a hydrogen-bond 
acceptor or to acidify the 2-amino substituents. 
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Fluorinating agents have become an area of interest due to their increasing use within 
medicinal chemistry.
169
 A class of reagents known as N-F reagents are becoming increasingly 
popular, as they are a stable and easy to handle source of ‘F+’.169 Selectfluor™ is one of the 
commonest reagents of this class, and there are examples within the literature of electrophilic 
substitution of aromatic rings using Selectfluor™, including the fluorination of pyrimidine 
compounds.
170-171
 The structure of Selectfluor™ (120) is shown below. 
 
Figure 45 
 
Compound 55 was treated with Selectfluor™ in acetonitrile at temperature up to 80 oC. 
LCMS monitoring indicated the formation of a new product. However, the reaction did not 
go to completion and on work-up and purification, no new product was obtained.  
 
 
Scheme 22 Proposed reagents and conditions; a) Cyclohexylmethanol, sodium, 160 
o
C, 2h, 
20 %; b) Selectfluor™, MeCN, 80 oC  
 
A further group of reagents within the N-F class of reagents, which also includes 
Selectfluor™, are the N-fluoropyridinium salts, which also act as a source of electrophilic 
fluorine.  On treating 55 with 1-fluoro-2,4,6-trimethylpyridinium salt, LCMS monitoring of 
the reaction suggested a new product was formed. However, after work-up and attempted 
purification only starting material was isolated (Scheme 23). 
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Scheme 23 Proposed reagents and conditions; a) Cyclohexylmethanol, Na, 160 
o
C, 2h, 20 %; 
b) 1-fluoro-2,4,6-trimethylpyridinium salt, MeCN, 18 h  
 
Furuya et al have reported the fluorination of aromatic species from boronic acids,
172
 using 
silver triflate and Selectfluor™. The reaction proceeds via transmetallation of the aromatic 
species from the boronic acid to silver, which is then followed by fluorination of the aromatic 
ring. To follow the synthetic procedure developed by Furuya et al, the 5-boronic acid 
analogue 121 was required. The bromo derivative 66 was accessed from 4-
cyclohexylmethoxy-2,6-diaminopyrimidine on treatment with NBS (Scheme 24). However, 
attempts to form the boronic acid, via the boronic ester, using bis(pinacolato)diboron, 
palladium acetate and potassium acetate
173
 in DMF rapidly resulted in protodeboronation. In 
view of these results the synthesis of 119 was abandoned. 
Scheme 24 Proposed reagents and conditions; a) Cyclohexylmethanol, sodium, 160 
o
C, 2h 20 
%; b) NBS, AcOH, 1 h 80 %; c) Bis(pinacolato)diboron, Pd(OAc)2, KOAc, DMF, 90 
o
C; d) 
AgOTf, NaOH, Selectfluor™ 
 
Cabaj et al have synthesised compound 122 using Selectfluor ™, but no experimental 
procedure was given. The compound is described as ‘moderately stable’ and only a crude 
yield is provided, suggesting that 5-fluoropyrimidines, with three electron-donating 
substituents are not especially stable. 
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4.5 Pyridine Analogues of mTOR Inhibitory Pyrimidines 
 
To separate mTOR inhibitory activity from CDK2 inhibitory activity, and to develop the 
structure-activity relationships for the pyrimidine ring, two pyridine-based analogues were 
synthesised. Each of these analogues probes the role of both of the pyrimidine nitrogens.  
 
 
Figure 46 
 
The first pyridine analogue 134 is capable of maintaining the triplet of hydrogen bonds, 
shown to be essential for CDK2 inhibitory activity but replaces the N3 nitrogen with CH. The 
proposed synthetic route utilises a reaction described by Manley et al, which attaches 
secondary amides α to pyridine N-oxides (Scheme 25).174 
 
 
4. The Development of ATP-competitive Inhibitors of mTOR 
 
103 
 
Scheme 25 Proposed reagents and proposed conditions; a) Conditions discussed below; b) m-
CPBA, CH2Cl2; c) N-benzylacetamide, oxalyl chloride, 2,6-lutidine, CH2Cl2; d) m-CPBA, 
CH2Cl2; e) N-benzylacetamide, oxalyl chloride, 2,6-lutidine, CH2Cl2 
 
The first step of the reaction is formation of the 4-cyclohexylmethoxypyridine (126). It was 
proposed to achieve formation of this product via a Mitsunobu reaction between 
cyclohexylmethanol and 4-pyridone (126) (the preferred tautomer of 4-hydroxypyridine 
(135)).  
 
On treating 4-pyridone in THF with DEAD, PPh3 and cyclohexylmethanol the highest 
isolated yield was 16%. Further analysis of the product also revealed that the compound was 
not the desired O-alkylated product, but instead the N-alkylation product. Although there are 
numerous examples within the literature of a Mitsunobu reaction performed on 2-pyridone , 
there are few examples of the Mitsunobu reaction with 4-pyridone.
175
 Comins et al suggest 
that THF is an appropriate solvent to form the O-alkylated product in a Mitsunobu reaction 
with 2-pyridone.  However, in our hands 4-pyridone in THF forms the N-alkylated product. 
The pKa of 2-pyridone (11.62)
175
 is similar to that of 4-pyridone (pKa of 11.09)
176
, so should 
not influence the reaction outcome. However, Schlegal et al suggest that a weak interaction 
can occur between the 2-hydroxy and pyridine nitrogen in 2-hydroxypyridine, stabilising the 
hydroxy form slightly, and it could be this form which reacts in the Mitsunobu reaction.
177
 
However, in view of the disappointing yield an alternative method of formation of 4-
cyclohexylmethyoxypyridine was investigated. 
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Figure 47 Proposed interaction between 2-hydroxy group and nitrogen of 2-hydroxypyridine 
 
Alkylation of 4-pyridone with (bromomethyl)cyclohexane in the presence of a base was 
investigated. Two products are possible from this reaction, the N-alkylated product and the 
O-alkylated product. By altering the reaction conditions the reaction could be tuned to 
provide the desired O-alkylated product (Table 8). All the reactions used 1 equivalent of 4-
pyridone, 1.5 equivalents of base, 5 equivalents of cyclohexylmethyl bromide and if used, 2 
equivalents of 18-crown-6 and followed the procedure as described for 1-
(cyclohexylmethyl)pyridin-4(1H)-one (137). 
 
Scheme 26 Reagent and conditions; a) (bromomethyl)cyclohexane, base and solvent  
 
18-Crown-6 was used as an additive to the reaction as previous work within the laboratory 
suggested that this would increase the yield of the O-alkylated product.
178
 Crownethers 
‘shield’ the cation allowing delocalisation of the negative charge. But in our hands this did 
not aid formation of the desired product. Both CsF and Cs2CO3 were used as a larger, softer 
cation may allow delocalisation of the negative charge, therefore resulting in O-alkylation. 
Caesium carbonate did result in formation of the greatest percentage of the desired product 
(127) but still a 1:1 ratio of product and unwanted isomer was formed. Both Hopkins et al 
and Comins et al suggest that silver salts favour formation of O-alkylated products in 
alkylation reactions of 2-pyridone,
175, 179
 and Hopkins et al also demonstrated selective O-
alkylation by using pentane as a solvent.
179
 In our case, silver salts gave particularly poor 
yields of any alkylated products. 
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Table 8 Conditions and yield for the 4-pyridone alkylation reaction 
Solvent Base Additive Conditions 
N-alkylation 
yield 
O-alkylation 
yield 
DMSO NaH - 18 h, RT 46% 26% 
DMSO K2CO3 - 26 h, RT 71% 24% 
DMSO NaH 18-crown-6 48 h, RT 49% 5 % 
DMSO K2CO3 18-crown-6 26h, RT 41% 14% 
DMSO Cs2CO3 - 5h, RT 42% 46% 
DMF Cs2CO3 - 21 h 38% 41% 
DMSO CsF - 
28 h RT, 4 
days, 30 
o
C 
48% 7% 
DMF CsF - 
28 h RT, 4 
days, 30 
o
C 
45% 8% 
DMF Ag2CO3 - 
2 days, RT, 60 
o
C, 16 h 
17% - 
Pentane Ag2CO3 - 
2 days, RT, 60 
o
C, 16 h 
- - 
 
Identification of the two isomers was possible via the 
13
C NMR spectrum and by comparison 
with the 4-methoxypyridine 
13
C spectrum. The NMR spectrum of the N-alkylated product has 
a signal at 179 ppm, which corresponds to the pyridone carbonyl carbon, whilst the O-
alkylated product has a signal at 166 ppm which corresponds with the pyridine C-O carbon. 
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Figure 48 
13
C NMR spectrum of the N-alkylated (left) and the O-alkylated product (right) 
 
To confirm the identity of the two possible isomers a crystal structure of the putative O-alkyl 
product was obtained. The N-alkylated product did not give appropriate crystals for X-ray 
crystallography. 
 
Figure 49 X-ray structure of the O-alkylated product (127) 
 
To avoid the formation of the undesired N-alkylated an alternative route to the desired 4-
cyclohexylmethoxypyridine was developed. Utilising a similar approach to pyrimidine 
derivatives the chloro group can be displaced from 4-chloropyridine by sodium alkoxide. To 
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o         vercome the less electron-deficient nature of the pyridine ring the reaction temperature 
was increased to 200 
o
C, and resulted in good conversion to the product in 3.5 h.  
 
To utilise the synthetic route developed by Manley et al the pyridine N-oxide must first be 
formed. This was achieved using m-CPBA at room temperature in good yield. 4-
Methoxypyridine was also used as a model compound for this reaction and was converted to 
pyridine N-oxide 140 in good yield. Manley et al formed imidolyl chloride (139) in situ from 
a secondary amide on treatment with oxalyl chloride and 2,6-lutidine.
174
 It is the imidoyl 
chloride species which then reacts with the pyridine N-oxide. 
 
Scheme 27 
 
N-benzylacetamide (138) was synthesised by treating benzylamine with acetic anhydride in 
27% yield. 138 was then treated with oxalyl chloride and 2,6-lutidine in DCM at 0 
o
C, and 
after 15 min 4-methoxypyridine N-oxide was added and the reaction was warmed to RT. 
Unfortunately, during the model reactions no reaction was observed, and so an alternative 
method to incorporate the desired 2,6-diamino motif was required. Treatment of pyridine N-
oxides with phosphorous oxychloride results in chlorination α to the nitrogen atom. The 
phosphorous oxychloride firstly reacts with the N-oxide which results in the loss of a chloride 
ion. This chloride ion can then attack the ring, which has been activated towards nucleophilic 
attack by formation an intermediate N-oxy species, which makes the ring more electron-
deficient. 
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The new proposed scheme is shown below (Scheme 28). Each reaction of the N-oxide will 
result in the addition of one chloro group. Therefore, the molecule must be re-oxidised to 
incorporate the second chloro group. After both chloro-groups have been incorporated they 
can be displaced using p-methoxybenzylamine, which can act as a protected form of the 
amino groups for the synthetic route. 
Scheme 28 Proposed reagents and conditions; a) Na, cyclohexylmethanol, 3.5 h, 200 
o
C, 
53%; b) m-CPBA, DCM, 2 days, 97%; c) POCl3, MeCN, 30 min, 160 
o
C, 56%; d) m-CPBA, 
DCM, 94%; e) POCl3, MeCN 
 
The optimal conditions for the chlorination were found to be with POCl3 in MeCN and 
microwave heating at 160 
o
C for 30 min giving compound 142 in a 56% yield. Conventional 
heating resulted in lower yields and required overnight heating. Re-oxidising to the N-oxide 
was achieved using mCPBA in good yield 94%. However, the second chlorination failed to 
occur, both with microwave and conventional heating and continual heating resulted in the 
formation of a number of by-products. 
 
An alternative synthetic route to the desired pyridine analogue was required. Braxmeier et al 
has synthesised 4-benzyloxy-2,6-diaminopyridine (148) in three steps from chelidamic acid, 
by utilising a Hofmann rearrangement to convert amide groups to amine groups (Scheme 
29).
180
 The benzyloxy pyrimidine derivatives are equipotent as mTOR inhibitors, so to allow 
direct comparison with the literature compounds, it was decided to synthesise compound 149. 
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The first step of the synthetic scheme is an alkylation of both carboxylic acid groups and the 
pyridine oxygen, followed by conversion to the amide, prior to the Hofmann rearrangement. 
In our hands these alkylation conditions resulted in the formation of multiple products, 
making it difficult to identify the desired products 
 
Scheme 29 Reagents and conditions; a) BnBr, K2CO3, acetone, 3 days, reflux, 71%; b) 
ammonia, methanol, 3 h, 93%; c) 5 M KOH(aq), Br2, 5 h, 90 
o
C, 76%
180
 
 
However, alternative procedures to dialkyl 4-alkoxy-pyridine-2,6-dicarboxylate rely on 
formation of the esters before alkylation.
181
  Conversion of chelidamic acid (150) to ethyl 
ester (153) followed by alkylation of the pyridine ring proved to be more reliable, with the 
alkylation achieved in particularly high yield (96%) (Scheme 31). The solvent was changed 
for the alkylation reaction, using DMF rather than acetone suggested by Kruizinga et al.
182
 
Conversion of the ester groups to amide was achieved using 7 M ammonia in methanol in 
good yield (Scheme 30).  
 
The Hofmann rearrangement was achieved using bromine in 5 M KOH, which procedes via a 
nitrene species, which can rearrange to an amine, via an isocyanate. The desired 2,6-diamino 
functionality was now in place. The amino groups were then protected using acetic acid and 
acetic anhydride at room temperature in 91% yield. The pyrimidine-based synthesis of nitrile 
analogues suggested that the motif must be protected to prevent chelation to the copper 
cyanide.
152
 As the pyridine ring has two potential sites of electrophilic addition it was decided 
the ring should be deactivated slightly to prevent over-substitution. Therefore, the acetyl 
protection was incorporated before the bromination. Bromination was achieved using NBS in 
acetic acid in a 77% yield. However, on treating the brominated pyridine with CuCN in DMF 
at 120 
o
C no product was formed.  Increasing the temperature only resulted in decomposition. 
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The reaction was then repeated at higher temperatures using microwave irradiation, with N-
methylpyrrolidinone as solvent. Under the conditions, only slight traces of the product were 
observed, with the majority of the starting material decomposing. The reaction was repeated 
with further equivalent of CuCN, with similar results, as well as with the deprotected 
compound, but no compound was isolated.  
 
 Nitrile groups can also be incorporated using a palladium-catalysed method. Maligres et al 
used Pd(dba)2 to catalyse the formation of aromatic nitriles from aromatic bromines using 
Zn(CN)2.
183
 However, under these conditions no reaction occurred. Replacing the catalyst 
with Pd(PPh3)4 also failed to give any product.  It was therefore decided to halt the attempted 
synthesis of this molecule. 
Scheme 30 Proposed reagents and conditions; a) SOCl2, EtOH, 2 h, reflux, 46%; b) benzyl 
bromide, K2CO3, DMF, 30 min, 80 
o
C, 96%; c) 7 M methanoic ammonia, 3.5 h, 88%; d) Br2, 
5 M KOH(aq), 2 h, 90 
o
C, 71%; d) Ac2O, AcOH, 3 days, 92%; e) NBS, AcOH, 30 min, 77%; 
f) i. CuCN, DMF; ii. ethylenediamine 
 
Whilst this work was ongoing the direct pyridine analogue of NU6027 was also synthesised. 
Using the previously developed methodology, compound 160 was synthesised using the route 
shown below. Formation of 160 proceeded cleanly in 30 min using standard nitrosating 
condition of NaNO2 in 30 % acetic acid in water to give the direct pyridine analogue of 
NU6027. 
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Scheme 31 Reagents and conditions; a) (bromomethyl)cyclohexane, K2CO3, DMF, 16 h, 80 
o
C, 70%; b) 7 M NH3 in MeOH, 1 h, 47%; c) Br2, 5M KOH, 90 
o
C, 2 h, 47%; d) NaNO2(aq), 
AcOH(aq), 30 min, 80 
o
C, 47% 
 
The alternative pyridine analogue of the ‘hit’ compounds was also required. Szczepankiewicz 
et al synthesised 2-alkoxy-3-carbonitrile-4,6-diaminopyridines from a bromo-substituted 
pyridine ring, with a sodium alkoxide to displace the bromo group.
155
 Szczepankiewicz et al 
synthesised the bromo-substituted pyridine ring (162) in a one-step cyclisation step as 
described by Carboni et al by treating malononitrile with gaseous hydrogen bromide.
184
 For 
safety reasons, the reaction was replicated using a liquid solution of 45% HBr in acetic acid, 
resulting in multiple products by TLC, and it was not possible to isolate the desired 
intermediate.  
 
Scheme 32 Proposed reagents and conditions; a) 48% HBr in AcOH; b) Na, 
cyclohexylmethanol 
 
Silver et al treated malononitrile with zinc chloride in the presence of ethanol to synthesise 3-
carbonitrile-4,6-diamino-2-ethoxypyridine.
185
 A proposed mechanism of formation of the 
pyridine ring is shown below. 
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Scheme 33 
 
The synthesis of compound 162 by treating malononitrile with ZnCl2 in the presence of 
cyclohexylmethanol was attempted. A number of products was observed by TLC, and 
although the LCMS suggested that the correct product had been formed, it was not possible to 
isolate the desired compound. The reaction was repeated using ethanol as described in the 
literature, but multiple products were formed. 
 
Scheme 34 Proposed reagents and conditions; a) ZnCl2, cyclohexylmethanol, 100 
o
C 
 
Junek et al treated 2-amino-1,1,3-tricyanopropene (163) with sodium alkoxide, synthesising a 
pyridine ring with the desired functionality.
186
 2-Amino-1,1,3-tricyanopropene is also known 
as malononitrile dimer and is proposed as the intermediate in the synthesis of the substituted 
pyridine described by Carboni et al, suggesting that this reaction may proceed by a similar 
mechanism, which is shown below.
184
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Scheme 35 
 
Nitrile 163 was treated with sodium methoxide for 48 h at reflux forming two products, as 
described by Junek et al.
186
 The two compounds had similar Rf to those described in the paper 
(0.3 and 0.6 in 4:1 diethyl ether to petrol). The major compound, with an Rf of 0.3, was 
isolated in 20%. It is this compound which Junek et al identified as being the desired isomer. 
The minor compound has an Rf of 0.6 and was produced in 5% yield. 
 
Scheme 38 Reagents and conditions; a) Na, MeOH, 48 h, reflux, 164 = 20%, 165 = 5% 
 
NMR experiments were undertaken to confirm the identity of the compounds. The proton 
NMR spectrum was insufficient to identify the compounds.  A 1D nOe (Nuclear Overhauser 
Effect) experiment was undertaken to observe interactions between the protons within the 
molecule. By the irradiation of a known proton (in this case the aromatic proton), an effect 
should be observed on protons which lie close within space to this proton.  For the desired 
isomer an interaction should be seen between the aromatic proton and both amino groups, 
and for the unwanted isomer an interaction should be seen between one amino group and the 
methyl group. On running the 1D nOe experiment on the major compound an interaction was 
seen between the aromatic proton and both amino groups. These results suggest the major 
compound is the desired isomer. However, when the same experiments were run on the minor 
compound no interaction was seen. As a result a new 
1
H NMR experiment was run, which 
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revealed significant decomposition of the compound, suggesting this compound is unstable in 
deuterated chloroform. This degradation would explain the apparent lack of interaction 
between protons in the nOe experiment. 
 
 
 
Figure 50 
1
H NMR spectrum and 1D nOe experiment performed on compound 165 
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A further experiment was therefore run to confirm the identity of 165. A 
15
N HMBC looks at 
the interaction between nitrogen atoms and the protons. The interaction between a proton and 
the nitrogen atoms can occur only over a distance of four bonds. With the desired compound 
the aromatic proton will interact with three nitrogen atoms, however the other isomer will 
only interact with 2 nitrogen atoms. After running the 
15
N HMBC experiment on the major 
product the aromatic proton was seen to interact with 3 nitrogen atoms, confirming that the 
major product is the desired isomer (165). 
 
Figure 51 
 
 
Scheme 37 Reagents and condition: a) Na, cyclohexylmethanol, 48 h, 120 
o
C, 4% 
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After successfully forming the methoxy analogue (165), synthesis of the direct pyridine 
analogue of NU6227 was undertaken using cyclohexylmethanol. The reaction mixture was 
heated at 120 
o
C for two days resulting in a complex mixture which required prep. HPLC. 
The 1D nOe experiment was not conclusive as irradiation at the frequency of the aromatic 
proton resulted in signal in both the diamino protons and the cyclohexylmethoxy CH2 
protons. However, the 
15
N HMBC showed that the aromatic proton interacts with three 
nitrogen nuclei, both amino nitrogens and the pyridine nitrogen. As this interaction occurs 
over a maximum of three bonds the aromatic proton must lie between the amino groups for 
this to occur. This suggests that the synthesised compound is the desired substance. 
 
The synthesis of both pyridine isomers of the modestly active pyrimidine compounds 
unfortunately failed to maintain activity against mTOR; therefore no further investigation of 
this heterocycle was undertaken. 
 
4.6 Biological Results 
 
4.6.1. Assay details 
 
Biological analysis was carried out at the Northern Institute for Cancer Research by Lan Zhen 
Wang. Testing was undertaken with a KLISA assay using a recombinant human mTOR 
protein, recombinant p70S6K-GST protein, ATP, an anti p70S6K-T389 antibody and a 
secondary antibody with immobilised horse radish peroxidase. 
 
A solution of p70S6K protein was added to a 96 well plate and incubated for 1 h at room 
temperature. Excess solution was then poured away and the plate dried. A solution of tris 
buffered solution (TBS) was used three times to wash the wells. The mTOR standard (protein 
and ATP) and the compound (dissolved in DMSO) were then added to the wells with a buffer 
solution; the plate was then covered and shaken for 30 seconds by a plate shaker, then 
incubated for 30 min at 30 
o
C. The kinase stop solution was then added and the plates 
washed. The anti p70S6K-T389 antibody solution was added and the plate incubated at room 
temperature for 1 h. The plate was washed and the horse radish peroxidase conjugate 
antibody added, then again incubated for 1 h and washed. A 3,3’,5,5’-tetramethylbenzidine 
(TMB) solution was added and the mixture was incubated for 10 min at room temperature, 
followed by the ELISA stop solution (2.5 M H2SO4). The plate was read at 450 nm.  
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Table 9 Biological results * indicates compounds first synthesised by other chemists 
Number Series R X Y 
mTOR 
inhibition                
(% inhibition 
at 10 µM) 
56* A 
 
NO NH2 80 
59* A 
 
CN NH2 64 
166* A 
 
NO NH2 23 
81 A 
 
CN NH2 12 
82 A 
 
CN NH2 34 
167* A 
 
NO NH2 42 
83 A 
 
CN NH2 42 
84 A 
 
CN NH2 40 
168* A 
 
NO NH2 43 
85 A 
 
CN NH2 N. D. 
169* A 
 
CN NH2 29 
170* A 
 
NO NH2 44 
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86 A H CN NH2 37 
95 A 
 
CN H 17 
118 A 
 
CH2CN NH2 0 
160 B 
 
NO NH2 34 
162 C 
 
CN NH2 0 
 
None of the new compounds that have been synthesised showed improved activity compared 
to the parent compounds. All newly synthesised compounds were weakly active, with an IC50 
against mTOR > 10 µM. The 5-nitroso or nitrile substituent has been demonstrated as 
important for activity, as is the triplet of hydrogen bonds. 
 
The series of O
4
-alkyl substituents demonstrated that the further the alkyl group is from the 
cyclohexylmethyl group, in both size and shape, the greater the loss of activity. A series of 
aromatic O
4
-derivatives have been synthesised and demonstrated a tolerance for large 
lipophilic groups – suggesting the alkyl groups are too small to fill the lipophilic pocket in 
which the O
4
-substituent sits.  Complete removal of the substituent at the 4-position, 
interestingly, has increasing biological activity over smaller alkoxy derivatives, suggesting 
that the oxygen atom itself is not forming an interaction with the protein, but is only acting as 
a link between the pyrimidine ring and the alkyl substituent. No substituent at the 4-position 
appears to be preferred over a small alkoxy substituent. 
 
Insertion of a CH2 group between the pyrimidine ring and the nitrile group in compound 117 
abolished activity. The binding site around the 5-position may be very narrow, and does not 
tolerate the additional chain length.  Or, the additional CH2 group positions the nitrile group 
in the incorrect alignment to form a hydrogen bond with the protein. Removal of the 2-amino 
groups also abolished activity, underlining the importance of the triplet of hydrogen bonds, 
for not only CDK2 inhibition but also for mTOR inhibitory activity. 
 
For both pyridine-based compounds, activity was significantly reduced. For compound 157, 
activity was approximately halved. Though the triplet of hydrogen bonds is maintained, a 
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nitrogen atom at the 3-position of the pyrimidines is deleted, which may be forming an 
interaction with the protein. However, the change from pyrimidine to pyridine heterocycles 
will also result in a change in pKa. This may result in a change of protonation state under 
assay conditions, which removes the acceptor moiety of the donor-acceptor-donor motif.  
Compound 160 completely abolishes mTOR inhibitory activity. Removal of the acceptor 
moiety of the triplet of hydrogen bonds resulted in a complete loss of activity. 
 
Interestingly, though mTOR activity is significantly reduced by the modification from the 
pyrimidine to the pyridine heterocycle, CDK2 activity does not follow the same trend. 
Compound 157, which retains the triplet of hydrogen bonds maintains biological activity, but 
compound 160, which lacks the triplet of hydrogen bonds has significantly reduced biological 
activity. 
 
Table 10 Biological activity against CDK2 
Number Series X 
CDK2 inhibition                  
% inhibition at 100 µM    
(IC50 (µM)) 
160 A NO (5.2) 
162 B CN 43 
 
 
 
 
 
 
 
 
 
 
4. The Development of ATP-competitive Inhibitors of mTOR 
 
120 
 
4.7 Future Work for the Development of Pyrimidine-based mTOR Inhibitors 
 
A 5-fluorinated pyrimidine was desired to determine the role of the 5-substituent, specifically 
the requirement to form an intermolecular hydrogen bond, or as an electron withdrawing 
group. Due to time constraints it was not possible to explore fully the alternative routes to 
access compound 122. One approach would involve the building of the pyrimidine ring with 
the 5-fluoro substituent in place. 
 
Joule et al proposed that the use of ethyl-2-cyanoacetate would allow the 6-amino group to be 
incorporated during the building up of the pyrimidine heterocycle.
187
 Protons which lie 
between the nitrile group and the ester groups are acidic, with a pKa value of ca. 13.
188
 
Deprotection followed by quenching the anion with a source of F
+
 should result in generation 
of compound 172. Formation of the pyrimidine from guanidine would allow incorporation of 
the 2-amino group. After chlorination of the oxo group with POCl3 and displacement with 
cyclohexylmethoxide the desired compound 119 would be obtained. 
 
Scheme 38 Proposed reagents and conditions; a) KOH, Selectfluor, THF; b) Na, methanol; c) 
POCl3 d) Na, cyclohexylmethanol 
 
Parks et al have reported the regiospecific displacement of fluorine atoms by nucleophiles 
from tetrafluoropyrimidine.
189
 Using a similar approach, the desired fluoro compound could 
be synthesised. The displacements are thought to occur first at the 4- and 6-position, followed 
by the 2-position. Therefore, adapting the synthetic route shown below, compound 122 could 
be synthesised. Hünig’s base was added by Parks et al to all reactions to neutralise any 
formed HF.
189
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Scheme 39 Proposed reagents and conditions; a) p-methoxybenzylamine, DIPEA, THF, 0
 o
C; 
b) Cyclohexylmethanol, NaH, THF, DIPEA, room temperature; c) p-methoxybenzyl amine, 
DIPEA, THF, 140
 o
C 
 
Nowak et al have described the synthesis of pyrazolopyrimidine-based potent mTOR 
inhibitors such as 179, with an IC50 of 4 nM.
72
 The 5-nitroso compound (180) has been 
demonstrated to form a hydrogen bond between the 5-nitroso substituents and the proton on 
the 6-amino group forming a pseudocycle. Therefore a pyrimidine with a 5-nitroso 
substituent may act as a mimetic for a pyrazolopyrimidine, and a scaffold–hopping approach 
will identify active substituents for the pyrimidine ring such as 180. 
 
 A SNAr reaction between sodium methoxide and trichloropyrimidine will result in 
substitution at the 2-position, the most reactive position. Two further SNAr reactions with 
morpholine and N-benzyl protected 4-aminopiperidine, will incorporate the desired 
functionality at both the 4- and 6-position. Removal of the methyl group with the Lewis acid 
boron tribromide, will also result in removal of the Boc protecting group. Triflation of the 
resulting hydroxyl group will generate the appropriate substituent for a Suzuki reaction, 
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which followed by nitrosation and treatment with benzoyl chloride should result in the 
formation of the desired compound. 
 
Scheme 40 Proposed reagents and conditions; a) Na, MeOH; b) Morpholine, DIPEA, THF; 
c) 4-amino-1-Boc-piperadine, DIPEA, THF; d) 1 M BBr3 in DCM, DCM; e) Tf2O, Et3N, 
THF; f) (3-hydroxyphenyl)boronic acid, Pd(PPh3)4, Na2CO3, dioxane, water; g) NaNO2, 
AcOH, water;  h) Benzoyl chloride, Et3N, THF 
 
4.8 Conclusion 
 
mTOR is an attractive anti-cancer target due to its function within the PI 3-K/Akt pathway, 
which frequently suffers from aberrant signalling within cancer. Our work on ATP-
competitive inhibitors of mTOR began with a series of pyrimidines with modest activity 
against mTOR. Synthetic efforts have identified the importance of the pyrimidine heterocycle 
through the synthesis of two pyridine analogues. The synthesis of a 2-unsubstituted analogue 
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of NU6227 has also identified the importance of the triplet of hydrogen bonds formed with 
the protein.  Modifications to the O
4
-substituent with a series of alkyl derivatives reduced 
activity, alkyl groups such as the sec-butyl which had comparable shapes and size to the 
cyclohexylmethyl group were shown to be the most active of the newly synthesised 
analogues, whilst smaller groups, such as the ethyl analogue, were shown to be less active 
than complete removal of the 4-substituent. A series of substituted benzyl analogues have 
also been synthesised and showed a flat SAR, suggesting that the O
4
-substituent sits within a 
large lipophilic pocket, which is not fully utilised by the alkyl substituents. The initial screen 
of compound which identified the 2,6-diaminopyrimidine scaffold, demonstrated that 5-
substituents capable of forming a hydrogen bond gave activity. An additional methylene 
group between the pyrimidine ring and the hydrogen bond forming substituent essentially 
abolished activity. Therefore, despite the extensive synthetic efforts no compound was 
synthesised with improved activity over the initial compound within the screen. 
 
Since work began at the NICR on the development of ATP-competitive inhibitors of mTOR a 
number of highly potent and selective inhibitors of mTOR have been published, and a 
number of these have progressed into clinical trials. Many of these inhibitors are, like the 
NICR series, based on nitrogen containing heterocycles.  The compound space has been 
covered extensively in this area, suggesting that continued synthetic efforts may not result in 
the synthesis of a novel compound.
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5. Isoindolinone-Based Inhibitors of the MDM2-p53 Protein-protein Interaction 
 
5.1 Development of Isoindolinone Based Inhibitors of the MDM2 p53 Protein-protein 
Interaction 
 
The Northern Institute for Cancer Research programme to discover inhibitors of the MDM2-
p53 protein-protein interaction was initiated by the identification of a number of 
isoindolinone-based compounds, by a preliminary screen of compounds using an in vitro 
binding assay.
190
 Compounds 189, 190 and 191 were identified as weak inhibitors with IC50s 
of around 200 µM,  were shown to have growth inhibitory activity in NCI 60 cell line screen 
and were classed as COMPARE negative against known classes of antitumour agents.
190
 
 
Figure 52 Structure of the initial isoindolinone hits 
 
A programme of library synthesis was undertaken, guided by a virtual screening to suggest 
desired compounds.
190
 Compounds 189 and 191 were docked into MDM2 to identify a 
single, low energy binding mode using the program easyDOCK.
190
 Both stereoisomers of the 
isoindolinones were docked into the 1YCR crystal structure of MDM2. However, due to the 
lipophilicity of both the compounds and the MDM2 binding site, along with the open shape 
of the compounds a large number of potential binding modes were identified.
190
 
 
A number of further compounds were synthesised, some suggested from ‘virtual screening’ 
by the selection of a single binding mode from those identified, others suggested by the 
availability of starting material during the synthesis of the isoindolinones. However, those 
suggested by the ‘virtual screening’ were found to be no more potent than those synthesised 
without docking.
190
 These results suggested that there may be multiple experimental binding 
modes for isoindolinones and MDM2, and that the use of multiple binding modes within 
computational chemistry may increase possibility of accurately predicting the experimental 
binding mode. This approach was used to identify a more diverse group of seed compounds 
which were used by to aid the identification of the experimental binding mode.
190
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Six seed compounds were selected and synthesised with activities ranging from 27 to 92 
µM.
190
 These compounds were again docked into the MDM2 crystal structure using both the 
easyDOCK and GOLD program which again generated a large number of solutions. 24 high 
scoring, unique binding modes were chosen as a starting point for further work. These 24 
modes were generated from the six seed compounds, one per stereoisomer of each compound 
per docking program. In each mode the position of the isoindolinone was preserved and 
unique compounds generated by varying R
1 
or R
2
 using commercial reagents. 
 
Figure 53 Structure of the isoindolinone core 
 
The interaction between the ligand and MDM2 protein was further explored using the 
program Skelgen.
190
 This explores the interaction of a ligand with that of the active site of a 
protein, defined as a rectangular box with selected fragments included. Ligands were selected 
which formed at least one interaction with the target residues within the MDM2 protein. The 
target residues included Leu54 O, Phe55 O, Gln59 NE2, Gln72 O and OE1, Val93 O, His96 
ND1 and Tyr100 OH.
190
 The parameters suggested 57 ‘virtual hits’ and of the 57, 43 were 
synthesised. These 43 compounds covered 14 of the 24 potential modes, with substituents 
selected which appeared in only one binding mode chosen to aid identification of the 
preferred binding mode.
190
 
 
Of the 43 synthesised compounds, five showed no appreciable inhibitory activity, 
approximately half showed inhibitory activity in the region of  100-400 µM, a further 12 
showed  activity in the 50-100 µM range, similar to the initial six seed compounds.
190
 Two 
compounds had activity that improved on the most potent of the seed compounds. From these 
compounds a number of binding modes were proposed, dependent on the R
1
 and R
2
 
substituents, the most important being those associated with the two most active 
compounds.
190
 
 
The first binding mode has the isoindolinone lying in the Trp23 pocket, with an N-
ethylacetamide group (R
1
) forming an H-bond interaction to Gln72 within the Phe19 pocket. 
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A tert-butylbenzyl group (R
2
) overlays the surface.
190
 The second binding mode has the 
isoindolinone overlying the surface with the Trp23 pocket occupied by the 3-phenyl group, 
syringic alcohol (3,5-dimethoxy-4-hydroxybenzyl alcohol) (R
2
) in the Leu26 pocket which 
forms an H-bond to Trp100 and an N-benzyl group (R
1
) in the Phe19 pocket.
190
  
 
A combinatorial approach was then undertaken using the most favourable substituents which 
are summarized below.
190
 This resulted in the design of 36 isoindolinones, with the number 
reduced as synthesis proved problematic or preliminary biological results proved 
disappointing. The 4-SEM group was found to be a poor substituent, suggesting that 
previously the group was forming a non-specific hydrophobic interaction. 4-Chlorophenyl 
was the preferred aromatic substituent, with the presence of this substituent suggesting that 
the compounds are making a favourable interaction with the hydrophobic Trp23 pocket.
190
 
This correlates with the second mode described. The most active compounds identified are 
shown below.
190
 
 
Figure 54 The isoindolinone scaffold with favoured substituents in each position 
 
 
Figure 55  
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Selected isoindolinones had also been shown to behave in a dose-dependent manner, with 
p53 related gene transcription increasing with increasing dose within a MDM2 amplified 
SJSA human sarcoma cell line.
191
 However, combinatorial chemistry and molecular docking 
were not providing sufficient increases in potency. Additional information about how the 
isoindolinone binds to MDM2 would validate the structure-activity relationships and suggest 
areas for further modification. Due to the moderate potency of these protein-protein inhibitors 
it can be difficult to gain further structural information. Computational methods are limited 
when interaction is due to hydrophobic interactions rather than H-bonds. Crystallography can 
also potentially prove difficult due to the weak infinities, poor solubility of the inhibitors and 
the flexibility of the protein. NMR studies would also prove difficult as the protein must be 
saturated and a micromolar affinity would result in line broadening.
191
 
 
A different approach uses 2D HSQC-NMR chemical shifts to determine the location of a 
ligand binding by observing changes in the chemical shift. The binding mode is determined 
by comparing the experimentally observed chemical shifts with those predicted for each of 
the suggested binding modes.
191
 
 
The 12 isoindolinones that were subjected to NMR analysis were divided into groups that 
differed in only one area of their chemical structure, either the isoindolinone N-substitution or 
substitution in the 3 position. The 3-position aromatic was fixed as a p-chlorophenyl moiety. 
The active site of the MDM2, in which the isoindolinone binds, can be summarised as 4 main 
sub-pockets.
191
 
 The pocket in which Trp23 of p53 binds is a shallow pocket, with the Trp23 forming 
a H-bond with Leu54 on MDM2 
 The Leu26 pocket formed by the residues Ile99 and Ile103 of MDM2 
 The Phe19 pocket around residue Ile61 
 A deep pocket in which the Trp23 side chain lies 
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Figure 56 Surface representation of MDM2 (1YCR) with the 4 sub-pocket highlighted.  
(1) Trp23 sub-pocket (2) Leu26 sub-pocket (3) Phe19 sub-pocket (4) Trp23 side chain sub-
pocket (Taken from reference 190) 
 
For the NMR studies 38 residues surrounding the isoindolinone binding site were monitored. 
The 38 residues were the most likely to be affected by the binding:  
 helix α2 (residues 50 to 63 and 67 to 75) 
 helix α1’ (residues 82 to 86) 
 helix α2’ (residues 91-106) 
Cluster analysis was then performed on each residue per group of compound, with closely 
clustered peaks suggesting similar binding. As each group only differs chemically in one 
area, the area of unclustered peaks will be the area of different binding. This was used to 
show which amino acid residue lies near each area of the isoindolinone.
191
 
 
As a result of these NMR studies the isoindolinones are thought to bind with either the 
isoindolinone or the 4-chlorophenyl group pointing into the deep pocket of MDM2, the Ile99 
pocket is thought to prefer aromatic groups, while both Leu54 and Ile 61 pockets are not 
selective for the type of group.
191
 NMR studies with compound 184 identified a significant 
shift in the signal for the Leu54 region, which was thought to be due to an interaction 
between Leu54 and the hydropropoxy chain. It was proposed that by introducing rigidity to 
the propyl chain activity could be improved. Replacement of the propyl chain with a 
cyclopropyl derivative increased activity to 3.0 µM.
192
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Figure 57 Structure of (R)-NU8165 (194) bound to MDM2 deduced from HSQC NMR 
studies (left) and modelling of a cyclopropyl derivative (Taken from reference 193) 
 
Further SAR studies with the 3-hydroxyisoindolinone identified small lipophilic groups at the 
4-position of the N-benzyl group as improving potency. Inclusion of a chlorine atom at this 
position resulted in a compound 17 times more potent than an initial parent compound. 
However, it was then found that inclusion of a nitro group at this position increased potency 
further, with activity 30 times greater than that of the parent.
192
  
 
Combining the optimal nitrobenzyl substituent with a racemic cyclopentyl ether side-chain 
was discovered to have an additive effect with an IC50 of 0.70 µM, and on synthesis of the 
cis-derivative gave an IC50 of 0.30 µM. A range of alkoxy derivatives were then incorporated 
to probe the SAR around this region, that identified the 1,1-bis(hydroxymethyl)cyclopropyl 
derivative as the optimal substituent at this position.
192
 Interestingly, in NMR studies with 
cyclopropyl derivative (195) the 2-cyclopropylpropanol chain is seen to interact with an area, 
which is not exploited by either the Nutlin series or the benzodiazepinedione series.
192
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 NMR studies were undertaken comparing isoindolinone, Nutlin-3 and p53 peptide binding to 
MDM2. The ‘footprint’ of isoindolinone, Nutlin-3 and p53 binding was then characterised.193 
A 2D NMR 
1
H 
15
N-heteronuclear single-quantum coherence (HSQC) titration was 
undertaken with a range of concentration of each inhibitor. The binding of ligands resulted in 
a shift in signal in the primary sequence of MDM2, apart from the C-terminal 10 residues. 
The average chemical shift is 0.045 to 0.083 ppm. Nutlin-3 has an average shift of 0.076 
ppm, p53 peptide has an average shift of 0.22 ppm and compound 195, the most potent 
isoindolinone compounds analyzed had an average shift of 0.075 ppm.
193
 The greatest 
observed shift was seen in the hydrophobic pocket, which is in direct contact with the 
ligands. The greatest shift was observed between the helix 2α (residues 51-63), the area 
surrounding β-strands β3 and β1’ (residues 66-77) and the region connecting β2’ to α2’ 
(residues 89-104). The N-terminal also has larger shift, due to the change in conformation 
from the closed to open position.
193
 Nutlin-3 was seen to induce a larger chemical shift on the 
beta sheet β3, while isoindolinone 195 has a greater effect on resides at the opposite side of 
the pocket helix α2’ and the back of Trp23 pocket.193 This underlines that whilst all 
MDM2/p53 inhibitors are acting as p53 α-helix mimetics; there are differences between 
binding modes of the inhibitors. 
 
As the nitro group is undesirable within drug molecules, due to the possibility of forming 
toxic metabolites, a number of classical and non-classical isosteres for the nitro group have 
previously been investigated. A table of the previously synthesised compounds and their 
activity is shown below.
194-195
 Compounds all have the structure type shown below 
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Table 11 Classical and non-classical isosteres attempted for replacement after the nitro 
benzyl group 
 
 
Compound number Structure of R group 
IC50 of activity against 
MDM2 (µM) 
195 
 
0.23 ± 0.11 
196 
 
23
a
 
197 
 
>10 
198 
 
210
a 
199 
 
180 
200 
 
8.9 ± 3.8 
201 
 
8.8 ± 4.2 
202 
 
250
a 
203 
 
> 200
a 
204 
 
29 ± 6.0 
205 
 
>200 
206 
 
11 ± 0.8 
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207 
 
32 ± 5.2 
208 
 
2.3 ± 0.059 
209 
 
1.8 ± 1.3 
210 
 
1.7 ± 0.73 
211 
 
2.3 ± 1.1 
212 
 
1.2 ± 1.2 
213 
 
1.0 ± 0.39 
214 
 
2.5 ± 0.86 
215 
 
180
a 
216 
 
> 20
a 
217 
 
> 50 
218 
 
15 ± 1.4 
219 
 
> 20 
a
 indicates n = 1 
 
Previous SAR studies around the ‘A’-ring showed that substitution around the isoindolinone 
further improved potency. A chloro-substituent in the 4-position was found to be optimal 
(220), increasing potency to 143 nM. A tert-butyl group in the 6-position was also shown to 
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be favourable, with an IC50 value of 152 nM. Some of the previously synthesised compounds 
are shown below.   
 
Table 12 Substitution patterns around the ‘A’ ring and the resulting activity against MDM2 
 
Compound Number ‘A’-ring and substituent 
IC50 of activity against 
MDM2 (µM) 
195 H 0.23 ± 0.11 
220 4-Cl 0.095 ± 0.096 
221 4-Me 0.30 ± 0.17 
222 5-
t
Bu 0.89 ± 0.29 
223 5-Br 0.90 ± 0.071 
224 6-
t
Bu 0.19 ± 0.10 
225 6-F 0.85 ± 0.090 
226 6-Br 1.0 ± 0.068 
227 5,6 Cl 3.7 ± 1.2 
228 4-Cl,5-F 0.31 ± 0.15 
 
Interestingly, the addition of the chlorine in the 4-position reduces the difference between the 
different benzyl substitutions. When the ‘A’-ring is unsubstituted the difference between the 
benzyl NO2 analogue and the bromo benzyl analogue is 5-fold. However, when the 4-chloro 
is placed on the ‘A’-ring the difference is less than 2 fold. These results are summarised 
below. 
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Table 13 Comparison activity of substituted isoindolinone with varying benzyl substitution 
Compound No. ‘A’-ring substitution Benzyl substitution 
IC50 of activity 
against MDM2 (µM) 
125 H NO2 0.23 ± 0.11 
212 H Br 1.2 ± 1.2 
209 H CN 1.8 ± 0.67 
220 4-Cl NO2 0.095 ± 0.096 
229 4-Cl Br 0.17 ± 0.003 
230 4-Cl CN 0.18
a
 
a
 indicated n = 1 
 
The values for all of the above compounds are for the racemic mixtures. When the most 
active compound 220 was separated into its two enantiomers, one was found to have an 
activity of 44 nM, with the alternative enantiomer shown to be significantly less potent. The 
inactive enantiomer was successfully crystallised, and the structure of the active enantiomer 
is that shown below. Treatment of SJSA-1 cell line with the active enantiomer of 220 
produced a concentration dependent inducement of MDM2, p53 and p21, treatment with the 
inactive enantiomer and resulted in a response at the highest dose of 20 µM. The dose-
dependent inducement of p21, p53 and MDM2 verifies that isoindolinones are acting via 
inhibition of the p53 MDM2 protein-protein interaction.
192
 
 
Figure 58 Active isomer of 220 
 
A final step forward in potency was discovered when attempting to add water-solubilising 
groups. A succinic ester group was added to the isoindolinone core via the diol side chain. 
Initially, the succinic ester group was added as a cleavable pro-drug, but the compound (231) 
displayed an increase in potency, with an activity of 11 nM. 
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Figure 59 The structure of 231 
 
The two compounds (220, 231) were the leads for the development of inhibitors of the 
MDM2-p53 protein-protein interaction described herein. 
 
5.2. Isoindolinone Formation 
 
The isoindolinone series of compounds were synthesised using methodology previously 
developed within the laboratory (Scheme 41).
192
 The first step of the synthetic route is a 
Friedel-Crafts reaction between the appropriate phthalic anhydride and chlorobenzene to give 
the benzoyl benzoic acid (233). The Friedel-Crafts reaction can be omitted when X = H as the 
required 2-(4-chlorobenzoyl)benzoic acid is commercially available. For compounds which 
require substitution around the ‘A’ ring of the isoindolinone, the initial step is synthesis of the 
benzoyl benzoic acid. The Friedel-Crafts reaction between the appropriate phthalic anhydride 
and chlorobenzene is mediated by aluminium chloride, generating the reactive acylium ion 
(236) via the mechanism below (Scheme 42). Stoichiometric amounts of AlCl3 must be used 
as it remains complexed to the oxygen and must be removed by hydrolysis at the end of the 
reaction.
196
  
Scheme 41 Reagents and conditions; a) PhCl, AlCl3, 90 
o
C, 2h; b) i. SOCl2, DMF, THF, 4 h; 
ii. Appropriate amine, Hünig’s base, THF, overnight; c) i. SOCl2, DMF, THF, 4 h; ii. 
Appropriate alcohol, K2CO3, THF, overnight 
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Scheme 42 Proposed mechanism of formation of the acylium ion 
 
In the case of substituted phthalic anhydrides, two possible isomers of the acylium ion may 
be formed, resulting in a mixture of isomers. For 3-chlorophthalic anhydride the major 
product formed is 3-chloro-2-(4-chlorobenzoyl)benzoic acid. The predominant formation of 
one isomer suggests that the chlorine atom plays a significant role in the reaction. One 
proposal is that the chlorine atom stabilises the acylium ion via conjugation (Scheme 43).
196
 
 
Scheme 43 Potential stabilisation of acylium ion 
 
Newman et al observed the same effect when performing a Freidel-Crafts reaction with 3-
chlorophthalic anhydride and benzene, with only the carbonyl alpha to the chloro atom 
reacting.
197
 Allahdad et al suggests that the aluminium chloride preferentially reacts with the 
most electron rich carbonyl group.
198
 For 3-chlorophthathlic anhydride the most electron-rich 
carbonyl group lies meta to the chloro group. If AlCl3 reacts with the meta carbonyl group, 
the acylium ion will be formed on the carbonyl group alpha to the chlorine atom. Both of 
these two different theories support formation of the acylium ion alpha to the chloro, which 
gives rise to the  3-chloro-2-(4-chlorobenzoyl)benzoic acid as the major product.
197
  
 
Scheme 44 Reagents and conditions; a) AlCl3, 2 h, 90 
o
C, 91% 
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The first work-up to the Friedel-Crafts reaction of 3-chlorophthalic anhydride and 
chlorobenzene an acidic solution resulted in the isolation of both possible isomers as a 
precipitate. However, on subsequent attempts the precipitate did not always occur and a 
further extraction into organic solvent was required, but re-extraction into organic solvent 
also resulted in the extraction of further impurities which were inseparable from the desired 
product. A simple alteration to the work-up avoided this problem. The benzoyl-benzoic acid 
was isolated as the sodium salt that precipitated reliably in good yield and purity (91 %). At 
this point the two isomers cannot be separated; the second step of the reaction is performed 
on the mixture of isomers. After formation of the isoindolinones the two isomers can then be 
separated. 
 
Scheme 45 The equilibrium between the open and cyclised form of ortho-benzoylbenzoic 
acids 
 
The second step of the synthetic route requires formation of the isoindolinone heterocycle via 
the formation of a ψ-acid chloride,199 as the reactive intermediate. Ortho-benzoylbenzoic 
acids are found in an open state (229) as a solid but in solution are in equilibrium between the 
open form and a cyclic form (230) (Scheme 45).
200
  
 
 
Scheme 46 Reagents and conditions; a) SOCl2, DMF, THF, 4 h 
 
Treatment of the cyclised form the benzoylbenzoic acids with the Vilsmeier reagent, 
synthesised from two equivalents of thionyl chloride and catalytic N,N-dimethylformamide, 
results in the synthesis of ψ-acid chloride (241)(Scheme 46). The 3-hydroxy group can attack 
the Vilsmeier reagent, which results in the formation of the chloride ion, which can then 
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attack the acetal, liberating DMF and forming the pseudo-acid chloride. The ψ-acid chloride 
(231) is an unstable intermediate and must be used immediately. Treatment with the 
appropriate benzylamine (either as the hydrochloride salt or the free amine) in the presence of 
Hünig’s base generates the isoindolinone.  
 
Scheme 47 Mechanism of formation of ψ-acid chloride 
 
The amine has a choice of two sites to attack, either the carbonyl carbon or the carbon 
substituted with the chlorine atom. Bhatt et al describes these two routes as pathway A or 
pathway B.
201
 Pathway A is a SN2 reaction at the chloro-substituted atom, replacing the 
chloro atom with the nucleophile, whilst pathway B has the nucleophile attacking at the 
carbonyl, and ring opening the lactone.  
 
Scheme 48  
5. Isoindolinone-Based Inhibitors of the MDM2 p53 Protein-protein Interaction 
 
139 
 
 
Route A is preferred by weaker nucleophiles whereas route B is preferred by stronger 
nucleophiles including amines.
201
 Sloan et al also found that the reaction of primary amines 
resulted in the formation of amides, rather than displacement of the halide.
202
 Sloan et al 
suggest that all nucleophiles attack initially at the chloro-substituted carbon but stronger 
nucleophiles form a looser transition state whilst weaker nucleophiles form tighter transition 
states.
202
 The looser transition state allows for delocalisation of the partial positive charge 
towards the carbonyl carbon, resulting in formation of the amide. The formation of this 
transition state may also be applied to the formation of the isoindolinone. A proposed 
mechanism is shown in Scheme 49. Formation of the isoindolinone is only possible via route 
B. Secondary attack on the ketone, formed by opening the lactone will result in the formation 
of the five-membered isoindolinone ring. If this step is attempted using the mixture of 
isomers from the previous step, two isomeric products will be synthesised. However, at this 
point the two isomers are separable by column chromatography. 
 
Figure 60 Proposed looser transition state formed during the nucleophilic attack, allowing 
delocalisation of the transition state 
 
 
Scheme 49 Mechanism of formation of the 3-hydroxyisoindolinone from the ψ-acid chloride 
of the benzoyl-benzoic acid 
 
Treatment of the benzoyl benzoic acid (239) with thionyl chloride and DMF for 4 h results in 
the formation of the pseudo acid chloride. This must be immediately treated with a 
nucleophile, for formation of an N-benzyl substituted isoindolinone a substituted 
benzylamine is used, in the presence of Hünig’s base. The reaction is then stirred overnight. 
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Substitution of the ‘A’-ring can play a significant role in the yield of this reaction. Synthesis 
of the 4-chloro isoindolinone can be low yielding.  
 
Formation of the isoindolinone gives rise to a characteristic 
1
H NMR spectrum. The 
diastereotopic benzyl methylene protons are expected to exhibit two pairs of doublets, at 
approximately δ 4-5. Each methylene protons only couples to the other methylene proton 
with geminal coupling constants of around 15 Hz.
196
  
 
Figure 61  
 
The standard final step of the synthetic route is formation of the ether linkage. The optimal 
substituent at this position has been shown previously to be the (1-
hydroxymethylcyclopropyl)methoxy ether group.
192
 The ether linkage is formed by using two 
equivalents of thionyl chloride with catalytic N,N-dimethylformamide in anhydrous THF. 
These reagents generate the Vilsmeier reagent in situ, resulting in chlorination at the 3-
position of the isoindolinone (243) (Scheme 50). The resulting halide species must be used 
immediately to generate the ether, by treatment with 1,1 bis-(hydroxymethane)cyclopropane 
with potassium carbonate. The lone pairs of the oxygen of the 3-hydroxyisoindoline attacks 
the Vilsmeier reagent which rearranges to reform the iminum ion and kick out the chloride 
ion, which then attacks the hemi-aminal carbon to displace DMF. The ether can then be 
formed either via an SN1 reaction or an SN2 reaction. In the SN1 reaction the chloride ion is 
displaced forming an iminium species, which is then attacked by the lone-pairs of the 
hydroxyl group of 1,1-bis(hydroxymethyl)cyclopropane. In the SN2 reaction, the chloride ion 
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is displaced by the hydroxy groups of 1,1-bis(hydroxymethyl)cyclopropane. The formation of 
the ether is thought to occur via the SN2 pathway. 
 
Scheme 50 Mechanism of formation of the ether linkage  
 
An alternative method for the formation of the ether linkage uses BF3.OEt2 and 10 
equivalents of the required diol. Lejkowski et al
203
 use this method for the formation of an 
allyl ether group alpha to the oxygen in a tetrahydropyran ring. This methodology proved 
useful for the synthesis of compounds without the chlorine in the 4-position, with reactions 
taking approximately 2.5 hours, in good yields. The formation of 245 was achieved in 2.5 h 
in 62% yield using the BF3.OEt2 chemistry. However, for the 4-chloroisoindolinone (246), 
the reaction was much slower, taking over 24 h, and the longer exposure to the harsher 
reagent resulted in a number of by-products were also generated. For comparison of reaction 
times between the two different reagents see Table 14 
 
5. Isoindolinone-Based Inhibitors of the MDM2 p53 Protein-protein Interaction 
 
142 
 
 
Table 14 Reagents and conditions for formation of 248 
Reagents Time (h) Yield 
SOCl2/DMF + diol (2 
eq) 
16 24% 
BF3.OEt2 (2.5 eq + 
2.5 eq) + diol (10 eq) 
42 86% 
 
The mechanism of formation of the ether differs when using the BF3.OEt2 from the 
chlorination method. The Lewis acid is thought to generate a cation at the 3-position, which 
is then quenched with the diol. Carey et al
204
 used BF3 to generate a trityl cation, and the 
cation on the 3-position of the isoindolinone could be considered to be equivalent to the trityl 
cation.  
 
Scheme 51 Formation of trityl cation achieved using BF3.OEt2
204
 
 
A distinctive pattern is again observed for the 
1
H NMR resonances from the ether side-chain. 
Each of the CH2 moieties within the side chain give a pair of doublets, with one proton 
coupling to the other within each CH2 unit, again displaying geminal coupling. The OCH2 
resonances typically lie between δ 2-3 whilst the CH2OH unit typically shows peaks between 
δ 3-4, and is occasionally observed to couple to the hydroxyl proton.  
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Figure 62 
 
Formation of the succinic ester group 
 
To improve the solubility of the isoindolinones a succinic half ester group was added to the 
ether side chain. The succinate group was initially added to the isoindolinone as a prodrug 
water-solubilising group. However, the addition of the succinate group was found to improve 
potency from an IC50 of 143 nM (220) to 11 nM (231). Therefore, for selected compounds the 
succinate esters have been prepared for comparison.  
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Table 15 IC50 values for the succinic ester derivatives 
 
Number X R IC50 (µM) 
220 NO2 H 0.95 
230 CN H 0.18 
229 Br H 0.17 
231 NO2 C(O)CH2CH2CO2H 0.020 
249 CN C(O)CH2CH2CO2H 0.097 
250 Br C(O)CH2CH2CO2H 0.118 
 
The succinate group is added using succinic anhydride, with catalytic 4-
dimethylaminopyridine (DMAP) and pyridine in refluxing THF. The DMAP activates the 
succinic anhydride to attack from the isoindolinone hydroxyl group. The addition of the 
succinate group proceeds cleanly in around 15 h in refluxing THF.  
 
Scheme 52 Mechanism of formation of the succinic ester 
 
5.3 Modifications to the N-benzyl Group 
 
The most potent compound identified within the isoindolinone series contains the 4-
nitrobenzyl group (210) with an IC50 of 143 nM. However, a nitro functionality is undesirable 
in a drug as it can be metabolised to a number of toxic metabolites. The metabolism can 
proceed via a nitro radical anion, the nitroso, the nitroxyl radical, the hydroxylamine and then 
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the primary amine. Hydroxylamines may cause methaemoglobinaemia and mutagenicity. 
Carcinogenic effects of nitro groups may be a result of nitro radicals, nitroso derivatives and 
hydroxylamines.
205
 A number of replacements for the nitro group have been synthesised 
previously. However, none of these have displayed equivalent potency to the nitro 
compound. Therefore the aim of this work was to find a nitro group replacement which is 
appropriate for use in a drug. 
 
Table 16 Key alternatives for the nitro group  
 
Number X Y IC50 (µM) 
220 Cl NO2 0.095 ± 0.096 
230 Cl CN 0.18
a 
229 Cl Br 0.17
a 
251 H CCH 0.50
a 
a
 n = 1 
 
5.3.1 Ethynyl Replacement of the Nitro Group 
 
An isoindolinone with an ethynyl group in the 4-benzyl position has previously been 
synthesised within the group. The ethynyl compound (250), with no substituent at the 4-
position, showed a 2-fold loss in potency compared with 220.  
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As addition of the chloro group at the 4-position of the isoindolinone has been shown to 
improve potency, synthesis of the chloro analogue of the ethynyl isoindolinone was desired. 
The synthetic route of the ethynyl compound is shown below (Scheme 53).  
 
Scheme 53 Reagents and conditions; a) AlCl3, chlorobenzene, 90 
o
C, 2h, 91%; b) i. SOCl2, 
DMF, THF, 4 h; ii. 4-iodobenzylamine hydrochloride, Hünig’s base, THF, overnight, 36%; c) 
Pd(PPh3)2Cl2, CuI, Et3N, TIPS-acetylene, THF, 15 h, 88%; d) i. SOCl2, DMF, THF, 4h ii. 
1,1-bis-(hydroxymethyl)-cyclopropane, K2CO3, THF, overnight, 24%; e) 1M TBAF in THF, 
THF, 75 min, 41% 
 
The 4-iodobenzyl substituted isoindolinone (252) was synthesised following the published 
synthetic route from 3-chlorophthalic anhydride and 4-iodobenzyl amine hydrochloride,
192
 
with the ethynyl functionality incorporated using a Sonogashira coupling reaction to give 247 
in a 88% yield. 
 
The Sonogashira reaction cross-couples an aryl iodo species and triisopropylsilyl protected 
acetylene using a palladium catalyst and a copper (I) species. The reaction was achieved 
using 0.03 equivalents of Pd(PPh3)2Cl2 and 0.02 equivalents of copper iodide. To improve 
conversion to the ethynyl product, the number of equivalents of TIPS-acetylene was 
increased from 1.1 to 1.3. Although this made little difference to the overall yield (95% 
conversion to 100% by LCMS) this resulted in significantly simpler purification as both the 
starting material and the product were close running during purification with medium 
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pressure column chromatography on silica. When using 1.3 equivalent of TIPS-acetylene the 
reaction proceeded cleanly and was readily purified in good yield (88%).  
 
The catalytic cycle of a Sonogashira reaction is shown below. The first step of the catalytic 
cycle is formation of the Pd (0) species from Pd (II). The Pd (0) species then undergoes 
oxidative insertion with the aryl-iodo species, returning to Pd (II). The TIPS-acetylene 
initially forms a copper species via deprotonation with triethylamine. Chelation of the copper 
to the alkyne activates the triisopropylacetylene to deprotonation, without the presence of the 
copper the alkyne would not be deprotonated by Et3N (pKa of 10.7)
196
 as acetylene has a pKa 
of ~25
196
 and usually requires a strong base to deprotonate. The acetylene-copper species 
then undergoes transmetallation resulting in formation of a palladium acetylene species, with 
the acetylene group and the aryl group are trans to each other, which isomerizes to give the 
cis species and then undergoes reductive elimination, giving rise to the aryl acetylene species 
and regenerating the Pd (0) species.
206
  
 
Figure 63 The catalytic cycle for a Sonogashira reaction 
 
Once the ethynyl group had been incorporated, the TIPS protecting group was left in place 
until the final step of the synthesis. The ether linkage was formed using the standard reaction 
conditions to give 248. Deprotection was achieved using a 1M solution of TBAF in THF at 
room temperature to give the desired product. The first batch of 253 was synthesised using 
the 3-chloro-2-(4-chlorobenzoyl)-benzoic acid which contained an inseparable impurity, 
which persisted through the synthetic route, purification by HPLC was required to obtain the 
95% purity required for testing. However, on resynthesis starting from the sodium salt of 3-
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chloro-2-(4-chlorobenzoyl)-benzoic acid no addition HPLC purification was required and the 
final compound 253 was achieved in a higher yield (88%). 
 
All isoindolinones are synthesised as racemic mixtures. Due to the favourable biological 
results compound 242 was resynthesised for separation of the enantiomers by chiral HPLC 
using a Daicel Chiralpak AD-H column, using 92.5:7.5 hexane:ethanol. Chiral separation 
gave two enantiomers, peak 1 (NCL-00018225, 254) with [α] = -9.16 o and peak 2 (NCL-
00018226, 255) with [α] = +11.4 o. NCL-00018225 is expected to be the R-enantiomer by 
analogy with NU8354 and NCL-00008406, and has the structure shown below. 
 
Figure 64 
 
As the ethynyl compound has already been shown to be potent, the succinate ester was also 
synthesised via a DMAP catalysed esterification. The TIPS protecting group was left in place 
to protect the ethynyl group until the final step of the synthesis route before removing via 1 
M TBAF (Scheme 54). 
 
Scheme 54 Reagents and conditions; a) Succinic anhydride, pyridine, DMAP, THF, reflux, 
overnight, 94%; b) 1M TBAF in THF, THF, 2 h 45 min, 81% 
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Succinic ester 257 is acid sensitive. An aliquot of the compound, left in deuterated 
chloroform, which is relatively acidic, resulted in decomposition, with loss of the succinate 
group. Acidic chloroform was catalysing hydrolysis of the ester linkage. Succinic ester 
groups are easily cleaved which might explain the compounds relative sensitivity. The 
compound was therefore resynthesised before testing. 
 
5.3.2 Trifluoromethylsulfone Replacement of the Nitro Group 
 
An alternative non-classical isostere for the nitro group is a trifluoromethylsulfonyl group. 
The trifluoromethylsulfonyl group has been used by Abbott pharmaceuticals as a replacement 
for the nitro group within their series of inhibitors of the Bcl-2 anti-apoptotic family protein-
protein interaction.
207-208
 The trifluoromethylsulfonyl group (259), which is slightly more 
electron withdrawing than the nitro group, was tolerated as a replacement for the nitro (258), 
whilst the methyl sulfonyl group (261) and the trifluoromethyl group (260) were not.
207-208
 A 
trifluoromethyl analogue of the isoindolinone has previously been synthesised and was not 
tolerated, a trifluoromethylsulfonyl may prove to be an ideal replacement for the nitro group.  
 
Figure 65 Replacement of the nitro group with trifluoromethylsulfonyl group in the Abbott 
pharmaceuticals compounds 
 
The trifluoromethylsulfonyl analogue of the isoindolinone was synthesised using the 
published route.
192
 The required benzylamine was not commercially available, so it was 
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prepared from 4-(trifluoromethylsulfonyl)benzonitrile by reduction with a 1M solution of 
BH3.THF complex in THF as described Leach et al.
209
 The compound was stored and used as 
a hydrochloride salt, as on standing as the free amine, the benzylamine converted from a solid 
to an oil.  
Scheme 55 Reagents and conditions; a) AlCl3, chlorobenzene, 90
 o
C, 2 h, 91%; b) i. SOCl2, 
DMF, THF, 4 h ii. 265, Hünig’s base, THF, X = Cl 35%, X =H 87%; c) X = Cl i. SOCl2, 
DMF, THF 4 h; ii. 1,1-bis(hydroxymethyl)cyclopropane, K2CO3, THF, overnight, 29%; X = 
H BF3.OEt2, 1,1-bis(hydroxymethyl)cyclopropane, DCM 0 
o
C-RT 2.5 h, 69%; d) i. 1M 
BH3.THF in THF, THF, reflux, 4 days ii. 1M HCl(aq), 51% 
 
For compound 245 the ether linkage was formed using BF3.OEt2 in good yield (69%). As the 
ether formation using BF3.OEt2 reaction has previously been shown to proceed slowly when 
the 4-Cl is in place, the Vilsmeier reaction was instead used to chlorinate, followed by 
displacement with 1,1-bis(hydroxymethyl)cyclopropyl to form 246, which previous 
experience had shown to take 24 h, though with lower yields.  
 
5.3.3. 3-Fluoro-4-Halo Benzyl Analogues 
 
3,4-Difluorobenzyl may mimic both the space-filling capacity of the nitro group and the 
electron-withdrawing nature of the nitro group. A single fluoro atom is less electron 
withdrawing than a nitro group. The σ value for a 4-fluoro group is 0.06 whilst for a 4-nitro 
group the σ value is 0.78.210 However if the values for a 3-fluoro group (0.34) and 4-fluoro 
5. Isoindolinone-Based Inhibitors of the MDM2 p53 Protein-protein Interaction 
 
151 
 
(0.06) are combined (0.40) the value becomes closer to that of the nitro group.
210
 Previous 
work has shown that a number of 4-halo compounds have been moderately potent; therefore a 
series of 3-fluoro-4-halo compounds may aid identification of a compound with similar 
potency to the 4-nitro compound. As a result of the favourable potency of the 4-ethynyl 
analogue, a 3-fluoro, 4-ethynyl analogue was also synthesised. The combined Hammett 
values for each analogue are shown below. 3-Substitution has not previously been tolerated 
around the benzyl ring, a fluoro group should be sufficiently small to be tolerated. 
 
 
Table 17 Literature σ values for 3 and 4 substituents210 and calculated combined values 
Substituent 3-Substituent Value 4-Substituent Value Total value 
4-NO2 - 0.78 0.78 
3-F,4-F 0.34 0.06 0.40 
3-F,4-Cl 0.34 0.23 0.57 
3-F,4-Br 0.34 0.23 0.57 
3-F,4-I 0.34 0.18 0.52 
3-F, 4-CCH 0.34 0.23 0.57 
 
 
The 4-chloro-3-fluoro analogue was particularly interesting in view of the activity of 
compound 253 as the literature has shown these groups can be interchangeable. The two 
EGFR kinase inhibitors Gefetinib and Erlotinib share significant structural similarities.
7
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The 3,4-difluoro analogue was synthesised from 3,4-difluorobenzylamine following the 
previously described isoindolinone synthetic route as shown in Scheme 56. 
Scheme 56 Reagents and Conditions; a) AlCl3, PhCl, 90 
o
C, 2 h, 91%; b) i. SOCl2, DMF, 
THF, 4 h; ii. 3,4-Difluorobenzylamine, Hünig’s base, THF, overnight, 39%; c) i. SOCl2, 
DMF, THF, 4 h; ii. 1,1-bis(hydroxymethyl)cyclopropane, K2CO3, THF, overnight, 23% 
 
For the remaining compounds in the series the required benzylamine was not commercially 
available. Both the 4-bromo-3-fluorobenzonitrile and 3-fluoro-4-iodobenzonitrile were 
commercially available and could be reduced following the previously developed 
methodology. Unfortunately, the 4-chloro-3-fluorobenzonitrile was considerably more 
expensive than for the bromo and iodo analogues. Therefore, it was decided instead to access 
the benzylamine via the 4-chloro-3-fluorobenzyl bromide. 
 
A search of the literature suggested that benzyl bromides could be converted to benzyl 
amines using methanolic ammonia at high temperatures.
211
 A table of the conditions used is 
shown below. 
 
Scheme 57 Reagents and conditions; a) 7 M methanoic ammonia, methanol, conditions and 
yield as described below 
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Table 18 Summary of conditions used in attempted synthesis of 271 
Concentration of 
benzyl bromide 
No. of 
equivalents 
Heating type 
Temperature 
(
o
C) 
Time Yield 
0.45 M 16 Conventional 80 3 h - 
0.23 M 32 Conventional 80 3 h - 
0.15 M 16 Conventional 80 5 h 28% 
0.23 M 16 - RT 2.5 days 15% 
0.23 M 16 Microwave 120 5 min ~ 35% 
 
The best yield (28%) was achieved using conventional heating at 80 
o
C for 5 h. LCMS 
monitoring of the microwave irradiated reaction suggest that 35% conversion was achieved, 
though the product was not isolated.  
 
The reactions all resulted in the formation of multiple products alongside the desired 
benzylamine. It was hypothesised that this is due to desired product (271) reacting with the 
starting material synthesising further compounds, as (270) may be highly reactive, due to the 
electron withdrawing substituents on the benzyl ring. 
 
Scheme 58 Reagents and conditions; 7 M methanoic ammonia, methanol, RT-120 
o
C, 3 h -
2.5 days 
 
An alternative route was therefore required. To reduce the reactive nature of the synthesised 
benzylamine, it was proposed to initially form a tertiary amine, which should reduce the 
reactivity of the amine group, the primary amine could then be released under mild 
conditions. Both a modified Gabriel with sodium diformylamide, an alternative reagent to 
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potassium phthalamide, which requires mild hydrolysis conditions and a Staudinger reaction 
have been attempted.
212-215
 
 
Table 19 
Reagents Conditions Observed outcome 
i. Sodium diformylamide, 18-
crown-6, MeCN; ii. 5% 
ethanoic HCl 
Reflux, then room 
temperature 
No product observed 
i. NaN3, DMF; ii. PPh3, H2O 
100 
o
C, then room 
temperature 
Major isolated product 
PPh3O 
 
While the displacement reactions with both sodium diformylamide and sodium azide were in 
progress it was observed that the TLC fraction of the starting material, which was stood at 
room temperature in solvent (EtOAc), began to degrade forming multiple products, 
suggesting that the starting material itself may not be especially stable, leading to the 
disappearance of starting material by TLC but without conversion to the product. 
 
While the above work was in progress, the commercial price for 4-chloro-3-
fluorobenzonitrile significantly reduced, and it was purchased and reduced to the desired 
product using 1 M BH3.THF in 63% yield using the optimised conditions developed in the 
synthesis of 277.   
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Scheme 59 Reagents and Conditions; a) i. SOCl2, DMF, THF 4 h; ii. 271, Hünig’s base, 
THF, overnight, 37%; b) i. SOCl2, DMF, THF, 4 h; ii. 1,1-bis(hydroxymethyl)cyclopropane, 
K2CO3, THF, overnight, 18% 
 
Once 271 had been synthesised in sufficient yield, isoindolinone 273 was synthesised from 
the sodium salt of 3-chloro-2-(4-chloro-benzoyl)-benzoic acid and 271, using the standard 
conditions, followed by the chlorination at the 3-hydroxy position and displacement with 1,1-
bis(hydroxymethyl)cyclopropane to give isoindolinone 274.  Unfortunately LCMS analysis 
showed that 274 contained a minor impurity which require multiple rounds of medium 
pressure column chromatography and reverse phase chromatography before an appropriate 
level of purity was obtained leading to a slightly lower than anticipated yield. 
 
Both the 3-fluoro-4-iodo and 4-bromo-3-fluoro benzonitrile compounds were commercially 
available and previous work suggested that the nitrile group could be reduced using borane. 
However reductions of both the 3-fluoro-4-iodobenzonitrile (275) and 4-bromo-3-
fluorobenzonitrile (276) with BH3.THF, the reaction proceeded very slowly (up to 5 days) so 
a series of alternative reduction agents were investigated (Table 20). 
 
Table 20 Alternative reagents and conditions for reduction of 275 
Reaction No. Reagent Conditions Observations 
1 LiAlH4 
0 
o
C for 15 min then 
warmed to RT 
Multiple spots by TLC 
2 LiAlH4 0 
o
C for 2 h Multiple spots by TLC 
3 Li(Et)3BH RT to 70 
o
C 
No significant change 
from starting material 
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Nitriles can also be reduced using hydrogenation with H2 and palladium on carbon. 
Reduction of 275 using an ‘H-Cube’, an hydrogenation flow reactor was attempted using 
atmospheric pressure of H2 at 70 
o
C. However, no reaction was observed. 
 
The BH3.THF reduction was reinvestigated. A concentrated solution of the benzonitrile (500 
mg in 1 mL) was used with 4 eq. of BH3.THF in an attempt to minimise the reaction times.  
After refluxing overnight, 3-fluoro-4-iodobenzonitrile in THF was reduced to the desired 
benzylamine (277) in good yield (82%). These conditions were then reproduced for the 4-
bromo-3-iodobenzonitrile analogue, again giving good yields (84%). All the benzylamines 
within the 3-fluoro-4-halogen series were prepared, stored and used as the free amine and 
appeared stable. 
 
Scheme 60 Reagents and conditions; a) 1M BH3.THF, THF, reflux, overnight X = Br 84%, X 
= I 82%)  
 
Compound 277 was then used to synthesise 3-hydroxyisoindolinone (279) using the 
previously discussed synthetic route giving the product (281) which required multiple rounds 
of medium pressure column chromatography before reaching the desired purity for biological 
testing. The iodo, fluoro analogue (280) was prepared under the same conditions to give 282 
in a 36% yield.  
 
Scheme 61 Reagents and Conditions; a) i. SOCl2, DMF, THF, 4 h; ii. 277 or 278, Hünig’s 
base, THF, overnight; X = Br 51%, X = I 33% b) i. SOCl2, DMF, THF, 4 h; ii. 1,1-
bis(hydroxymethyl)cyclopropyl, K2CO3, THF, overnight, X = Br 19%, X = I 36% 
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The 4-ethynyl benzyl analogue (253) has proved to be potent so the 4-ethynyl-3-fluoro 
analogue was synthesised to explore the effects of the electronic of the ring. The 3-fluoro-4-
iodo compound (280) was used as a precursor in a Sonogashira reaction, as described for the 
4-iodo compound (223). Fluoro groups are poor leaving groups in palladium catalysed 
reactions, so selectivity problems were not anticipated. Compound 280 was instead as the 
precursor to 284 rather than compound 282 to allow incorporation of a range of alternative 
ether groups.  
Scheme 62 Reagents and conditions; a) Triisopropylsilylacetylene, Et3N, Pd(PPh3)2Cl2, CuI, 
THF, 15 h, 95%; b) i. SOCl2, DMF, THF, 4 h; ii. 1,1-bis(hydroxymethyl)cyclopropyl, K2CO3, 
THF, overnight, 26%; c. 1M TBAF in THF, THF, 1 h, 62% 
 
Compound 283 was synthesised using the previously optimised Sonogashira conditions from 
triisopropylsilylacetylene and compound 280 in excellent yield (95%). Vilsmeier conditions 
were used to incorporate the ether linkage and the TIPS group removed using 1 M TBAF in 
THF to give 285. 
 
5.3.4. Benzoxadiazoles as Isosteres for the Nitro Group 
 
The benzoxadiazole group has been reported as a replacement for a nitrophenyl group,
205, 216-
217
 as it maintains a number of atoms in similar positions from the nitro group. 
Benzo[c]oxadiazol-5-ylmethanamine (288) is not commercially available but 5-
(bromomethyl)-2,1,3-benzoxadiazole (276) is available and the patent literature suggest that 
compound 288 could be formed from 286 via a Gabriel reaction. In this case hydrazine was 
not used to liberate the amine, instead, Ohlmeyer et al used an excess of methylamine to open 
the phthalamide ring and liberate the free amine.
218
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Scheme 63 Reagents and conditions; a) potassium phthalamide, DMF, 16 h; b) 40% 
MeNH2(aq), EtOH, 25 h, 53% 
 
Treatment of bromide 286 with potassium phthalamide gave 287. A 
1
H NMR showed that 
286 formed the phthalamide 287 on treatment with potassium phthalamide in DMF. The 
crude material was worked up and used immediately in the second step. However, on 
addition of methylamine, the intermediate 287 rapidly disappeared within 30 min, but only a 
low yield of 25% product was obtained. A repeat reaction with LCMS monitoring 
demonstrated that after 1 h phthalamide 287 had completely disappeared but the product 
(288) had not been formed as the major product. Phthalamide 287 is rapidly converted to ring 
opened amide 289, however, the attack from the second molecule of methylamine is much 
slower, with the reaction requiring approximately 24 h.  
 
Scheme 64 
 
The reaction gave a modest yield of amine 288 (53%), which was then used to synthesise 
compound 290 (Scheme 65). 
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Scheme 65 Reagents and conditions; a) i. SOCl2, DMF, THF, 4 h; ii. 277, Hünig’s base, 
THF, overnight, 15 %; b) BF3.OEt2, DCM, 0 
o
C-RT, 3 days, 36% 
 
Synthesis of 290 from sodium 3-chloro-2-(4-chlorobenzyoyl)benzoate occurred in poor yield, 
due to being an unoptimised reaction and the product required multiple rounds of medium 
pressure column chromatography. This resulted in the loss of further material before 
compound 290 could be used in the next synthetic step.  
 
As only around 100 mg of compound 290 had been synthesised it was decided rather than 
using the SOCl2/DMF methodology for incorporation of the ether linkage, the BF3.OEt2 
synthetic route would be used instead. The use of the BF3.OEt2 methodology would lead to a 
longer reaction time but these reagents usually have a higher yield, necessary in this case. 
Treatment of 290 with BF3.OEt2 for 3 days gave 291 as a colourless oil, which required both 
medium pressure column chromatography and semi-preparative HPLC before reaching the 
required purity for biological testing. 
 
5.3.5. Replacement of the 4-Nitro Group with 4-Azide 
 
A further proposed replacement of the nitro group is an azido group. The azido group is only 
thought to be featured in one drug on the market (AZT (292), an antiretroviral drug).
219
 
However, azido groups can be used in labelling studies. Parang et al have used azido groups 
to observe protein cross linking with azido labelled ATP. Irradiation of the azido group with 
UV light results in release of N2 and formation of a nitrene.
220
 The reactive nitrene species 
then react with C-H bonds within the protein, labelling the residues at the binding site.
221
 
Singlet nitrenes are thought to react via addition and rearrangement with aryl CH and triplet 
nitrenes insert in alkyl C-H bonds via hydrogen abstraction.
222
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Scheme 66  
 
Zhu et al
221
 describe the CuI catalysed synthesis of aryl azides from aromatic iodides. The 
formation of the azide requires L-proline (0.2 eq) and sodium hydroxide (0.2 eq) alongside 
sodium azide (1.2 eq) and copper iodide (0.1 eq). The sodium hydroxide and L-proline form 
the sodium salt of L-proline which then forms a complex with the copper, resulting in the 
active species via 293.
221
 The copper species can then couple the azide with the aromatic 
iodide species. Ma et al
223
 suggest that the formation of the aryl azide species occur via an 
Ullman-type reaction. However, traditional Ullman reactions require high temperatures, but 
with Zhu et al copper-catalysed reaction the temperature is lower as the reaction is promoted 
by the use of amino acids.
223
 Ma et al propose the reaction occurs via oxidative insertion of 
the iodoaryl species to the copper/amino acid complex. The formation of this amino 
acid/copper complex activates the copper to oxidative insertion and is also thought to 
stabilise the product of the oxidative addition, which allows the coupling reaction to occur.
223
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Scheme 67 
 
To form the azido isoindolinone the copper catalysed reaction was initially attempted with 4-
iodobenzylamine hydrochloride (294). The reaction was heated in DMSO for 20 h at 60 
o
C. 
However, the progress of the reaction was difficult to observe, even using amino TLC plates. 
IR analysis of the crude mixture suggested that the aromatic azido product had been formed, 
as a strong peak at around 2000 cm
-1
 was observed. However, on purification the product was 
not isolated. 
 
Scheme 68 Reagents and conditions; a) L-proline, CuI, NaOH, DMSO, 60 
o
C 
 
The basic nature of the benzylamine prevent monitoring and purification of the benzylamine 
it was decided to form the isoindolinone with the 4-iodobenzyl group in place. This should 
reduces the basicity of the azido-incorporated product, which should make monitoring and 
purifying the reaction easier, but will also mean that the potentially sensitive azido group will 
not be carried through a number of steps through the formation of the isoindolinone and 
incorporation of the ether  but can instead be added in the final step. However, attempts to 
synthesise the desired product (295) proved unsuccessful, after heating overnight in the 
presence of CuI and L-proline, only starting material was observed.  
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Scheme 69 Proposed reagents and conditions; a) i. SOCl2, DMF, THF, 4 h; ii. 1,1-
bis(hydroxymethyl) cyclopropane, K2CO3, THF, overnight, 52%; b) L-proline, NaOH, CuI, 
DMSO, 60 
o
C 
 
Given the unreactivity of the isoindolinone to this methodology and inherent safety issues of 
using azide species with copper, which would prevent scaling up of reactions it was decided 
to access this molecule via an alternative route. Griffin et al prepared 4-azidobenzyl alcohol 
from 4-aminobenzyl alcohol via a diazonium intermediate,
224
 which could then potentially be 
converted to 4-azidobenzylamine via the bromide.  
 
Scheme 70 Reagents and conditions; a) 5M HCl(aq), NaNO2, NaN3, 0-5 
o
C, 1 h, 86%; b) PBr3, 
Et2O, 45 min, 0 
o
C-RT, 73%; c) i. NaN(CHO)2, 18-crown-6, MeCN, 95 
o
C, 24 h; ii. 5% 
ethanolic HCl, 3 days, 96% 
 
Using the literature method 4-azidobenzyl alcohol 299 was successfully synthesised. The 
benzyl alcohol was then converted to the benzyl bromide using PBr3 following the procedure 
developed by Takatori et al
225
 which used 0.4 eq of PBr3 at 0 
o
C-RT. However, in our hands 
0.8 eq of PBr3 was required to give full conversion to the benzyl bromide in good yield 
(73%). The modified Gabriel reaction, using sodium diformylamide,
213-214
 with the milder 
conditions than the traditional Gabriel reaction was used to convert the benzyl bromide to the 
benzylamine. Treatment of 4-azidobenzyl bromide in MeCN with 2.7 eq of sodium 
diformylamide with 18-crown-6 (0.1 eq) at 95 
o
C for 24 h resulted in complete conversion to 
the intermediate, and hydrolysis of the formyl groups was achieved using 5% ethanoic HCl 
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overnight, with an overall yield of 96%. As the azido group is light sensitive all reactions 
with either sodium azide or with molecules which incorporated the azido group were carried 
out in the dark and were stored at 4 
o
C in the dark. However, the azide group did appear to be 
robust enough to allow formation of the benzylamine, and compounds were stable for up to 1 
year when stored at 4 
o
C in the dark. 
 
Scheme 71 Proposed reagents and conditions; a) i. SOCl2, DMF, THF, 4 h; ii. 284, Hünig’s 
base, THF, overnight, 78%; b) i. SOCl2, DMF, THF, 4 h; ii. 1,1-
bis(hydroxylmethyl)cyclopropane, K2CO3, THF, overnight  
 
4-Azidobenzyl amine was then used to synthesise hydroxy isoindolinone 290. When 
repeating these conditions to synthesis the 4-chloro analogue (292), the 
1
H NMR spectrum of 
the isolated product did not correlate with the structure of the isoindolinone. However, as this 
reaction was only attempted once, the incorrect product simply may have been isolated.  
 
When attempting to form compound (291) using the SOCl2/DMF synthetic route, no product 
was observed, instead two new compounds which were not isoindolinones as they lacked the 
characteristic isoindolinone pair of doublets for the benzyl protons.  
 
We doubted whether the sensitive azide group would survive the BF3.OEt2 conditions for 
forming the ether. Therefore, the reaction with BF3.OEt2 was attempted on a small scale, and 
after stirring at room temperature overnight with 2.5 eq of BF3.OEt2, no reaction or 
significant degradation was observed. In previous examples with the 4-H isoindolinone the 
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BF3.OEt2 reaction quickly proceeds to completion, but with the more hindered 4-Cl reactions, 
several additions of 2.5 eq and a longer reaction time is required. As the azido group does not 
appear as sensitive to BF3. OEt2 a further 2.5 eq was added to try and push the reaction. 
Unfortunately, after stirring the reaction for a further 5 h no reaction was observed. 
 
The lack of success in these reactions prompted the search for alternative methods. 
Compound 293 was synthesised to be used as a model compound for alternative methods in 
these reactions. The alternative methodologies used can be broadly divided into two classes, 
the first is alternative methods of chlorinating the 3-OH group of the isoindolinone, the 
second looks at alternative methods of activating the 3-OH to displacement by the 1,1-
bis(hydroxymethyl)cyclopropane. 
 
Scheme 72 Reagents and conditions; a). i. SOCl2, DMF, THF, 4 h; ii. 4-nitrobenzylamine 
hydrochloride, Hünig’s base, THF, overnight, 63% 
 
The first question to address is why the SOCl2/DMF method of chlorination, which is used in 
the formation of the azido isoindolinone and tolerated, when used to chlorinate the 3-hydroxy 
isoindolinone results in some degradation but no reaction? When forming the isoindolinone 
the SOCl2/DMF reagents are used in the first step. For the second step of the reaction, the 
Hünig’s base is always added before the benzylamine, so any HCl generated will be 
neutralised before the addition of the benzylamine. For the azido analogue this could be vital 
as azides are known to be sensitive to acid.
222
 In the second step, however, the azido 
functionality is present in the starting isoindolinone, and it must survive the SOCl2/DMF 
conditions before the base (K2CO3) is added. The first alternative chlorination method 
attempted was the use of a commercial source of the Vilsmeier reagent. Thus, isoindolinone 
(293) was treated with (chloromethylene)dimethyliminium chloride (Vilsmeier reagent) in 
THF and the standard experimental procedure followed. This gave compound 195 in a poor 
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yield (22%). Reaction of the azido analogue 301, under the same conditions resulted in no 
reaction. 
 
Scheme 73 Reagents and conditions; a) i. (chloromethylene)dimethyliminium chloride, THF, 
4 h; b) 1,1-bis(hydroxymethyl)cyclopropyl, K2CO3, THF, overnight, 22% 
 
An alternative chlorination, using Ghosez reagent (1-chloro-N,N,-2-trimethylpropenamine) 
(305) was also attempted. Ghosez reagent have been used for the synthesis of acid chlorides 
from carboxylic acids and maintains essentially neutral conditions.
226
 Bendall et al also 
described the use of Ghosez reagent for the chlorination of primary, secondary and tertiary 
alcohols.
226
 The mechanism of Ghosez reagent is shown below (Scheme 74). The first step of 
the mechanism is attack of the hydroxyl group on the carbon alpha to the chloro atom, the 
lone pair of electron on the nitrogen then forms the iminium ion, breaking the C-Cl bond. The 
chloride ion can then attack the alkyl group to form the alkyl halide species. 
 
Scheme 74 
 
3-Hydroxyiosindolinone (304) was treated with Ghosez reagent at -78 
o
C. No reaction was 
observed at room temperature or at 60 
o
C. The failure in this case may be due to the hindered 
nature of the isoindolinone OH, in comparison to the literature examples. 
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Therefore, an alternative less bulky chlorination methodology may prove more effective. Oka 
et al used oxalyl chloride to chlorinate tertiary alcohols, where each alkyl group is a phenyl 
ring.
227
 3-Hydroxy isoindolinone (304) was treated with oxalyl chloride giving 195 in 62% 
yield. These same conditions were applied to the azido analogues with the addition of 1 eq. of 
Hünig’s base. However, on addition of the oxalyl chloride to the solution of isoindolinone 
(301) the reaction mixture rapidly changed colour from pale yellow to black and significant 
decomposition of the isoindolinone was observed by TLC. 
 
Scheme 75 Reagents and conditions; a) i. (COCl)2, DCM, 2 h; ii. 1,1-bis(hydroxymethyl) 
cyclopropane, Hünig’s base, DCM, 15 h, 62% 
 
Alternative methods of activating the 3-hydroxy to displacement were explored. Firstly, 
triflation of the 3-OH group was attempted using N-phenyltriflimide. However on heating the 
3-hydroxyisoindolinone (304) with N-phenyltriflimide and Hünig’s base, no reaction was 
observed. 
 
Scheme 76 Proposed reagents and conditions; a) i. N-phenyltriflimide, Hünig’s base, THF, 
RT-70 
o
C, ii) 1,1-bis(hydroxymethyl)cyclopropane, Hünig’s base, THF, overnight 
 
An alternative methodology for activating hydroxyl groups to displacement is to convert 
them to isoureas,
228
 commonly by reacting the hydroxyl group with N,N,-dialkyl 
carbodiimide in the presence of Cu(OTf)2 or CuCl.
229
 Attack of a nucleophile will generate 
urea, thus driving the reaction.
228
 Formation of an isourea followed by attack of a nucleophile 
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is commonly used to form esters
228, 230-232
 however Liu suggests that it can be used to form 
ethers.
229
 The reaction proceeds via attack of the N,N,-dialkyl carbodiimide by the hydroxy 
species forming the isourea, which activates the hydroxy species to attack by a nucleophile 
forming the urea and in this example the ester species (Scheme 77). 
 
Scheme 77 
 
Treatment of 3-hydroxyisoindolinone 304 with diisopropylcarbodiimide and Cu(OTf)2 in 
MeCN with microwave heating failed to give a new product on quenching aliquots with 
methanol. The reaction order was switched, first reacting 1,1-bis(hydroxymethyl)cyclopropyl 
with DIC, however no new product was formed. In view of these unsuccessful results, and 
the time restraints it was decided to discontinue work on the synthesis of the azido analogue. 
 
5.3.6. Biological Results for Benzyl Analogues  
 
 All final compounds from the benzyl series were submitted for biological testing. For assay 
details see chapter 5.9.  
 
Table 21 Biological results for modifications to the benzyl group * indicate compounds 
synthesised by other chemists  
 
Number Rotation X R Ar 
Biological 
Activity IC50 (µM) 
195* (+/-) H H 
 
0.23 ± 0.11 
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220* (+/-) Cl H 
 
0.095 ± 0.096 
251* (+/-) H H 
 
0.50
a
 
253 (+/-) Cl H 
 
0.15 ± 0.084 
257 (+/-) Cl 
C(O)CH2C
H2CO2H  
0.053
a 
254 (-) Cl H 
 
0.041 ± 0.022 
255 (+) Cl H 
 
2.4 ± 1.5 
245 (+/-) H H 
 
43% inhibition at 
5 µM 
246 (+/-) Cl H 
 
9.0
a
 
306* (+/-) Cl H 
 
0.13 ± 0.016 
229* (+/-) Cl H 
 
0.17
a
 
258 (+/-) Cl H 
 
0.41 ± 0.021 
274 (+/-) Cl H 
 
0.20
a
 
281 (+/-) Cl H 
 
0.19 ± 0.069 
282 (+/-) Cl H 
 
0.53 ± 0.083 
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285 (+/-) Cl H 
 
0.19 ± 0.026 
291 (+/-) Cl H 
 
0.28 ± 0.13 
a
 indicates n = 1 
 
The ethynyl compound 253 has similar potency to the nitro group. It is structurally dissimilar 
to the nitro group, suggesting that the nitro group is not forming a direct electrostatic 
interaction which a replacement must replicate. Instead, it is the size and electron-
withdrawing nature of the nitro group which must be replicated. The 4-ethynyl des-chloro 
analogue (251) was relatively potent (IC50 = 0.50 µM), few analogues have potency in the 
nanomolar range without the ‘A’-ring 4-chloro group, but a greater increase in potency is 
observed when going from the (251) to (253) than from (195) to (220). This suggests that 
compound 253 shifts slightly in relation to compound 220 which positions the 4-chloro of the 
isoindolinone ‘A’-ring in a slightly more optimal position. 
 
The crystal structure of an isoindolinone bound to MDM2 (see chapter 5.7.1) suggests that 
the 4-chloro forms a halogen bond to the protein. This acts to pull the isoindolinone into a 
slightly different position in comparison to des-chloro analogues. In this position it would 
appear that the ethynyl substitution is positioned in a more optimal arrangement, than in 
comparison to the des-chloro analogue. 
 
The proposed shift in position is supported by the biological activity of compound 257. When 
converting 220 to the succinic ester analogue 231 an increase in potency of around 130 nM is 
observed, however, when adding the succinic ester to compound 253 an increase in potency 
of only around 30 nM is observed. In optimally positioning the ethynyl group within the 
pocket, the succinic group is shifted from its optimal position. 
 
Separation of the enantiomers (254 and 255) demonstrates that the biological activity resides 
in the (-) isomer. The residual activity observed for the opposite enantiomer suggests that 
potency is strongly controlled by the benzyl group and substituent choice. The absolute 
stereochemistry of 254 is yet to be determined. It is anticipated to be the R-enantiomer by 
comparison with NU8354 and NU8604. 
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The trifluoromethylsulfone substituent appears to be too large to be tolerated within the 
MDM2 pocket. However, the increase in potency is still observed on addition of the 4-chloro 
group to the isoindolinone ‘A’-ring. By comparing the Cresset Fieldview modelling of the 
negative field (areas which like to interact with positive areas or electron-deficient of the 
protein) of the nitro (220) and the trifluoromethylsulfone (246) compounds, we can see that 
these compounds are similar. However, observing the compounds for an alternative angle we 
can see that this is not the case. The negative field for the benzyl group is disrupted by the 
presence of the trifluoromethyl group. 
 
Figure 66 Cresset Fieldview modelling of the nitro (220) (left) and trifluoromethylsulfone 
(246) right, the blue surface represents the negative field 
 
 
Figure 67 Cresset Fieldview modelling of nitro (220) (left) and trifluoromethylsulfone (246) 
(right) compounds showing the negative field 
 
The series of 3-fluoro-4-halo or ethynyl compounds shows some interesting results. For both 
the 4-chloro and the 4-ethynyl compounds, which both have similar levels of potency to 
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compound 220, addition of the fluoro group reduces activity. However, for compound 281, 
which without the fluoro is slightly less potent than the nitro analogue, although within the 
range of error, there is little change in the potency. The addition of the fluoro group can 
adjust the electronic of the benzyl ring sufficiently but any change is within the margin of 
error. The 3,4-fluoro motif appear to be small to fulfil the shape filling requirement whilst the 
3-fluro-4-iodo appears to be slightly too large to be the optimal substituent.  
 
The benzoxadiazole substituent (291) is tolerated, with a small decrease in potency from that 
of the nitro substituent. This demonstrates that this substituent can be effective as a 
replacement for the nitro group in both steric and electronic properties. The Fieldview 
modelling of the negative field of compound 220 and 291 shows a similar distribution 
between both compounds. 
 
Figure 68 Comparison of the negative field of 220 (left) and 291 (right)  
 
5.4 Analogues of the Ethynyl Group 
 
Due to the potency of 4-chloroisoindolinone (253) a series of analogues were synthesised to 
develop the structure-activity relationships around the ethynyl analogue. Previously 
synthesised analogues have shown that substitution at the 3-position is not tolerated, to 
confirm this is also true for the benzyl ethynyl analogues, the 3-ethynyl analogue was 
synthesised via 3-iodobenzyl precursor. The 3-ethynyl analogue can be synthesised following 
a similar synthetic route to 4-ethynyl analogue, which is shown below in Scheme 78. 
Synthesis of 310 was achieved in similar yields to the synthesis of 253 in an overall yield of 
6%.  
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Scheme 78 Reagents and conditions; a) i. SOCl2, DMF, THF, 4 h; ii. 3-iodobenzylamine 
hydrochloride, Hünig’s base, THF, overnight, 37%; b). Triisopropylsilylacetylene, Et3N, CuI, 
Pd(PPh3)2Cl2, THF, 16 h, 80%; c) i. SOCl2, DMF, THF, 4 h ii. 1,1-bis(hydroxymethyl) 
cyclopropyl, K2CO3, THF, overnight, 37% v. 1 M TBAF in THF, THF, 61% 
 
Based on previous models the ethynyl group was thought to sit close to the bottom of the 
pocket of MDM2, leaving little room for further substitution. To probe whether any further 
substitution on the ethynyl group is tolerated two compounds were synthesised i.e. 311, 
which adds a methyl group to the terminal end of the ethynyl group and compound 312, 
which adds a phenyl ring to the terminal end of the ethynyl  
 
Figure 69 
 
The synthesis of compound 313 was achieved using a Sonogashira reaction between the 4-
iodobenzyl substituted isoindolinone (252) and propyne. Unfortunately, unlike 
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triisopropylacetylene, propyne is not a liquid but a gas, and therefore requires an alternative 
set-up of the reaction. The reaction mixture was prepared and degassed and cooled to -78 
o
C 
before the addition of the condensed propyne from a cold finger and the reaction gradually 
warmed to room temperature. As propyne is a gas at room temperature, it was not possible to 
measure 1.3 equivalents as the propyne boils within the needle syringe, therefore a large 
excess (as measured by the change in solvent level) was added. The general reaction scheme 
for the synthesis of 311 and 312 is shown below (Scheme 79). 
 
Scheme 79 Reagents and conditions; a) R = CH3 Pd(PPh3)2Cl2, CuI, Et3N, propyne, THF, 18 
h, 94%; R = C6H11 Pd(PPh3)2Cl2, CuI, Et3N, phenyl acetylene, THF, 17 h, 91%; iv. 1. SOCl2, 
DMF, THF, 4 h 2. 1,1-bis(hydroxymethyl)cyclopropyl, K2CO3, THF, overnight, R = CH3 
20%, R = C6H5 36% 
   
Using the optimised Sonogashira conditions compound 314 was synthesised in excellent 
yield (91%), the complete synthetic route to synthesise the final compound is shown above. 
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5.4.1. Biological Results for Ethynyl Analogues 
 
Table 22 Biological activity for the ethynyl analogues 
 
Number Structure 
Biological Activity 
IC50 (µM) 
310 
 
2.0 ± 0.75 
311 
 
0.7
a 
312 
 
2.9
a
 
a
 indicates results where n = 1 
 
Compound 310 demonstrates the narrow structure activity relationships for the benzyl 
substituents. No tolerance is observed for substituents larger than a fluoro group in the 3-
benzyl position, suggesting that the benzyl group sits in a narrow deep pocket, ideal for a 4-
ethynyl group, but intolerant of a change in position. Both compounds 311 and 312 
demonstrate that there is insufficient space for any further extension from the ethynyl group, 
suggesting that the terminal hydrogen of the ethynyl sits close to the bottom of the pocket. 
Interesting, compound 312 has a smaller loss of potency than expected, suggesting that 
compound 312 may adopt an alternative binding mode. 
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A number of compounds have now been synthesised with a variety of substituents on the 
benzyl ring. Several highly activity substituents have been identified; to increase activity 
attention has been be directed to alternative areas of the molecule. 
 
5.5 Further SAR for the Isoindolinone Ether-Groups 
 
Previous work with the Northern Institute for Cancer Research drug discovery laboratories 
identified the oxymethyl-cyclopropyl methanol substituent optimal for the C3 position of the 
isoindolinone e.g. NU8604 (220). The addition of the cyclopropyl group to the ether side-
chain significantly increased potency over the n-propoxy derivative the improvement was 
rationalised by the ability of the cyclopropyl to restrict the freedom of rotation of the propyl 
chain thus removing an entropic penalty to binding. However, addition of the cyclopropyl 
ring increases the clogP which is unfavourable for solubility and can cause more metabolic 
liability and the ether side chain may be a site for metabolic attack of the molecule in vivo.  
 
Table 23 Ether derivatives with IC50 values and clogP values 
 
Number R IC50 (µM) clogP 
315  0.52 ± 0.14 4.4 
316 
 
0.34 ±0.26 5.2 
185 
 
0.23 ± 0.11 4.8 
 
The gem-dimethyl group also improved activity, whilst commonly used to block metabolism, 
also increases the lipophilicity of molecules which can in turn place molecules at higher risk 
of metabolism.  
 
Wuitschik et al
233-235
 have replaced a gem-dimethyl group with an oxetane ring. The van der 
Waals volumes of the gem-dimethyl group and the oxetane ring are thought to be similar but 
the oxetane ring is more hydrophilic. Within simple model systems the replacement of a tert-
5. Isoindolinone-Based Inhibitors of the MDM2 p53 Protein-protein Interaction 
 
176 
 
butyl group with a 3-methyl-oxetanyl group improved the solubility of the compounds and 
reduced the logD value by one unit. The oxetane ring was also shown to have good stability 
within human and mice microsomes, a potential indicator of metabolic stability.
235
 
 
As the isoindolinone molecules have poor solubility (with a clogP of 5.7 for 253), making 
aqueous formulation difficult and leaving the molecule prone to metabolism, the inclusion of 
an oxetane ring may be beneficial. Therefore, the synthesis of oxetane 317 was proposed. 
 
Oxetane 317 required the synthesis of the 3,3-bis(hydroxymethyl)oxetane (318). The 
synthesis of 3,3-bis(hydroxymethyl)oxetane from pentaerythritol (2-bis-hydroxymethyl-
propane-1,3-diol) (319) using diethyl carbonate and potassium carbonate in ethanol has been 
reported.
236
 The reaction employs a catalytic amount of potassium hydroxide, as the reaction 
generates ethoxide ions to act as a base for further reactions (Scheme 80). The reaction was 
repeated following literature procedure. However, no product was observed using this 
reaction. 
 
Scheme 80 Proposed mechanism for formation of oxetane ring using diethyl carbonate 
 
An alternative route, used by Issidorides et al
237
 proved more successful, this route uses 2-
(bromomethyl)-2-(hydroxymethyl) propan-1,3-diol (320) with potassium hydroxide in 
ethanol.  320 was stirred at room temperature for 2 h, then heated to reflux. The length of 
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time the reaction was at reflux was gradually increased to optimise the yield of the reaction, 
the time and yield is shown below (Scheme 81 and Table 24). 
 
Scheme 81 Reagents and conditions; a) KOH, Ethanol, RT-reflux 
 
Table 24 Comparison of reaction time with yield 
Length of time at reflux 
(min) 
Yield (%) of 318 
7 26 
10 26 
15 78 
20 62 
1.5 h 62 
 
 
Scheme 82 Proposed reagents and conditions; a) i. SOCl2, DMF, THF, 4 h ii. 4-
nitrobenzylamine hydrochloride, Hünig’s base, THF, overnight, 28%; c) i. SOCl2, DMF, 
THF, 4 h ii. 3,3-bis(hydroxymethyl)oxetane, K2CO3, THF, overnight or BF3.OEt2, 3,3-
bis(hydroxymethyl)oxetane, DCM 0 
o
C-RT 
 
Formation of the ether linkage was then attempted using 3,3-bis(hydroxymethyl) oxetane in 
the standard synthetic procedure, with thionyl chloride and DMF. However, the synthesis of 
the desired product did not proceed as cleanly as previously seen when using 
bis(hydroxymethyl) cyclopropane and two minor spots were observed by TLC. Therefore the 
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reaction time was extended by 24 h, but no significant change was observed. On workup and 
purification of the reaction both compounds were isolated, but, only small amounts of each 
compound were isolated and the NMR spectrum of indicated poor purity. Both spectrum 
contained characteristic isoindolinone resonances. Full assignment was not possible.  
 
The alternative BF3.OEt2 route to ether formation was then attempted. 3,3-
Bis(hydroxymethyl)oxetane is not soluble in DCM so the solvent was switched to THF. 
However, rather than forming a yellow solution on addition of the BF3.OEt2 and a colourless 
solution on addition of the alcohol as is usually observed, a precipitate was instead observed, 
and no reaction occurred. The reaction was repeated, DCM was used as the main solvent, 
with 3,3-bis(hydroxymethyl)oxetane dissolved in the minimum of THF and added to the 
reaction, still no reaction was observed.  
 
2-(Bromomethyl)-2-(hydroxymethyl)-propan-1,3-diol (320), which is used as the precursor to 
3,3-bis(hydroxymethyl)oxetane is a white solid which is soluble in THF. It was decided to try 
and form the ether with 309 and then form the oxetane ring in situ. The cyclisation to form 
the oxetane ring should occur as previously seen, with compound 322 behaving as a 
monoprotected bromomethyl analogue. Formation of the ether was achieved in good yield 
under Vilsmeier conditions (42%) and cyclisation was achieved by stirring for 2 h at room 
temperature in the presence of potassium hydroxide in ethanol followed by 1 h at reflux in 
68% yield (see Scheme 83). The 4-ethynyl derivative was prepared by the same route in an 
overall 13% yield (Scheme 84) 
 
Scheme 83 Reagents and conditions; a) i. SOCl2, DMF, THF, 4 h; ii. 2-(bromomethyl)-2-
(hydroxymethyl)-propan-1.3-diol, K2CO3, THF, overnight, 42%; b) KOH, EtOH, 3 h, RT-
reflux, 68% 
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Scheme 84 Reagent and conditions a) i. SOCl2, DMF, THF, 4 h; ii. 2-(bromomethyl)-2-
(hydroxymethyl)-propan-1,3-diol, K2CO3, THF, overnight; 31% b) KOH, EtOH, 3 h, RT-
reflux, 63%; c) 1 M TBAF in THF, THF, 1 h, 89% 
 
Both compounds separated by chiral HPLC. Compound 317 was separated using a Daicel 
Chiralpak AD-H using hexane:ethanol 85:15 to give two compounds, both a foamy solid. 
NCL-00018566 (peak 1, 326) with [α] = -10.7 o and NCL-00018565 (peak 2, 327) with [α] = 
+ 30.3 
o
. Compound 325 was separated using tert-butyl methyl ether:isopropanol 95:5. Peak 
1 (NCL-00018710, 328), was a fluffy solid with optical rotation of with [α] = -7.74 o, whilst 
peak 2 (NCL-00018711, 329) was a colourless oil which gradually solidified to a white solid. 
329 had an optical rotation of [α] = +4.65 o.  Assignment of the absolute stereochemistry has 
not been possible as the compounds fail to give suitable crystals. The faster eluting peaks are 
expected to have an (R)-configuration by analogy with NU8354.
192
 A chiral HPLC trace is 
shown below (Figure 70) demonstrating the clear separation between compound 326 and 327 
on the chiral column. 
 
Figure 70 
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5.5.1. Biological Results for Isoindolinone Ether Groups 
 
Table 25 Biological results for ether derivatives * indicates compounds synthesised by other 
chemist  
Number Rotation X R 
Biological 
Activity IC50 
(µM) 
clogP 
Measured 
Solubility 
(midpoint) 
220* (+/-) NO2 
 
0.095 ± 0096 5.6 6.5 µM 
317 (+/-) NO2 
 
0.048 ± 0.0091 4.7 18.75 µM 
326 (-) NO2 
 
0.025 ± 0.0061 4.7 - 
327 (+) NO2 
 
0.83 ± 0.12 4.7 - 
253 (+/-) CCH 
 
0.15 ± 0.084 6.1 3.75 µM 
325 (+/-) CCH 
 
0.090 ± 0.032 5.2 11.5 µM 
328 (-) CCH 
 
0.12 ± 0.096 5.2 - 
329 (+) CCH 
 
3.5 ± 1.7 5.2 - 
 
 The replacement of the cyclopropyl ring with an oxetane is calculated to give an 
improvement in the physical properties of the molecule, reducing the clogP by one unit. In 
the case of the 220 to 317 an increase in potency is also observed. Wuitschik et al describes 
3-disubstituted oxetanes as possessing significant influence over the conformation of the 
carbon chain to which it is joined. With a gem-dimethyl substituted chain a staggered 
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conformation is adapted, however, with a oxetane the chain form a gauche conformation.
233
 
The introduction of the oxetane ring may therefore be holding the propyl chain in the ideal 
conformation, accounting for the increase in potency.  
 
 
 
Figure 71 
 
When changing from the cyclopropyl ring to the oxetane ring with compound 253 to 325, the 
two compounds are essentially equipotent suggests that the isoindolinone adopts a somewhat 
different binding mode in MDM2 when substituted with an ethynyl group in comparison to 
the nitro analogues. When separating compound 317 into the two enantiomers 326 and 327, 
the (-)-enantiomer (326) improves activity beyond the parent compound. However, with 
compound 328, the (-)-enantiomer of compound 325, the activity is lower than the parent 
compound. It should be noted that this is the result of initial testing, and has a large error 
within the results, so further testing may result in improved activity.  
 
The oxetane confers good properties without compromising the potency of the analogues. 
Consequently, it should be included in subsequent series of a future isoindolinones. 
 
5.6 tert-Butyl ‘A’-Ring Analogues 
 
The isoindolinone series has poor aqueous solubility, well below the target solubility for an 
orally available drug of 50 µM. Measurements of the aqueous solubility of a number of 
compounds by Cyprotex, a company which specialises in the measuring of physical 
properties of molecules developed by academia and pharmaceutical industry, observed that a 
significant difference could be seen within molecules of the isoindolinone series. Table 26 
shows some of the results of a number of compounds below. The solubility was measured 
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using a turbidimetric solubility assay, which measures kinetic solubility by a diluting DMSO 
solution of the drug with an aqueous buffer at a pH of 7.4 and a temperature of 37 
o
C. 
Turbidity was measured at 620 nm.
238
 Results are quoted as start point, midpoint and end 
point of precipitation. The solubility midpoint was obtained by measuring the first 
concentration at which precipitation is observed and the concentration where complete 
precipitation is observed. From this a midpoint is calculated. 
 
Table 26 Structure and related midpoint of solubility  
 
Number X Ar 
Lower 
Solubility 
point (µM) 
Upper 
Solubility 
point (µM) 
Solubility 
Midpoint 
(µM) 
253 4-Cl 
 
1 6.5 3.75 
185 - 
 
1 3 2 
220 4-Cl 
 
3 10 6.5 
224 6-
t
Bu 
 
10 30 20 
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From Table 26 compound 253 can be seen to have particularly poor solubility. Interestingly, 
the change from compound 220 to compound 224 has a 3-fold change in solubility, which is 
a large difference for simply changing the ‘A’-ring 4-chloro to a 6-tBu. A tert-butyl group 
would be expected to decrease the aqueous solubility, as it increases lipophilicity. In terms of 
dissolution from a solid into a solution tert-butyl groups are known to have an interesting 
affect on solubility. Law describes tert-butyl as increasing organic solubility within a series 
of compounds.
239
 The tert-butyl increases steric hindrance, which reduces the interaction 
between molecules thus increasing solubility, a principle which can also be applied to 
aqueous solubility. 
 
Compound 224, whilst having essentially equipotent biological activity (IC50 = 194 nM) as 
compound 220 has significantly improved aqueous solubility. Compound 330, which 
maintains the favourable ethynyl substitution of the benzyl ring, and incorporates the 
solubilising tert-butyl group on the isoindolinone ‘A’-ring was therefore synthesised. 
 
Compound 224 was synthesised starting from 4-tert-butylphthalic anhydride, forming the 
benzoyl benzoic acid via a Friedel-Crafts acylation analogous to 4-chloro analogues.
240
 
Therefore, we hoped to utilise this synthetic route to access compound 330. The proposed 
synthetic route is shown below. 
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Scheme 85 Proposed reagents and conditions; a) AlCl3, PhCl, 2 h, 90 
o
C; b) i. SOCl2, DMF, 
THF, 4 h ii. 4-iodobenzylamine hydrochloride, Hünig’s base, THF, overnight; c) 
Triisopropylsilyl acetylene, Pd(PPh3)2Cl2, CuI, Et3N, THF; d) i. SOCl2, DMF, THF, 4 h ii. 
1,1-bis(hydroxymethyl)cyclopropyl, K2CO3, THF, overnight e) 1 M TBAF in THF, THF, 1 h 
 
Previous work undertaken within the laboratory identified that the Friedel-Crafts reaction 
between 3-tert-butyl phthalic anhydride and chlorophenyl would give approximately 1:1 
mixture of the 5- and 6- isomers of the substituted benzoyl benzoic acid.
240
 The preparation 
was repeated as described and unfortunately, it proved to be very erratic in yield, and also 
very difficult to dry the product to a suitable level for the following reaction in the scheme. 
Therefore, an alternative method for formation of the benzoyl benzoic acid was sought. 
 
An alternative synthetic route to the benzoyl benzoic acid had recently been developed in-
house.
241
 It utilises a lead tetraacetate mediated rearrangement to form a benzoyl 
benzaldehyde from 2-hydroxyhydrazide.
242
 To utilise this new synthetic method the correctly 
substituted 2-hydroxyhydrazine was required. Jacq et al synthesised 2-hydroxyhydrazine 
from 2-hydroxybenzaldehydes and hydrazides,
242
 a protocol which should provide access to 
the desired intermediates for synthesis of the desired final compound. 
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Scheme 86 Reagents and conditions; a) benzhydrazide, AcOH, 15 min, RT, 91%
242
 
 
Synthesis of the 6-tert-butylsubstituted isoindolinones following this synthetic scheme 
requires use of 5-tert-butyl-2-hydroxybenzaldehyde (340), which can be synthesised in one 
step from 4-tert-butyl phenol (339). The Duff reaction is a method of installing aromatic 
formyl groups via electrophilic aromatic substitution.
243
 The reaction uses 
hexamethylenetetramine (HMTA) as a formaldehyde equivalent, which, when catalysed by 
trifluoroacetic acid will formylate an aromatic ring.
196
 The mechanism of is shown below. 
Acid catalysis results in formation of an iminium species, which is then attacked by the 
aromatic ring, to form the Wheland intermediate, a further iminium species then extracts a 
hydride from the benzylic position, forming a further iminium species, which on aqueous 
work-up will result in formation of the desired aldehyde. 
 
Scheme 87 
 
Lindoy et al have synthesised 5-tert-butyl-2-hydroxybenzaldehyde (340) from HMTA and 4-
tert-butylphenol  in refluxing TFA for in 29%.
243
 In-house development of this reaction 
suggested microwave heating was appropriate for this reaction. A solution of 4-tert-
butylphenol and HMTA in TFA was heated at 120 
o
C for 30 min in a yield of 46%. LCMS 
monitoring of this reaction suggested no starting material remained, but the lower yield 
suggests a large number of minor impurities are formed. 
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Benzaldehyde 340 was converted to hydrazide 341 on treatment with 4-chlorobenzhydrazide 
in acetic acid in excellent yield (94%) following the procedure described by Jacq et al.
242
  
The correct substituents for the rearrangement reaction to give the benzoyl benzaldehyde 
were now in place. The synthetic scheme to give key intermediate benzoyl benzoic acid is 
shown below. 
 
Scheme 88 Reagents and conditions; a) HMTA, TFA, 120 
o
C, 30 min, 46%; b) 4-
chlorobenzhydrazide, AcOH, 15 min, 94%; c) Pb(OAc)4, THF, 2 h, 0 
o
C, 73%; d) NaClO2, 
H2NSO3H, MeCN, 1.5 h, 85% 
 
The mechanism of the lead tetraacetate induced rearrangement has been extensively explored 
by Katritzky et al.
244
 Treatment of monosubstituted hydrazones (e.g. 344) leads to formation 
of acetoxyazo compounds like 345 (where R’’ = H). However, when R’’ = COAr e.g. 346 a 
cyclisation can occur to give 1,3,4-oxadiazolines such as 338. 
 
 
Scheme 89 
 
Scheme 90 
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When R’ = 2-phenol further rearrangement can occur, with the hydroxyl group replaced with 
the acyl substituent. This rearrangement leads to the formation of the desired benzoyl 
benzaldehydes. Katritzky et al demonstrated that the benzoyl benzaldehyde is formed via an 
intramolecular reaction, and proved that Pb(OAc)4 does not act as an acid catalyst via minor 
contamination with acetic acid.
244
 Instead, the proposed mechanism is shown below (Scheme 
91). Co-ordination to lead (IV) acetate is followed by attack of an acetate ion on the imine, 
with displacement of lead (II) acetate. This can result in either a cis or trans double bond, 
with the cis required for the following mechanism to proceed. However this step of the 
mechanism may be reversible, allow reformation of the imine, preventing the loss of the trans 
product. Attack of the carbonyl with an acetate ion breaks the double bond, with the electrons 
displacing the first acetate ion and forming a 1,3,4-oxadiazolines. The second acetate ion is 
then displaced by the lone pair of electron of the phenol oxygen, this species then rearranges 
to extrude nitrogen and rearomatises to the benzoyl benzaldehyde. Labelling studies 
undertaken by Katritzky et al demonstrated that the acyl group oxygen eventually becomes 
the aldehyde oxygen, rather the hydroxyl oxygen atom via formation of 1,3,4-oxadiazolines 
as was seen previously. 
 
Scheme 91 Mechanism of Pb(OAc)4 induced rearrangement of 2-hydroxyacyl hydrazones to 
benzoyl benzaldehyde
244
 
 
The benzoyl benzoic aldehyde (342) was synthesised following the procedure described by 
Jacq et al.
242
 The yield of this reaction was observed to be somewhat inconsistent, ranging 
from 54-73% and producing numerous minor side-products. A number of analogues with a 
range of substituents on the ‘A’-ring have been synthesised and a general trend has been 
observed, electron-donating substituents on the phenolic ring lowers the yield of the reaction 
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(Table 27). The few examples of electron-donating phenolic substituents reported also have a 
lower yield (e.g. 46% for a methoxy analogue).
242
 Benzoyl benzaldehyde (342) was oxidised 
to benzoyl benzoic acid (343) following the procedure of Lampe et al
245
 which, after 
recrystallisation gave 343 as a fluffy white solid.   
 
Table 27 Yields for lead (IV) acetate mediated rearrangement with a variety of phenolic 
substituents, * indicates results obtained by other chemists 
Phenolic ring substituents Yields (%) 
 
73 
 
91* 
 
94* 
 
56* 
 
30* 
 
74* 
 
Compound 343, which had previously been synthesised in one step from a Friedel-Crafts 
reaction (in 92% yield, mixture of isomers) has now been synthesised in 4-step route an 
overall yield of 26%. Although this scheme adds further synthetic steps to the synthesis of 
benzoyl benzoic acid (343), the regioselectivity removes the need for the difficult separation 
of isomers, as used in the Friedel-Crafts route. The desired final compound 330 can now be 
synthesised (Scheme 92). 
 
Formation of the isoindolinone, using SOCl2/DMF, is achieved in significantly higher yield 
when using 5-tert-butyl-2-(4-chlorobenzoyl)benzoic acid (323) (86%) rather than 36% for 4-
chloro 241, (even allowing for the mixture of isomers). The 4-chloro atoms appears to hinder 
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formation of the isoindolinone, either sterically, perhaps hindering formation of the Ψ acid 
chloride or electronically, due to the electron withdrawing nature of the chloro substituent.  
 
The acetylene moiety was incorporated using the optimised Sonogashira conditions in 
excellent yield (91%). Formation of the ether linkage via the Vilsmeier chemistry was 
achieved in moderately higher yield for compound 336 in comparison to the 4-Cl analogue 
(238) (50% versus 24%), influenced by the change in steric and electronic factors. 
Deprotection of acetylene groups with TBAF gave compound 330 in 80% yield. 
 
Scheme 92 Reagents and conditions; a) i. SOCl2,
 
DMF, THF, 4 h; ii. 4-iodobenzylamine 
hydrochloride, Hünig’s base, THF, overnight, 86%; b) Pd(PPh3)2Cl2, CuI, Et3N, 
triisopropylsilylacetylene, THF, 16 h, 91%; c) i. SOCl2, DMF, THF, 4 h ii. 1,1-
bis(hydroxymethyl)cyclopropyl, K2CO3, THF, overnight, 50%; d) 1 M TBAF in THF, THF, 
1 h, 80% 
 
Previous results showed that compound 224 displayed similar biological activity to the 4-Cl 
analogue, the replacement of the (hydroxymethyl)cyclopropylmethoxide side chain, with the 
alternative (hydroxymethyl)oxetanemethoxide side chain, with the aim of improving physical 
properties, was desired. The synthetic route is shown below and utilises the methodology of 
incorporating the bromomethyl species and forming the oxetane in situ. 
 
It was decided to use the BF3.OEt2 reaction to incorporate the 2-(bromomethyl)-2-
(hydroxymethyl)-propan-1,3-diol as it lacked the steric hindrance of the 4-Cl analogue. 
5. Isoindolinone-Based Inhibitors of the MDM2 p53 Protein-protein Interaction 
 
190 
 
Formation of the ether 349 was achieved in 4.5 h and as previously observed, conversion to 
the ether using BF3.OEt2 is high yielding, forming 349 in 87%. The cyclisation to form the 
oxetane ring was achieved in 78% yield on treatment with KOH in ethanol, and deprotection 
of the acetylene group gave the desired final compound (351). 
 
Scheme 93 Reagents and conditions; a) 2-(bromomethyl)-2-(hydroxymethyl)propan-1,3-diol, 
BF3.OEt2, THF, 4.5 h 0 
o
C-RT, 87%; b) KOH, EtOH, 3 h, RT-reflux, 78%; c) 1 M TBAF in 
THF, THF, 1 h, 59% 
 
Both compounds 351 and 330 were selected for separation of the two enantiomers for chiral 
HPLC and are currently awaiting separation. 
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5.6.1. Biological Results for tert-Butyl Analogues  
 
Table 28 Biological activity for tert-butyl analogues * indicates compounds synthesised by 
other chemists 
 
Number R X Ar Rotation 
Biological 
Activity IC50 
(µM) 
220
* 
 
4-Cl 
 
(+/-) 
0.095 ± 
0.096 
224* 
 
6-
t
Bu 
 
(+/-) 0.19 ± 0.10 
253 
 
4-Cl 
 
(+/-) 0.15 ± 0.083 
330 
 
6-
t
Bu 
 
(+/-) 0.078
a
 
325 
 
4-Cl 
 
(+/-) 
0.090 ± 
0.032 
351 
 
6-
t
Bu 
 
(+/-) 0.028
a 
352* 
 
4-Cl, 6-
t
Bu 
 
(+/-) 0.14 ± 0.055 
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353* 
 
4-Cl, 6-
t
Bu 
 
(+/-) 0.27 ± 0.015 
a
 indicates n = 1 
 
A change in ‘A’-ring substituent from the 4-chloro 253 to 6-tert-butyl 330 gives equipotent 
compounds. However, when the oxetane side chain is also incorporated, an increase in 
potency is observed for the 
t
Bu 351 suggesting that the 4-chloro substituted isoindolinone and 
the 6-
t
Bu substituted isoindolinone are slightly shifted in position within MDM2 pocket, 
allowing the oxetane to adopt a more favourable position. Interestingly, when the 4-Cl, 6-
t
Bu 
A-ring substituents, which are active when combined with the cyclopropyl-substituted ether 
side-chain, is not when combined with the oxetane-substituted ether side-chain. This supports 
the evidence for a slightly different binding mode for the tert-butyl substituted isoindolinone, 
which adopts the optimal position for the oxetane substituted, whilst the chloro substituted 
isoindolinone does not. 
 
5.7 Protein Crystallography of Isoindolinone-based Inhibitors of p53/MDM2 Protein-
protein Interaction 
 
Protein crystallography is an important aid for the drug discovery process. Although a 
number of MDM2/p53 inhibitors have been crystallised bound to the protein, no crystal 
structure of the isoindolinone has previously been available. Collaborators at the University 
of Oxford Biochemistry Department have previously identified the binding mode of 
isoindolinones through NMR studies,
191
 and suggested proposed which would lead to further 
increases in potency,
192
 a crystal structure would give further insights into the interactions 
between the isoindolinones and the protein. 
 
Protein crystallography is traditionally used in lead optimisation to guide chemical 
modification.
96
 For X-ray crystallography to successfully obtain a structure a well-ordered 
crystal must first be grown. Protein crystals are less ordered that small molecule crystals, and 
frequently contain channels of disordered solvent.
246
 Protein crystallisation requires the 
synthesis of sufficient volumes of purified protein to screen a variety of crystallisation 
conditions. The development of molecular biology has aided that production of larger 
volumes of protein. Bacteria, such as E-coli, can be used to express the desired protein in 
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large quantities, through the introduction of plasmids containing the gene of the target 
protein. Within crystal structure of MDM2 the protein is stabilised by other molecules of 
MDM2 resulting in a number of molecules of MDM2 per unit cell. The crystal structure of 
Nutlin-2a (PDB code 1RV1) contains three molecules of MDM2 (Figure 72). 
 
 
Figure 72  
 
To gain understanding of the processes behind protein crystallography a period of four 
months was spent working alongside colleagues at the University of Oxford working on 
protein purification and protein crystallography. Both mutants and wild type samples of the 
MDM2 binding site were purified, of either residues 17-109 or 17-125 of MDM2. Removal 
of residues 110-125 removes an unstructured loop which may prevent crystallisation. A 
number of mutants were developed which replace either one, two or three residues with 
alanine residues. Crystals develop when good contacts are formed between protein 
molecules, and two residues, lysine and glutamic acid, have been shown to be prone to 
preventing the formation of good contacts between protein molecules. Therefore, Lys and 
Glu residues which commonly lie on the surface of proteins can be replaced by Ala to aid 
crystallography.
247
  
 
A number of wild type and mutant MDM2 protein samples were then purified using the 
methodology shown below, all included a Glutathione S-Transferase tag to aid purification. 
E-coli bacteria were employed to grow the protein in 1 L cultures, centrifuged and the 
supernatant removed. The remaining pellet was resuspended in PBS buffer (40 mL) and flash 
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frozen by co-workers in Oxford before my work began. For methodology for protein 
purification see appendix one. 
 
A number of MDM2 samples were prepared and are summarised below. 
 
K94A   (17-109) 
K94E95A  (17-109) 
MDM2  (17-109) 
E69K70A  (17-109) 
E69A   (17-109) 
E69K70E94A  (17-125)  
E69A   (17-125) 
 
All mutants were expressed in sufficient volumes for crystallography with the exception of 
K94E95A, and E69K70E94A which only allowed a small volume of crystallography tray to 
be set up. After purification the purified protein was concentrated to approximately 2 mg/mL 
and incubated overnight with a series of inhibitors – Nutlin-3a, NU8354a, NCL00013774, 
NCL00013775, NCL00018225 and NCL00018226, which includes the most active 
compound synthesised at the NICR, the less active opposite enantiomers, and Nutlin-3a, the 
classical example of an MDM2/p53 inhibitor. 1.5 equivalents of the inhibitor in DMSO was 
incubated at 4 
o
C overnight, followed by washing with Hepes buffer and concentrating to a 
concentration of approximately 12 mg/mL. 
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Figure 73 
 
The protein and inhibitor mix was then set up into crystallisation trays. These were either 
purchased trays, to give a range of conditions to identify which conditions give crystals or 
custom trays, with a narrower range of conditions, with the aim of identifying optimal 
conditions for crystallisation. Purchased trays were dispensed in a 96-well plate using liquid 
handling robots and had a range of protein concentrations within each well. Trays were then 
sealed and stored in a fridge with automated image collection at 4 
o
C to allow monitoring of 
each well. Custom trays were alternatively set up in 24 well plates and the crystallisation 
conditions were prepared by hand to give a much smaller range of conditions, all based 
around conditions which had previously been identified from purchased screens as leading to 
crystals. Previous work undertaken at Oxford at identified polyethylene glycol (PEG) 
containing conditions as optimal for MDM2 crystallisation, therefore all custom trays were 
based either around PEG4000, PEG5000 or PEG8000. Each well contained a 500 µL 
reservoir and the raised well for the protein. Each reservoir was made up to 500 µL with 
water (volume determined by percentage of PEG used). Both ammonium sulphate and 
sodium acetate (from a 1 M stock of each) were used as additives to the solution, with the pH 
of the sodium acetate solution adjusted in some cases to pH 4.6. To the raised well was added 
1 µL of the protein and inhibitor solution and 1 µL of the reservoir solution. These were also 
sealed and stored at 4 
o
C for crystallisation. All custom trays were prepared in this manner 
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with the exception of the E69K70A mutant. Previous work had resulted in the growth of 
small spike-like crystals which were too small to be useful for X-ray structure determination. 
Therefore, a custom tray was prepared with only NCL-00018225 and NCL-00013775 as only 
these inhibitors had formed crystals, stored to two days at 4 
o
C before being seeded with 
fragments of these small needle-like crystals. Seeding provides a surface for crystallisation to 
occur and can result in the formation of larger crystals. A summary of crystallisation 
conditions is shown in appendix one. An illustrative example of the set up of a 24 well plate 
is also shown in appendix one. 
 
From the crystallography tray seeded with the E69K70A mutant, a needle-like crystal was 
isolated. X-ray crystallography undertaken at the diamond synchrotron in Oxford with a 3 
GeV electron beam, with a micro focus beamline under the supervision of Dr Ed Lowe and 
obtained a diffraction pattern of sufficiently high resolution to give a crystal structure which 
is shown below.
248
 The crystal structure was obtained with a resolution of 2.9 Å and the 
structural insights gained by this crystal structure will be discussed in more detail below. 
 
To validate the use of mutants as a more crystallisable form of MDM2, we must firstly 
confirm that the isoindolinone bind to a similar manner to both the mutants and wild-type 
MDM2. For this confirmation two assay types were selected, a Thermofluor assay and a 
fluorescence anisotropy assay. Assays were initially run on the wild-type MDM2 and the 
E69K70A mutant, the only mutant at this point to crystallise in the presence of an 
isoindolinone ligand. 
 
Thermofluor was a technique originally developed as high-throughput manner of identifying 
ligands for drug discovery targets.
249
 It requires a hydrophobic fluorescent probe or dye to 
distinguish between folded and unfolded proteins.
249-250
 When the protein is folded the probe 
is exposed to the aqueous environment, which quenches fluorescence. On heating, the protein 
will begin to unfold, exposing its hydrophobic core, to which the probe can then bind, and the 
fluorescence will no longer be quenched. This allows a measurement of unfolding as a 
function of temperature.
249
 This process can be undertaken using a real-time PCR machine in 
a 96-well plate. By introducing ligands to the wells, those which bind to the protein will 
stabilise it, and increase the thermal stability, increasing the melting temperature. This can be 
used to measure affinity of the ligand for the protein, a greater affinity will lead to a greater 
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increase in temperature. Results obtained should be consistent with results gained from other 
assays such as enzymatic assays.
251
 
 
The Thermofluor assay was used to compare the melting of wild-type and mutant MDM2 in 
the presence of ligands. The hydrophobic probe used was sypro orange, a fluorescent dye. 
Firstly the optimal conditions for fluorescence were identified using a range of protein 
concentration and dye concentrations. Sypro orange is sold at a concentration of 2000 x, so 
was therefore diluted with Hepes buffer to create a range of concentration 5 x, 10 x, 15 x and 
20 x. The set up of the plate is shown is appendix one. 
 
From this experiment, optimal conditions for monitoring of the protein melting was 
determined as 10 x dye concentration and after further optimisation the protein concentration 
was maintained at 9 µM. The inhibitor was added in a 2:1 inhibitor to protein ratio, with the 
inhibitor concentration maintained at 18 µM. To measure the inhibitor’s affinity, each plate 
contained 7.5 µL of 10 x dye, 1.76 µL protein at 77 µM and 0.54 µL inhibitor (from 500 µM 
DMSO stocks) and each well was made up to 15 µM with Hepes buffer. As a control, another 
well was run with identical conditions, with 0.54 µL of DMSO, and as a second control a 
well contained just dye and protein. A second row acted as a control for each inhibitor – each 
well contained 7.5 µL of 10 x dye and 0.54 µL inhibitor (or DMSO). For comparison a p53 
peptide (sequence SQETFSDLWKLLPEN) was also included in these studies. 
 
For the wild-type protein optimal concentrations were identified as 20 x concentration of 
sypro dye, 5 µM concentration of dye and 10 µM concentration of dye. With plates made up 
of 10 µL of 20x sypro dye, 0.56 µL protein (178 µM), 0.4 µL of inhibitor (500 µM) and were 
made up to 20 µL with Hepes buffer. 
 
For both proteins fluorescence was measured over a temperature range of 25-89 
o
C, with 
three readings taken at each temperature, with each temperature maintained for one minute. 
The observed melting points are shown below for each protein; average change in melting 
point was calculated using DMSO as the blank for all inhibitors except the p53 peptide. As 
the peptide was an aqueous solution the buffer solution was used as the blank for this well. 
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Table 29 Melting point for E69K70A protein with inhibitors 
Inhibitor 
Melting point repeat 
1 (
o
C) 
Melting point repeat 
2 (
o
C) 
Average change in 
melting point from 
control (
o
C) 
No Inhibitor 59 50 - 
DMSO 58 54 - 
NU8354a 70 69 13 
NCL-00013774 75 64 14 
NCL-00013775 71 68 13 
NCL-00018225 77 77 21 
NCL-00018226 72 74 17 
Nutlin-3a 79 77 22 
p53 peptide 63 59 3.7 
 
Table 30 Melting point for wt MDM2 17-109 protein with inhibitors 
Inhibitor 
Melting point 
repeat 1 (
o
C) 
Melting point 
repeat 2 (
o
C) 
Melting point 
repeat 3 (
o
C) 
Average change 
in melting point 
from control 
(
o
C) 
No inhibitor 62 64 63 - 
DMSO 68 64 67 - 
NU8354a 72 75 76 8.0 
NCL-00013774 75 79 76 12 
NCL-00013775 64 71 70 2.2 
NCL-00018225 76 70 77 7.6 
NCL-00018226 65 68 68 1.0 
Nutlin-3a 90 82 80 20 
Peptide 67 70 68 5.1 
 
A comparison of the change in melting point between the E69K70A and wild-type protein is 
shown below, along with the ELISA assay IC50 values for each isoindolinone. 
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 Table 31 Comparison of change in melting point between each protein and ELISA assay 
values for the wild-type protein 
Inhibitor 
E69K70A change in 
melting point 
Wt MDM2 change in 
melting point 
ELISA assay IC50 
(µM) 
NU8354a 13 8.0 0.17 
NCL-00013774 14 12 0.044 
NCL-00013775 13 2.2 0.73 
NCL-00018225 21 7.6 0.041 
NCL-00018226 17 1.0 2.4 
Nutlin-3a 22 20 - 
peptide 3.7 5.1 - 
 
By drawing a graph comparing the change in melting point against the IC50 value it can be 
observed that for wild-type MDM2 some correlation can be observed between the 
thermofluor values and IC50 values 
 
 
 
However, when looking at the graph for the E69K70A mutant little correlation is observed 
between the change in melting points and the IC50. For the (+)-isomers NCL-00013775 and 
NCL-00018226, a significant change in melting point is observed, unlike the wild-type 
protein. 
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The fluorescence anisotropy assay was then undertaken to give a further comparison between 
the mutant and wild-type protein. Fluorescence anisotropy uses a fluorescently labelled p53 
peptide and monitors the displacement from MDM2 on titration of increasing concentration 
of inhibitor.  
 
A fluorescent molecule, if excited by polarized light, will emit polarized light. However, in 
solution, the polarized light will be randomized, due to the rotation of the molecule in 
solution. Fluorescence anisotropy is based on the observation that the size of molecules can 
affect the polarization of fluorescence. A larger molecule results in less scattering of the 
polarized light than a smaller molecule.
252
 Therefore, when the p53 fluorescently labelled 
peptide is in complex with MDM2, the fluorophore behaves as a large molecule, but on 
titration of increasing concentrations of inhibitors, the p53 will be displaced from the 
p53/MDM2 complex and will behave as a smaller fluorophore. By monitoring the degree of 
scattering, the increasing levels of displacement can be observed. By plotting concentration 
of inhibitor against levels of polarization, a sigmoidal curve should be observed, of the type 
shown below, measured by Zhang et al.
253
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Figure 74 A graph monitoring fluorescence polarisation (FP) against inhibitor 
concentration(Taken from reference 252)  
 
Firstly the optimised concentrations without inhibitor were identified using a range of MDM2 
and fluorescently labelled p53 concentrations (Table 35 Appendix one). Each well was made 
up to a final concentration of 20 µL with Hepes buffer. 
 
For each concentration of MDM2 an increase in intensity of fluorescence was observed with 
increasing concentration of fluorescently labelled peptide. A MDM2 concentration of 10 nM 
was identified as the optimal concentration to use for the titration of inhibitor and a 
fluorescently labelled peptide concentration of 2 nM was used. NU8354a (345) was used as 
the inhibitor, and due to the extensive pipetting involved in the preparation of each 
experiment; conditions were optimised using a single inhibitor first. The concentration of 
inhibitor ranged from 2-57 nM from a DMSO solution, and to maintain a constant DMSO 
concentration each well was made up to a DMSO volume of 1.2 µL along with a blank well 
containing just DMSO. The volume for each well was maintained at 20 µL using Hepes 
buffer. However, on measuring the polarization no curve was observed.  
 
After discussion with co-workers it was decided to alter the range of inhibition concentration, 
to give a range of 1-256 nM to give a range of values either side of the IC50 value. On 
measuring the polarization, no curve was obtained. It was proposed that a greater 
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concentration of fluorescently labelled peptide was required. At low concentration of 
inhibitor, there are sufficient binding sites on MDM2 for both peptide and inhibitor; therefore 
the displacement of the peptide may not occur. By increasing the concentration of the 
peptide, the peptide should be displaced by the inhibitor of the peptide at a lower 
concentration, which should be observed by a change in fluorescence polarization.  
 
Therefore, whilst both the MDM2 concentration and the range of inhibitor concentrations 
were maintained, the peptide concentration was increased to 5 nM. However, no curve was 
again observed. The experiment was repeated with Nutlin-3a to verify that the isoindolinone 
was not affecting the experiment, but this gave identical results. Work on this assay was 
therefore stopped. However, colleagues at Oxford, who continued to optimise this assay after 
my placement was completed, suggested that by saturating the MDM2 binding site with 
peptide, a curve can be observed on addition of the inhibitor. 
 
The inhibitor may induce a change of behaviour of the MDM2 protein when in solution. To 
monitor this an analytical size S75 size exclusion column was used. Size exclusion columns 
separate proteins according to size, with larger proteins coming off the column quicker. A 
sample of protein in Hepes buffer was run through the column, and the trace showed a peak 
at 12 min. The protein was then incubated with NU8354a (356) for 1 h in a 1:1 ratio of 
protein to inhibitor and the size exclusion column was then repeated. The trace showed two 
peaks, one at 12 min which corresponds to the protein in solution, and another peak at 4.2 
min. This suggests that in the presence of the inhibitor the MDM2 protein forms a complex of 
a number of units of the protein. To identify the size of the complex a calibration column of 
proteins of known mass must be used. Two proteins; bovine serum albumin (66 kDa) and 
carbonic anhydrase (29 kDa) were mixed together and ran through the size exclusion column. 
The largest of these two proteins appeared on the trace at 4.2 min, which agrees with the time 
of the MDM2 complex, suggesting a mass of 66 kDa. The wt MDM2 (17-109) has a mass of 
approximately 11 kDa, therefore six molecules of MDM2 form the complex. 
 
The unusual behaviour of the MDM2 protein in the presence of inhibitors may influence the 
results of the fluorescence anisotropy and Thermofluor assay leading to the unusual results. 
Coworkers at Oxford are continuing work on assay optimisation. 
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5.7.1. Crystal Structure of NCL00013774 
 
 
Figure 75 X-ray crystallography of NCL-00017734 modelled using CCP4MG, the electron 
density map of the isoindolinone is shown 
 
  
Figure76 Image of NCL-00013774 in MDM2 binding site modelled in PyMOL and (right) 
with surrounding residues displayed 
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Figure 77 Modelling of crystal structure of NCL00013774 (top) and Nutlin-2a (bottom left) 
and p53 (bottom right), with the MDM2 protein represented as ribbons  
 
A crystal structure of an isoindolinone was achieved using E69K70A mutant of MDM2 17-
109 with a resolution of 2.9Å. From the crystal structure it can be observed that the 
chlorophenyl ring lies within the Trp23 pocket, the nitrobenzyl ring sits within the Leu26 
pocket and the isoindolinone moiety lies over the Phe19 pocket. 
 
Figure 78 Halogen bond between 4-Cl and Gly58 of MDM2  
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The ‘A’-ring 4-Cl is observed to a halogen bond with a backbone carbonyl group of a glycine 
residue, with a length of 3.3Å. The electron cloud surrounding the chloro atom interacts with 
the lone pair of the carbonyl. Chlorine, bromine and iodine atoms attached to either aryl or 
electron withdrawing alkyl groups can form bonds to electrophiles, nucleophiles and other 
halogens,
254
 dependent on direction of the interaction.
255
 A σ-hole is formed when halogen 
atoms are attached to either aryl or electron withdrawing alkyl groups. A  σ-hole is a positive 
area within electron density, which lies opposite the carbon-halogen bond and is formed by 
the three pairs of unpaired electrons on the halogen, forming a ring of electron density 
surrounding the centre of the halogen atom, while any remaining electrons are involved in 
bonding to the carbon.
254
 A representation of the different interactions is shown below. 
Halogen bonds lie approximately 180 
o 
to the C-X bond, though this angle can be as little as 
155 
o
.
256
 Halogen bonds are weaker than H-bonds but the larger the halogen atom the stronger 
the halogen bond.
254
  They can be increased in strength by increasing the electron-
withdrawing nature of  the substituents on the aromatic ring. The halogen bond acts to pull 
the isoindolinone in closer to the protein into a slightly different binding mode to the 
unsubstituted isoindolinone ‘A’-ring. This may account for differing degrees of activity 
between unsubstituted and substituted analogues. 
 
Figure 79 Representation of halogen and hydrogen bonds formed by a halogen atom (X) and 
hydrogen atom (H) (Taken from reference 254)  
 
An edge-face stacking interaction is observed between the protons at the 5- and 6-position of 
the ‘A’-ring and Tyr67 within MDM2, an interaction which would not observed when the 6-
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tert-butyl group is in place. The 7-position of the isoindolinone points out into solvent and 
should prove an interesting area to incoporate solubilising groups. 
 
 
Figure 80 The crystal structure demonstrates that the cyclopropyl substituted ether group lies 
along the surface of the protein 
 
The cyclopropyl group of the ether side-chain was initially incorporated to restrict rotational 
freedom of the propyl ring.
192
 However, the protein crystallography (Figure 80) suggests that 
the cyclopropyl ring nestles up to the protein, contributing to the binding energy. The 
hydroxyl group itself points out into solution and does not form an interaction with the 
protein. 
 
From the crystal structure it is unclear what role the nitro group is fulfilling. A direct 
interaction is not observed between the protein and the nitro group. Similarly, a clear role for 
the ethynyl functionality cannot be proposed, although His and Tyr residues are present at the 
bottom of the pocket, so this may be the ideal environment for the ethynyl group. The 
preference for the ethynyl over the nitro functionality in 253 and 220 may be a result of the 
halogen bond. By pulling the isoindolinone ‘A’ ring closer to the protein, the benzyl ring is 
pulled out of the Leu26 pocket. However, with the longer ethynyl substituent this may be 
counteracted. 
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Figure 81 X-ray crystallography of NCL00013774 (left) and Nutlin-3a modelled using 
CCP4MG 
 
From Figure 81 we can see that the benzyl aromatic ring of 354 does not protrude as deeply 
into the Leu26 pocket as Nutlin-3a. The ‘lid’ component, which partially covers the aromatic 
ring of Nutlin-3a does not cover NCL00013774, an area which could potential be utilised be 
isoindolinone to give a further increase in potency. 
 
The Tyr23 pocket of MDM2 is filled with a chlorophenyl ring on MDM2 binding. An 
overlay of a number of inhibitors of the MDM2/p53 interaction suggests that this ring is 
always filled with a chlorophenyl ring, suggesting the optimal substituent for this position has 
been identified. The crystal structure of 354 bound to MDM2 will guide the direction of 
synthetic efforts and a number of potential compounds designed as a result of this crystal 
structure will be discussed in chapter 5.8. 
 
5.8 Future Work for MDM2/p53 
 
The crystal structure of NCL-00013774 identified a number of areas to address to attempt to 
improve potency. A series of compounds designed to exploit these areas should result in an 
improvement in potency. NCL-00013774 was shown to -  
 Form a halogen bond with the protein 
 Form an edge-face interaction with a tyrosine residue  
 C7 position of the isoindolinone points into solution 
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 Halogen bonds and edge-face interactions can be enhanced by an electrodeficient aromatic 
ring.
254
 As the C
7
 position points out into solution, replacement of the isoindolinone phenyl 
ring with a pyridine ring may be tolerated, and should strengthen the halogen bond. The 
inclusion of a pyridine ring will also reduce the clogP from 6.6 for 253 to 5.6 for 357. 
Compound 357 may prove a useful compound to synthesise. 
 
Figure 82 
 
An ‘isoindolinone’ type molecule in which the pyridine ring replaced the phenyl ring has 
previously been synthesised from the furo[3,4-b]pyridine-5,7-dione, however no chloro 
substituted analogue is available. Spaeth et al forms the chloro substituted anhydride from 4-
chloroquinoline via the diacid.
257
 However, formation of the benzoyl benzoic acid from the 
anhydride allows no control over which isomer is formed. Alternatively, the lead (IV) acetate 
mediated chemistry could be employed to synthesise the desired isomer of the benzoyl 
benzoic acid (359) (Scheme 93).  
 
The retrosynthesis of this molecule is shown below. To utilise this synthetic route 4-chloro-2-
formyl-3-hydroxypyridine must first be synthesised. Belley et al synthesised 4-chloro-2-
formyl-3-methoxypyridine from (4-chloro-3-methoxypyrid-2-yl)methanol oxidising the 
hydroxymethyl group to an aldehyde using Dess-Martin periodinate.
258
 Masaaki et al 
synthesised (4-chloro-3-methoxypyrid-2-yl)methanol (364) from 4-chloro-3-methoxy-2-
methylpyridine (366) via the N-oxide (365). Treatment of the pyridine N-oxide (354) with 
acetic anhydride followed by potassium hydroxide can incorporate the hydroxymethyl 
functionality. Formation of the N-oxide acidifies the alkyl protons, allowing deprotonation 
with potassium hydroxide. To access 4-chloro-3-methoxy-2-methylpyridine (366), 3-
methoxy-2-methylpyridin-4(1H)-one (367) can be chlorinated using POCl3 as described by 
Kohl et al.
259
 To synthesise the pyridone ring methyl maltol can be treated with a methylating 
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agent, followed by heating with ammonia as described by Ma et al will access compound 
367.  
 
Scheme 93 
 
The proposed synthetic route should allow access to compound 361 from which the lead (IV) 
acetate mediated chemistry can be utilised to form the desired isomer of the 3-(4-
chlorobenzoyl)picolinaldehyde. Electron-withdrawing groups have shown to improve the 
yield of the Pb(OAc)4 mediated rearrangement, suggesting that the electron-deficient nature 
of the pyridine ring will not hinder rearrangement. 
 
The crystal structure of NCL-00013774 also demonstrates that the isoindolinones fail to 
exploit the depth of the Leu26 pocket as fully as the Nutlin-type molecules. It was proposed 
that by replacing the benzyl moiety with phenylethyl moiety, the aromatic ring would sit 
deeper within the Leu26 pocket, mimicking the Nutlin series. Previously compound 370, 
failed to improved potency, compound 371 has an IC50 of 0.36 µM whilst compound 370 
with the addition CH2 unit has an IC50 of 3.3 µM. However, with the ‘A’-ring 4-chloro 
substituent forming a halogen bond, the molecules are expected to have a slightly different 
binding mode which may result in tolerance for the addition CH2 moiety. 
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Figure 83  
 
Both compounds 378 and 379 can be synthesised as analogues of the most potent non-nitro 
compounds. 4-Chloro substituted phenylethyl compound 372 can be purchased and via 
Buchwald-type Sonogashira reaction can be used to access 375 using chemistry optimised in-
house.
260
 This utilises the chemistry developed by Gelman et al to couple acetylene-
derivative to aromatic chloro species.
261
 
 
However, the different vector of the substituent due to the addition CH2 may lead to the 
aromatic ring not taking the optimal position within the pocket – resulting in a loss of 
potency. The addition flexibility of the chain may overcome this. The loss of potency that 
occurs in changing from the ethylene to the propylene substituent on the aromatic ring also 
suggests that the addition of the CH2 to the N-benzyl substituent may not result in an increase 
in potency. However, by synthesising these two compounds 378 and 379 the SAR around the 
N-benzyl substituent will be developed further.  
 
Scheme 94 Proposed reagents and conditions; a) Boc2O, Amberlyst, 3 min; b) 
PdCl2(CH3CN)2, XPhos, CsCO3, MeCN, 110 
o
C, overnight; c) TFA, DCM, 1 h  
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The isoindolinone compounds 375 and 376 can be synthesised using the previously discussed 
synthetic route. 
 
Scheme 95 Proposed reagents and conditions; a) i. SOCl2, DMF, THF, 4 h: ii. X = Cl, 369, 
Hünig’s base, THF, overnight, X = CCH, 375, Hünig’s base, THF, overnight; b) i. SOCl2, 
DMF, THF, 4 h ii. 1,1-bis(hydroxymethyl)cyclopropane, K2CO3, THF, overnight 
 
An overlay of the crystal structures of NCL-00013774 and a number of published inhibitors 
identified that the spirooxindole series occupies a unique area of the binding pocket, in which 
a number of water-solubilising groups are located. This area lies between the isoindolinone 
phenyl ring and the benzyl groups as shown below. However, the published crystal structure 
of the spirooxindole series is not the same diastereoisomer as the preclinical candidates 
2’R,3R,4’S,5’R for the crystallised form rather than 2’R,3S,4’R,5’R  . In the preclinical 
candidates the water-solubilising groups lies in a similar orientation as the Nutlin-3a water 
solubilising group. However, there are only slight differences in biological activity between 
the two diastereoisomers.
146
 
 
 
Figure 84 Crystal structure of an analogue of MI-63 
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Figure 85 
 
This area of the pocket could be accessed by substituents from the ortho-position of the 
benzyl ring. To confirm that substituents at this position are tolerated compound 377 could be 
synthesised. If compound 380 retains potency the alcohol group could provide synthetic 
access to a range of substituents at this position. 
 
Nelson et al have synthesised (2-(aminomethyl)-5-chlorophenyl)methanol (384) from methyl 
5-chloro-2-cyanobenzoate (383) by reducing the ester and nitrile group simultaneously with 
Zn(BH4)2. Copper cyanide was used to form methyl 5-chloro-2-cyanobenzoate from methyl 
2-bromo-5-chlorobenzoate,
262
 and the analogous carboxylic acid is commercially available 
(Scheme 96). Following this synthetic scheme will allow formation of the required 
benzylamine, from which isoindolinone 380 can be synthesised. 
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Scheme 96 Proposed reagents and conditions; a) H2SO4, MeOH; b) CuCN, DMF; c) 1 M 
BH3.THF in THF 
 
Compounds 357, 378, 379 and 380 can act as a series of probes investigated areas suggested 
by the crystal structure of NCL-00013774. This will develop the SAR further for the 
isoindolinones, and potentially lead to a further increase in potency and improve physical and 
chemical properties. 
 
5.9 p53/MDM2 Assay Details 
 
Biological testing of compounds was undertaken by bioscientists at the NICR using an 
ELISA assay.
190
 A 96-well plate was incubated overnight at 96 
o
C with streptavidin in a 
coating buffer. Plates were then rinsed 5 times with dissociation enhanced lanthanide 
immunoassay buffer, then incubated for 3 h at room temperature with a saturation buffer to 
block non-specific protein binding. After removal, plates were dried in sterile fumehood at 
room temperature before incubating at 4 
o
C for 1 h with biotinylated IP3 peptide
263
 in 0.05% 
DMSO in PBS buffer, then plates were washed three times with PBS. 
 
For initial testing compounds and controls were plated out in triplicate to give final 
concentrations of 500 µM, 100 µM and 20 µM. Controls were 5% DMSO as a negative 
control and 100 nM active peptide as a positive control.
264
 Compounds and controls that were 
aliquoted in 96-well plate were preincubated with for 20 min at 20 
o
C with 190 µL aliquots of 
concentrated of in vitro translated MDM2, then transferred to the streptavidin coated plates 
and incubated at 4 
o
C for 90 min. Plates were then washed three times with PBS buffer, 
incubated for 1 h at 20 
o
C with TBS-Tween buffered solution of mouse monoclonal anti-
MDM2 antibody, then washed three times with TBS-Tween solution, then incubated for 45 
min at 20 
o
C with goat-antimouse house radish peroxidise conjugate secondary antibody. 
Unbound secondary antibody was removed by washing three times with TBS-Tween 
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solution. HRP activity measured using oxidation of diacylhydrazide substrate luminal. The 
IC50 were calculated using plot of % MDM2 inhibition versus concentration.
190
 
 
5.10 Conclusion 
 
The p53/MDM2 protein-protein interaction is an important anti-cancer target. Isoindolinones 
have proved to be a valuable scaffold for the development of small molecules targeting the 
p53/MDM2 interaction, allowing elaboration of the scaffold in a number of positions. 
Modifications to the isoindolinone have led to a significant increase in potency from 
inhibitors with activity in the micromolar range to low nanomolar range. 
 
The lead compound NCL-00008406 contains an undesirable nitro substituent on the benzyl 
group, however, synthetic efforts have identified appropriate replacements for the nitro 
group, which either improve or maintain activity against MDM2. The SAR around the benzyl 
group has been shown to be very narrow, substitution at the 3-position of the benzyl ring is 
only tolerated with small substituents, such as a fluoro group. Substituents at the 4-position of 
the benzyl ring have also demonstrated that the benzyl ring sits close to the bottom of the 
pocket. An ethylene group is tolerated, but addition of a terminal methyl group to the 
ethylene group is not tolerated, suggesting that this substituent is too large. The SARs around 
the isoindolinone A-ring have been developed and demonstrate that a number of substituents 
around the A-ring confer activity. Further investigation is required. Synthesis of an 
alternative ether chain, incorporating an oxetane ring has also shown to be tolerated.  
 
An alternative regioselective synthesis of the important benzoyl benzoic acid intermediate 
has also been developed which is proving more versatile in the synthesis of new molecules. 
Although adding a number of steps to the synthetic route, the new synthetic route results in 
only the desired isomer and the additional steps are mostly trivial and high yielding. 
 
The crystal structure of an isoindolinone bound to MDM2 has been solved recently. This will 
guide the synthesis of more potent molecules, as well as allowing the incorporation of groups 
to improve the properties to the molecules, without disrupting the interaction with MDM2. 
 
Several potent inhibitors of the MDM2/p53 interaction have been published, and the 
biological activity of lead isoindolinone compounds is comparable to those in the public 
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domain. Interesting, biological studies have suggested that both Nutlin-3a and MI-63 are both 
substrates for PGP transporters, whereas isoindolinones series are not. It was demonstrated 
that isoindolinones induced p21 in a cell-line in which PGP is upregulated, unlike Nutlin-3a 
and MI-63 which failed to induce p21.
265
 Zhang et al have also observed that Nutlin-3a is an 
inhibitor of the breast cancer resistance protein efflux pump, by inhibition of the ATPase 
activity of BCRP.
266
 Nutlin-3a was shown to inhibit the efflux of the anti-cancer agent 
Mitoxantrone. The inhibition of efflux-pumps may impact on the pharmacokinetic, 
pharmacodynamic and safety profile of any anti-cancer agents which are substrates for efflux 
pumps. As isoindolinones do not appear to be either a target of efflux pumps or an inhibitor 
of efflux pumps, these safety fears can be negated. 
 
Isoindolinones have proved a versatile scaffold for the development of inhibitors of the 
MDM2/p53 protein-protein interaction. Synthetic efforts have successfully identified a 
replacement for the toxic nitro group of the lead compound NCL-00008406. The SAR has 
also been developed further around the isoindolinone ‘A’-ring and an alternative ether chain 
has been identified. The recent solving of the crystal structure of NCL-00013774 will guide 
further synthetic effort and the incorporation of groups to improve solubility. Isoindolinones 
are not substrates for cellular transporters which is unique amongst potent inhibitors of the 
p53/MDM2 interaction. 
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6. Overall Conclusion 
 
Anti-cancer drug discovery has moved away from the development of broad spectrum 
cytotoxic agents towards the development of targeted agents, inhibiting a number of targets 
including receptors, kinases and protein-protein interactions. The drug discovery process 
entails a number of steps, and medicinal chemists are involved in a number of these steps, 
including hit and lead identification, hit validation and lead optimisation. The importance of 
the compound series has been demonstrated by the synthetic efforts towards the development 
of small molecule inhibitors of both mTOR and MDM2.   
 
The pyrimidine-based series was shown to inhibit mTOR after a small screen of compounds. 
The molecules were originally developed as CDK2 inhibitors, so had modest activity against 
both mTOR and CDK2, and the pyrimidine heterocycle was already substituted at all 
available position around the pyrimidine. Design of a potent and selective inhibitor of mTOR 
required both the optimisation of mTOR activity and reduction of CDK2 activity around a 
ring which was already optimally substituted. 
 
Alternatively, the isoindolinone series of inhibitors were identified as having cellular 
inhibitory activity and were then identified as inhibitors of the MDM2/p53 interaction, 
ensuring from the outset that compounds had cellular activity. As the isoindolinone scaffold 
was largely unsubstituted wide-ranging SAR studies have been undertaken to identify 
optimal substituents and position. As the isoindolinone compound were not part of a 
compound series directed at an alternative biological target, efforts were solely directed 
towards identification of active compounds. 
 
The importance of hit compounds within the drug discovery process has lead to the 
development of a wide-range of techniques for the identification of compounds with activity 
against a particular biological target. Early techniques such as the use of natural compounds, 
screens of existing compounds and a me-too approach are being joined by more innovative 
techniques such as fragment-based drug discovery and computer-based techniques, making 
the drug discovery process increasingly efficient.
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7. Experimental  
 
Commercially available starting materials were purchased from fine chemical vendors 
and used as purchased unless otherwise stated. N,N,N,N-tetramethylethylenediamine 
was distilled over potassium hydroxide before use. Anhydrous THF, DMF, methanol, 
ethanol, DCM, acetonitrile and pyridine were obtained from Aldrich in SureSeal
 ™ 
bottles or Acros in Acroseal™. Petrol refers to petroleum ether with the boiling range 
of 40-60 
o
C. All reactions, unless otherwise stated were carried out under an inert 
atmosphere of nitrogen or argon. Palladium and rhodium catalysed reactions were 
degassed by bubbling N2 through the reaction for the specified length of time. 
 
All microwave assisted synthesis was performed using an Initiator Sixty Biotage 
apparatus. Hold temperature mode was used in all experiments. 
 
LC-MS spectra were recorded either using a Micromass Platform LC in combination 
with a Waters 996 Photodiode Array Detector, a Waters 600 Controller and a Waters 
2700 Sample Manager. Separation was achieved on a Waters Symmetry C18 column 
(4.6 x 20 nm) or Waters Atlantis C18 column (4.6 x 50 nm) using gradient elution 
with (A) 0.1% aqueous formic acid and (B) acetonitrile. The gradient used was A: B 
95:5 to 5:95 over 3.5 min for the Symmetry column and 4.0 min for the Atlantis 
column. The Symmetry column had an overall time of 5.00 min and is referred to as 
(1) within experimental procedures. The Atlantis column has an overall time of 12.00 
min and is referred to as (2) within experimental procedures. Alternatively, samples 
were run using a Waters Acquity UPLC system with PDA and ELSD. Separation was 
achieved using an Acquity UPLC BEH C18, 1.7 µM, 2.1 50 mm column. With a 
mobile phase of (A) 0.1% v/v aqueous formic acid and (B) 0.1% formic acid in 
acetonitrile  A:B 95:5 to 5:95 over 1.5 min, overall times were either 2.00 min (3), 
2.50 min (4) or 3.00 min (5) achieved with a range of hold times. 
 
Thin-layer chromatography (TLC) was performed using precoated silica gel 60 F254 or 
NH2F254s plates (amino silica) with aluminium backing and was visualised with ultra-
violet (UV) light or potassium permanganate. Column chromatography was 
performed either on Davisil silica gel 40-63 µm or on automated medium pressure 
chromatography apparatus, a Biotage SP4 system running a graduated system as 
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specified with either Biotage flash prepacket column KP-Sil, KP-NH (amino silica) 
and KP-C18 or Agilent Si 50 or 35 and NH (amino silica). Chromatography refers to 
medium pressure column chromatography or Biotage SP4 under the given conditions 
unless otherwise stated. 
 
Chiral semi-preparative HPLC was performed using  a Varian Prostar instrument 
equipped with a Daicel Chiralpak AD-H250 x 10mm column eluting with solvent (as 
specified), at a flow rate of 4.0 mL/min, monitoring by UV at λ = 254 nm. Analytical 
HPLC was performed using Waters XTerra RP185 µm (4.6 x 150 mm) column at 1 
mL/min, with either (A) 0.1% aqueous ammonia and acetonitrile (B) 0.1% aqueous 
formic acid and acetonitrile (B), with a gradient of 5-100% acetonitrile over 25 min 
with the lowest purity quoted. 
 
NMR spectra were recorded on a Bruker Spectrospin AC 300E spectrometer (
1
H at 
300 MHz, 
13
C at 75 MHz) or using a Bruker Ultrashield 500 plus (
1
H at 500 MHz, 
13
C 
at 125 MHz) with CDCl3, d6-DMSO or d3-MeCN as the solvent.  Chemical shifts (δH) 
are reported in parts per million (ppm) downfield from tetramethylsilane (TMS).  
Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet), br (broad); or combinations thereof.  Coupling constants (J) were 
measured in Hertz (Hz). 
 
Melting points were measured on either Stuart Scientific melting point apparatus 
(SMP3) or Stuart automatic melting point apparatus (SMP40) and are uncorrected.  
 
IR spectra were recorded on a Bio-Rad FTS 3000MX diamond ATR as a neat sample. 
UV spectra were recorded on a Hitachi U-2800A spectrophotometer and were 
performed in ethanol.  
 
High resolution mass spectra were performed by the EPSRC National mass 
spectrometry service, University of Wales, Swansea, Singleton Park, Swansea, SAZ 
8PP. Elemental analyses were performed by The School of Pharmacy, Analytical 
Facility, University of London, WC1N 1AX. 
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7.1 mTOR Experimental Procedures 
 
4-(Cyclohexylmethoxy)pyrimidine-2,6-diamine (55) 
 
Sodium (0.40 g, 17 mmol, 1.3 eq) was added, in portions, to cyclohexylmethanol 
(20.0 mL, 189 mmol, 14 eq) and the mixture was heated to 160 
o
C until the sodium 
had dissolved. 4-Chloro-2,6-diaminopyrimidine (2.00 g, 13.8 mmol, 1 eq) was added 
to the solution and the temperature was increased to 180 
o
C. After 90 min the reaction 
mixture was cooled to room temperature and neutralised with acetic acid. Methanol 
(10 mL) was added and the solution was allowed to cool to 4 
o
C and then left 
overnight. The resulting white solid was filtered and recrystallised (methanol). 
Additional precipitation of crude product was brought about by the addition of 
methanol to the remaining crude oil to give 55 as a white powder (0.55 g, 20%). Rf = 
0.38 (100% EtOAc); mp = 137.5-138.8 
o
C (lit. 142 
o
C)
147; UV λmax (EtOH): 266.5 
nm; IR ʋmax 3344 (NH), 2920, 2850, 1589 cm
-1
; δH (500 MHz d6-DMSO) 0.93-1.00 
(2H, m, C6H11), 1.34-1.23 (3H, m, C6H11), 1.63-1.73 (6H, m, C6H11) 3.88 (2H, d, J = 
6.6 Hz, CH2), 5.04 (1H, s, H
5
), 5.83 (2H, s, N
1
H2), 5.99 (2H, s, N
2
H2); δC (125 MHz, 
d6-DMSO): 25.2 (C6H11), 26.0 (C6H11), 29.3 (C6H11),  36.9 (CCH2O), 69.7 (OCH2), 
76.0 (C
5
), 162.9 (C
2
), 165.9 (C
6
), 170.3 (CO); LCMS Rt = 2.31 min, (1); MS (ESI+) 
m/z 223.15 [M+H]
+
      
 
4-Cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine (56) 
 
4-(Cyclohexylmethoxy)pyrimidine-2,6-diamine (100 mg, 0.45 mmol, 1 eq) was 
dissolved in acetic acid (30% in water, 5 mL) at 80 
o
C. Sodium nitrite solution (40 mg 
in 0.8 mL of water, 0.58 mmol, 1.3 eq) was added dropwise to the solution, resulting  
in a purple solution being formed instantly which was stirred at 80 
o
C for 40 min and 
then cooled to room temperature. The resulting purple precipitate was filtered and 
recrystallised in ethanol to give a purple powder (97 mg, 86%). Rf  = 0.41 (15:85 
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MeOH:DCM); mp = 247.8-248.5 
o
C (lit. 254 
o
C)
147
; UV λmax (EtOH): 334.5, 235.0 
nm; IR ʋmax 3499 (NH), 3161, 1570, 1508 (NO), 1262 cm
-1
; δH (300 MHz d6-DMSO): 
0.99-1.33 (5H, m, C6H11), 1.64-1.86 (6H, m, C6H11), 4.29 (2H, d, J = 6.3 Hz, CH2) 
7.77 (1H, s, N
1
H2), 7.82 (1H, s, N
1
H2), 8.00 (1H, s, N
2
HH), 10.09 (1H, s, N
2
HH); δC 
(75 MHz d6-DMSO): 25.5 (C6H11), 26.3 (C6H11), 29.5 (C6H11), 37.2 (CCH2O), 71.9 
(CH2O), 140.1 (C
6
), 164.0; LCMS Rt = 2.94 min, (1); MS (ESI+) m/z 252.20 [M+H]
+
      
 
5-Bromo-4-(cyclohexylmethoxy)pyrimidine-2,6-diamine (66) 
 
To a solution of 4-(cyclohexylmethoxy)-pyrimidine-2,6-diamine (300 mg, 1.35 mmol, 
1eq) in acetic acid (5.0 mL, 87 mmol, 64 eq) was added N-bromosuccinimide (240 
mg, 1.35 mmol, 1 eq) and the mixture heated to 60 
o
C for 1 h then and diluted with 
water (10 mL) giving a white suspension and neutralised with 2.5M aqueous NaOH 
solution. The resulting white precipitate was filtered and redissolved in DCM (20 
mL). The solution was dried over Na2SO4 and evaporated in vacuo. Chromatography 
(silica, 15% MeOH, DCM) gave 66 as a white solid (326 mg, 80 %). Rf = 0.58 (100% 
EtOAc); mp = 193.7 – 194.5 oC (193-194 oC)148; UV λmax (EtOH): 338.5, 327.5, 
273.5, 233.5 nm; IR ʋmax 3497 (NH), 3472, 1053 cm
-1
; δH (300 MHz d6-DMSO): 
0.93-1.29 (5H, m, C6H11), 1.62-1.72 (6H, m, C6H11), 3.98 (2H, d, J = 6.3 Hz, CH2), 
6.09 (2H, s, N
1
H2), 6.25 (2H, s, N
2
H2); δC (75 MHz d6-DMSO) 25.6 (C6H11), 26.4 
(C6H11), 29.5 (C6H11), 37.3 (CCH2O), 71.1 ,(CH2O) 161.5 (CNH2), 162.2 (CNH2), 
165.4 (CO); LCMS Rt = 2.99 min, (1); MS (ESI+) m/z 301.23 [M+H]
+
      
 
N,N’-(5-Bromo-4-(cyclohexylmethoxy)pyrimidine-2,6-diyl)diacetamide (67) 
 
5-Bromo-4-(cyclohexylmethoxy)pyrimidine-2,6-diamine ( 200 mg, 0.66 mmol, 1 eq) 
was added to a mixture of acetic acid (2.5 mL, 44 mmol, 66 eq) and acetic anhydride 
(2.5 mL, 26 mmol, 40 eq) under nitrogen. The solution was heated to reflux overnight 
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resulting in a colour change from yellow to pale brown, then cooled to room 
temperature and poured into water (10 mL), resulting in a white precipitate,  
neutralised with concentrated ammonia and extracted into ethyl acetate (3 x 20 mL). 
The combined organic layers were then washed with NaHCO3 (3 x 30 mL) and then 
water (3 x 30 mL) dried over Na2SO4, filtered and evaporated in vacuo. Recrystallised 
(acetonitrile) gave 67 as a white solid (135 mg, 53%). Rf = 0.5 (100% EtOAc); mp = 
178.4-178.8 
o
C (lit. 179-182)
148
; UV λmax (EtOH): 388.0, 228.0, 205.5 nm; IR ʋmax 
3389 (NH), 1671 (C=O), 1258, 1111, 1067, 1036 cm
-1
; δH (300 MHz, d6-DMSO): 
0.98-1.31 (5H, m, C6H11), 1.69-1.79 (6H, m, C6H11), 2.17 (3H, s, COCH3), 2.20 (3H, 
s, COCH3), 4.20 (2H, d, J = 6.3 Hz, CH2), 9.98 (1H, s, NH), 10.48 (1H, s, NH); δC (75 
MHz d6-DMSO): 24.2 (CH3), 25.1 (CH3), 25.5 (C6H11), 26.3 (C6H11), 29.4 (C6H11), 
37.1 (CCH2O), 73.0 (CH2O), 157.5 (C-N), 166.9 (CO), 169.5 (C=O), 169.6 (C=O); 
LCMS Rt = 3.21 min, (1); MS (ESI+) m/z 385.35 [M+H]
+
      
 
2,6-Diamino-4-(cyclohexylmethoxy)pyrimidine-5-carbonitrile (59) 
 
To a solution of N,N’-(5-bromo-4-(cyclohexylmethoxy)pyrimidine-2,6-
diyl)diacetamide (100 mg, 0.26 mmol, 1 eq) in DMF (5 mL) CuCN (28 mg, 0.31 
mmol, 1.2 eq) was added, the mixture was heated to reflux for 5 h, then cooled to 
room temperature, ethylenediamine (1.4 mL, 20 mmol, 77 eq) was added and stirred 
overnight at room temperature. The mixture was filtered through Celite and washed 
with DMF (2 x 5 mL), water (10 mL) was added to the filtrate and the product 
extracted into ethyl acetate (3 x 20 mL). The combined organic layers were washed 
with brine (50 mL), dried over Na2SO4 and evaporated under vacuum. 
Recrystalliation (ethyl acetate / petrol) gave 59 as cream crystals (45 mg, 70%). Rf
 
= 
0.64 (100 % EtOAc); mp = 187.5 – 188.3 oC (lit. 186-188 oC)148; UV λmax (EtOH): 
367.5, 267.0, 251.5, 234.5 nm; IR ʋmax 3512 (NH), 3381, 2210 (CN), 1549, 1226 cm
-
1
; δH (300 MHz d6-DMSO): 0.96-1.26 (5H, m, C6H11), 1.63-1.75 (6H, m, C6H11), 4.06 
(2H, d, J = 6.3 Hz, CH2), 6.90 (2H, d, J = 15.3 Hz, N
1
H2) 7.95 (2H, s, N
2
H2); 
1δC (75 
MHz d6-DMSO): 25.5 (C6H11), 26.3 (C6H11), 29.4 (C6H11), 35.2 (CCH2O), 71.1 
(CH2O), 163.8 (CNH2), 166.3 (CNH2), 177.9 (CO)  
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4-Ethoxypyrimidine-2,6-diamine (385) 
 
Ethanol (15 mL, 260 mmol, 19 eq) was added slowly to sodium (0.50 g, 22 mmol, 1.5 
eq). Once the gas evolution had stopped the solution was heated to 80 
o
C until all the 
sodium had dissolved. 4-Chloro-2,6-diaminopyrimidine (2.00 g, 13.8 mmol, 1 eq) was 
added and the temperature increased to 98 
o
C for 5 h before cooling to room 
temperature, neutralising with acetic acid and evaporated in vacuo. The residue was 
suspended in water and extracted into ethyl acetate (3 x 20 mL). The combined 
organic layers were dried over Na2SO4, filtered and evaporated in vacuo resulting in 
cream crystals. Recrystallised (ethyl acetate /petrol) gave 385 as a white solid (1.25g, 
58%). Rf = 0.44 (1:9 MeOH:EtOAc); mp = 134.7 – 136.1 
o
C, (lit. 167-169 
o
C)
148
; UV 
λmax (EtOH): 366.5, 284.5, 279.5, 267.0, 204.0 nm; IR ʋmax 3426 (NH), 1344, 1208, 
1040 cm
-1
; δH (300 MHz, d6-DMSO): 1.21 (3H, t, J = 7.0, CH3), 4.12 (2H, q, J = 7.0 
Hz, CH2), 5.01 (1H, s, H
5
), 5.85 (2H, s, N
1
H2), 5.99 (2H, s, N
2
H2); δC (75 MHz d6-
DMSO): 16.0 (CH3), 61.5 (CH2), 77.8 (C
5
), 167.4 (CNH2), 171.5 (CNH2), 173.1 
(CNH2); LCMS Rt = 2.16 min, (2); MS (ESI+) m/z 155.20 [M+H]
+
      
 
5-Bromo-6-ethoxypyrimidine-2.6-diamine (386) 
 
To a solution of 4-ethoxypyrimidine-2,6-diamine (1.00 g, 6.49 mmol, 1eq) in acetic 
acid (8.0 mL, 140 mmol, 22 eq) was added N-bromosuccinimide (1.17 g, 6.57 mmol, 
1 eq) and the solution heated to 60 
o
C for 90 min, cooled to room temperature, diluted 
with water (45 mL) and neutralised with 2.5 M aqueous NaOH solution. Solution then 
extracted with ethyl acetate (3 x 50 mL) and combined organic layers were then dried 
over Na2SO4, filtered and evaporated in vacuo. Recrystallisation (methanol) to give 
386 as a pale yellow powder which was then dried over P2O5 before further use (0.724 
g, 48%). Rf = 0.35 (100% EtOAc); mp = 179.7-180.5 
o
C; UV λmax (EtOH): 353.5, 
275.5, 235.5 nm; IR ʋmax 3426 (NH), 3344, 1206, 1047 cm
-1
; δH (300 MHz, d6-
DMSO): 1.25 (3H, t, J = 7.1 Hz, CH3), 4.23 (2H, q, J = 7.1 Hz, CH2) 6.09 (2H, s, 
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N
1
H2), 6.27 (2H, s, N
2
H2); δC (75 MHz d6-DMSO): 14.9 (CH3), 62.0 (CH2), 72.4 (C
5
), 
161.5 (CNH2), 162.2 (CNH2), 179.3 (CO); LCMS Rt = 5.53 min, (2); MS (ESI+) m/z 
233.06 [M+H]
+
      
 
N,N’-(5-Bromo-4-ethoxypyrimidine-2,6-diyl)diacetamide (387) 
 
A solution of 5-bromo-6-ethoxypyrimidine-2.6-diamine (500 mg, 2.15 mmol, 1 eq) in 
acetic acid (5.5 mL, 96 mmol, 45 eq) and acetic anhydride (7.5 mL, 68 mmol, 32 eq) 
was heated to reflux for 48 h, then cooled to room temperature, diluted with water (20 
mL) and neutralised with concentrated ammonia, and extracted with  ethyl acetate (3 
x 30 mL). The combined organic extracts were washed with saturated NaHCO3 (3 x 
50 mL) followed by water (3 x 50 mL) and dried (Na2SO4). Recrystallised (methanol) 
gave 387 as off-white solid (0.19 g, 27%). Rf = 0.48 (100% EtOAc); mp = 181.4 – 
182.8 
o
C; UV λmax (EtOH): 353.0, 256.0, 227.5, 207.0 nm; IR ʋmax 3362 (NH), 1676 
(C=O), 1261, 1097, 1023 cm
-1
; δH (300 MHz, d6-DMSO): 1.35 (3H, t, J = 7.1, Hz, 
CH2CH3), 2.17 (3H, s, COCH3), 2.21 (3H, s, COCH3), 4.44 (2H, q, J =7.0 Hz, 
CH2CH3), 9.96 (1H, s, N
1
H), 10.49 (1H, s, N
2
H); δC (75 MHz d6-DMSO): 14.5 
(CH2CH3), 24.1 (CH3) , 25.1 (CH3), 64.3 (CH2), 155.2 (CNH2), 157.5 (CNH2), 166.7 
(CO), 169.4 (C=O), 169.6 (C=O); LCMS Rt = 6.55 min, (2); MS (ESI+) m/z 247.07 
[M+H]
+
      
 
2,6-Diamino-4-ethoxypyrimidine-5-carbonitrile (81) 
 
To a solution of N,N’-(5-bromo-4-ethoxypyrimidine-2,6-diyl)diacetamide (110 mg, 
0.35 mmol, 1 eq) in DMF (5 mL) was CuCN (48 mg, 0.54 mmol, 1.5 eq). The 
resulting green solution was heated to reflux for 3.5 h the solution before cooling  to 
room temperature and ethylene diamine (2.5 mL, 37 mmol, 106 eq) added. The dark 
blue solution was stirred overnight, filtered through Celite and washed with further 
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DMF (8 mL). Water (25 mL) was added to the filtrate and the product was extracted 
into ethyl acetate (3 x 50 mL), dried over Na2SO4 and concentrated in vacuo. 
Chromatography (silica, 100% EtOAc) followed by recrystallisation (methanol) gave 
81 as an off-white solid (0.047 g, 75%). Rf = 0.66 (100% EtOAc); mp = 226.7-227.1 
o
C; UV λmax (EtOH): 251.5, 216.5 nm; IR ʋmax 3433 (NH), 3372, 3093, 2199 (CN), 
1668, 1615, 1539 cm
-1
; δH (300 MHz, d6-DMSO): 1.27 (3H, t, J=7.1 Hz, CH3), 4.30 
(2H, q, J=7.1 Hz, CH2), 6.88 (2H, s, N
1
H2), 6.93 (2H, s, N
2
H2); δC (75 MHz d6-
DMSO): 14.8 (CH3), 62.2 (CH2), 116.1 (CN), 163.4 (CNH2), 166.3 (CNH2), 171.2 
(CO); LCMS Rt = 1.29 min, (1); MS (ESI+) m/z 180.12 [M+H]
+
; HRMS m/z;  Calc. 
for C7H10N5O: 180.0880 [M+H]
+
. Found 180.0880 [M+H]
+
. Analytical HPLC: 98.2% 
purity 
 
4-Isopropoxypyrimidine-2,6-diamine (80) 
 
To isopropanol (4.8 mL, 62 mmol, 18 eq) under constant flushing with nitrogen was 
gradually added sodium (0.13 g, 5.65 mmol, 1.6 eq). Once all gas evolution had 
stopped the solution was heated at 50 
o
C until all sodium had dissolved. 4-Chloro-2,6 
diaminopyrimidine (0.50 g, 3.46 mmol, 1 eq) was added, which was sealed and 
irradiated for 20 min at 160 
o
C, then neutralised using acetic acid and evaporated. The 
resulting white solid was suspended in water (20 mL) and extracted with ethyl acetate 
(3 x 20 mL) and the resulting organic layers were dried over Na2SO4 and evaporated. 
Recrystallisation (ethyl acetate /petrol) gave 80 as a white solid (0.39 g, 68%). Rf = 
0.31 (100% EtOAc); mp = 112.8-113.0 
o
C; UV λmax (EtOH): 379.0, 267.0 nm; IR ʋmax 
3356 (NH), 1317, 1208 cm
-1
; δH (300 MHz d6-DMSO): 1.19 (6H, d, J = 6.2 Hz, 2 x 
CH3), 4.97 (1H, s, H
5
), 5.10 (1H, septet, J = 6.2 Hz, CH) 5.81 (2H, s, N
1
H2), 5.94 
(2H, s, N
2
H2); δC (75 MHz d6-DMSO): 22.4 (CH3), 66.7 (OCH), 77.5 (C
5
), 163.4 
(CNH2), 166.4 (CNH2), 172.0 (CO); LCMS Rt = 4.59 min, (2); MS (ESI+) m/z 
169.21 [M+H]
+
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5-Bromo-4-isopropoxypyrimidine-2,6-diamine (388) 
 
To a solution of 4-isopropoxypyrimidine-2,6-diamine (250 mg, 1.49 mmol, 1 eq) in 
acetic acid (5 mL, 87 mmol, 59 eq) was added N-bromosuccinimide (265 mg, 1.49 
mmol, 1 eq),  and the mixture was stirred at RT for 45 min, then diluted with water 
(10 mL) and neutralised using 2.5 M aqueous solution of NaOH. The resulting white 
precipitation was filtered, redissolved in methanol (15 mL), dried over Na2SO4, and 
evaporated. Recrystallisation (methanol) gave 388 as a white solid (21 mg, 58%). Rf = 
0.74 (100% EtOAc); mp = 160.9 – 161.2 oC; UV λmax (EtOH): 379.0, 274.5, 232.0, 
205.0 nm; IR ʋmax 3426 (NH), 1335, 1206, 1047 cm
-1
; δH (300 MHz d6-DMSO): 1.24 
(6H, d, J=6.2 Hz, CH3), 5.19 (1H, septet, J = 6.3 Hz, CH) 6.05 (2H, s, N
1
H2), 6.23 
(2H, s, N
2
H2); δC (75 MHz d6 DMSO) 29.9 (CH3), 73.2 (OCH), 161.6 (CNH2), 162.3 
(CNH2), 179.5; LCMS Rt = 6.20 min, (2); MS (ESI+) m/z 247.10 [M+H]
+
; CHN 
Calculated C 34.03 H 4.49 N 22.67 Found C 34.65 H 4.18 N 21.78 
 
N,N’-(5-Bromo-4-isopropoxypyrimidine-2,6-diyl)diacetamide (389) 
 
To a solution of 5-bromo-4-isopropoxypyrimidine-2,6-diamine (150 mg, 0.61 mmol, 
1 eq) in acetic acid (2.5 mL, 44 mmol, 72 eq) was added acetic anhydride (5 mL, 53 
mmol, 86 mmol). The mixture heated to 160 
o
C for 16 h followed by 170
o
C for a 
further 8 h, diluted with water (10 mL) and neutralised with concentrated ammonia. 
The solution was then extracted into ethyl acetate (3 x 20 mL). The combined organic 
layers washed with saturated NaHCO3 solution (1 x 50 mL) dried over Na2SO4, 
evaporated in vacuo. The residue was redissolved in petrol and evaporated to give 389 
as a cream solid (184 mg, 91%). Rf = 0.71 (100% EtOAc); mp = 174.4 – 174.9 
o
C; 
UV λmax (EtOH): 367.0, 254.5, 227.5, 204.0 nm; IR ʋmax 3375 (NH), 1669 (C=O), 
1313, 1262, 1221, 1096 cm
-1
; δH (300 MHz, d6-DMSO): 2.69 (6H, d, J = 6.3 Hz, 
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CH(CH3)2) , 2.15 (3H, s, COCH3), 2.20 (3H, s, COCH3), 5.31 (1H, septet, J = 6.3 Hz, 
CH), 10.0 (1H, s, N
1
H), 10.45 (1H, s, N
2
H); δC (75 MHz d6-DMSO): 22.0 (COCH3), 
22.3 (COCH3), 25.0 (CH(CH3)2), 71.7 (OCH), 99.6 (C
5
), 157.7 (C
2
), 166.8 (C
6
), 168.5 
(CO), 169.5 (C=O), 169.9 (C=O); LCMS Rt = 3.01 min, (1), MS (ESI+) m/z 331.22 
[M+H]
+
      
 
2,6-Diamino-4-isopropoxypyrimidine-5-carbonitrile (82) 
 
To a solution of N,N’-(5-bromo-4-isopropoxypyrimidine-2,6-diyl)diacetamide (200 
mg, 0.60 mmol, 1 eq) in DMF (5 mL) was added CuCN (73 mg, 0.81 mmol, 1.4 eq). 
The reaction mixture was heated at 120 
o
C for 2 h, to room temperature and 
ethylenediamine (5 mL, 75 mmol, 125 eq) added and the mixture stirred overnight. 
The resulting blue solution was filtered through Celite, washed with DMF (10 mL) 
and diluted with water (50 mL). Solution was extracted with ethyl acetate (3 x 70 
mL). The combined organic extracts were washed with brine (150 mL), dried 
(Na2SO4) and evaporated in vacuo. Chromatography (silica, 10% MeOH, EtOAc) 
followed by (SP4, silica, 15-100% EtOAc, PE). Final purification using HPLC (0.1% 
NH3 aqueous solution: acetonitrile 75:25) to give 82 as a white solid (29 mg, 25%). Rf 
= 0.64 (1:9 MeOH:EtOAc); mp = 190.5-190.8 
o
C; UV λmax (EtOH): 267.0, 252.0, 
217.5 nm; IR ʋmax 3381 (NH), 3129, 2208 (CN), 1669, 1614 cm
-1; δH (300 MHz, d6-
DMSO): 1.26 (6H, d, J = 5.1 Hz, CH3), 5.27 (1H, septet, J = 6.3 Hz, CH), 6.84 (2H, s, 
N
1
H2), 6.89 (2H, s, N
2
H2); δC (75 MHz, d6-DMSO): 22.2 (CH(CH3)2), 69.2 
(OCH(CH3)2), 116.2 (CN), 163.5 (C
2
), 166.4 (C
6
), 170.9 (CO);  LCMS Rt = 2.59 min, 
(1); MS (ESI+) m/z 194.04 [M+H]
+
; HRMS m/z: Calc. for C8H12N5O: 194.1036 
[M+H]
+
. Found 194.1035 [M+H]
+
. Analytical HPLC: 99.7% purity 
 
4-sec-Butoxypyrimidine-2,6-diamine (390) 
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To sodium (0.45 g, 19.6 mmol, 1.4 eq) under nitrogen was slowly added sec-butanol 
(18 mL, 196 mmol, 14 eq) and heated to 120 
o
C and until all sodium has dissolved. 4-
Chloro-2,6-diaminopyrimidine (2.00 g, 13.8 mmol, 1 eq) was added and the mixture 
heated to reflux for 5.5 hours, then cooled to room temperature, neutralised with 
acetic acid and concentrated in vacuo. Crude was suspended in water (20 mL) and 
extracted into ethyl acetate (3 x 30 mL), combined organic layers were dried over 
Na2SO4, concentrated in vacuo resulting in a yellow solid. This crude product was 
recrystallised (ethyl acetate /petrol) to give 390 as a cream solid (1.20 g, 48%). Rf = 
0.44 (100% EtOAc); mp = 92.7-93.1 
o
C; UV λmax (EtOH): 265.5, 234.5, 206.0 nm; IR 
ʋmax 3356 (NH), 1315, 1208, 1098 cm
-1
; δH (300 MHz d6-DMSO): 0.86 (3H, t, J = 
7.4, CH2CH3), 1.16 (3H, d, J = 6.2 Hz, CHCH3), 1.47 -1.62 (2H, m, CH2), 4.88- 4.98 
(1H, m, OCH), 5.01 (1H, s, H
5
), 6.00 (2H, s, N
1
H2), 6.12 (2H, s, N
2
H2); δC (75 MHz 
d6-DMSO): 9.8 (CH3CH2), 18.9 (CH3CH), 29.0 (CH3CH2), 71.3 (OCH2), 77.4 (C
5
), 
163.4 (CNH2), 166.5 (CNH2), 170.5 (CO); LCMS Rt = 5.39 min, (2), MS (ESI+) m/z 
183.18 [M+H]
+ 
 
5-Bromo-4-sec-butoxypyrimidine-2,6-diamine (391) 
 
To a solution of 4-sec-butoxypyrimidine-2,6-diamine (250 mg, 1.37 mmol, 1 eq) in 
acetic acid (5 mL, 87 mmol, 64 eq), was added N-bromosuccinimide (249 mg, 1.39 
mmol, 1 eq). After 15 min of stirring at room temperature the yellow solution was 
diluted with water (10 mL) and neutralised with 2.5M aqueous NaOH solution. The 
product was extracted into ethyl acetate (3 x 30 mL), dried over Na2SO4, concentrated 
in vacuo giving 391 as a cream solid (257 mg, 72%) which was used without further 
purification. Rf = 0.76 (100% EtOAc); mp = 103.7 – 104.2 
o
C; UV λmax (EtOH): 
344.0, 274.0, 234.5, 204.0 nm; IR ʋmax 3451 (NH), 3411, 3357, 1043 cm
-1
; δH (300 
MHz d6-DMSO): 0.88 (3H, t, J = 7.4 Hz, CH2CH3), 1.20 (3H, d, J = 6.2 Hz, 
OCHCH3), 1.53-1.59 (2H, m, CH2CH3), 4.97-5.07 (1H, m, OCH), 6.06 (2H, s, N
1
H2), 
6.26 (2H, s, N
2
H2); δC (75 MHz d6-DMSO): 9.6 (CH3CH2), 19.8 (CH3CH), 28.9 (CH-
3CH2), 73.1 (OCH), 161.5 (CNH2), 162.3 (CNH2), 165.1 (CO); HRMS m/z: Calc. for 
C8H14
79
BrN4O: 261.0346 [M+H]
+
. Found 261.0343 [M+H]
+
. 
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N,N’-(5-Bromo-4-secbutoxypyrimidine-2,6-diyl)diacetamide (392) 
 
A solution of 391 (2.38 g, 9.65 mmol, 1 eq) in AcOH (23 mL, 405 mmol, 42 eq) and 
Ac2O (58 mL, 1.01 mol, 105 eq) was heated to 170 
o
C for 40 h, cooled to room 
temperature, water (60 mL) and basified using conc. ammonia, the beige precipitate 
was collected by filtration, dissolved in DCM (30 mL) and dried over Na2SO4 and 
concentrated in vacuo. Chromatography (silica, 100% EtOAc) gave 392 as a white 
solid (0.86 g, 26%). Rf = 0.66 (100% EtOAc); mp = 139.3-142.0 
o
C; UV λmax (EtOH):  
253.5, 228.0 nm; IR ʋmax 3215 (NH), 2974, 1677 (C=O), 1571, 1311 cm
-1
; δH (500 
MHz, d6-DMSO): 0.92 (3H, t, J = 7.4 Hz, CH3CH2), 1.32 (3H, d, J = 6.1 Hz, 
CHCH3), 1.65-1.74 (2H, m, CH2CH3), 2.18 (3H, s, COCH3), 2.21 (3H, s, COCH3), 
5.15-5.19 (1H, m, OCHCH3), 9.89 (1H, s, NH), 10.4 (1H, s, NH); δC (125 MHz, d6-
DMSO): 9.4 (CH3CH2), 19.0 (CH3CH), 23.7 (COCH3), 24.7 (COCH3), 28.2 
(CH3CH2), 75.9 (CH3CHO), 90.3 (C
5
), 154.8 (C
2
), 157 (C
6
), 166.1 (C-O), 168.9 
(C=O), 169.2 (C=O) 
 
2,6-Diamino-4-sec-butoxypyrimidine-5-carbonitrile (83) 
 
To a solution of N,N’-(5-bromo-4-sec-butoxypyrimidine-2,6-diyl)diacetamide (300 
mg, 0.87 mmol, 1 eq) in DMF (5 mL) was added CuCN (99 mg, 1.1 mmol, 1.3 eq) 
and the reaction mixture was heated to 120 
o
C for 6 h, then cooled to room 
temperature. Ethylenediamine (5 mL, 75 mmol, 86 eq) was added and the reaction 
mixture was stirred for 4 h, and the resulting blue solution was filtered through Celite, 
washed with DMF (8 mL) and diluted with water (30 mL). The filtrate was then 
extracted with ethyl acetate (3 x 50 mL) and the combined organic layers washed with 
brine (2 x 100 mL), dried over Na2SO4 and concentrated in vacuo. The residue was 
suspended in water (100 mL), extracted in to ethyl acetate (3 x 70 mL), dried over 
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Na2SO4 and concentrated in vacuo. Recrystallisation (methanol / petrol) gave 83 as a 
white solid (0.093 mg, 51%). Rf = 0.71 (7:3 EtOAc:PE); mp = 165.6-166.4 
o
C; UV 
λmax (EtOH): 265.5, 251.5, 218.0, 202.5 nm; IR ʋmax 3380 (NH), 3125, 2199 (CN), 
1660, 1628, 1572 cm
-1
; δH (300 MHz, d6-DMSO): 0.88 (3H, t, J = 7.5 Hz, CH2CH3), 
1.23 (3H, d, J = 6.0 Hz, CHCH3), 1.54-1.66 (2H, m, CH2CH3), 5.07-5.16 (1H, m, 
CHCH3), 6.83 (2H, s, N
1
H2), 6.89 (2H, s, N
2
H2); δC (75 MHz, d6-DMSO): 9.6 
(CH3CH2), 19.6 (CH3CH), 28.8 (CH3CH2), 73.6 (OCH), 116.1 (CN), 163.6 (CNH2), 
166.4 (CNH2), 171.3 (CO); LCMS Rt = 3.11 min, (1), MS (ESI+) m/z 208.18 
[M+H]
+
;
 
HRMS m/z: Calc. for C9H15N5O: 208.1193 [M+H]
+
. Found 208.1191 
[M+H]
+
. Analytical HPLC: 96.8% purity 
 
4-Isobutoxypyrimidine-2,6-diamine (393) 
 
Sodium (0.45 g, 19.6 mmol, 1.4 eq) was added to (2-methyl-1-propanol (16 mL, 173 
mmol, 13 eq) then heated to 80 
o
C until all the sodium had dissolved resulting in a 
yellow solution. 4-Chloro-2,6-diaminopyrimidine (2.00 g, 13.7 mmol, 1 eq) was 
added  and the temperature increased to 120 
o
C for 1 h then 140 
o
C for 3 h, then 
cooled to room temperature, neutralised with acetic acid and evaporated. The 
resulting yellow solid was suspended in water (30 mL), and extracted in ethyl acetate 
(3 x 30 mL). The organic layers were dried over Na2SO4, evaporated resulting in a 
yellow oil that was triturated to form a cream solid. Recrystallisation (ethyl acetate 
/petrol) gave a sticky white solid which was dried over P2O5, then covered in diethyl 
ether (20 mL) which was allowed to slowly evaporate giving 393 as a white solid 
(1.31 g, 53%). Rf = 0.39 (100% EtOAc); mp = 81.8-82.8 
o
C; UV λmax (EtOH): 379.0, 
266.5, 205.5 nm; IR ʋmax 3439 (NH), 3323, 1213, 1027 cm
-1
; δH (300 MHz d6-
DMSO): 0.90 (6H, d, 6.6 Hz, 2 x CH3), 1.87-1.96 (1H, m, CH), 3.84 (2H, d, J = 6.6 
Hz, CH2), 5.03 (1H, s, H
5
), 5.88 (2H, s, N
1
H2), 6.01 (2H, s, N
2
H2); δC (75 MHz d6-
DMSO): 19.4 (2 x CH3), 27.3 (CH), 71.2 (CH2), 76.8 (C
5
), 163.3 (CNH2), 166.4 
(CNH2), 170.9 (CO); LCMS Rt = 5.70 min, (2); MS(ESI+) m/z  183.18 [M+H]
+ 
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5-Bromo-4-isobutoxypyrimidine-2,6-diamine (394) 
 
To 4-isobutoxypyrimidine-2,6-diamine (250 mg, 1.37 mmol, 1 eq) in acetic acid (5 
mL, 87 mmol, 64 eq) was added N-bromosuccinimide (255 mg, 1.43 mmol, 1 eq). 
After stirring at room temperature for 15 min the reaction was diluted with water (10 
mL) and the neutralised with 2.5M aqueous NaOH solution,  resulting in a white 
precipitate which was collected by filtration. The precipitation was redissolved in 
water (50 mL) and extracted into ethyl acetate (3 x 50 mL), dried over Na2SO4 and 
evaporated in vacuo giving 394 as a cream solid used without any further purification 
(309 mg, 86 %). Rf = 0.77 (100% EtOAc); mp = 136.3 – 136.7 
o
C; UV λmax (EtOH): 
379.0, 274.5, 234.0, 204.0 nm; IR ʋmax 3451 (NH), 3406, 1292, 1048 cm
-1
; δH (300 
MHz d6-DMSO): 0.93 (6H, d, J = 6.6 Hz, CH3), 1.89-2.02 (1H, m, CH), 3.95 (2H, d, 
J = 6.6 Hz, CH2), 6.10 (2H, s, N
1
H2), 6.29 (2H, s, N
2
H2); δC (75 MHz d6-DMSO): 
19.2 (CH3), 27.9 (CH), 72.2 (CH2), 161.5 (CNH2), 162.2 (CNH2), 165.3 (CO); LCMS 
Rt = 2.83 min, (1); MS (ESI+) m/z  261.10 [M]
+
; CHN Calculated C 36.80, H 5.02, N 
21.45 Found C 36.81 H 4.81 N 21.49 
 
N,N’-(5-Bromo-6-isobutoxypyrimidine-2,6-diyl)diacetamide (395) 
 
A mixture of 5-bromo-4-isobutoxypyrimidine-2,6-diamine (150 mg, 0.57 mmol, 1 eq) 
in acetic acid (2.5 mL, 44 mmol, 76 eq) and acetic anhydride (5 mL, 52.9 mmol, 92 
mmol) was heated to 150 
o
C for 28 h then to 160 
o
C for 11 h., then cooled to room 
temperature, diluted with water (10 mL) and neutralised with concentrated ammonia, 
then extracted into ethyl acetate (3 x 70 mL). The combined organic extracts were 
dried over Na2SO4, filtered and evaporated. Recrystallisation (methanol) gave 395 as 
a beige solid which was washed with petroleum ether (3 x 5 mL) (0.16 g, 79%). Rf = 
0.61 (100% EtOAc); mp = 129.7-130.4 
o
C; UV λmax (EtOH): 254.5, 216.5 nm; IR ʋmax 
3395 (NH), 1670 (C=O), 1142, 1310, 1142, 1001 cm
-1
; δH (300 MHZ d6-DMSO): 
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0.98 (6H, d, J = 6.9 Hz, 2 x CH3), 1.98-2.13 (1H, m, CH), 2.17 (3H, s, COCH3), 2.02 
(3H, s, COCH3), 4.17 (2H, d, J = 6.6 Hz, CH2),  9.97 (1H, s, N
1
H), 10.48 (1H, s, 
N
2
H); δC (75 MHz d6-DMSO): 19.1 (CH(CH3)2), 24.2 (COCH3), 25.1 (COCH3), 27.7 
(CH), 75.0 (CH2), 155.2 (CNH2), 157.5 (CNH2), 166.8 (CO), 169.4 (C=O), 169.5 
(C=O); LCMS Rt = 3.16 min, (1); MS (ESI+) m/z 345.13 [M+H]
+ 
 
2,6-Diamino-4-isobutoxypyrimidine-5-carbonitrile (84) 
 
To a solution of N,N’-(5-bromo-4-isobutoxypyrimidine-2,6-diyl) (200 mg, 0.58 
mmol, 1 eq) in DMF (5 mL) was added CuCN (70 mg, 0.78 mmol, 1.3 mmol) and the 
reaction heated to 120 
o
C for 7 h. The mixture was then cooled to room temperature, 
ethylenediamine (4 mL, 60 mmol, 103 eq) added and the reaction stirred for 17 h, 
filtered through Celite, washing with DMF (10 mL), the filtrate was diluted with 
water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic 
layers were washed with brine (100 mL), dried over Na2SO4 and evaporated in vacuo 
resulting in a cream solid. Recrystallisation (MeOH/petrol). Chromatography (SP4, 
silica, 10-80% EtOAc, petrol) gave 84 as a white solid (36 mg, 30%). Rf = 0.58 
(100% EtOAc); mp = 197.4-198.2 
o
C; UV λmax (EtOH): 266.0, 251.0, 217.5 nm; IR 
ʋmax 3344 (NH), 3204, 2207 (CN), 1628 cm
-1
; δH  (300 MHz, d6-DMSO): 0.93 (6H, d, 
J = 6.6 Hz, CH(CH3)2), 1.89-2.04 (1H, m, CH), 4.03 (2H, d, J = 6.6 Hz, OCH2),  6.87 
(2H, s, N
1
H2), 6.93 (2H, s, N
2
H2); δC  (75 MHz, d6-DMSO): 19.1 ( CH3), 27.9 (CH), 
72.3 (CH2), 163.5 (CNH2), 166.3 (CNH2), 171.6 (CO); HRMS m/z: Calc. for 
C9H14N5O: 208.1193 [M+H]
+
. Found 208.1193 [M+H]
+
. Analytical HPLC: 97.1% 
purity 
 
4-Cyclopropylmethoxypyrimidine-2,6-diamine (396) 
 
Sodium (0.55 g, 23.9 mmol, 1.7 eq) was added in portions to a flask containing 
cyclopropylmethanol (20 mL, 247 mmol, 18 eq) and heated to 60 
o
C until all the 
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sodium had dissolved. 4-Chloro-2,6-diaminopyrimidine (2.00g, 13.8 mmol, 1 eq) was 
added to the solution and the mixture was heated to 120 
o
C for 90 min, cooled to RT, 
neutralised with acetic acid, and evaporated. The resulting brown oil was suspended 
in water (50 mL) and extracted with EtOAc (3 x 70 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Chromatography (silica, 
100% Ethyl acetate) gave 396 as a yellow oil (1.90 g, 77%). Rf = 0.33 (100% EtOAc); 
UV λmax (EtOH): 265.0, 233.0, 206.0 nm; IR ʋmax 3338 (NH), 3188, 1564 cm
-1; δH 
(300 MHz, d6-DMSO): 0.22-0.27 (2H, m, CH2), 0.47-0.53 (2H, m, CH2), 1.15-1.20 
(1H, m, CH), 3.91 (2H, d, J = 6.9 Hz, OCH2), 5.01 (1H, s, H
5
), 5.84 (2H, s, N
1
H2), 
5.98 (2H, s, N
2
H2); δC (75 MHz, d6-DMSO): 3.4 (cyclopropyl), 10.6 (cyclopropyl), 
69.4 (OCH2), 76.9 (C
5
), 163.3 (CNH2), 166.5 (CNH2), 170.7 (CO); LCMS Rt = 0.33 
min, (1); MS (ESI+) m/z 181.15 [M+H]
+
      
 
5-Bromo-4-cyclopropylmethoxypyrimidine-2,6-diamine (397) 
 
A mixture 4-cyclopropylmethoxypyrimidine-2,6-diamine (0.72 g, 4.00 mmol, 1 eq) 
and N-bromosuccinimide (0.72 g, 4.06 mmol, 1.01 eq)  was dissolved in acetic acid 
(8.0 mL, 130 mmol, 32 eq) was stirred at room temperature for 15 min  neutralised 
using 2.5 M aqueous solution of NaOH resulting in a white precipitate which was 
filtered, redissolved in DCM (50 mL) and dried over Na2SO4 giving 397 as a white 
solid  (1.03 g, 99%). Rf = 0.8 (100% EtOAc); mp = 147.6-147.8 
oC; UV λmax (EtOH): 
274.0, 236 nm; IR ʋmax 3447 (NH), 3407, 3349, 3152, 1634, 1549 cm
-1; δH (300 MHz, 
d6-DMSO) 0.27-0.32 (2H, m, CH2), 0.49-0.54 (2H, m, CH2), 1.15-1.25 (1H, m, CH), 
4.03 (2H, d, J = 7.2 Hz, OCH2), 6.09 (2H, s, N
1
H2), 6.28 (2H, s, N
2
H2); δC (75 MHz, 
d6-DMSO): 3.3 (cyclopropyl), 10.5 (cyclopropyl), 70.4 (cyclopropyl), 161.4 (CNH2), 
162.2 (CNH2), 165.3 (CO); LCMS Rt = 2.34 min, (1); MS (ESI+) m/z 259.91 [M+H]
+
   
HRMS m/z: Calc. for C8H12
79
BrN4O: 259.0192 [M+H]
+
. Found 259.0192 [M+H]
+
. 
Analytical HPLC: 98.5% purity 
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N,N’-(5-Bromo-4-cyclopropylmethoxypyrimidine-2,6-diyl)diacetamide (398) 
 
A mixture of 5-bromo-4-cyclopropylmethoxypyrimidine-2,6-diamine (1.03 g, 3.97 
mmol, 1 eq) in acetic acid (12 mL, 207 mmol, 53 eq) and acetic anhydride (10 mL, 
106 mmol, 27 eq) was heated to 80 
o
C for 17 h, cooled to room temperature and 
basified concentrated ammonia resulting in a white precipitate. The suspension was 
extracted into ethyl acetate (3 x 100 mL) and the combined organic layers washed 
with a saturated aqueous solution of NaHCO3 (250 mL), dried over Na2SO4 and 
evaporated in vacuo. Chromatography (silica, EtOAc) gave 398 as a white solid 
(0.75g, 54%). Rf = 0.60 (100% EtOAc); mp = 191.3-192.5 
o
C; UV λmax (EtOH): 
256.0, 227.0 nm; IR ʋmax 3207 (NH), 3140, 3003, 2925, 1674 (C=O), 1574, 1498 cm
-
1;  δH (300 MHz, d6-DMSO): 0.35-0.41 (2H, m, CH2), 0.52-0.60 (2H, m, CH2), 1.24-
1.37 (1H, m, CH), 2.17 (3H, s, COCH3), 2.19 (3H, s, COCH3), 4.25 (2H, d, J = 7.2 
Hz, OCH2), 9.96 (1H, s, N
1
H), 10.49 (1H, s, N
2H); δC (75 MHz, d6-DMSO) 3.4 
(cyclopropyl), 10.1 (cyclopropyl), 24.3 (COCH3), 25.1 (COCH3), 72.7 (CH2), 
169.5,157.5; LCMS Rt = 3.07 min, (1); MS (ESI+) m/z 247.91 [M+H]
+
      
 
2,6-Diamino-4-(cyclopropylmethoxy)pyrimidine-5-carbonitrile (85)  
 
To a solution of 384 (80 mg, 0.23 mmol, 1 eq) in DMF (3 mL) was added CuCN (42 
mg, 0.49 mmol, 2 eq) and the reaction heated to 120 
o
C for 4 h. After cooling to room 
temperature, ethylenediamine (1.20 mL, 18.0 mmol) was added and stirring continued 
for 20 h. The mixture was before diluted with water (10 mL), filtered through Celite 
and washed with further water (2 x 5 mL). The filtrate solution was extracted with 
EtOAc (3 x 30 mL), and the combined organic extracts washed with brine (40 mL), 
dried over Na2SO4 and concentrated in vacuo. Chromatography (SP4, silica, 18-100% 
EtOAc, PE) gave 85 as a white solid (39 mg, 82%). Rf = 0.55 (7:3 EtOAc:PE); mp = 
216.2-217.7 
o
C; UV λmax (EtOH): 265.5, 251.0, 216.5 nm; IR ʋmax 3500 (NH), 3437, 
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3379, 3096, 2202 (CN), 1666 cm
-1; δH (500 MHz, d6-DMSO): 0.05-0.08 (2H, m, 
cyclopropyl), 0.30 (2H, ddt, J = 4.2, 5.8 and 7.9 Hz, cyclopropyl CH2), 0.94-.1.00 
(1H, m, cyclopropyl), 3.87 (2H, d, J = 7.2 Hz, OCH2), 6.60 (2H, s, N
1
H2), 6.65 (2H, s, 
N
2
H2); δC (125 MHz, d6-DMSO): 3.09 (cyclopropyl), 9.90 (cyclopropyl), 62.7 (C
5
), 
70.4 (OCH2), 116.1 (CN), 162.9 (C
2
), 165.8 (C
6
), 170.8 (C
4
); LCMS Rt = 1.01 min 
(3); MS (ESI+) m/z = 206.3 [M+H]
+
; HRMS m/z: Calc. for C9H11N5O: 206.1036 
[M+H]
+
. Found 206.1034 [M+H]
+
.; Analytical HPLC: 98.6% purity  
 
6-Amino-2-(4-methoxybenzylamino)pyrimidine-5-carbonitrile (88) 
 
6-Amino-2-chloropyrimidine-5-carbonitrile (250 mg, 1.25 mmol, 1 eq) was dissolved 
in DMF (10 mL) and 4-methoxybenzylamine (0.5.4 mL, 3.88 mmol, 2.4 eq) was 
added. The reaction temperature was increased to 100 
o
C. After 3 h the reaction 
mixture was cooled to room temperature and diluted with water (40 mL) resulting in a 
white precipitate  which was collected by filtration to give 88 as a white solid used 
without further purification (375 mg, 91%). Rf = 0.50 (1:1 EtOAc:PE); mp = 227.6-
228.2 
o
C; UV λmax (EtOH): 220.0, 257.5; IR ʋmax 3431 (NH), 3337 (NH), 3206, 2210 
(CN), 1641, 1578, 1504 cm
-1
; δH (300 MHz d6-DMSO): 3.72 (3H, s, OCH3), 4.39 
(2H, d, J = 5.5 Hz, NHCH2), 6.86-6.88 (2H, m, Ar-H), 7.13 (1H, s, NH
1
), 7.23-7.25 
(2H, m, Ar-H), 7.82 (1H, s, NH
2
), 8.00 (1H, s, NH), 8.17 (1H, s, H
4); δC (125 MHz 
d6-DMSO): 43.1 (CH2), 55.0 (OCH3), 77.7 (C
5
), 113.7 (benzyl Ar-H), 117.5 (CN), 
128.6 (benzyl Ar-H), 131.6 (CCH2), , 158.1 (COCH3), 162.2 (CH), 162.2 (CNH), 
163.2 (CNH2); LCMS Rt = 2.10 min, (1); MS (ESI+) m/z 256.06 [M+H]
+
  
 
2,6-Diaminopyrimidine-5-carbonitrile (86) 
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 6-Amino-2-(4-methoxybenzylamino)pyrimidine-5-carbonitrile (88) (334 mg, 1.31 
mmol, 1 eq) was suspended in DCM (4.5 mL) was TFA (10.5 mL) added slowly and 
the mixture heated to reflux for 18 h, then cooled  room temperature, neutralised using 
saturated sodium bicarbonate, and extracted using DCM (4 x 100 mL). The combined 
organic layers were concentrated in vacuo. The resulting white solid was redissolved 
in THF (300 mL) and dried over Na2SO4 and evaporated. Chromatography (100% 
EtOAc) gave the title compound as a white solid (138 mg, 77%). Rf = 0.35 (100% 
EtOAc); mp > 300 
o
C (lit. 318 
o
C)
267
; UV λmax (EtOH): 284.5; IR ʋmax 3430 (NH), 
3082, 2201 (CN), 1647, 1582, 1545 cm
-1
; δH (500 MHz d6-DMSO): 6.93 (1H, s, 
NH
1
), 7.03 (1H, s, NH
2
), 7.15 (2H, s, NH2), 8.20 (1H, s, H
4); δC (125 MHz d6-
DMSO): 78.3 (C
5
), 162.3 (CH), 163.2 (CNH2), 163.6 (CNH2); HRMS m/z: Calc. for 
C5H6N5: 136.0618 [M+H]
+
. Found 136.0617 [M+H]
+
.; Analytical HPLC: 98.9% 
purity     
 
4-Chloro-N-(6-methoxybenzyl)pyrimidin-4-amine (91) 
 
A mixture of 4,6-dichloropyrimdine (103 mg, 0.69 mmol, 1 eq), 4-
methoxybenzylamine (0.078 mL, 0.60 mmol, 0.86 eq)  and  DIPEA(0.23 mL, 1.34 
mmol, 1.9 eq) in 2-propanol (2.5 mL) was heated by microwave for 20 min at 120 
o
C. 
After cooling to room temperature the solvent was evaporated in vacuo. 
Chromatography (silica, 30% EtOAc, PE) gave the title compound as a white solid 
(140 mg, 83%). Rf = 0.31 (3:7 EtOAc:PE); mp = 132.3-133.0 
o
C (lit. 118-120 
o
C)
268
; 
UV λmax (EtOH): 248.5 nm; IR ʋmax 3221 (NH), 3077, 1595, 1561, 1506 cm
-1
; δH (300 
MHz CDCl3): 3.82 (3H, s, CH3), 4.44 (2H, broad s, CH2), 6.35 (1H, s, H
5
), 6.90 (2H, 
d, J = 8.4 Hz, Ar-H), 7.25 (2H, d, J = 8.4 Hz, Ar-H), 8.23 (1H, s, H
2
); δC (125 MHz 
CDCl3): 45.2 (CH2), 55.3 (CH3), 114.3 (Benzyl CH), 128.9 (benzyl CH), 158.4 (C
2
), 
159.4 (CCl), 163.2 (CNH); LCMS Rt = 2.77 min, (1); MS (ESI+) m/z 250.0 [M+H]
+
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4-(Cyclohexylmethoxy)-N-(4-methoxybenzyl) pyrimidin-6-amine (92) 
 
Method A: using conventional heating 
 
To cyclohexylmethanol (5.0 mL, 40 mmol, 20 eq) was added sodium (0.06 g, 2.6 
mmol, 1.3 eq) in portions, the reaction mixture was heated at 160 
o
C until all sodium 
had dissolved, 4-chloro-N-(6-methoxybenzyl) pyrimidin-4-amine (91) (500 mg, 2.0 
mmol, 1 eq) was added and the temperature increased to 180 
o
C for 30 min, then 
cooled to room temperature and neutralised using acetic acid. Petrol (30 mL) was 
added and the solution cooled to 4 
o
C overnight. The resulting precipitate was 
collected by filtration and the filtrate evaporated. Further petroleum ether (20 mL) 
was added to this filtrate and the solution cooled to 4 
o
C. This was repeated until no 
further solid formed. Recrystallisation (methanol) gave 92 as a white solid (500 mg, 
76%). 
 
 Method B: using microwave assisted heating 
 
To a solution of cyclohexylmethanol (1.30 mL, 10.6 mmol, 5.3 eq) in THF (10 mL) 
was added . NaH (140 mg, 5.83 mmol, 2.9 eq) and the mixture stirred at room 
temperature for 45 min. 4-Chloro-N-(6-methoxybenzyl)pyrimidin-4-amine (91) (500 
mg, 2.00 mmol, 1 eq) was added and the reaction mixture was stirred for 20 min at 
room temperature. The vial was then heated at 120 
o
C for 18 min then cooled to room 
temperature and neutralised using acetic acid. The solvent was evaporated to give a 
cream coloured oily solid. Petroleum ether (100 mL) was added to the residue and it 
was then cooled to 4 
o
C. The resulting white precipitate was then filtered. The filtrate 
was then evaporated and further petrol (100 mL) was added and cooled to 4 
o
C any 
further precipitate was then collected by filtration. The combined solid was 
recrystallised (methanol) to give 92 as a white solid (471 mg, 72%).  
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Rf = 0.79 (8:2 EtOAc:PE); mp = 112.4-113.2 
o
C; UV λmax (EtOH): 245.5, 356.0 nm; 
IR ʋmax 3216 (NH), 2917, 2850, 1588, 1561, 1510 cm
-1
; δH (300 MHz CDCl3) 0.97-
1.31 (5H, m, C6H11), 1.60-1.85 (6H, m, C6H11), 3.83 (3H, s, CH3), 4.07 (2H, d, J = 6.3 
Hz, OCH2), 4.39 (2H, d, J = 5.4 Hz, NHCH2), 5.15 (1H, s, NH), 5.66 (1H, s, H
5
), 6.90 
(2H, d, J = 8.4Hz, 2 x Ar-H), 7.25-7.28 (m, 2 x Ar-H), 8.27 (1H, s, H
2
); δC (125 MHz 
CDCl3): 25.8 (C6H11), 26.5 (C6H11), 29.8 (C6H11), 37.4 (CHCH2O), 45.3 (NCH2), 55.3 
(OCH3), 85.1 (OCH2), 114.2 (benzyl Ar-H)), 128.7 (benzyl Ar-H), 129.7 (CCH2NH), 
157.8 (COCH3), 159.1 (CH), 164.1 (CNH), 170.3 (CO); LCMS Rt = 3.17 min, (1); 
MS (ESI+) m/z 328.25 [M+H]
+
      
  
5-Bromo-4-(cyclohexylmethoxy)-N-(6-methoxybenzyl)pyrimidin-4-amine (93) 
 
To a solution of 4-(cyclohexylmethoxy)-N-(4-methoxybenzyl)pyrimidin-6-amine (92) 
(100 mg, 0.31 mmol, 1 eq) in acetic acid (5 mL) was added N-bromosuccinimide (59 
mg, 0.33 mmol, 1 eq) and the reaction stirred at room temperature for 1 h, then 
neutralised using 2.5 M aqueous solution of NaOH and extracted with ethyl acetate (3 
x 30 mL). The combined organic extracts were dried over MgSO4 and evaporated. 
Chromatography (silica, 30% EtOAc, PE) gave 93 as a white solid (87 mg, 69%). Rf = 
0.86 (3:7 EtOAc:PE); mp = 62.4-63.7 
o
C; UV λmax (EtOH): 213.5, 251.0 nm; IR ʋmax 
3417 (NH), 2922, 2843, 1578, 1503 cm
-1
; δH (300 MHz CDCl3): 1.02-1.37 (5H, m, 
C6H11), 1.68-1.88 (6H, m, C6H11), 3.28 (3H, s, CH3), 4.19 (2H, d, J = 6 Hz, OCH2), 
4.65 (2H, d, J = 5.4 Hz, NHCH2), 5.53 (1H, s, NH), 6.90 (2H, d, J = 8.7 Hz, 2 x Ar-
H), 7.28 (2H, d, J = 8.7 Hz, 2 x Ar-H), 8.22 (1H, s, H
2
); δC (75 MHz CDCl3): 26.1 
(C6H11), 26.9 (C6H11), 30.1 (C6H11), 37.9 (CHCH2O), 45.4 (CH2NH), 55.7 (COCH3), 
72.7 (OCH2), 86.6 (C
5
), 114.7 (benzyl Ar-H), 129.2 (benzyl Ar-H), 131.2 (CCH2NH), 
155.9 (COCH3), 159.7 (CH), 160.3 (CNH), 165.3 (CO); LCMS Rt = 4.51 min, (1); 
MS (ESI+) m/z 406.26 [M+H]
+
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4-(Cyclohexylmethoxy)-6-(4-methoxybenzylamino)pyrimidine-5-carbonitrile (94) 
 
 To a solution of 5-bromo-4-(cyclohexylmethoxy)-N-(6-methoxybenzyl)pyrimidin-4-
amine (93) (280 mg, 0.69 mmol, 1 eq) in DMF (5 mL) was added CuCN (79 mg, 89 
mmol, 1.3 eq) and the reaction  heated to 120 
o
C. After 3 days the reaction was cooled 
to room temperature and ethylenediamine (5 mL, 75 mmol, 108 eq) added. After 
stirring at room temperature for 3 days the mixture was filtered through Celite, 
washed with further DMF (15 mL), diluted with water (30 mL) and extracted with 
EtOAc (3 x 100 mL). The combined organic layers were then dried (MgSO4) and 
evaporated to give a brown oil. Chromatography (silica, 20% EtOAc, PE) gave the 
title compound as a white solid (68 mg, 28%). Rf = 0.59 (2:8 EtOAc:PE); mp = 119.8-
120.4 
o
C; UV λmax (EtOH): 228.0, 249.0, 296.5 nm; IR ʋmax 3337 (NH), 2925, 2855, 
2218 (CN), 1582, 1512 cm
-1
; δH (500 MHz CDCl3): 0.92-1.24 (5H, m, C6H11), 1.60-
1.76 (6H, m, C6H11), 3.74 (3H, s, OCH3), 4.14 (2H, d, J = 6.5 Hz, OCH2), 4.59 (2H, d, 
J = 5.5 Hz, NHCH2), 6.81 (2H, d, J = 8.5 Hz, 2 x Ar-H), 7.18 (2H, d, J = 8.5 Hz, 2 x 
Ar-H), 8.29 (1H, s, H
2); δC (125 MHz CDCl3): 25.7 (C6H11), 26.4 (C6H11), 29.5 
(C6H11), 37.2 (CHCH2O), 44.8 (CH2NH), 55.4 (OCH3), 72.8 (OCH2), 114.2 (benzyl 
Ar-H), 129.2 (benzyl Ar-H), 159.3 (COCH3), 159.9 (CH), 163.5 (CNH), 170.5 (CO) 
 
4-Amino-6-(cyclohexylmethoxy)pyrimidine-5-carbonitrile (95) 
 
4-(Cyclohexylmethoxy)-6-(4-methoxybenzylamino)pyrimidine-5-carbonitrile (94) 
(63.9 mg, 0.18 mmol, 1 eq) was dissolved in DCM (3.5 mL) and TFA (1.5 mL) added 
dropwise. The reaction was heated to reflux for 18 h then neutralised using saturated 
sodium bicarbonate and extracted using DCM (3x 40 mL). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Chromatography (silica, 
50% EtOAc, PE) gave white solid, compound (95) (21 mg, 50%). Rf = 0.64 (1:1 
EtOAc:PE); mp = 133.1-134.0 
o
C; UV λmax (EtOH): 283.5, 343.0, 384.0 nm; IR ʋmax 
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3378 (NH), 3336, 3211, 2919, 2847, 2220 (CN), 1666, 1574, 1551 cm
-1
; δH (500 MHz 
CDCl3): 0.93-1.26 (5H, m, C6H11), 1.61-1.77 (6H, m, C6H11), 4.16 (2H, d, J = 3.6 Hz, 
OCH2), 5.62 (2H, broad s, NH2), 8.23 (1H, s, H
2); δC (125 MHz CDCl3): 25.7 (C6H11), 
26.4 (C6H11), 29.7 (C6H11), 37.1 (CHCH2O), 73.1 (CH2O), 113.5 (CN), 160.0 (C
2
), 
165.0 (CNH), 170.6 (CO); LCMS Rt = 3.25 min, (1); MS (ESI+) m/z 232.90 [M+H]
+
; 
HRMS m/z: Calc. for C12H17N4O: 233.1397 [M+H]
+
.
 
Found 233.1395 [M+H]
+
. 
Analytical HPLC: 95.5% purity 
 
4-(Cyclohexylmethoxy)-N-(6-methoxybenzyl)-5-nitrosopyrimidin-4-amine (96) 
 
To a solution of 4-(cyclohexylmethoxy)-N-(4-methoxybenzyl)pyrimidin-6-amine (96) 
(100 mg, 0.31 mmol, 1 eq) in 30% acetic acid in water (5 mL) at 80 
o
C. Sodium nitrite 
(30 mg, 0.43 mmol, 1.3 eq) in water (0.56 mL, resulting in a 0.7 M solution) was 
added dropwise and the mixture was stirred at 80 
o
C for 1 h, cooled to room 
temperature and neutralised using a 2.5 M aqueous solution of NaOH, then extracted 
with ethyl acetate (3x 50 mL). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. Chromatography (silica, 50% EtOAc, PE) gave 96 as a 
yellow oil (87 mg, 79%). Rf =  0.95 (8:2 EtOAc:PE); UV λmax (EtOH): 224.5, 275.0 
nm; IR ʋmax 3007 (NH), 2933, 2917, 2849, 1585, 1562 (NO), 1510 cm
-1
; δH (300 MHz 
CDCl3): 1.04-1.32 (5H, m, C6H11), 1.75-1.86 (6H, m, C6H11), 3.76 (3H, s, CH3),  4.21 
(2H, d, J = 6 Hz, OCH2), 5.31 (2H, s, NHCH2), 6.79 (2H, d, J = 8.7 Hz, 2 x Ar-H), 
7.25 (2H, d, J = 8.4 Hz, 2 x Ar-H), 7.32 (1H, s, NH), 8.71 (1H, s, H
2
); δC (125 MHz 
CDCl3): 25.7 (C6H11), 26.4 (C6H11), 29.7 (C6H11), 37.3 (CHCH2O), 43.1 (CH2NH), 
55.2 (OCH3), 72.5 (CH2O), 93.5 (C
5
), 113.8 (benzyl Ar-H), 127.0 (benzyl Ar-H), 
130.0 (CCH2NH), 157.9 (COCH3), 159.0 (C
2
), 161.6 (CNH), 171.0 (CO); LCMS Rt = 
4.22 min, (1); MS (ESI+) m/z 357.28 [M+H]
+
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4-(Cyclohexylmethoxy)pyrimidin-6-amine (99) 
 
4-(Cyclohexylmethoxy)-N-(4-methoxybenzyl) pyrimidin-6-amine (92) (500 mg, 1.53 
mmol, 1 eq) was dissolved in DCM (13.5 mL) and TFA (6 mL) was added dropwise. 
The reaction was heated to reflux for 41 h, then neutralised using a saturated sodium 
bicarbonate, then extracted using DCM (3x 40 mL). The combined organic layer were 
dried over MgSO4 and evaporated. Chromatography (silica, 70% EtOAc, PE) gave 
compound (99) a white solid (245 mg, 77%). Rf = 0.33 (7:3 EtOAc:PE); mp = 179.6-
180.1 
o
C; UV λmax (EtOH): 283.5, 343.0, 384.0 nm; IR ʋmax 3378 (NH), 3336, 3211, 
2919, 2847, 2220, 1666, 1574, 1551 cm
-1
; δH (300 MHz d6-DMSO): 0.95-1.24 (5H, 
m, C6H11) 1.67-1.74 (6H, m, C6H11), 3.97 (2H, d, J = 6.3 Hz, OCH2), 5.66 (1H, s, H
5
), 
6.58 (2H, s, NH2), 8.06 (1H, s, H
2); δC (75 MHz d6-DMSO): 25.6 (C6H11), 26.4 
(C6H11), 29.6 (C6H11), 37.3 (CHCH2O), 70.7 (CH2O), 86.0 (C
5
), 158.0 (C
2
), 165.9 
(CNH2), 169.7 (CO); LCMS Rt = 2.60 min, (1); MS (ESI+) m/z 240.03 [M+H]
+
      
 
N-Allyl-4-chloropyrimidin-6-amine (100)  
 
To a solution of 4,6-dichloropyrimidine (500 mg, 3.36 mmol, 1 eq) in THF (10 mL) 
was added triethylamine (0.49 mmol, 3.52 mmol, 1.05 eq) and allylamine (264 µL, 
3.52 mmol, 1.05 eq). The reaction was stirred at room temperature for 24 h then the 
solvent  was evaporated in vacuo. The resulting solid was suspended in water (40 mL) 
and extracted using DCM (3 x 50 mL). The combined organic layers were dried 
(MgSO4) and evaporated in vacuo. Chromatography (SP4, silica, 15-100% EtOAc, 
PE) gave 100 as a colourless oil which solidified to a white solid (560 mg, 98%). Rf = 
0.52 (1:1 EtOAc:PE) mp = 87.4-88.1 
o
C; UV λmax (EtOH): 340.5, 246.0 nm; IR ʋmax 
3233 (NH), 3054 (alkene C-H), 3015, 2965, 1598 (alkene C-C), 1568, 1531 cm
-1
; δH 
(500 MHz CDCl3): 3.89 (2H, s, NHCH2), 5.16-5.22 (2H, m, NHCH2CHCH2), 5.79-
7.5.86 (1H, m, NHCH2CHCH2), 6.29 (1H, s, H
5
), 8.28 (1H, s, H
2) δC (125 MHz 
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CDCl3): 43.9 (NHCH2), 117.3, (NHCH2CHCH2), 132.8 (NHCH2CHCH2), 158.2 (C
2
), 
163.2 (C-Cl) 
 
N-Allyl-4-(cyclohexylmethoxy)pyrimidin-6-amine (101) 
 
Cyclohexylmethanol (1.01 mL, 8.84 mmol, 5 eq) was added to a microwave vial 
followed by THF (4mL) and NaH (0.13 mg, 3 eq). The reaction was stirred at rt for 30 
min before N-allyl-4-chloropyrimidin-6-amine (300 mg, 177 mmol, 1 eq) was added, 
and the reaction irradiated at 120 
o
C for 20 min. The solvent was removed in vacuo. 
Chromatography (SP4, silica, 12-100 % EtOAc, PE) followed by SPE (C18 isoelute, 
20-80% MeOH with 0.1 % formic acid, 0.1 % formic acid(aq) gave 101 as a white 
solid (331 mg, 75%). Rf = 0.78 (1:1 EtOAc:PE); mp = 62.4-63.5 
o
C; UV λmax (EtOH): 
340.5, 245.0, 211.0 nm; IR ʋmax 3231 (NH), 3080 (Alkene C-H), 2918, 2849, 1596 
(Alkene C-C), 1573 cm
-1
; δH (500 MHz CDCl3): 0.94-1.24 (5H, m, C6H11), 1.60-1.77 
(6H, m, C6H11), 3.79-3.81 (2H, m, NHCH2), 4.00, (2H, d, J = 6.6 Hz, OCH2), 5.13 
(1H, dd, J = 10.3 and 1.3 Hz, 1 x NHCH2CHCH2), 5.20 (1H, dd, J = 17.2 and 1.3, 1 x 
NHCH2CHCH2), 5.57 (1H, s, H
5
), 5.85-5.78 (1H, m NHCH2CH2), 8.16 (1H, s, H
2
); 
δC (125 MHz CDCl3): 25.7 (C6H11), 26.6 (C6H11), 29.8 (C6H11), 37.4 (CCH2O), 44.1 
(NHCH2), 71.6 (OCH2), 85.1 (C
5
), 116.8 (NHCH2CHCH2), 133.5 (NCH2CHCH2), 
157.5 (C
2
), 163.8 (CNH), 170.4 (CO); LCMS Rt = 2.82 min; (ESI+) m/z 248.13 
[M+H]
+
      
 
N-Allyl-4-(cyclohexylmethoxy)-5-nitrosopyrimidin-6-amine (102) 
 
To a solution of N-allyl-4-(cyclohexylmethoxy)pyrimidin-6-amine (50 mg, 0.20 
mmol, 1 eq) in acetic acid (1.5 mL) and water (3.5 mL) was added NaNO2 (15 mg, 
0.22 mmol, 1.1 eq) in water (1 mL) and the reaction heated to 80 
o
C for 75 min before 
then neutralised with a saturated NaHCO3,and extracted with DCM (3 x 25 mL). The 
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combined organic layers dried (MgSO4) and evaporated in vacuo. Chromatography 
(silica, 50% EtOAc, PE) gave 102 as a yellow oil (37 mg, 66%). Rf = 0.94 (1:1 
EtOAc:PE); UV λmax (EtOH): 340.5 nm; IR ʋmax 2922, 1656 (Alkene C-C), 1588 
(NO) cm
-1
;  δH (500 MHz CDCl3): 0.96-1.26 (5H, m, C6H11), 1.61-1.79 (6H, m, 
C6H11), 4.14 (2H, d, J = 6.3 Hz, OCH2), 4.70-4.71 (2H, m, NHCH2), 4.98-5.08 (1H, 
m, NHCH2CHCH2), 5.03-5.06 (1H, m, NHCH2CHCH2), 5.60-5.68 (1H, m, 
NHCH2CHCH2), 8.60 (1H, d, J = 0.9 Hz, H
2); δC (125 MHz CDCl3): 25.5 (C6H11), 
25.7 (C6H11), 26.4 (C6H11), 37.2 (CCH2O), 42.6 (NHCH2), 72.5 (OCH2), 93.3 (C-
NO), 118.1 (NHCH2CHCH2), 129.5 (NHCH2CHCH2), 158.0 (CNH), 161.4 (CO), 
171.0 (C
2
); LCMS Rt = 3.98min (1); MS (ESI+) m/z 277.14 [M+H]
+
      
 
6-(Benzyloxyamino)-4-chloropyrimidin-2-amine (109) 
 
A mixture of 2-amino-4,6-dichloropyrimidine (100 mg, 0.61 mmol, 1 eq), DMSO (5 
mL), DIPEA(0.35 mL, 2.01 mmol, 3.3 eq) and O-benzylhydroxylamine (0.11 mL, 
0.91 mmol, 1.5 eq) was heated to 130 
o
C for 6 h then cooled to room temperature, 
diluted with water (30 mL) and extracted using ethyl acetate (3 x 40 mL). The organic 
layers were dried over Na2SO4 and evaporated. Chromatography (silica, 30-50% 
EtOAc, PE) gave 109 as a white solid (101 mg, 66%). Rf = 0.14 (3:7 EtOAc:PE); mp 
= 172.3-172.9 
o
C; UV λmax (EtOH): 208.5, 288.0, 341.5; IR ʋmax 3470 (NH), 3298 
(NH), 3173, 2918, 1632, 1593, 1546 cm
-1
; δH (500 MHz d6-DMSO): 4.84 (2H, s, 
OCH2), 5.97 (1H, s, H
5
), 6.73 (2H, s, NH2), 7.44-7.46 (5H, m, Ar-H), 10.28 (1H, s, 
NH); δC (125 MHz d6-DMSO): 77.0 (CH2), 90.2 (C
5
), 128.4 (Ar-H), 128.9 (Ar-H), 
136.0 (Ar-H), 159.5 (CCl), 162.5 (CNH2), 167.0 (CNH); LCMS Rt = 2.66 min, (1); 
MS (ESI+) m/z 251.03 [M+H]
+
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4-Chloro-6-(methoxyamino)pyrimidin-2-amine (108)  
 
A solution of methoxyamine hydrochloride (229 mg, 2.7 mmol, 4.5 eq) and DIPEA 
(0.90 mL, 7.3 mmol, 12 eq) in DMSO (5 mL) was stirred at room temperature for 30 
min. 2-Amino-4,6-dichloropyrimidine (100 mg, 0.61 mmol, 1 eq) was added and the 
mixture heated to 130 
o
C for 16 h then diluted with water (30 mL) and extracted with 
EtOAc (3 x 70 mL). The combined organic layers were dried over Na2SO4 and 
evaporated. Chromatography (silica, 50% EtOAc, PE) gave the title compound as a 
white solid (55 mg, 52%). Rf = 0.38 (1:1 EtOAc:PE); δH (500 MHz d6-DMSO): 3.61 
(3H, s, CH3), 5.93 (1H, s, H
5
), 6.66 (2H, s, NH2), 10.17 (1H, s, NH); LCMS Rt = 0.72 
min, (1); MS (ESI+) m/z 174.93 [M+H]
+
      
 
4-Chloro-6-(cyclohexylmethoxy)pyrimidin-2-amine (112) 
 
To cyclohexylmethanol (15 mL, 122 mmol, 10 eq) was added sodium (0.25 g, 11.0 
mmol, 0.9 eq) in portions, and the mixture heated to 100 
o
C until all sodium had 
dissolved. 2-Amino-4,6-dichloropyrimdine (2.00 g, 12.2 mmol, 1 eq) was added and 
the mixture stirred at 100 
o
C for 20 min, then cooled to room temperature, neutralised 
using acetic acid, diluted with petroleum ether (30 mL) and cooled to 4 
o
C. The 
precipitated solid was collected and purified using chromatography (silica, 30% 
EtOAc, PE). The filtrate was evaporated, diluted with petroleum ether and cooled to 4 
o
C. The collected solid was recrystallised from boiling methanol. The products were 
combined to give compound (112), a white solid (1.83 g 62%). Rf = 0.61 (3:7 
EtOAc:PE); mp = 108.6-109.3 
o
C; UV λmax (EtOH): 233.0, 278.0; IR ʋmax 3349 (NH), 
3221, 2926, 2849, 1653, 1538 cm
-1
; δH (300 MHz d6-DMSO): 0.92-1.30 (5H, m, 
C6H11), 1.63-1.74 (6H, m, C6H11), 4.03 (2H, d, J = 6.3 Hz, OCH2), 6.08 (1H, s, H
5
), 
7.04 (2H, s, NH2); δC (75 MHz d6-DMSO): 25.8 (C6H11), 26.5 (C6H11), 29.8 (C6H11), 
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37.4 (CHCH2O), 71.8 (CH2O), 162.2 (Ar), 172.3 (CO); LCMS Rt = 3.36 min, (1); MS 
(ESI+) m/z 242.01 [M+H]
+
      
 
4,6-Bis(cyclohexylmethoxy)pyrimidin-2-amine (113) 
 
To cyclohexylmethanol (4.5 mL, 36 mmol, 60 eq) was added sodium (0.08, 3.49 
mmol, 5.7 eq) in portions. The reaction mixture was heated to 120 
o
C and until all 
sodium had dissolved, 2-amino-4,6-dichloropyrimidine (100 mg, 0.61 mmol, 1 eq) 
was added and stirring continued at 120 
o
C followed by neutralisation using acetic 
acid. The mixture was diluted with petroleum ether (30 mL) cooled to 4 
o
C, and the 
white precipitate collected by filtration. Recrystallisation (methanol) gave the title 
compound as a white solid (65 mg, 33%). Rf = 0.70 (3:7 EtOAc:PE); mp = 114.0-
114.7 
o
C; UV λmax (EtOH): 299.5, 260.5; IR ʋmax 3350 (NH), 3235, 2920, 2820, 1644, 
1566 cm
-1
;  δH (500 MHz d6-DMSO): 0.88-1.18 (10H, m, C6H11), 1.54-1.65 (12H, m, 
C6H11), 3.88 (4H, d, J = 3.6 Hz, 2 x OCH2), 5.21 (1H, s, H
5
), 6.36 (2H, s, NH2); δC 
(125 MHz CDCl3): 25.8 (C6H11), 26.5 (C6H11), 29.8 (C6H11), 37.4 (CHCH2O), 71.8 
(CH2O), 79.6 (C
5
), 162.2 (CNH2), 172.4 (CO); LCMS Rt = 3.86 min, (1); MS (ESI+) 
m/z 320.23 [M+H]
+
      
 
2-(2,4-Diamino-6-oxo-1,6-dihydropyrimidin-5-yl)acetonitrile (116) 
 
To a solution of 2,6-diaminopyrimidone (250 mg, 1.98 mmol, 1 eq) and NaHCO3 
(366 mg, 4.36 mmol, 2.2 eq) in DMF (5 mL) was added bromoacetonitrile (0.30 mL, 
4.36 mmol, 2.2 eq). The reaction was stirred at room temperature for 4 days, then 
concentration in vacuo, and water (40 mL) was added and the resulting precipitate 
was collected by filtration. Recrystallisation (ethanol) gave the title compound as 
beige needles (46 mg, 9%). Rf = 0.63 (3:7 MeOH:EtOAc); mp = dec; UV λmax 
(EtOH): 211.5, 269.5; IR ʋmax 3437 (NH), 3363 (Amide NH), 2903, 2829, 2712, 2246 
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(weak, CN), 1630 (C=O), 1591 (Amide C-N) cm
-1
; δH (300 MHz d6-DMSO) 3.36 
(2H, CH2), 6.23 (4H, m, 2 x NH2), 10.08 (1H, s, NH); δC (75 MHz d6-DMSO): 11.9 
(CH2), 78.1 (C
5
), 119.7 (CN), 154.4 (CNH2), 162.2 (CNH2), 162.4 (C=O); LCMS Rt 
= 1.99 min, (2); MS (ESI+) m/z 166.12 [M+H]
+
      
 
2-(2,4-Diamino-6-(cyclohexylmethoxy)pyrimidin-5-yl)acetonitrile (117) 
 
 A solution of 116 (244 mg, 1.48 mmol, 1 eq) and K2CO3 (230 mg, 1.63 mmol, 1.1 
eq) in DMF (5 mL) was stirred at room temperature for 90 min, then (bromomethyl) 
cyclohexane (0.68 mL, 7.39 mmol, 5 eq) was added and the solution heated to 100 
o
C 
for 15h, cooled to room temperature, and poured into ice. The aqueous solution was 
extracted with EtOAc (4 x 70 mL), dried (Na2SO4) and concentrated in vacuo. 
Chromatography (silica, 100% EtOAc) and crystallisation gave 117 as a brown solid 
(84 mg, 22%). Rf = 0.6 (100 % EtOAc); mp = 172.6-173.4 
o
C; UV λmax (EtOH): 
267.0, 234.5; IR ʋmax 3438 (NH), 3355, 3140, 2932, 2854, 2251 (weak, CN), 1624, 
1569 cm
-1
; δH (500 MHz d6-DMSO): 1.04-1.35 (6H, m, C6H11), 1.70-1.85 (5H, m, 
C6H11), 3.54 (2H, s, CH2CN), 4.05 (2H, d, J = 6.0 Hz, OCH2), 6.05 (2H, s, N
1
H2), 
6.32 (2H, s, N
2
H2); δC (500 MHz d6-DMSO): 25.3 (C6H11), 26.0 (C6H11), 29.1 
(C6H11), 36.9 (CHCH2O), 70.3 (CH2O), 77.9 (C
5
), 119.0 (CN), 161.7 (CNH2), 162.9 
(CNH2), 167.2 (CO); LCMS Rt = 2.29 min, (1); MS (ESI+) m/z 262.12 [M+H]
+
; 
HRMS m/z: Calc. for: C13H20N5O 262.1662 [M+H]
+
. Found 262.1666 [M+H]
+
.; 
Analytical HPLC: 96.0% purity 
 
4-Methoxypyridine 1-oxide (140) 
 
To 4-methoxypyridine (0.50 mL, 4.92 mmol, 1 eq) in DCM (10 mL) was added m-
CPBA (1.28 g, 7.41 mmol, 1.5 eq) in portions, and the mixture stirred for 20 h, then 
evaporated. Chromatography (silica, 30% MeOH , EtOAc) gave 140 as a cream solid 
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(0.48g, 79%). Rf = 0.14 (3:7 MeOH:EtOAc); mp = 101.7-102.3 
o
C (lit. 82-84 
o
C)
269
; 
UV λmax (EtOH): 205.0, 268.0; IR ʋmax 1561, 1286, 1207 cm
-1
; δH (300 MHz, d6-
DMSO): 3.82 (3H, s, CH3), 7.02 (2H, d, J = 7.8 Hz, Ar-H), 8.1 (2H, d, J = 7.8 Hz, Ar-
H); δC (75 MHz d6-DMSO): 56.6 (CH3), 112.7 (Ar-H) , 139.8 (CO), 156.7 (CHN) 
 
N-Benzylacetamide (138) 
 
Benzylamine (2.0 mL, 18.3 mmol, 1 eq) and acetic anhydride (2.6 mL, 28 mmol, 1.5 
eq) were heated to 150 
o
C for 2 h then cooled to room temperature, neutralised using 
2.5 M NaOH solution, and extracted into ethyl acetate (3 x 50 mL). The combined 
organic layers were dried over MgSO4 and concentrated in vacuo, resulting in a 
yellow oil which then crystallised. Chromatography (100% ethyl acetate) gave 138 as 
a white solid (0.74 g, 27%). Rf = 0.33 (100% EtOAc); mp = 62.9 – 63.8 
o
C (lit. 149.19 
o
C)
270
; UV λmax (EtOH): 379.5, 278.0, 244.5; IR ʋmax 3289 (NH), 1635 (C=O) cm
-1
; δH 
(300 MHz, d6-DMSO): 1.87 (3H, s, CH3), 4.24 (2H, d, J = 5.1 Hz, CH2), 7.23-7.32 
(5H, m, 5 x Ar-H), 8.35 (1H, s, NH); δC (75 MHz d6-DMSO): 22.9 (COCH3), 42.6 
(CH2), 127.0, 127.6, 128.5, 140.0 (CCH2), 169.4 (C=O) 
 
1-(Cyclohexylmethyl)pyridin-4(1H)-one (137) 
 
4-Pyridone (100 mg, 1.05 mmol, 1 eq) was added to a microwave vial in the dark, 
then DMSO (2 mL) was added, followed by the potassium carbonate (218 mg, 1.58 
mmol, 1.5 eq) and the mixture was stirred for 1h at room temperature. 
Cyclohexylmethanol (0.5 mL, 5.26 mmol, 5 eq) was added and the reaction then 
stirred at rt for 26 h. The mixture was added to ice water (50 mL) and extracted using 
DCM (3 x 50 mL). The combined organic layers were dried over MgSO4 and 
evaporated. Chromatography (SP4, silica, 7-60% MeOH, EtOAc) gave the title 
compound as a colourless oil which solidified on standing (82 mg, 41%). Rf = 0.5 (3:7 
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MeOH:EtOAc); mp = 132.2-133.4 
o
C; UV λmax (EtOH): 263.5; IR ʋmax 3427 (NH), 
3366, 3427, 3366, 3289, 2918, 2849, 1638 (C=O), 1531 cm
-1
; δH (300 MHz CDCl3) 
0.82-1.24 (5H, m, C6H11), 1.56-1.72 (6H, m, C6H11), 3.51 (2H, d, J = 6.9 Hz, NCH2), 
6.30 (2H, d, J = 7.5 Hz, CHCO), 7.17 (2H, d, J = 7.5 Hz, CHN; δC (75 MHz CDCl3): 
25.8 (C6H11), 26.4 (C6H11), 39.6 (C6H11), 41.5 (CHCH2N), 63.5 (CH2N), 118.9 
(CHC=O), 140.2 (CHN), 179.1 (C=O), LCMS Rt = 1.76 min, (1); MS (ESI+) m/z 
192.09 [M+H]
+
    
  
4-(Cyclohexylmethoxy)pyridine (127) 
 
To cyclohexylmethanol (30 mL, 244 mmol, 18 eq) was added to sodium (1.30 g, 56.5 
mmol, 4.3 eq) in portions and the mixture heated to 140 
o
C until all the sodium had 
dissolved the solution. The solution was allowed to cool for 10 min then 4-
chloropyridine hydrochloride (2.00 g, 13.3 mmol, 1 eq) was added and the reaction 
temperature increased to 200 
o
C with vigorous stirring for 3.5 h. The reaction mixture 
was cooled to room temperature and neutralised using acetic acid, diluted with 
petroleum ether (100 mL) and the precipitate filtered. The filtrate was concentrated in 
vacuo, diluted with DCM (100 mL) and extracted using 1 M HCl (6 x 70 mL). The 
combined acidic layers were basified using 2.5 M NaOH, and extracted using DCM 
(12 x 100 mL). The combined organic layers were dried over MgSO4 and evaporated 
to give a yellow oil. Chromatography (silica, 80% EtOAc, PE) gave 127 as a pale 
yellow solid (1.02 g, 53%). Rf = 0.47 (8:2 EtOAc:PE); mp = 60.2-61.6 
o
C; UV λmax 
(EtOH): 218.0, 328.0; IR ʋmax 2923, 2847, 1586, 1567 cm
-1
; δH (300 MHz CDCl3): 
1.01-1.32 (5H, m, C6H11), 1.72 -1.90 (6H, m, C6H11), 3.81 (2H, d, J = 5.4 Hz, CH2), 
6.80 (2H, d, J = 4.8 Hz, 2 x Ar-H), 8.42 (2H, d, J = 4.8 Hz, 2 x Ar-H); δC (75 MHz 
CDCl3): 26.1 (C6H11), 26.8 (C6H11), 30.2 (C6H11), 37.9 (CHCH2O), 73.6 (CH2O), 
110.7 (CHCO), 151.4 (CHN), 165.7 (CO); LCMS Rt = 1.24 min, (1); MS (ESI+) m/z 
192.08 [M+H]
+
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4-(Cyclohexylmethoxy)pyridine-1-oxide (128) 
 
To a solution of 4-cyclohexylmethoxpyridine (1.52 g, 7.93 mmol, 1 eq) in DCM (15 
mL) was added mCPBA (2.29 g of 65% purity, 18.0 mmol, 1.5 eq) with stirring at 
room temperature for 2 days. The reaction mixture was then diluted with DCM (20 
mL) and washed with a sat. NaHSO3 (3 x 50 mL). The organic layer was then dried 
over MgSO4 and evaporated. Chromatography (silica, 3-30% MeOH, EtOAc) to give 
the title compound as a white solid (1.59 g, 97%). Rf = 0.17 (1:9 MeOH:EtOAc); UV 
λmax (EtOH): 202.0, 208.0, 261.0, 265.0, 268.5, 276.0; IR ʋmax 3105, 3028, 2924, 
2850, 1611, 1553 cm
-1
; δH (300 MHz CDCl3): 0.99-1.33 (5H, m, C6H11), 1.75-1.85 
(6H, m, C6H11), 3.79 (2H, d, J = 6 Hz CH2), 6.80 (2H, d, J = 7.5 Hz, 2 x Ar-H), 8.13 
(2H, d, J = 7.5 Hz, 2 x Ar-H); δC (75 MHz CDCl3): 26.0 (C6H11), 26.7 (C6H11), 30.0 
(C6H11), 37.8 (CHCH2O), 75.0 (CH2O), 112.5, 140.4; LCMS Rt = 9.40 min, (2); MS 
(ESI+) m/z 208.19 [M+H]
+
      
 
2-Chloro-4-(cyclohexylmethoxy)pyridine (142) 
 
A solution of 4-(cyclohexylmethoxy)pyridine 1-oxide (128) (0.646 g, 3.11 mmol, 1 
eq) in acetonitrile ( 6 mL) was added phosphorus oxychloride (7.5 mL, 107 mmol, 34 
eq) was added and the mixture was heated at 160 
o
C for 30 min in a microwave, then 
poured into ice (2 x 20 mL) and stirred overnight. The aqueous solution was basified 
using 1M aqueous KOH solution and extracted using DCM (9 x 100 mL). The 
combined organic layers were then dried over MgSO4 and concentrated in vacuo to 
give a brown oil. Chromatography (silica, 100% EtOAc) gave the title compound as a 
brown oil (0.40 g, 56%). Rf = 0.87 (100% EtOAc); mp = 49.2-49.8 
o
C; UV λmax 
(EtOH): 217.5; IR ʋmax 3073, 2922, 2846, 1730, 1584, 1551 cm
-1
; δH (300 MHz 
CDCl3) 0.78-1.25 (5H, m, C6H11), 1.62-1.78 (6H, m, C6H11), 3.72 (2H, d, J = 6.0 Hz, 
CH2), 6.66 (1H, dd, J = 2.4 and 6.0 Hz, CHCO ), 6.74 (1H, d, J = 2.1 Hz, CHCCl), 
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8.09 (1H, d, J = 6.0 Hz, NCH); δC (75 MHz CDCl3): 26.0 (C6H11), 26.7 (C6H11), 30.1 
(C6H11), 37.8 (CHCH2O), 74.3 (CH2O), 110.3 (C
2
) , 110.4 (C
1
), 150.5 (CCl), 153.1 
(C
3
), 167.4 (CO); LCMS Rt = 3.93 min, (1); MS (ESI+) m/z 226.11 [M+H]
+
      
 
Diethyl 4-oxo-1,4-dihydropyridine-2,6-dicarboxylate (153) 
 
To a solution of chelidamic acid monohydrate (500 mg, 2.73 mmol, 1 eq) in ethanol 
(15 mL) was added thionyl chloride (0.8 mL, 10.9 mmol, 4 eq) dropwise. The 
reaction heated to reflux for 2 h, then cooled to room temperature and the solvent 
evaporated. The mixture was neutralised using a saturated sodium bicarbonate 
solution, and the solvent evaporated. The residue was diluted with water (15 mL) and 
extracted using EtOAc (3 x 40 mL). The combined organic extracts were dried over 
MgSO4 and concentrated in vacuo. Chromatography (SP4, silica, 12-100% EtOAc, 
PE) gave the title compound as a white solid (0.30 g, 46%). Rf = 0.38 (100% EtOAc); 
mp = 118.2-118.8 
o
C (lit 115-116 
o
C)
271
; UV λmax (EtOH): 214.5; IR ʋmax 2985, 1722 
(Ester C=O), 1603 (Pyridone C=O), 1568 cm
-1
; δH (500 MHz CDCl3): 1.29 (6H, t, J = 
7.5 Hz, CH3), 4.34 (4H, q, J = 7.5 Hz, CH2), 7.49 (2H, s, Ar-H); δC (125 MHz 
CDCl3): 14.1 (CH3), 63.0 (CH2), 118.7 (Ar-H), 162.6 (COOEt); LCMS Rt = 2.34 min, 
(1); MS (ESI+) m/z 240.01 [M+H]
+
      
 
Diethyl 4-(benzyloxy)pyridine-2,6-dicarboxylate (154) 
 
To a solution of diethyl 4-oxo-1,4-dihydropyridine-2,6-dicarboxylate (153) (500 mg, 
2.09 mmol, 1 eq) in DMF (5 mL) was added K2CO3 (318 mg, 2.30 mmol, 1.1 eq) and 
benzyl bromide (0.255 mL, 2.14 mmol, 1.03 eq). The reaction was heated to 80 
o
C for 
30 min, then cooled to room temperature and water (20 mL) was added, and extracted 
using EtOAc (3 x 50 mL). The combined organic layers were dried over Na2SO4 and 
evaporated. Chromatography (silica, 40% EtOAc, PE) gave compound 154 a white 
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solid (659 mg, 96%). Rf = 0.46 (4:6 EtOAc:PE); mp = 74.6-75.2 
o
C; UV λmax (EtOH): 
215.5; IR ʋmax 3075, 2975, 1712 (Ester C=O), 1592, 1567 cm
-1
; δH (300 MHz CDCl3): 
1.35 (6H, t, J = 7.2 Hz, CH3), 4.37 (4H, q, J = 7.2 Hz, CH2), 5.13 (2H, s, OCH2), 
7.26-7.34 (5H, m, C6H5), 7.78 (2H, s, Ar-H); δC (75 MHz CDCl3): 13.2 (CH3), 61.2 
(CH2CH3), 69.9 (OCH2), 113.6 (Ar-H), 126.7 (benzyl Ar-H), 127.7 benzyl (Ar-H), 
127.9 (benzyl Ar-H), 134.1 (CCH2), 149.7 (CCO2Et), 163.7 (C-O), 165.7 (C=O); 
LCMS Rt = 3.81 min, (1); MS (ESI+) m/z 330.14 [M+H]
+
      
 
4-(Benzyloxy)pyridine-2,6-dicarboxamide (152) 
 
A solution of diethyl 4-(benzyloxy)pyridine-2,6-dicarboxylate (150) (290 mg, 0.88 
mmol, 1 eq) in 7 N methanolic ammonia in methanol (10 mL, 70 mmol, 80 eq) was 
stirred for 3.5 h. The white precipitate was collected by filtration and used without 
further purification. The filtrate was concentrated in vacuo. Chromatography (SP4, 
silica, 2-20% MeOH, EtOAc) gave a white solid compound (152) (212 mg, 88%) in 
total. Rf = 0.26 (100% EtOAc); mp = 271.3-272.1 
o
C (lit: > 220 
o
C)
180
; UV λmax 
(EtOH): 214.0 nm; IR ʋmax 3076 (NH), 1711, 1663 (Amide C=O), 1591, 1564 (NH) 
cm
-1
; δH (500 MHz d6-DMSO): 5.29 (2H, s, OCH2), 7.28-7.42 (5H, m, Ar-H), 7.65 
(2H, s, NH), 7.67 (2H, s, Ar-H), 8.77 (2H, s, NH); δC (125 MHz d6-DMSO): 69.8 
(CH2), 110.5 (Ar-H), 127.7 (benzyl Ar-H), 128.1 (benzyl Ar-H), 128.8 (benzyl Ar-H), 
135.8 (CCH2O), 151.2 (CCONH2), 165.1 (CO), 166.7 (C=O); LCMS Rt = 3.04 min, 
(1); MS (ESI+) m/z 272.00 [M+H]
+
      
 
4-Benzyloxy-2,6-diaminopyridine (153) 
 
To an aqueous solution of 5M KOH (60 mL, 300 mmol, 55 eq) was added bromine 
(700 µL, 13.6 mmol, 2.5 eq) followed by 4-benzyloxypyridine-2,6-dicarboxamide 
(1.48 g, 5.45 mmol, 1 eq). The mixture was heated to 90 
o
C for 2 h, cooled to room 
temperature, and extracted with DCM (6 x 100 mL), and THF (3 x 60 mL). The 
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combined organic layers were dried (MgSO4). Chromatography (SP4, silica, 3-20% 
MeOH, EtOAc) gave 153 as a white solid (837 mg, 71%). Rf = 0.2 (1:9 
MeOH:EtOAc); mp. = 166.2 -167.0 
o
C (lit. 164-166 
o
C)
180
; UV λmax (EtOH): 289.0, 
248.0 nm; IR ʋmax 3372 (NH), 3188, 2198, 1590, 1559 cm
-1
; δH (500 MHz d6-DMSO): 
5.02 (2H, s, OCH2), 5.39 (2H, s, Ar-H), 5.40 (4H, s, NH2), 7.38-7.45 (5H, m, benzyl); 
δC (125 MHz d6-DMSO): 68.3 (OCH2), 82.3 (Ar-H), 127.4 (benzyl Ar-H), 127.7 
(benzyl Ar-H), 128.4 (benzyl Ar-H), 137.1 (CCH2O), 159.7 (CNH2), 167.1 (CO); 
LCMS Rt = 2.00 min (1); MS (ESI+) m/z 216.04 [M+H]
+
      
 
N,N’-(4-Benzyloxypyridine-2,6-diyl)diacetamide (155) 
 
A mixture of 4-benzyloxy-2,6-diaminopyridine (193 mg, 0.90 mmol, 1 eq), acetic 
acid (3 mL) and acetic anhydride (3 mL) was stirred at room temperature for 3 days, 
then diluted with water (15 mL) and neutralised with ammonia. The resulting 
precipitate was collected by filtration, dissolved in DCM (20 mL), dried (MgSO4) and 
the solvent removed in vacuo. Chromatography (silica, 10% MeOH, EtOAc) gave 155 
as a white solid (247 mg, 92%). Rf = 0.66 (1:9 MeOH:EtOAc) mp.= 116.6-117.3 
o
C; 
UV λmax (EtOH): 340.5, 283.0, 218.5 nm; IR ʋmax 3322 (NH), 1663 (C=O), 1618, 
1580, 1521 cm
-1
;  δH (500 MHz CDCl3):  2.08 (6H, s, 2 x CH3), 5.05 (2H, s, OCH2), 
7.25-7.36 (5H, m, benzyl), 7.55 (2H, Ar-H), 7.70 (2H, s, NH); δC (125 MHz CDCl3): 
23.7 (CH3), 69.4 (OCH2), 95.5 (Ar-H), 126.7 (benzyl Ar-H), 127.2 (benzyl Ar-H), 
127.6 (benzyl Ar-H), 134.7 (CCH2O), 149.5 (CNH), 167 (CO);  LCMS Rt = 2.49 min; 
MS (ESI+) m/z 300.16 [M+H]
+
      
 
N,N’-(4-Benzyloxy-3-bromopyridine-2,6-diyl)diacetamide (156) 
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To a solution of N,N’-(4-benzyloxypyridine-2,6-diyl)diacetamide (117 mg,0.39 mmol, 
1 eq) and acetic acid (7 mL), N-bromosuccinimide (69 mg, 0.39 mmol, 1 eq) was 
added, then stirred at room temperature for 30 min and neutralised with NaOH (2.5 
M). The resulting precipitate was collected by filtration, dissolved in DCM (30 mL), 
dried (MgSO4) and evaporated in vacuo. Chromatography (silica, 10% MeOH, 
EtOAc) to give 156 as a white solid (0.115 mg, 77%). Rf = 0.7 (1:9 MeOH:EtOAc) 
mp. = 212.0-212.6 
o
C; UV λmax (EtOH): 340.5, 257.5, 221.5 nm; IR ʋmax 3327 (NH), 
1669 (C=O), 1590, 1590, 1559, 1511 cm
-1
; δH (500 MHz d6-DMSO): 2.06 (3H, s, 
CH3), 2.13 (3H, s, CH3), 5.31 (2H, s, OCH2), 7.41-7.7.56 (5H, m, benzyl), 7.95 (1H, 
s, Ar-H), 9.97 (1H, s, NH), 10.68 (1H, s, NH); δC (125 MHz d6-DMSO): 22.8 (CH3), 
24.0 (CH3), 70.4 (OCH2), 96.5(Ar-H), 127.6 (benzyl Ar-H), 128.2 (benzyl Ar-H), 
128.5 (benzyl Ar-H), 135.6 (CCH2O), 148.6 (CNH2), 151.1 (CNH2), 163.1 (carbonyl), 
168.5 (carbonyl), 169.6 (CO); LCMS Rt = 2.80 min (1); MS (ESI+) m/z  378.06 
[M+H]
+
      
 
4-Cyclohexylmethoxypyridine-2,6-dicarboxylic acid diethyl ester (157) 
 
A mixture of diethyl 5-oxocyclohexa-3,6-diene-1,3-dicarboxylate (1.00 g, 4.18 mmol, 
1 eq), DMF (7 mL), K2CO3 (0.64 g, 4.60 mmol, 1.1 eq) and (bromomethyl) 
cyclohexane (0.70 mL, 5.02 mmol, 1.2 eq) was heated to 80 
o
C for 16 h, cooled to 
room temperature, diluted with saturated NaHCO3 (20 mL) and extracted using DCM 
(3 x 30 mL). The combined organic layers were dried (MgSO4) and evaporated in 
vacuo. Chromatography (silica, 50% EtOAc, PE) gave 157 as a colourless oil (491 
mg, 70%). Rf = 0.75 (1:1 EtOAc:PE); UV λmax (EtOH): 340.5, 213.5 nm; IR ʋmax  
2926, 2853, 1717 (Ester C=O), 1593 cm
-1
; δH (500 MHz CDCl3): 1.00 (5H, m, 
C6H11), 1.38 (6H, t, 7.2 Hz,  OCH2CH3), 1.62-1.81 (6H, m, C6H11), 3.85 (2H, d, J = 
6.0 Hz, OCH2), 4.40 (4H, q, J = 7.2 Hz, OCH2CH3), 7.70 (2H, s, Ar-H); δC (125 MHz 
CDCl3): 14.1 (CH3), 25.6 (C6H11), 26.3 (C6H11), 29.6 (C6H11), 37.4 (CCH2O), 62.4 
(OCH2CH3), 74.3 (OCH2), 114.4 (Ar-H), 150.1 (CCO2Et), 164.8 (CO), 167.2 (C=O)  
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4-Cyclohexylmethoxypyridine-2,6-dicarboxamide (158) 
 
4-Cyclohexylmethoxypyridine-2,6-dicarboxylic acid diethyl ester (270 mg, 0.80 
mmol, 1 eq) was dissolved in 7 M methanoic ammonia (7 mL, 49 mmol, 61 eq) and 
stirred at room temperature for 1h. The white precipitate was collected by filtration 
and recrystallised from boiling methanol to give the title compound as a white solid 
(105 mg, 47%). Rf = 0.68 (1:9 MeOH:EtOAc) mp = 269.0-269.9 
o
C; UV λmax (EtOH): 
340.5, 212.0 nm; IR ʋmax 3447 (NH), 3341, 3181, 2921, 2845, 1672 (C=O), 1588 
(NH) cm
-1
; δH (500 MHz d6-DMSO) 1.08-1.35 (5H, m, C6H11), 1.69-1.86 (6H, m, 
C6H11), 4.05 (2H, d, J = 5.9 Hz, OCH2), 7.68 (2H, s, Ar-H), 7.76 (2H, d, J = 1.8 Hz, 
NH), 8.89 (2H, d, J = 1.75 Hz, NH) δC (125 MHz d6-DMSO): 25.1 (C6H11), 25.9 
(C6H11), 28.9 (C6H11), 39.0 (CCH2O), 73.3 (OCH2), 110.0 (Ar-H), 151.2 (CCONH2), 
165.2 (CO), 167.2 (C=O); LCMS Rt = 2.73 min (1); ESI+ m/z 278.12 [M+H]
+
      
 
4-Cyclohexylmethoxy-2,6-diaminopyridine (159) 
 
To an aqueous solution of 5M KOH (3.96 mL, 19.8 mmol, 55 eq) was added bromine 
(46 µL, 0.90 mmol, 2.5 eq) followed by 4-cyclohexylmethoxypyridine-2,6-
dicarboxylic acid diamine (100 mg, 0.36 mmol, 1 eq). The reaction mixture was 
heated to 90 
o
C for 2 h, cooled to room temperature, extracted with DCM (3 x 25 
mL). The combined organic layers were dried (MgSO4) and evaporated. 
Chromatography (SP4, silica, 3-20% MeOH, EtOAc) to give 4-cyclohexylmethoxy-
2,6-diaminopyridine as a white solid (35 mg, 44%). Rf = 0.18 (1:9 MeOH:EtOAc); 
mp = 152.0-152.8 
o
C; UV λmax (EtOH): 289.5, 246.5 nm; IR ʋmax 3435 (NH), 3363, 
3333, 3187, 2926, 2854, 1626, 1578 cm
-1
; δH (500 MHz d6-DMSO): 0.97-1.25 (5H, 
m, C6H11), 1.64-1.76 (6H, m, C6H11), 3.65 (2H, d, J = 6.5 Hz, OCH2), 5.27 (2H, s, Ar-
H), 5.42 (4H, s, NH2); δC (125 MHz d6-DMSO): 25.2 (C6H11), 26.0 (C6H11), 29.2 
(C6H11), 36.9 (CCH2O), 71.9 (OCH2), 82.1 (Ar-H), 159.2 (CNH2), 167.6 (CO); 
LCMS Rt = 2.33 min (1); MS (ESI+) m/z 222.16 [M+H]
+
      
7. mTOR Experimental Procedures 
 
254 
 
4-Cyclohexylmethoxy-3-nitrosopyridine-2,6-diamine (160) 
 
A solution of 4-cyclohexylmethoxy-2,6-diaminopyridine (50 mg, 0.23 mmol, 1 eq), in 
acetic acid (1.5 mL) and water (3.5 mL) was heated to 80 
o
C and NaNO2 (17 mg, 0.25 
mL, 1.1 eq) in water (1 mL) was added. The brown solution was stirred at 80 
o
C for 
30 min, cooled to room temperature, neutralised using a saturated NaHCO3 and 
extracted using DCM (4 x 25 mL). The combined organic layers were dried (Na2SO4), 
and evaporated in vacuo. Chromatography (silica, 10% MeOH, EtOAc), followed by 
recrystallisation (methanol) gave 160 as a purple solid (24 mg, 42%). Rf = 0.57 (1:9 
MeOH:EtOAc); mp = 253.0-254.2 
o
C; UV λmax (EtOH): 365.0, 323.5, 247.5, 204.0 
nm; IR ʋmax 3151 (NH), 2920, 2848, 1608, 1506 (NO) cm
-1
; δH (500 MHz, d6-
DMSO): 1.04-1.31 (5H, m, C6H11), 1.66-1.85 (6H, m, C6H11), 3.91 (2H, d, J = 6.05 
Hz, OCH2), 5.62 (1H, s, H
3
), 7.46 (1H, s, N
1
H
1
), 7.06 (1H, s, N
1
H
2
), 7.66 (1H, d, J = 
5.25 Hz, N
2
H
1
), 11.14 (1H, d, J = 5.2 Hz, N
2
H
2); δC (125 MHz, d6-DMSO): 25.2 
(C6H11), 25.9 (C6H11), 29.1 (C6H11), 37.8 (CCH2O), 73.3 (OCH2), 83.3 (Ar-H), 142.3 
(Ar-NO), 148.8 (CNH2), 165.0 (CNH2), 166.0 (CO); LCMS Rt = 2.16 min (1); MS 
(ESI+) m/z 251.10 [M+H]
+
  HRMS m/z: Calc. for C12H19N4O2: 251.1503 [M+H]
+
. 
Found: 251.1506 [M+H]
+
.; Analytical HPLC: 97.0% purity  
 
4,6-Diamino-2-methoxynicotinitrile (165) 
 
Sodium (0.72 g, 30.0 mmol, 3 eq) was added in portions to methanol (30 mL, 698 
mmol, 70 eq), after all the sodium had dissolved 2-amino-1,1,3-tricyanopropene (1.32 
g, 9.99 mmol, 1 eq) was added and the reaction heated to reflux for 48 h, then  cooled 
to room temperature and the solvent removed in vacuo. The resulting oil was diluted 
with ice water (5 mL) and chilled to 4 
o
C for 2 days. The precipitate was collected by 
filtration and purified by chromatography (silica, 4:1 Et2O:PE) to give the title 
compound as a white solid (0.33 g, 20%). Rf = 0.26 (4:1 Et2O:PE); mp. = 183.3-183.8 
o
C (lit. 176 
o
C)
186
; UV λmax (EtOH): 267.5, 220.5 nm; IR ʋmax 3511 (NH), 3398, 3337, 
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3240, 2197 (CN), 1638, 1597, 1547 cm
-1
; δH (500 MHz d6-DMSO): 3.82 (3H, s, 
CH3), 5.39 (1H, s, Ar-H), 6.26 (2H, s, NH2), 6.32 (2H, s, NH2); δC (125 MHz d6-
DMSO): 53.0 (CH3), 67.5 (CCN), 82.5 (Ar-H), 116.7 (CN), 158.4 (CNH2), 160.2 
(CNH2), 165.7 (CO); LCMS Rt = 1.56 min (1); MS (ESI+)+ m/z 164.98 [M+H]
+
      
 
4,6-Diamino-2-methoxynicotinitrile (164) 
 
The title compound was synthesised as a by-product of the above reaction as a pale 
yellow solid (77 mg, 5%). Rf = 0.53 (4:1 Et2O:PE); mp = 139.5-140.9 
o
C; UV λmax 
(EtOH): 341.0, 293.5, 225.5 nm; IR ʋmax 3357 (NH), 3232, 2195 (CN), 1626, 1569 
cm
-1
; δH (500 MHz CDCl3): 3.74 (3H, s, CH3), 4.52 (2H, s, NH2), 4.87 (2H, s, NH2), 
5.36 (1H, s, Ar-H); δC (125 MHz CDCl3): 53.7 (CH3), 70.4 (CCN), 83.8 (Ar-H), 
116.5 (CN), 157.6 (CNH2), 160.3 (CNH2), 167.0 (CO); LCMS Rt = 2.45 min (1); MS 
(ESI+) m/z 165.06 [M+H]
+
      
 
4,6-Diamino-2-cyclohexylmethoxynicotinitrile (162) 
 
Sodium (0.73 g, 31.2 mmol, 3.2 eq) was added in portions to cyclohexylmethanol (30 
mL, 244 mmol, 24 eq) and the reaction heated to 160 
o
C until the sodium had 
dissolved, the reaction mixture was cooled to 120 
o
C and 2-amino-1-propene-1,1,3-
tricarbonitrile (1.32 g, 10 .0 mmol, 1 eq) added. The temperature was maintained at 
120 
o
C for 48 h before cooling to room temperature. The solvent was removed in 
vacuo. The resulting solid was dissolved in DCM (250 mL) and the precipitate was 
removed by filtration. The filtrate was purified using repeated rounds of medium 
pressure column chromatography (silica, 80% Et2O, PE) followed by (silica, 40% 
EtOAc, PE). The crude product was then purified by semi-preparative HPLC (60:40 
0.1% formic acid in MeCN:0.1 % aqueous formic acid) to give 162 as a off-white 
solid (0.11g, 4%). Rf = 0.8 (6:4 EtOAc:PE); mp = 85.2-86.0 
o
C; UV λmax (EtOH): 
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341.5, 268.0, 223.0 nm; IR ʋmax 3442 (NH), 3327, 3215, 2922, 2849, 2203 (C=N), 
1599, 1552 cm
-1
; δH (500 MHz CDCl3): 0.93-1.21 (5H, m, C6H11), 1.59-1.77 (6H, m, 
C6H11), 3.98 (2H, d, J = 6.6 Hz, OCH2), 4.45 (2H, s, NH2), 4.54 (2H, s, NH2), 5.28 
(1H, s, Ar-H); δC (125 MHz CDCl3): 25.8 (C6H11), 26.5 (C6H11), 29.7 (C6H11), 37.8 
(CCH2O), 71.2 (CCN), 71.7 (OCH2), Ar-H (OCH2), 116.8 (CN), 158.0 (CNH2), 159.5 
(CNH2), 166.3 (CO); LCMS Rt = 3.18 min (1); MS (ESI+) m/z 247.04 [M+H]
+
; 
HRMS m/z: Calc. for C13H19N4O: 247.1553 [M+H]
+
. Found 247.1554 [M+H]
+
.; 
Analytical HPLC: 98.1% purity       
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7.2 MDM2 Experimental Procedures 
 
General Procedure A – Freidel-Crafts Reaction 
 
To the appropriate phthalic anhydride (1 eq) was added chlorobenzene (8 eq) and 
AlCl3 (2.4 eq) under N2. The reaction mixture was heated to 90 
o
C for 2 h before 
cooling to room temperature and quenching with ice. Concentrated HCl (1 mL per 3 
mmol of anhydride) was added and the solution extracted with DCM (3 x 3 mL per 
mmol of anhydride). The combined organic layers were washed using 20 % Na2CO3 
aqueous solution (3 mL per mmol of anhydride). On standing a precipitate formed 
which was collected by filtration, giving the desired 2-(4-chlorobenzoyl) benzoic acid 
as the sodium salt. 
 
General procedure B – Formation of the 2-aryl-3-(4-chlorophenyl)-3-
hydroxyisoindolin-1-one 
 
To the appropriate 2-benzoyl benzoic acid (1 eq) in THF was added thionyl chloride 
(2 eq) followed by DMF (4 drops) under N2. The reaction mixture was stirred at room 
temperature for 4 h before then concentrated in vacuo. The residue was dissolved in 
THF and DIPEA (2.2 eq) and the appropriate benzylamine or benzylamine 
hydrochloride salt (1.1 eq) was added. The reaction mixture was stirred for 16 h at 
room temperature, then the solvent removed in vacuo. The residue was partitioned 
between ethyl acetate (1 mL per 0.1 mmol of benzoyl benzoic acid) and water (1 mL 
per 0.1 mg). The aqueous layer was extracted with ethyl acetate (2 x 1 mL per 0.1 
mmol of benzoyl benzoic acid). The combined organic layers were washed with brine 
(1 mL per 0.1 mmol of benzoyl benzoic acid), dried (MgSO4), filtered and evaporated 
in vacuo. Chromatography (silica, with appropriate solvents) gave the desired 3-
hydroxyisoindolinone. 
 
General procedure C – Synthesis of the alkoxy isoindolinones via 3-chloride 
 
To the appropriate 3-hydroxy isoindolinone (1 eq) in THF was added thionyl chloride 
(2 eq) and DMF (4 drops) under N2 and stirred for 4 h at room temperature, then 
concentrated in vacuo. The residue was dissolved in THF and K2CO3 (2 eq) and the 
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appropriate diol (2 eq) were added and the reaction stirred at room temperature for 16 
h then conentrated in vacuo and the residue partitioned between ethyl acetate (1 mL 
per 0.1 mmol of isoindolinone) and water (1 mL per 0.1 mmol of isoindolinone). The 
aqueous layer extracted using ethyl acetate (2 x 1 mL per 0.1 mmol of isoindolinone). 
The combined organic layers were washed with brine (1 mL per 0.1 mmol of 
isoindolinone), dried over Na2SO4 and evaporated in vacuo. Chromatography (silica, 
appropriate solvents) gave the desired compound. 
 
General procedure D – Synthesis of alkoxy isoindolinone via Lewis acid catalysis 
 
To a solution of the appropriate 3-hydroxyisoindolinone (1 eq) in either DCM (1.5 
mL per 100 mg of isoindolinone) at 0 
o
C was added BF3.OEt2 (2.5 eq) under N2. After 
stirring at 0 
o
C for 15 min, the appropriate diol (10 eq) in DCM (1 mL per 10 mmol of 
diol) was added dropwise to the reaction mixture. After stirring at 0 
o
C for 1.5 h the 
reaction was warmed to room temperature and stirred until the reaction is complete. 
Saturated NH4Cl (10 mL per 1 mmol of isoindolinone) was then added and extracted 
using DCM (3 x 40 mL per mmol of isoindolinone). The combined organic layers 
were dried over Na2SO4 and evaporated in vacuo. Chromatography (silica, 
appropriate solvents) gave the desired compounds. 
 
General procedure E – Formation of alkoxy isoindolinone succinic esters 
 
To a solution of the required 2-(4-aryl)-3-(4-chlorophenyl)-3-((1-(hydroxymethyl) 
cyclopropyl)methoxy)isoindolin-1-one in THF (3 mL per mmol) was added DMAP 
(0.2 eq), pyridine (2 eq) and succinic anhydride (2 eq) and the mixture was heated to 
reflux for 14 h, cooled to room temperature and concentrated in vacuo. The residue 
was partitioned between ethyl acetate (5 mL per and 0.01 mmol) and water (10 mL 
per 0.01 mmol). The aqueous layer was extracted with ethyl acetate (2 x 5 mL per 
0.01 mmol). The combined organic layers were washed with brine (10 mL per 0.01 
mmol), dried over Na2SO4 evaporated in vacuo. Chromatography (silica, appropriate 
solvent) gave the title compound. 
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General procedure F- Sonogashira Reaction 
 
To a solution of the required 3-(4-chlorophenyl)-3-hydroxy-2-(4-
iodobenzyl)isoindolin-1-one (1 eq) in THF (4 mL per mmol) was added Pd(PPh3)2 
(0.03 eq) and CuI (0.02 eq) and the solution degassed for 5 min. Et3N (2.5 eq) and 
appropriate substituted acetylene (1.3 eq) were added and the solution degassed for a 
further 15 min, before stirring overnight in the dark, filtering through Celite and 
washing with MeOH (60 mL per mmol of isoindolinone). Crude product concentrated 
in vacuo and purified (Chromatography, silica, appropriate solvent). 
 
General procedure G – Triisopropylsilyl group deprotection 
 
To 3-(alkoxy)-3-(4-chlorophenyl)-2-(4-((triisopropylsilyl)ethynyl)benzyl)isoindol-1-
one (1 eq) in THF (mL per mmol) was added 1M tetrabutylammonium fluoride in 
THF (1.5 eq) and the reaction stirred at room temperature for 1 h. The solvent was 
removed in vacuo and the crude product purified using chromatography (silica, 
appropriate solvents). 
 
General procedure H – Formation of the oxetane ring 
 
To a solution of 3-(3-bromo-2,2-bis(hydroxymethyl)propoxyisoindolinone (1 eq) in 
ethanol (10 mL per mmol) was added powdered potassium hydroxide (1.5 eq) and the 
reaction mixture stirred at room temperature for 2 h, then heated to reflux for 1 h. The 
reaction mixture was then cooled to room temperature and neutralised using 1 M 
aqueous HCl and concentrated in vacuo. The residue was partitioned between water 
(30 mL per mmol) and EtOAc (100 mL per mmol). The aqueous solution was 
extracted further with EtOAc (2 x mL per mmol) and the combined organic layers 
dried over Na2SO4 and evaporated in vacuo. Chromatography (silica, appropriate 
solvents) gave the desired compound. 
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Sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (238)  
 
General procedure A: 3-chlorophthalic anhydride (5.00 g, 27.00 mmol). White solid 
(7.85 g, 91%). Dried over P2O5 before use. Rf = 0.5 (100 % EtOAc);  mp > 350 
o
C; 
UV λmax (EtOH): 256 nm; IR ʋmax 2163, 1975, 1666 (Acid C=O), 1608 (Ketone C=O), 
1583, 1556 cm
-1
; δH (500 MHz d6-DMSO) 7.40-7.49 (4H, m, 4 x Ar-H), 7.54-7.57 
(2H, m, 2 x Ar-H), 7.87 (1H, dd, J = 1.3 and 7.4 Hz, CHCOOH); δC (125 MHz d6-
DMSO): 128.3, 128.4, 128.9, 129.4, 129.7, 129.8, 136.4, 137.0, 138.9, 141.7 (H
7
), 
167.0 (acid carbonyl), 193.0 (ketone carbonyl); LCMS Rt = 3.18 min, (1); MS (ESI+) 
m/z  295.02 [M+H]
+
  
 
 4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-iodobenzyl)isoindolin-1-one (252) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (846 mg, 2.87 
mmol) and 4-iodobenzylamine hydrochloride (850 mg, 3.15 mmol). Chromatography 
(SP4, silica, 7-60% EtOAc, petrol) gave 252 white solid (523 mg, 36%). Rf = 0.35 
(3:7 EtOAc:PE); mp =  233.7-234.3 
o
C; UV λmax (EtOH): 340.5, 227.5 nm; IR ʋmax 
3194, 2929, 1655 (C=O), 1587 (amide C-N ) cm
-1
; δH (500 MHz, d6-DMSO): 4.20 
(1H, d, J = 15.7 Hz, NCH2), 4.32 (1H, d, J = 15.7 Hz, NCH2), 6.92 (2H, d, J = 8.3 Hz, 
Ar-H), 7.22-7.7.29 (3H, m, Ar-H), 7.43 (1H, s, OH), 7.50 (2H, d, J = 8.3 Hz, Ar-H), 
7.61-7.62 (2H, m,  Ar-H), 7.77 (1H, dd, J = 2.6 and 5.8 Hz, H
7); δC (125 MHz d6-
DMSO): 41.5 (NCH2), 89.8 (Ar-I), 92.4 (hemi-aminal carbon), 121.6, 128.0, 128.4, 
128.6, 130.2, 131.8, 132.8, 133.2, 133.6, 136.5, 136.6, 137.5, 144.3 (CCCl), 165.3 
(carbonyl); LCMS Rt = 3.78 min,(1); MS (ESI+) m/z 510.06 [M+H]
+
; HRMS m/z: 
Calc. for C21H15
35
Cl2INO2: 509.9519 [M+H]
+
. Found 509.9507 [M+H]
+
.       
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3-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-((triisopropylsilyl)ethynyl)benzyl) 
isoindolin-1-one (247) 
 
General procedure F: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-iodobenzyl)-
isoindolin-1-one (500 mg, 0.98 mmol) and triisopropylsilylacetylene (286 µL, 1.27 
mmol). Chromatography (silica, 30% EtOAc, PE) to give 247 as an off-white solid 
(488 mg, 88%). Rf = 0.54 (3:7 EtOAc:PE); mp =  192.6-193.4 
o
C; UV λmax (EtOH): 
266.5, 254.5, 232.0 nm; IR ʋmax 3231, 2942, 2865, 2155 (Ethynyl stretch), 1680 
(C=O), 1587 (Amide C-N) cm
-1
; δH (500 MHz CDCl3): 1.03 (18H, s, CH(CH3)2), 1.18 
(3H, m, CH(CH3)2), 3.35 (1H, s, OH), 3.98 (1H, d, J = 15.1 Hz, NCH2), 4.43 (1H, d, J 
= 15.1 Hz, NCH2), 6.97 (2H, d, J = 8.3 Hz, Ar-H), 7.14-7.16 (6H, m, Ar-H), 7.33-
7.35 (2H, m, Ar-H), 7.57 (1H, dd, J = 3.1 and 5.35, H
7 ); δC (125 MHz CDCl3): 11.3 
(CH(CH3)2), 18.7 (3 x C(CH3)2, 42.6 (NCH2), 90.7 (hemi-aminal carbon), 91.0 
(ethynyl), 106.8 (ethynyl), 122.0 (Ar-ethynyl), 122.4, 128.3, 128.5, 128.6, 129.6, 
131.5, 131.9,  132.9, 134.0, 134.7, 134.9, 137.7, 143.9 (CCCl), 166.3 (carbonyl); 
LCMS Rt = 4.74 min; MS (ESI+) m/z 564.36 [M+H]
+
; HRMS m/z: Calc. for 
C32H36
35
Cl2NO2Si: 564.1887 [M+H]
+
. Found: 564.1884 [M+H]
+
.     
 
4-Chloro-3-(4-chlorophenyl)-3-(((1-hydroxymethyl)cyclopropyl)methoxy)-2-(4-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-2-one (248) 
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General procedure C: 3-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-
((triisopropylsilyl)ethynyl)benzyl)-isoindolin-1-one (308 mg, 0.55 mmol) and 1,1-
bis(hydroxymethyl)cyclopropane (0.11 mL, 1.15 mmol). Chromatography (SP4, 
silica, gradient 7-60% EtOAc, petrol) gave 248 as a colourless oil (85 mg, 24%). Rf = 
0.24 (4:6 EtOAc:PE); UV λmax (EtOH): 340.5, 267.0, 254.5 nm; IR ʋmax 3388, 2940, 
2862, 2157 (Ethynyl stretch), 1682 (C=O), 1588 (Amide C-N) cm
-1
; δH (500 MHz 
CDCl3): 0.15-0.17 (1H, m, cyclopropyl), 0.29-0.31 (1H, m, cyclopropyl), 0.44-0.46 
(2H, m, cyclopropyl), 1.12 (18H, s, CH3), 2.83 (1H, d, J = 9.1 Hz, OCH2), 2.91 (1H, 
d, J = 9.1 Hz, OCH2), 3.44 (1H, d, J = 11.5 Hz, CH2OH), 3.52 (1H, d, J = 11.5 Hz, 
CH2OH), 4.21 (1H, d, J = 15.0 Hz,  NCH2), 4.48 (1H, d, J = 15.0 Hz, NCH2),  7.07 
(2H, d, J = 8.25 Hz, Ar-H), 7.20-7.28 (6H, m, Ar-H), 7.46 (1H, dd, J = 1 and 7.9 Hz, 
H
5
), 7.50-7.53 (2H, Ar-H), 7.81 (1H, dd, J = 1.0 and 7.4 Hz, H
7
); δC (125 MHz 
CDCl3): 8.6 (cyclopropyl), 8.6 (cyclopropyl), 18.7 (CH(CH3)2), 22.1 (cyclopropyl), 
42.7 (NCH2), 67.9 (CH2OH), 68.1 (OCH2), 90.9 (ethynyl), 94.6 (ethynyl), 106.7 
(hemi-aminal carbon), 122.3, 122.6, 128.3, 128.5, 128.9, 129.7, 131.8, 133.9, 134.2, 
134.7, 135.0, 137.2, 140.8, 166.7 (carbonyl); LCMS Rt = 4.78 min, (1); HRMS m/z: 
Calc. for C37H44
35
Cl2NO3Si: 648.2462 [M+H]
+
. Found: 648.2447 [M+H]
+
. 
 
4-Chloro-3-(4-chlorophenyl)-2-(4-ethynylbenzyl)-3-((1-(hydroxymethyl)cyclopropyl) 
methoxy)isoindolin-1-one (253) 
 
To a solution of 4-chloro-3-(4-chlorophenyl)-3-(((1-hydroxymethyl)cyclopropyl) 
methoxy)-2-(4-((triisopropylsilyl)ethynyl)benzyl)isoindolin-2-one (99 mg, 0.15 
mmol, 1 eq) in THF (2 mL) was added 1M TBAF in THF (0.23 mL, 0.23 mmol, 1.5 
eq). The reaction was stirred at for 75 min, concentrated in vacuo. Chromatography 
(silica, EtOAc:PE), followed by semi-preparative HPLC (1:1 MeCN: 0.1% aqueous 
formic acid) gave 253 as a colourless oil (30 mg, 41%). Rf = 0.44 (1:1 EtOAc:PE); 
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UV λmax (EtOH): 229.5 nm; IR ʋmax 3438 (OH), 3296, 2924, 2874, 1693 (C=O), 1588 
(Amide C-N) cm
-1
; δH (500 MHz, CDCl3) 0.05-0.11 (1H, m, cyclopropyl), 0.24-0.30 
(1H, m, cyclopropyl), 0.40-0.44 (2H, m, cyclopropyl), 1.67 (1H, s, OH), 2.79 (1H, d, 
J = 9.1 Hz, OCH2), 2.90 (1H, d, J = 9.1 Hz, OCH2) 3.04 (1H, s, CCH), 3.40 (1H, d, J  
= 11.4 Hz , CH2OH) 3.50 (1H, d, J = 11.4 Hz, CH2OH), 4.16 (2H, d, J = 15.0 Hz, 
NCH2), 4.50 (1H, d, J = 15.0 Hz, NCH2), 7.11-7.30 (8H, m, Ar-H) 7.44-7.52 (2H, m, 
Ar-H), 7.85 (1H, dd, J = 0.65 and 7.3 Hz, H
7
); δC (125 MHz, CDCl3): 8.5, 
(cyclopropyl) 8.5 (cyclopropyl), 22.1 (cyclopropyl), 42.7 (NCH2), 67.9 (OCH2), 68.1 
(CH2OH), 83.3 (ethynyl CH), 94.7 (hemi-aminal carbon),121.2 (C-ethynyl), 122.3, 
128.3, 128.5, 129.0, 129.7, 131.9, 133.0, 134.0, 134.1, 134.7, 135.0, 137.9, 140.7, 
166.7 (carbonyl carbon); LCMS Rt = 3.71 min, (1); MS (ESI+) m/z 492.24 [M+H]
+
;
 
HRMS m/z: Calc. for C28H24
35
Cl2NO3: 492.1128 [M+H]
+
. Found: 492.1124 [M+H]
+
.; 
Analytical HPLC: 99.9% purity 
 
Chiral Separation: mobile phase hexane:ethanol 92.5:7.5 
254 Peak 1: (33.8 mg, 42%); Specific rotation [α] = -9.16 o (at 21.0 oC, wavelength = 
589 nm, tube length = 0.1 dm, concentration = 0.328 g per 100 mL);  
255 Peak 2: (33.8 mg, 42%); Specific rotation [α] = +11.4 o (at 21.0 oC, wavelength = 
589 nm, tube length = 0.1 dm, concentration = 0.336 g per 100 mL) 
 
4-Chloro-3-(4-chlorophenyl)-3-(((1-methoxy(succinic ester))cyclopropyl)methyoxy)-
2-(((4-triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (256) 
 
General procedure E: 4-chloro-3-(4-chlorophenyl)-3-(((1-hydroxymethyl) 
cyclopropyl)methoxy)-2-(4-((triisopropylsilyl)ethynyl)benzyl)isoindolin-2-one (248) 
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(84 mg, 0.13 mmol). Chromatography (silica, 50-85 % EtOAc, petrol) gave 256 as a 
pale yellow oil (92 mg, 94%). Rf = 0.15 (85:15 EtOAc:PE); UV λmax (EtOH): 266.5, 
254.5 nm; IR ʋmax 2942, 2865, 2158 (Ethynyl stretch), 1708 (Carboxylic acid C=O), 
1608 (Amide C=O), 1582 (Amide C-N), 1556 cm
-1
; 
 δH (500 MHz CDCl3) 0.18-0.20 
(1H, m, cyclopropyl), 0.29-0.36 (1H, m, cyclopropyl), 0.47-0.52 (2H, m, 
cyclopropyl), 1.11 (18H, s, CH3), 1.24-1.27 (3H, m,  CH(CH3)2), 2.55-2.64 (4H, m, 
succinic ester CH2), 2.71 (1H, d, J = 9.3 Hz, OCH2), 2.86 (1H, d, J = 9.3 Hz, OCH2), 
3.93 (1H, d, J = 11.4 Hz, CH2OH), 4.21 (1H, d, J = 11.4 Hz, CH2OH), 4.29 (1H, d, J 
=15.0 Hz, NCH2), 4.35 (1H, d, J =15.0 Hz, NCH2), 7.00 (2H, d, J = 8.2 Hz, Ar-H), 
7.15-7.23 (6H, m, Ar-H), 7.43 (1H, dd, J = 1.0 and 8.0 Hz, H
5
), 7.48-7.51 (1H, m, 
H
6
), 7.84 (1H, dd, J = 1.0 and 7.4 Hz, H
7
); δC (125 MHz CDCl3): 8.9 (cyclopropyl), 
11.3 (cyclopropyl), 18.7 (CH(CH3)2), 19.4 (CH(CH3)2), 28.8 (CH2CO2H), 28.9 
(COCH2), 42.6 (NCH2), 66.5 ( OCH2), 68.4 (CH2OH),  90.8 (ethynyl), 94.4 (ethynyl), 
106.8 (hemi-aminal), 122.2 (Ar-ethynyl), 122.5, 128.3, 128.4, 128.9, 129.9, 131.7, 
131.8, 133.8, 134.1, 134.6, 134.8, 137.1, 140.8, 167.0 (isoindolinone carbonyl), 172.1 
(succinic ester carbonyl), 177.2 (succinic acid carbonyl) 
 
4-Chloro-3-(4-chlorophenyl)-2-(4-ethynylbenzyl)-3-(((1-methoxy(succinic 
ester))cyclopropyl)methoxy)isoindolin-1-one (257) 
 
To 4-chloro-3-(4-chlorophenyl)-3-(((1-methoxy(succinic ester))cyclopropyl) 
methyoxy)-2-(((4-triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (81 mg, 0.11 mol) 
in THF (2 mL) was added 1M TBAF in THF (162 µL, 0.16 mmol). The reaction was 
stirred for 165 min and concentrated in vacuo. Chromatography (SP4, silica, 3-20% 
MeOH, EtOAc) to give 257 as a colourless oil (53 mg, 81%). Rf = 0.56 (1:9 
MeOH:EtOAc); UV λmax (EtOH): 228.5 nm; IR ʋmax 3295, 2927, 1706 (Carboxylic 
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acid C=O), 1588 (Amide C-N) cm
-1
; δH (500 MHz CDCl3): 0.20-0.22 (1H, m, 
cyclopropyl), 0.36-0.39 (1H, m, cyclopropyl), 0.50-0.53 (2H, m, cyclopropyl), 2.57-
2.64 (4H, m, succinic 2 x CH2), 2.80 (1H, d, J = 9.3 Hz, OCH2), 2.84 (1H, d, J = 9.3 
Hz, OCH2), 3.04 (1H, s, ethynyl), 4.00 (1H, d, J = 11.5 Hz, CH2OH), 4.16 (1H, d, J = 
11.5 Hz, CH2OH), 4.32 (1H, d, J = 15.0 Hz, NCH2), 4.39 (1H, d, J = 15.0 Hz, NCH2), 
7.06 (2H, d, J = 8.3 Hz, Ar-H), 7.18-7.28 (6H, m, Ar-H), 7.45 (1H, dd, J = 1.0 and 8.0 
Hz, H
5
), 7.49-7.52 (1H, m, H
6
), 7.86 (1H, dd, J = 1.0 and 7.4 Hz, H
7
); δC (125 MHz 
CDCl3): 8.9 (cyclopropyl), 8.9 (cyclopropyl), 19.4 (cyclopropyl), 28.8 (CH2CO2H), 
29.0 (COCH2), 42.6 (NCH2), 66.5 (OCH2), 68.4 (CH2O), 83.3 (ethynyl), 94.5 
(ethynyl), 121.2 (Ar-ethynyl), 122.2, 128.3, 128.4, 129.0, 131.0, 131.9, 133.8, 134.2, 
134.7, 134.9, 137.7, 140.8, 167.0 (isoindolinone CO), 172.0 (succinic ester carbonyl), 
176.0 (succinic acid carbonyl); LCMS Rt = 3.67 min, (1);  MS (ESI+) m/z  592.11 
[M+H]
+
 HRMS m/z: Calc. for C32H28
35
Cl2NO6: 592.1288 [M+H]
+
. Found: 592.1290 
[M+H]
+
.; Analytical HPLC: 95.8% purity 
  
4-((Trifluoromethyl)sulfonyl)benzylamine hydrochloride (265) 
 
To 4-((trifluoromethyl)sulfonyl)benzonitrile (400 mg, 1.70 mmol, 1 eq) in THF was 
added 1M BH3.THF complex in THF (13.6 mL, 13.60 mmol, 8 eq) and the reaction 
mixture stirred at room temperature for 1 h then heated to reflux for 4 days before 
cooling to room temperature. A 1:1 mixture of water (5 mL) and acetic acid (5 mL) 
was added slowly and stirred at room temperature for 15 min, then concentrated in 
vacuo. The resulting white solid was suspended in water (10 mL) cooled in an ice-
bath, the pH was adjusted to 8 with a saturated sodium bicarbonate solution then 
extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried 
(MgSO4), and concentrated in vacuo. Chromatography (SP4, silica, 3- 20% MeOH, 
EtOAc). The resulting yellow oil was redissolved in the minimum amount of 
methanol and 1M HCl (5 mL) added, then evaporated in vacuo to give 265 as a white 
solid (240 mg, 51%) and dried (P2O5). Rf = 0.14 (1:9 MeOH:EtOAc) mp. = 278.1-
278.8 
o
C; UV λmax (EtOH): 271.0 nm; IR ʋmax 2860, 2162, 1361 (Sulfone), 661 (C-F) 
cm
-1
; δH (500 MHz d6-DMSO): 4.26 (2H, s, CH2), 7.97 (2H, d, J = 8.5 Hz, Ar-H), 
8.24 (2H, d, J = 8.5 Hz, Ar-H), 8.68 (3H, s, NH3); δC (125 MHz d6-DMSO): 41.2 
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(CH2), 120.7, 129.2, 130.9, 131.0, 144.6; δF (470 MHz d6-DMSO): -78.4; LCMS Rt = 
0.44 min, (1); MS (ESI+) m/z 239.99 [M+H]
+
     
 
4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(((4-trifluoromethyl)sulfonyl)benzyl) 
isoindolin-1-one (263) 
 
 General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (156 mg, 0.49 
mmol) and 4-((trifluoromethyl)sulfonyl)benzylamine hydrochloride. Chromatography 
(SP4, silica, 12-100% EtOAc, petrol) to give 263 as an off-white solid (90 mg, 35%). 
Rf = 0.7 (1:1 EtOAc:PE); mp = 228.3-229.1 
o
C; UV λmax (EtOH): 340.5 nm; IR ʋmax 
3269 (OH), 1682 (C=O), 1590 (Amide C-N), 1363 (sulfone) cm
-1
; δH (500 MHz 
CDCl3): 3.05 (1H, s, OH), 4.32 (1H, d, J = 15.5 Hz, NCH2), 4.59 (1H, d, J = 15.5 Hz, 
NCH2), 7.13-7.14 (4H, m, Ar-H), 7.39-7.45 (4H, m, Ar-H), 7.73-7.76 (3H, m, Ar-H); 
δC (125 MHz d6-DMSO): 41.4 (NCH2), 89.6 (hemi-aminal) 121.8, 123.2, 127.5, 
127.9, 128.4, 128.7, 129.7, 130.3, 131.9, 132.8, 133.0, 133.8, 136.4, 144.2, 148.6, 
165.5 (C=O); δF (470 MHz d3-MeCN): -78.4; LCMS Rt = 3.74 min, (1);  MS (ESI+) 
m/z 516.04 [M+H]
+
; HRMS m/z: Calc. for C22H14
35
Cl2F3NO4S: 514.9967 [M+H]
+
. 
Found: 514.9962 [M+H]
+
.  
 
4-Chloro-3-(4-chlorophenyl)-3-(1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-
((trifluoromethyl)sulfonyl)benzyl)isoindolin-one (246) 
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General procedure C: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(((4-
trifluoromethyl)sulfonyl)benzyl)isoindolin-1-one 252 (162 mg, 0.31 mmol) and 1,1-
bis(hydroxymethyl)cyclopropane (0.06 mL, mmol). Chromatography (SP4, silica, 12-
100 % EtOAc, petrol) gave 246 as a colourless oil (55 mg, 29%). Rf = 0.34 (1:1 
EtOAc:PE); UV λmax (EtOH): 225.5 nm; IR ʋmax 3457 (OH), 2925, 2877, 1703 (C=O), 
1597 (Amide C-N), 1364 (Sulfone), 1194 (CF3), 1139 cm
-1
; δH (500 MHz d3-MeCN): 
0.04-0.06 (1H, m, cyclopropyl), 0.13-0.16 (1H, m, cyclopropyl), 0.19-0.23 (2H, m, 
cyclopropyl), 2.36 (1H, t, J = 5.5 Hz, OH), 2.56 (1H, d, J = 9.1 Hz, OCH2), 2.89 (1H, 
d, J = 9.1 Hz  OCH2), 3.23 (1H, dd, J = 5.0 and 11.2 Hz, CH2OH),  3.34 (1H, dd, J = 
5.0 and 11.2 Hz, CH2OH), 4.14 (1H, d, J = 15.9 Hz, NCH2), 4.57 (1H, d, J = 15.9 Hz, 
NCH2), 6.86-6.97 (4H, m, Ar-H), 7.19 (2H, d, J = 8.0 Hz,  Ar-H), 7.35 (1H, dd, J = 
1.1 and 8.0 Hz, H
5
), 7.39-7.42 (1H, m, H
6
), 7.55 (2H, d, J = 8.5 Hz, Ar-H), 7.63 (1H, 
dd, J = 1.1 and 7.4 Hz, H
7
); δC (125 MHz d3-MeCN): 7.3 (cyclopropyl, 7.4 
(cyclopropyl), 21.6 (cyclopropyl), 41.2 (NCH2), 64.9 (CH2OH) 66.1 (OCH2), 93.2 
(hemi-aminal C), 120.7, 121.7, 127.6, 128.3, 128.4, 129.3, 129.8, 130.1, 132.0, 133.6, 
133.6, 133.9, 135.5, 140.3, 147.6 (CF3), 166.1 (C=O); δF (470 MHz d3-MeCN) -93.9; 
LCMS Rt = 3.78 min, (1); HRMS m/z: Calc. for C27H25
35
Cl2F3N2O5S: 617.0886 
[M+NH4]
+
.
 
Found: 617.0884 [M + NH4]
+
.; Analytical HPLC: 96.7% purity 
 
3-(4-Chlorophenyl)-2-(4-((trifluoromethyl)sulfonyl)benzyl)isoindolin-1-one (262) 
 
General procedure B: 2-(4-chloro-benzoyl)benzoic acid (56 mg, 0.21 mmol) and 4-
((trifluoromethyl)sulfonyl)benzylamine hydrochloride (65 mg, 0.24 mmol). 
Chromatography (SP4, silica, 15-100 % EtOAc, petrol) gave the title compound as a 
white solid (88 mg, 87%). Rf = 0.55 (1:1 EtOAc:PE);  mp = 208.8-209.2 
o
C; UV λmax 
(EtOH): 340.5 nm; IR ʋmax 2393, 1655 (C=O), 1598 (Amide C-N), 1365 (Sulfone) 
cm
-1
; δH (500 MHz d6-DMSO): 4.52 (1H, d, J = 16.4 Hz, NCH2), 4.63 (1H, d, J = 
16.4 Hz, NCH2), 7.23-7.27 (4H, m, Ar-H), 7.31 (1H, d, J = 7.2 Hz, Ar-H), 7.41 (1H, 
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s, OH), 7.57-7.64 (4H, m, Ar-H), 7.81 (1H, dd, J = 0.7 and 6.8 Hz, Ar-H), 7.93 (2H, 
d, J = 8.4 Hz, H
7); δC (125 MHz d6-DMSO): 41.8 (NCH2), 90.0 (hemi-aminal 
carbon), 122.8, 122.9, 127.4, 128.0, 128.2, 129.6, 129.8, 129.9, 130.4, 132.8, 133.1, 
138.5, 148.9, 149.0, 166.9 (carbonyl); δF (470 MHz, d6-DMSO) -78.6; LCMS Rt = 
3.64 min, (1); MS (ESI+) m/z 482.11 [M+H]
+
; HRMS m/z: Calc. for 
C22H16
35
ClF3NO4S: 482.0435 [M+H]
+
. Found: 482.0431 [M+H]
+
. 
 
3-(4-Chlorophenyl)-3-(1-((hydromethyl)cyclopropyl)methoxy)-2-(((trifluoromethyl) 
sulfonyl)benzyl)isoindolin-1-one (245) 
 
General procedure D: 3-(4-chlorophenyl)-2-(4-((trifluoromethyl)sulfonyl) 
benzyl)isoindolin-1-one (209 mg, 0.43 mmol) and 1,1-bis(hydroxymethyl) 
cyclopropyl (0.27 mL, 4.34 mmol). The reaction was quenched after 1.5 h at 0 
o
C and 
1 h at room temperature. Chromatography (SP4, silica, 15-100% EtOAc, petrol) gave 
245 as a colourless oil (151 mg, 62%). Rf = 0.43 (1:1 EtOAc:PE); UV λmax (EtOH): 
203.0 nm; IR ʋmax 3408 (OH), 2159, 1698 (C=O), 1597 (Amide C-N), 1364 (Sulfone), 
1216 (CF3), 1191 cm
-1
; δH (500 MHz d3-MeCN): 0.15-0.18 (1H, m, cyclopropyl), 
0.20-0.23 (1H, cyclopropyl), 0.36-0.38 (2H, m, cyclopropyl), 2.56 (1H, t, J = 5.7 Hz, 
OH), 2.82 (1H, d, J = 9.3 Hz, OCH2), 2.87 (1H, d, J = 9.3 Hz, OCH2), 3.41 (1H, dd, J 
= 6.2 and 11.2 Hz, CH2OH), 3.47 (1H, dd, J = 6.2 Hz and 11.2 Hz, CH2OH), 4.43 
(1H, d, J = 15.8 Hz, NCH2), 4.72 (1H, d, J = 15.8 Hz, NCH2), 7.10 (2H, d, J = 8.9 Hz, 
Ar-H), 7.18-7.20 (3H, m, Ar-H), 7.46 (2H, d, J = 8.6 Hz, Ar-H), 7.59-7.61 (2H, m  
Ar-H), 7.79 (2H, d, J = 8.4 Hz, Ar-H), 7.86-7.88 (1H, m, H
7) δC (125 MHz d3-
MeCN): 7.3, 7.3 (cyclopropyl), 21.6 (cyclopropyl), 41.4 (NCH2), 64.9 (CH2OH), 65.7 
(OCH2), 93.5 (hemi-aminal carbon), 122.9, 123.0, 127.8, 128.0, 128.5, 129.9, 130.1, 
133.5, 137.3, 144.8, 148.0 (CCCl), 167.5 (carbonyl); δF (470 MHz d3-MeCN): -79.8; 
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LCMS Rt = 3.69 min, (1); HRMS m/z: Calc. for C27H27
35
Cl2 F3N2O5S: 583.1261 
[M+NH4]
+
. Found: 583.1276 [M + NH4]
+
. ; Analytical HPLC: 99.6% purity 
 
4-Chloro-3-(4-chlorophenyl)-2-(3,4-difluorobenzyl)-3-hydroxyisoindolinone (268) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (750 mg, 2.37 
mmol) and 3,4-difluorobenzylamine (618 µL, 5.22 mmol). Chromatography (SP4, 
silica, 7-60% EtOAc, PE) gave 268 as a white solid (390 mg, 39%). Rf  = 0.45 (3:7 
EtOAc:PE); mp = 147.3-149.1 
o
C; UV λmax (EtOH): 210.0 nm; IR ʋmax 3244 (OH), 
2162, 1686 (C=O), 1588 (amideC-N), 1278 (C-F), 815, 757 (C-Cl) cm
-1
; δH (500 
MHz CDCl3): 3.83 (1H, s, OH), 4.03 (1H, d, J = 14.7 Hz, NCH2), 4.33 91H, d, J = 
14.7 Hz, NCH2), 6.71-6.74 (1H, m, benzyl Ar-H), 6.83 (1H, ap. dt, J = 8.2 and 10.2 
Hz, benzyl Ar-H), 6.88 (1H, ddd, J = 2.1, 7.7 and 11.0 Hz, benzyl Ar-H), 7.15-7.19 
(4H, m, Ar-H), 7.36-7.36 (2H, m, H
5
 and H
6
), 7.58-7.60 (1H, m, H
7); δC (125 MHz 
CDCl3): 41.9 (NCH2), 90.8 (hemi-aminal), 116.8 (d, J = 17.1 Hz, benzyl Ar-H), 117.7 
(d, J = 17.3 Hz, benzyl Ar-H), 122.0, 124.8 (dd, J = 3.6 and 6.4 Hz, benzyl Ar-H), 
128.2, 128.5, 129.7, 131.6, 134.1, 134.4 (dd, J = 4.0 and 5.3 Hz, benzyl Ar-H), 134.8, 
134.9, 143.8, 148.7 (dd, J = 12.6 and 34.7 Hz, benzyl Ar-H), 150.7 (dd, J = 12.6 and 
35.1 Hz, benzyl Ar-H), 166.3 (C=O); δF (470 MHz CDCl3) -139.7 (d, J = 20.7 Hz), -
137.7 (d, J = 21.1Hz); LCMS Rt = 1.63 min, (4); MS (ESI+) m/z 420.2 [M+H]
+
; 
HRMS m/z: Calc. for C21H13
35
Cl2F2NO2: 420.03.64 [M+H]
+
.
 
Found 420.0365 
[M+H]
+
.      
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4-Chloro-3-(4-chlorophenyl)-2-(3,4-difluorobenzyl)-3-((1-
(hydroxymethyl)cyclopropane)methoxy)isoindolin-1-one (269) 
 
General procedure C: 4-Chloro-3-(4-chlorophenyl)-2-(3,4-difluorobenzyl)-3-
hydroxyisoindolinone (210 mg, 0.50 mmol) and 1,1-bis(hydroxymethyl)cyclopropane 
(0.1 mL, 1.00 mmol). Chromatography (SP4, silica, 10-80% EtOAc, PE) gave 269 as 
a colourless oil (59 mg, 23%). Rf  = 0.24 (4:6 EtOAc:PE); UV λmax (EtOH):  232.0, 
258.0 nm; IR ʋmax 2925, 1694 (C=O), 1516 (Amide C-N), 1280 (C-F) cm
-1
; δH (500 
MHz CDCl3): 0.17-0.20 (1H, m, cyclopropyl), 0.32-0.35 (1H, m, cyclopropyl), 0.45-
0.51 (2H, m, cyclopropyl), 1.78 (1H, s, OH), 2.86 (1H, d, J = 9.2 Hz, OCH2), 2.92 
(1H, d, J = 9.2 Hz, OCH2), 3.49 (1H, d, J = 11.4 Hz, CH2OH), 3.56 (1H, d, J = 11.4 
Hz, CH2OH), 4.28 (1H, d, J = 15.0 Hz, NCH2), 4.34 (1H, d, J = 15.0 Hz, NCH2), 
6.79-6.82 (1H, m, Benzyl Ar-H), 6.91 (1H, ap. dt, J =  8.3 and 10.2 Hz, benzyl Ar-H), 
6.97 (1H, ddd, J = 2.1, 7.6 and 10.7, benzyl Ar-H), 7.18-7.19 (4H, m, Ar-H), 7.45 
(1H, dd, J = 1.0 and 8.0 Hz, H
5
), 7.49-7.52 (1H, m, H
6
), 7.84 (1H, d, J = 1.0 and 7.4, 
H
7
); δC (125 MHz CDCl3): 8.6 (cyclopropyl), 8.6 (cyclopropyl), 22.2 (cyclopropyl), 
41.9 (NCH2) 67.7 (CH2OH), 68.0 (OCH2), 94.4 (hemi-aminal), 116.8 (d, J = 17.1 Hz, 
benzyl Ar-H), 118.1 (d, J = 17.3, benzyl Ar-H), 122.3, 125.1 (dd, J = 3.6 and 6.2, 
benzyl Ar-H), 128.3, 128.4, 129.8, 131.9, 134.0, 134.8, 135.0, 140.7, 148.8 (dd, J = 
6.4 and 21.0, benzyl Ar-F), 150.7 (dd, J = 12.7 and 21.3, benzyl Ar-H), 166.7 (C=O); 
δF (470 MHz CDCl3) -138.88 (d, J = 21.9), -137.62 (d, J = 21.9); LCMS Rt =1.66 
min, (3); HRMS m/z: Calc. for C26H22
35
Cl2F2NO3: 504.0939 [M+H]
+
. Found: 
504.0937 [M+H]
+
.; Analytical HPLC: 98.3% purity 
 
 
 
 
 
7. MDM2/p53 Experimental Procedures 
 
271 
 
4-Chloro-3-fluorobenzylamine (271) 
 
To a solution of 4-chloro-3-fluorobenzonitrile (500 mg, 3.21 mmol, 1 eq) in THF (1 
mL) was added 1M BH3.THF in THF (13 mL, 12.9 mmol, 4 eq) and the mixture 
stirred at room temperature for 15 min then heated to reflux for 16 h, cooled, and 
diluted by dropwise addition of a 1:1 solution of AcOH (10 mL) and water (10 mL). 
stirred at RT for 15 min, concentrated in vacuo. The residue was cooled in an ice-bath 
and basified to pH 9 by sat. NaHCO3, then extracted using EtOAc (3 x 50 mL). 
Combined organic extracts were washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo. Chromatography (SP4, amino silica, 50-100% EtOAc, PE) 
gave 271 as a white solid (321 mg, 63%). Rf  = 0.71 (1:4 EtOAc:PE, amino silica); mp 
= 93.5-95.9 
o
C; UV λmax (EtOH): 253.5, 217.0 nm; IR ʋmax 3295 (N-H), 2491, 2172, 
1231 (C-F) cm
-1
; δH (500 MHz CDCl3): 1.48 (2H, s, NH2), 3.86 (2H, s, CH2), 7.04 
(1H, d, J = 8.0 Hz, CHCF ), 7.14 (1H, d, J = 10.0 Hz, CHCCl), 7.34 (1H, ap. t, J = 8.0 
Hz, Ar-H); δC (125 MHz CDCl3): 45.2 (CH2), 115.2 (d, J = 20.9 Hz, CHCF), 119.0 
(d, J = 17.5 Hz, CCl), 123.3 (d, J = 14.1 Hz, Ar-H), 130.5 (CHCCl), 144.1 (CCH2), 
158.2 (d, J = 227.2 Hz, CF); 
1δF (470 MHz CDCl3): -115.6; LCMS (Rt = 0.81 min, 
(3); MS (ESI+) m/z 160.1 [M+H]
+
; HRMS m/z: Calc. for C7H8
35
ClFN: 160.0324 
[M+H]
+
. Found 160.0320 [M+H]
+
.        
 
4-Chloro-2-(4-chloro-3-fluorobenzyl)-3-(4-chlorophenyl)-3-hydroxyisoindolinone 
(273) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (1.06 g, 3.34 
mmol) and 4-chloro-3-fluorobenzylamine (587 mg, 3.63 mmol). Chromatography 
(SP4, silica, 7-60 % EtOAc, PE) gave 273 as a white solid (538 mg, 37%). Rf  = 0.39 
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(3:7 EtOAc:PE); mp = 184.7-187.0 
o
C; UV λmax (EtOH): 231.0 nm; IR ʋmax 3217, 
2158, 2028, 1683 (C=O), 1586 (amide C-N), 1093 (C-F), 814, 757 (C-Cl) cm
-1
; δH 
(500 MHz CDCl3): 3.44 (1H, s, OH), 4.03 (1H, d, J = 15.2 Hz, NCH2), 4.42 (1H, d, J 
= 15.2 Hz, NCH2), 6.79 (1H, d , J = 7.9 Hz, CHCF), 6.88 (1H, d, J = 9.8 Hz, CHCCl), 
7.09 (1H, ap. t, J = 7.9 Hz, benzyl Ar-H), 7.17-7.18 (4H, m, Ar-H), 7.37-7.40 (2H, m, 
H
5
 and H
6
), 7.64 (1H, dd, J = 2.4 and 5.8 Hz, H
7); δC (125 MHz CDCl3): 42.0 
(NCH2), 90.8 (hemi-aminal), 116.9 (d, J = 21.4 Hz, CHCF), 119.8 (d, J = 17.6Hz, 
CCl), 122.1, 125.1 (d, J = 3.6 Hz, benzyl Ar-H), 128.2, 128.6, 129.7, 130.2, 131.7, 
132.8, 134.1, 134.9 (d, J = 20.6 Hz, CHCCl), 138.4 (d, J = 25.8 Hz, CCH2), 143.7, 
157.7 (d, J = 247.4 Hz, CF), 166.2 (C=O); δF (470 MHz CDCl3): -115.3; LCMS Rt = 
1.68 min, (4); MS (ESI+) m/z 436.2 [M+H]
+
; HRMS m/z: Calc. for C21H14
35
Cl3FNO3: 
436.0069 [M+H]
+
. Found 436.0068 [M+H]
+
. 
 
4-Chloro-2-(4-chloro-3-fluorobenzyl)-3-(4-chlorophenyl)-3-((1-(hydroxymethyl) 
cyclopropyl)methoxy)isoindolin-1-one (274) 
 
General procedure C: 4-chloro-2-(4-chloro-3-fluorobenzyl)-3-(4-chlorophenyl)-3-
hydroxyisoindolinone (501 mg, 1.15 mmol) and 1,1-bis(hydroxymethyl)cyclopropane  
(0.22 mL, 2.29 mmol). Chromatography (SP4, silica,7-60% EtOAc, PE) followed by 
(SP4, C60, 40-100% 0.1% HCOOH in MeCN, 0.1% HCOOH in water) to give 274 as 
a white oily solid (107 mg, 18%). Rf  = 0.25 (3:7 EtOAc:PE); UV λmax (EtOH): 224.0 
nm; IR ʋmax 3375 (OH), 2925, 2361, 1694 (C=O), 1585 (Amide C-N), 1489, 1063 (C-
F) cm
-1
; δH (500 MHz CDCl3): 0.17-0.20 (1H, m, cyclopropyl), 0.32-0.35 (1H, m, 
cyclopropyl), 0.45-0.51 (2H, m, cyclopropyl), 1.66 (1H, s, OH), 2.86 (1H, d, J = 9.1 
Hz, OCH2), 2.92 (1H, d, J = 9.1 Hz, OCH2), 3.48 (1H, d, J = 11.1 Hz, CH2OH), 3.56 
(1H, d, J = 11.1 Hz, CH2OH), 3.21 (1H, d, J = 15.0 Hz, NCH2), 4.36 (1H, d, J = 15.1, 
NCH2), 6.83 (1H, d, J = 8.2 Hz, Benzyl Ar-H), 6.93 (1H, dd, J = 1.7 and 9.8 Hz, 
benzyl Ar-H), 7.14-7.20 (5H, m, Ar-H), 7.47 (1H, d, J = 7.9 Hz, H
5
), 7.50-7.53 (1H, 
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m, H
6
), 7.85 (1H, d, J = 7.4 Hz, H
7
); δC (125 MHz CDCl3):  8.5 (cyclopropyl), 8.6 
(cyclopropyl), 22.1 (cyclopropyl), 41.9 (NCH2), 67.7 (CH2OH), 67.9 (OCH2), 94.4 
(hemi-aminal), 117.3 (d, J = 21.2 Hz, CHCF), 120.0 (d, J = 17.5 Hz, CCl), 122.3, 
125.4 (d, J = 3.6 Hz, benzyl Ar), 128.3, 128.5, 130.0, 130.2, 132.0, 134.0, 134.0, 
134.9 (d, J = 10.2 Hz, benzyl Ar), 137.8 (d, J = 6.4 Hz, benzyl Ar), 140.6, 157.6 (d, J 
= 247.9 Hz, C-F), 166.7 C=O); δF (470 MHz CDCl3): -115.2; LCMS Rt = 1.74 min, 
(3); MS (ESI+) m/z 520.3 [M+H]
+
; HRMS m/z: Calc. for C26H22
35
Cl3FNO3: 520.0644 
[M+H]
+
. Found 520.0643 [M+H]
+
.; Analytical HPLC: 97.7% purity 
 
4-Bromo-3-fluorobenzylamine (278) 
 
To a solution of 4-bromo-3-benzonitrile (500 mg, 2.50 mmol, 1eq), in THF (1 mL) 
was added 1M BH3.THF in THF (10 mL, 10.0 mmol, 4 eq) and the reaction was 
stirred at RT for 20 min then heated to reflux for 14 h, cooled, and a 1:1 solution of 
AcOH(10 mL) and water (10 mL) was added dropwise with stirring for 15 min, 
concentrated in vacuo. The resulting solid was cooled in an ice-bath, suspended in 
water (10 mL) and basified to pH 9 with sat. NaHCO3 solution, and extracted using 
EtOAc (3 x 70 mL). The combined organic extracts were washed with brine (50 mL), 
dried over MgSO4 and concentrated in vacuo. Chromatography (SP4, amino silica, 
60-100% EtOAc, PE) gave 278 as a white solid (432 mg, 84%). Rf  = 0.87 (7:3 
EtOAc:PE, amino silica); mp = 90.8-93.0 
o
C; UV λmax (EtOH): 256.0 nm; IR ʋmax 
3297 (N-H), 2873, 1574, 1237 (C-F) cm
-1
; δH (500 MHz CDCl3): 1.48 (2H, s, NH2), 
3.85 (2H, s, CH2), 6.99 (1H, d, J = 8.1 Hz, CHCF), 7.12 (1H, d, J = 9.5 Hz, Ar-H), 
7.48 (1H, s, ap. t, J = 7.6 Hz, Ar-H); δC (125 MHz CDCl3): 45.5 (CH2), 115.1 (d, J = 
22.1 Hz, CHCF), 123.8 (d, J = 13.1 Hz, CHCCH2), 133.4 (CHCBr), 145.2 (CCH2), 
159.2 (d, J = 248.7, CF); LCMS Rt = 0.31 min, (1) ; MS (ESI+) m/z 203.8 [M+H]
+
; 
HRMS m/z: Calc. for C7H8
79
BrFN: 203.9819 [M+H]
+
. Found: 203.9822 [M+H]
+
. 
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2-(4-Bromo-3-fluorobenzyl)-4-chloro-3-(4-chlorophenyl)-3-hydroxyisoindolinone 
(279) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (989 mg, 3.12 
mmol) and 4-bromo-3-fluorobenzylamine (700 mg, 3.43 mmol). Chromatography 
(SP4, silica, 7-60% EtOAc, PE) gave 279 as an off-white solid (765 mg, 51%). Rf  = 
0.43 (3:7 EtOAc:PE); mp = 192.4-195.1 
o
C; UV λmax (EtOH): 230.0 nm; IR ʋmax 3236 
(O-H), 2157, 1685 (C=O), 1587 (Amide C-N), 1400, 1093 (C-F), 818, 756 (C-Cl) cm
-
1
; δH (500 MHz CDCl3): 3.08 (1H, s, OH), 4.03 (1H, d, J = 15.2 Hz, NCH2), 4.46 (1H, 
d, J = 15.2 Hz, NCH2), 6.77 (1H, dd, J = 1.8 and 4.1 Hz, benzyl Ar-H), 6.89 (1H, dd, 
J = 1.8 and 9.4 Hz, CHCF), 7.18-7.19 (4H, m, Ar-H), 7.26 (1H, dd, J = 7.3 and 8.1 
Hz, CHCBr), 7.37-7.42 (2H, m, H
5
 and H
6
), 7.68 (1H, dd, J = 1.7 and 6.7 Hz, H
7); δC 
(125 MHz CDCl3): 42.0 (NCH2), 90.8 (hemi-aminal), 107.8 (d, J = 20.8 Hz, C-Br), 
116.8 (d, J = 22.5 Hz, CHCF), 122.2, 125.5 (d, J = 3.5 Hz, benzyl Ar-H), 128.2, 
128.6, 129.6,  131.8, 132.8, 133.2, 134.2, 134.9 (d, J = 26.7 Hz, CHCBr), 139.3 (d, J 
= 6.6 Hz, benzyl CH2C) , 143.6, 158.7 (d, 246.2 Hz, CF), 166.1; δF (470 MHz 
CDCl3): -107.2; LCMS Rt = 1.70 min, (4); MS (ESI+) m/z 579.4 [M+H]
+
; HRMS 
m/z: Calc. for C21H13
79
Br
35
Cl2FNO2: 479.9564 [M+H]
+
. Found 479.9551 [M+H]
+
.      
 
2-(4-Bromo-3-fluorobenzyl)-4-chloro-3-(4-chlorophenyl)-3-((1-(hydroxymethyl) 
cyclopropane)methoxy)isoindolin-1-one (281) 
 
General procedure C: 2-(4-bromo-3-fluorobenzyl)-4-chloro-3-(4-chlorophenyl)-3-
hydroxyisoindolinone (294 mg, 0.61 mmol) and 1,1-bis(hydroxymethyl)cyclopropane 
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(0.12 mL, 1.22 mmol). Chromatography (SP4, silica, 7-60% EtOAc, PE) followed by 
(SP4, silica, 20-100% EtOAc, PE) gave 281 as an oily white solid (65 mg, 19%). Rf = 
0.33 (6:4 EtOAc:PE); UV λmax (EtOH): 260.0, 225.0, 205.0 nm; IR ʋmax 3458 (OH), 
2925, 2872, 2360, 2159, 1694 (C=O), 1587 (Amide C-N), 1075 (C-F) cm
-1
; δH (500 
MHz CDCl3): 0.17-0.20 (1H, m, cyclopropyl), 0.32-0.35 (1H, m, cyclopropyl), 0.45-
0.51 (2H, m, cyclopropyl), 1.67 (1H, s, OH), 2.86 (1H, d, J = 9.2 Hz, OCH2), 2.92 
(1H, d, J = 9.2 Hz, OCH2), 3.48 (1H, d, J = 11.4 Hz, CH2OH), 3.55 (1H, d, J = 11.4 
Hz, CH2OH), 4.27 (1H, d, J = 15.1 Hz, NCH2), 4.36 (1H, d, J = 15.1 Hz, NCH2), 6.78 
(1H, dd, J = 2.0 and 8.2 Hz, benzyl Ar-H), 6.91 (1H, dd, J = 2.0 and 9.3 Hz, CHCF), 
7.19-7.20 (4H, m, Ar-H), 7.31 (1H, dd, J = 7.1 and 8.2 Hz, CHCBr), 7.46 (1H, dd, J = 
1.1 and 8.0 Hz, H
5
), 7.50-7.53 (1H, m, H
6
), 7.85 (1H, dd, J = 1.1 and 7.4 Hz, H
7
); δC 
(125 MHz CDCl3): 8.6 (cyclopropyl), 8.6 (cyclopropyl), 22.1 (cyclopropyl), 42.0 
(cyclopropyl), 67.8 (CH2OH), 68.0 (OCH2), 94.4 (hemi-aminal), 107.9 (d, J = 20.7 
Hz, C-Br), 117.2 (d, J = 22.5 Hz, CHCF), 122.4 (C
4
), 125.6 (d, J = 3.4 Hz, benzyl Ar-
H), 128.2, 128.5, 129.8, 132.0 (C
6
), 133.1 (CHCBr), 134.0, 134.0,  138.7 (d, J = 6.4 
Hz, benzyl C),134.9, 134.9, 140.6, 158.6 (d, J = 246.5 Hz, C-F), 166.7 (C=O); δF (470 
MHz CDCl3): -107.2; LCMS Rt = 1.75 min, (3); HRMS m/z: Calc. for 
C26H22
79
Br
35
Cl2FNO3: 564.0139 [M+H]
+
. Found 564.0137 [M+H]
+
.; Analytical 
HPLC: 95.3% purity 
 
3-Fluoro-4-iodobenzylamine (277) 
 
To a solution of 3-fluoro-4-iodobenzonitrile (500 mg, 2.02 mmol, 1 eq) in THF (1 
mL) was added 1M BH3.THF in THF (8.1 mL, 8.10 mmol, 4 eq) and the reaction 
stirred at RT for 30 min then heated to reflux for 18 h, cooled, diluted with 1:1 AcOH 
(10 mL) and water (10 mL) added dropwise with stirring for 15 min before 
concentrated in vacuo. The resulting solid was cooled in an ice-bath, diluted with 
water (10 mL) and basified to pH 9 using sat. NaHCO3 solution, and extracted using 
EtOAc (3 x 70 mL). The combined organic extracts were washed with brine (50 mL) 
and dried over MgSO4. Chromatography (SP4, amino silica, 60-100% EtOAc, PE) to 
give 277 as a white solid (414 mg, 82%). Rf  = 0.46 (Amino silica) (9:1 EtOAc:PE); 
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mp = 96.9-99.3 
o
C; UV λmax (EtOH): 230.0 nm; IR ʋmax 3283 (N-H), 2861, 2158, 
1559, 1414, 1023 (C-F) cm
-1
; δH (500 MHz CDCl3): 1.44 (2H, s, NH2), 3.84 (2H, s, 
CH2), 6.87 (1H, d, J = 8.0 Hz, CHCI), 7.06 (1H, d, J = 8.7 Hz, CHCF), 7.67 (1H, dd, 
J = 6.7 and 7.8 Hz, Ar-H); δC (125 MHz CDCl3): 45.5 (CH2), 78.6 (d, J = 26.3 Hz, 
CI), 114.3 (d, J = 24.0 Hz, CHCF) 124.4 (d, J = 3.8 Hz, Ar-H), 139.2 (d, J = 1.3 Hz, 
CHCI), 146.4 (d, J = 6.3 Hz, CCH2), 161.9 (d, 243.8 Hz, CF); δF (470 MHz CDCl3): -
94.2; LCMS Rt = 0.61 min, (3); MS (ESI+) m/z 252.0 [M+H]
+
  
 
4-Chloro-3-(chlorophenyl)-3-hydroxy-2-(3-fluoro-4-iodobenzyl)isoindolin-1-one 
(280) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (818 mg, 2.58 
mmol) and 3-fluoro-4-iodobenzylamine (712 mg, 2.84 mmol). Chromatography (SP4, 
silica, 7-60% EtOAc, PE) to give 280 as a off-white solid (443 mg, 33%). Rf = 0.48 
(3:7 EtOAc:PE); mp = 197.5-200.0 
o
C; UV λmax (EtOH): 227.0 nm; IR ʋmax 3264 
(OH), 2362, 1683 (C=O), 1587 (Amide C-N), 1092 (C-F), 816, 757 (C-Cl) cm
-1
; δH 
(500 MHz CDCl3): 3.32 (1H, s, OH), 4.02 (1H, d, J = 15.2 Hz, NCH2), 4.43 (1H, d, J 
= 15.2 Hz, NCH2), 6.63 (1H, dd, J = 1.6 and 8.1 Hz, benzyl Ar-H), 6.81 (1H, dd, J = 
1.6 and 8.7 Hz, benzyl Ar-H), 7.17-7.7.41 (6H, m, Ar-H), 7.44 (1H. dd. J = 6.7 and 
7.9 Hz, H
6
), 7.65 (1H, dd, J = 2.1 and 6.3 Hz, H
7); δC (125 MHz CDCl3): 42.0 
(NCH2), 90.8 (hemi-aminal), 116.0 (d, J = 24.1 Hz, benzyl Ar-H), 122.2, 126.1 (d, J 
= 3.4Hz, benzyl Ar-H), 128.2, 128.6, 129.6, 131.7, 132.8, 132.2, 134.7, 135.0, 139.0, 
140.5 (d, J = 7.4 Hz, benzyl Ar-H)143.7, 161.4 (d, J = 245.2 Hz, C-F), 166.1 (C=O); 
δF (470 MHz CDCl3): -93.9; LCMS Rt = 1.72 min, (4); MS (ESI+) m/z 528.1[M+H]
+
; 
HRMS m/z: Calc. for C21H14
35
Cl2FINO3: 527.9425 [M+H]
+
. Found 527.9411 [M+H]
+
.       
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4-Chloro-3-(4-chlorophenyl)-3-((1-(hydroxymethyl)cyclopropane)methoxy)-2-(3-
fluoro-4-iodobenzyl)isoindolin-1-one (282) 
 
General procedure C: 4-chloro-3-(chlorophenyl)-3-hydroxy-2-(3-fluoro-4-
iodobenzyl)isoindolin-1-one (332 mg, 0.63 mmol) and 1,1-bis(hydroxymethyl) 
cyclopropane (0.12 mL, 1.26 mmol). Chromatography (SP4, silica, 7-60 % EtOAc, 
PE) gave 282 as a colourless oil (138 mg, 36%). Rf  = 0.22 (3:7 EtOAc:PE); UV λmax 
(EtOH): 227.5 nm; IR ʋmax 3481 (OH), 2924, 2876, 2158, 1693 (C=O), 1588 (Amide 
C-N), 1012 (C-F), 727 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 0.16-0.19 (1H, m, 
cyclopropyl), 0.31-0.34 (1H, m, cyclopropyl), 0.44-0.49 (2H, m, cyclopropyl), 1.73 
(1H, s, OH), 2.86 (1H, d, J = 9.1 Hz, OCH2), 2.91 (1H, d, J = 9.1 Hz, OCH2), 3.48 
(1H, d, J = 11.4, CH2OH), 3.54 (1H, d, J = 11.4 Hz, CH2OH), 4.27 (1H, d, J = 15.1, 
NCH2), 4.35 (1H, d, J = 15.1 Hz, NCH2), 6.65 (1H, dd, J = 1.8 and 8.1 Hz, benzyl Ar-
H), 6.77 (1H, dd, J = 1.8 and 8.7 Hz, CHCF), 7.17-7.18 (4H, m, Ar-H), 7.45-7.52 
(3H, m, H
5
, H
6
 and CHCI), 7.84 (1H, dd, J = 0.7 and 7.4 Hz, H
7
); δC (125 MHz 
CDCl3): 8.5 (cyclopropyl), 8.6 (cyclopropyl), 22.1 (cyclopropyl), 41.9 (NCH2), 67.1 
(CH2OH), 67.9 (OCH2), 79.7 (d, J = 25.4 Hz, C-I), 94.4 (hemi-aminal), 116.4 (d, J = 
24.1 Hz, CHCF), 122.4, 126.4 (d, J = 3.2 Hz, benzyl C-H), 128.3, 128.5, 129.8, 131.9, 
134.0, 134.0, 134.9 (d, J = 2.8 benzyl CCH2), 139.8 (d, J = 6.6 Hz, CHCI), 139.8, 
139.9, 140.6, 161.3 (d, J = 244.7 Hz, C-F), 166.7 (C=O); δF (470 MHz CDCl3): -93.8; 
HRMS m/z: Calc. for C26H22
35
Cl2FINO3: 612.0000 [M+H]
+
. Found 612.0001 
[M+H]
+
.; Analytical HPLC: 99.2% purity 
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4-Chloro-3-(4-chlorophenyl)-2-(3-fluoro-4-((4-triisopropylsilyl)ethynyl)benzyl)-3-
hydroxyisoindolin-1-one (283) 
 
General procedure F: 4-chloro-3-(chlorophenyl)-3-hydroxy-2-(3-fluoro-4-
iodobenzyl)isoindolin-1-one (250 mg, 0.47 mmol) and triisopropylsilylacetylene (138 
µL, 0.62 mmol). Chromatography (SP4, silica, 7-60% EtOAc, PE) to give 283 as an 
oily brown solid (261 mg, 95%). Rf  = 0.66 (3:7 EtOAc:PE); mp = 180.0-182.2 
o
C; 
UV λmax (EtOH): 224.0 nm; IR ʋmax 3305 (OH), 2159 (Ethynyl stretch), 1687 (C=O), 
1588 (Amide C-N), 1092 (C-F), 757 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 1.04 (18H, s, 
CH3), 3.51 (1H, s, OH), 3.99 (1H, d, J = 15.3 Hz, NCH2), 4.45 (1H, d, J = 15.3 Hz, 
NCH2), 6.76-6.79 ( 2H, m, Ar-H), 7.13-7.19 (5H, m, Ar-H), 7.35-7.40 (H
5
 and H
6
), 
7.62 (1H, dd, J = 2.2 and 6.2 Hz); δC (125 MHz CDCl3): 11.2 (CH3), 18.6 
(CH(CH3)2), 42.3 (NCH2), 90.0 (CSi(C3H7)3), 96.9 (CCSi(C3H7)3), 99.9 (C- 
CCSi(C3H7)3), 115.6 (d, J = 21.3 Hz, benzyl Ar-H), 122.1, 124.0, 124.0 (d, J, 8.0 Hz, 
benzyl Ar-H), 128.2, 128.6, 129.6, 131.6, 132.7, 133.5, 134.1, 134.8 (d, J = 14.2 Hz, 
benzyl Ar-H), 140.1 (d, J = 7.2 Hz, benzyl Ar-H), 143.8, 166.2 (C=O); δF (470 MHz 
CDCl3): -109.6; LCMS Rt = 2.25 min, (4); MS (ESI+) m/z 582.4 [M+H]
+
; HRMS 
m/z: Calc. C32H35
35
Cl2FNO2Si: 582.1793 [M+H]
+
. Found 582.1780 [M+H]
+
.      
 
 
 
 
 
 
 
 
 
7. MDM2/p53 Experimental Procedures 
 
279 
 
4-Chloro-3-(4-chlorophenyl)-2-(3-fluoro(4-((triisopropylsilyl)ethynyl)benzyl)-3-(1-
((hydroxymethyl)cyclopropane)methoxy)isoindolin-1-one (284) 
 
General procedure C: 4-chloro-3-(4-chlorophenyl)-2-(3-fluoro-4-((4-
triisopropylsilyl)ethynyl)benzyl)-3-hydroxyisoindolin-1-one (261 mg, 0.45 mmol) 
and 1,1-bis(hydroxymethyl)cyclopropane (0.09 mL, 0.45 mmol). Chromatography 
(SP4, silica, 7-60% EtOAc, PE) gave 284 as a colourless oil (77 mg, 26%). Rf  = 0.23 
(3:7 EtOAc:PE); UV λmax (EtOH): 260.5 nm; IR ʋmax 3397, 2943, 2865, 2160, 1698 
(C=O), 1588 (Amide C-N), 1013 (C-F), 760 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 0.13-
0.16 (1H, m, cyclopropyl), 0.26-0.28 (1H, m, cyclopropyl), 0.37-0.41 (2H, m, 
cyclopropyl), 1.04 (18H, s, CH3), 1.73 (1H, s, OH), 2.81 (1H, d, J = 9.2 Hz, OCH2), 
2.84 (1H, d, J = 9.2 Hz, OCH2), 3.42 (1H, d, J = 11.4 Hz, CH2OH), 3.48 (1H, d, J = 
11.4 Hz, CH2OH), 4.23 (1H, d, J = 15.0 Hz, NCH2), 4.29 (1H, d, J = 15.0 Hz, NCH2), 
6.73 (1H, dd, J = 1.4 and 8.0 Hz benzyl Ar-H), 6.76 (1H, dd, J = 1.4 and 9.8 Hz, 
CHCF), 7.10-7.15 (5H, m, Ar-H), 7.38 (1H, dd, J = 1.0 and 8.0 Hz, H
5
), 7.42-7.45 
(1H, m, H
6
), 7.78 (1H, dd, J = 1.0 and 7.4 Hz, H
7); δC (125 MHz CDCl3): 7.5 
(cyclopropyl), 7.6 (cyclopropyl), 10.2 (CH3),  17.6 (CH(CH3)2), 21.1 (cyclopropyl), 
41.2 (NCH2),  66.7 (CH2OH), 66.9 (OCH2), 93.4 (ethynyl), 95.9 (d, J = 3.2 Hz, 
ethynyl), 98.5 (hemi-aminal), 110.1 (d, J = 16.1 Hz, C-CC), 115.0 (d, J = 21.4 Hz, 
CHCF), 121.3, 123.3 (d, J = 3.3 Hz, benzyl Ar-H), 127.2, 127.4, 128.7, 130.9, 132.4, 
132.9, 133.0, 133.8 (d, J = 6.8 Hz, benzyl Ar-H), 138.4 (d, J = 7.1 Hz, benzyl Ar-H), 
139.6, 161.7 (d, J = 251.2 Hz, C-F), 165.6 (C=O); δF (470 MHz CDCl3): -109.6; 
LCMS Rt = 2.33 min, (5); MS (ESI+) m/z 666.5 [M+H]
+
; HRMS m/z: Calc. for 
C37H43
35
Cl2FNO3Si: 666.2368 [M+H]
+
 Found 666.2362 [M+H]
+ 
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4-Chloro-3-(4-chlorophenyl)-2-(4-ethynyl-3-fluorobenzyl)-3-(1-((hydroxymethyl) 
cyclopropane)methoxy)isoindolin-1-one (285) 
 
General procedure G: 4-chloro-3-(4-chlorophenyl)-2-(3-fluoro(4-((triisopropylsilyl) 
ethynyl)benzyl)-3-(1-((hydroxymethyl)cyclopropane)methoxy)isoindolin-1-one (90 
mg, 0.14 mmol). Chromatography (SP4, silica, 7-60 % EtOAc, PE) gave the title 
compound as colourless oil (44 mg, 62%). Rf  = 0.22 (3:7 EtOAc:PE); UV λmax 
(EtOH): 230.0 nm; IR ʋmax 3296 (OH), 2361 (Ethynyl stretch), 1696 (C=O), 1588 
(Amide C-N), 1012 (C-F), 761 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 0.15-0.18 (1H, m, 
cyclopropyl), 0.31-0.33 (1H, m, cyclopropyl), 0.44-0.49 (2H, m, cyclopropyl), 1.73 
(1H, s, OH), 2.85 (1H, d, J = 9.1 Hz, OCH2), 2.92 (1H, d, J = 9.1 Hz, OCH2), 3.26 
(1H, s, ethynyl), 3.47 (1H,d, J = 11.3 Hz, CH2OH), 3.54 (1H, d, J = 11.3 Hz, 
CH2OH), 4.26 (1H, d, J = 15.1 Hz, NCH2), 4.40 (1H, d, J = 15.1 Hz, NCH2), 6.64-
6.88 (2H, m, benzyl Ar-H), 7.19-7.26 (5H, m, Ar-H), 7.46 (1H, dd, J = 1.0 and 8.0 
Hz, H
5
), 7.50-7.53 (1H, m, H
6
), 7.85 (1H, dd, J = 1.0 and 7.4 Hz, H
7
); δC (125 MHz 
CDCl3): 8.5 (cyclopropyl), 8.6 (cyclopropyl), 22.1 (cyclopropyl), 42.2 (NCH2), 67.7 
(CH2OH), 68.0 (OCH2), 76.7 (ethynyl), 82.6 (d, J = 3.2 Hz, ethynyl), 94.5 (hemi-
aminal), 109.6 (d, J = 15.6 Hz, C-CCH), 116.1 (d, J = 21.3 Hz, CHCF), 122.4, 124.5 
(d, J = 3.3 Hz, benzyl Ar-H), 128.3, 128.5, 129.8, 131.9, 133.6, 134.0, 134.0, 134.9 
(d, J = 3.6 Hz, benzyl Ar-H), 140.3 (d, J = 7.5 Hz, benzyl Ar-H), 140.7, 162.9 (d, J = 
251.3 Hz, C-F), 166.7 (carbonyl); δF (470 MHz CDCl3): -110.0; HRMS m/z: Calc. for 
C28H22
35
Cl2FNO3: 510.1034 [M+H]
+
. Found 510.1034 [M+H]
+
.; Analytical HPLC: 
98.1% purity    
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Benzo[c][1,2,5]oxadiazol-5-ylmethanamine (288) 
 
To a solution of 5-(bromomethyl)-2,1,3-benzoxadiazole (500 mg, 2.35 mmol, 1 eq) in 
DMF (6 mL) was added potassium phthalamide (435 mg, 2.35 mmol, 1 eq) and the 
reaction was stirred at room temperature for 16 h. The solvent was removed in vacuo, 
and the resulting white solid was suspended in water (20 mL) and extracted into 
EtOAc (3 x 20 mL). The organic extracts were dried over MgSO4, and concentrated in 
vacuo. The resulting solid was dissolved in EtOH (5 mL) and 40% aq. methylamine 
(5 mL) added and the reaction was stirred for 25 h, concentrating in vacuo, the white 
solid was suspended in water (50 mL) and extracting with EtOAc (3 x 50 mL). The 
combined organic extract was dried (MgSO4) and concentrated in vacuo. 
Chromatography (SP4, silica, 2-20% MeOH, EtOAc) gave 288 as an orange gummy 
solid (186 mg, 53%). Rf  = 0.07 (1:9 MeOH:EtOAc); UV λmax (EtOH): 289.5 nm; IR 
ʋmax 2891, 2358, 2159, 1977, 1521 (Oxadiazole ring), 878, 800 cm
-1
; δH (500 MHz 
CDCl3): 1.55 (2H, s, NH2), 4.02 (2H, s, CH2), 7.40 (1H, dd, J = 1.1 and 9.2 Hz, 
CHCCH2), 7.77-7.78 (1H, m, NCCHCCH2), 7.80 (1H, d, J = 14.3, NCCHCH); δC 
(125 MHz CDCl3): 46.2 (CH2), 111.7 (NCCHCCH2), 116.3 (NCCHCH), 132.7 
(CHCCH2), 147.0 (CCH2), 148.9 (C=N), 149.5 (C=N) 
 
2-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)-4-chloro-3-(4-chlorophenyl)-3-
hydroxyisoindolin-1-one (290) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (504 mg, 
mmol) and benzo[c][1,2,5]oxadiazol-5-ylmethanamine (261 mg, 1.75 mmol). 
Chromatography (SP4, silica, 7-60% EtOAc) and (silica, 1:1 EtOAc:PE) gave 290 as 
a gummy yellow solid (100 mg, 15%). Rf  = 0.61 (1:1 EtOAc:PE); UV λmax (EtOH): 
271.5 nm; IR ʋmax 3285 (OH), 2158, 2018, 1691 (C=O), 1665 (Oxadiazole ring), 1586 
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(Amide C-N), 820, 760 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 4.14 (1H, d, J = 15.8 Hz, 
NCH2), 4.48 (1H, d, J = 15.8 Hz, NCH2), 5.25 (1H, s, OH), 7.10-7.13 (3H, m, Ar-H), 
7.17-7.19 (2H, m, Ar-H), 7.29-7.32 (2H, m, Ar-H), 7.35 (1H, dd, 1.0 and 7.9 Hz, H
5
), 
7.51 (1H, dd, J = 0.6 and 9.4 Hz, H
6
), 7.53 (1H, dd, J = 1.0 and 7.3 Hz, H
7
); δC (125 
MHz CDCl3): 42.7 (NCH2), 91.0 (hemi-aminal), 114.3 (benzyl Ar-H), 116.1 (benzyl 
Ar-H), 121.9, 128.2, 128.6, 129.8, 131.6, 132.4, 132.9, 134.3, 134.8, 135.0, 141.4, 
144.0, 148.3 (C=N), 148.7 (C=N), 166.7 (C=O); LCMS Rt = 1.55 min, (3); MS 
(ESI+) m/z 426.2 [M+H]
+
 HRMS m/z: Calc. for C21H14
35
Cl2N3O3: 426.0407 [M+H]
+
. 
Found 426.0405 [M+H]
+
. 
 
2-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)-4-chloro-3-(4-chlorophenyl)-3-((1-
(hydroxymethyl)cyclopropyl)methoxy)isoindolin-1-one (291) 
 
General procedure D: compound 290 (80 mg, 0.19 mmol) and 1,1-
bis(hydroxymethyl)cyclopropane (0.18 mL, 1.88 mmol, 10 eq). Further additions of 
BF3.OEt2 at 0 
o
C occurred after 18 h and stirred for a further 2 days. Chromatography 
(SP4, silica, 17-100 % EtOAc, PE) followed by semi-preparative HPLC (95-0% 
acetonitrile, 0.1% formic acid (aq)) to give 291 as a colourless oil (35 mg 36%). Rf  = 
0.55 (3:7 EtOAc:PE); UV λmax (EtOH) 268.0 nm; IR ʋmax 3465 (OH), 2922, 2159, 
2032, 1699 (C=O), 1588 (Amide C-N),1011, 818, 760 (C-Cl) cm
-1
; δH (500 MHz 
CDCl3): 0.17-0.24 (1H, m, cyclopropyl), 0.36-0.41 (1H, m, cyclopropyl), 0.43-0.48 
(2H, m, cyclopropyl), 1.62 (1H, s, OH), 2.90 (1H, d, J = 9.1 Hz, CH2OH), 4.60 (1H, 
d, J = 9.1 Hz, CH2OH), 3.50-3.55 (2H, m, OCH2), 4.41 (1H, d, J = 15.3 Hz, NCH2), 
4.57 (1H, d, J = 15.3 Hz, NCH2), 7.07-7.26 (4H, m, Ar-H), 7.32 (1H, dd, J = 1.1 and 
9.3 Hz, benzyl CHCCH2), 7.37 (1H, s, benzyl CCHCN), 7.27 (1H, dd, J = 0.6 and 7.9 
Hz, H
5
), 7.31-7.34 (1H, m, H
6
), 7.40 (1H, J = 9.3 Hz, benzyl CHCN), 7.66 (1H, dd, J 
= 0.6 and 7.4 Hz, H
7
); δC (125 MHz CDCl3): 8.5 (cyclopropyl), 8.7 (cyclopropyl), 
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22.2 (cyclopropyl), 42.6 (NCH2), 67.5 (CH2OH), 67.7 (OCH2), 94.3 (hemi-aminal), 
115.3 (benzyl CCHCN), 116.4 (CHCN), 122.4 (C
7
), 128.2, 128.5, 129.9, 132.1 (C
6
), 
133.1 (benzyl CHCCH2), 133.8, 134.2 (C
5
), 135.0, 140.6, 140.7, 148.2 (C=N), 148.8 
(C=N), 166.8 (C=O); LCMS Rt = 1.58 min, (3); MS (ESI+) m/z 510.3 [M+H]
+
; 
HRMS m/z: Calc. for C26H22
35
Cl2N3O4: 510.0982 [M+H]
+
. Found: 510.0979 [M+H]
+
.; 
Analytical HPLC: 98.1% purity  
 
4-Chloro-3-(4-chlorophenyl)-2-(4-iodobenzyl)-3-((1-(hydroxymethyl)cyclopropyl) 
methoxy)isoindolin-1-one (296) 
 
General procedure C: 4-chloro-3-(4-chlorophenyl)-2-(4-iodobenzyl)-3-(1-
((hydroxymethyl)cyclopropyl)methoxy)isoindolin-1-one (120 mg , 0.24 mmol) and 
1,1-bis(hydroxymethyl)cyclopropane (0.045 mL, 0.47 mmol). Chromatography (SP4, 
silica, 7-60% EtOAc, petrol) gave 296 as a colourless oil (75 mg, 52%). Rf = 0.33 (7:3 
PE:EtOAc); UV λmax (EtOH): 227.0 nm; IR ʋmax 2360, 2160, 1684 (C=O), 1588 
(Amide C-N) cm
-1
; δH (500 MHz CDCl3): 0.11-0.13 (1H, m, cyclopropyl), 0.28-0.32 
(1H, m, cyclopropyl), 0.42-0.47 (2H, m, cyclopropyl), 2.80 (1H, d, J = 9.1 Hz, 
OCH2), 2.89 (1H, d, J = 9.1 Hz, OCH2), 3.43 (1H, d, J = 11.2 Hz, CH2OH), (1H, d, J 
= 11.2 Hz, CH2OH), 4.16 (1H, d, J = 15.0 Hz, NCH2), 4.41 (1H, d, J = 15.0 Hz, 
NCH2), 6.88 (2H, d, J = 8.3 Hz, Ar-H), 7.18-7.20 (4H, m, Ar-H), 7.44-7.52 (4H, m, 
Ar-H), 7.84 (1H, dd, J = 7.4 and 0.8 Hz, H
7) δC (125 MHz CDCl3): 8.6 (cyclopropyl), 
22.1 (cyclopropyl), 42.4 (NCH2), 67.0 (CH2OH), 68.8 (OCH2), 92.9 9 (Ar-I), 94.6 
(hemi-aminal C), 122.3, 128.3, 128.5, 129.7, 131.0, 131.8, 133.9, 134.1, 134.8, 135.0, 
136.7, 137.3, 140.7, 166.7 (carbonyl) 
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4-Azidobenzyl amine (299) 
 
To a solution of 4-aminobenzyl alcohol (100 mg, 0.81 mmol, 1eq) in 5 M aqueous 
HCl (3 mL) at 0 
o
C was added dropwise over 30 min an aqueous solution of NaNO2 
(71 mg, 1.03 mmol, 1.27 eq in 2 mL of water), followed by NaN3 (CAUTION) (228 
mg, 3.51 mmol, 4.3 eq) in portions over a further 30 min. The reaction mixture was 
stirred at 0 
o
C for a further 1 h before diluting with water (15 mL) and basifying with 
saturated aqueous solution of NaHCO3 to around pH 8, then extracted into EtOAc (3 
x 25 mL), dried over MgSO4 and concentrated in vacuo. Chromatography (SP4, silica, 
7-60% EtOAc, PE) gave the title compound as a colourless oil which solidified on 
standing to give a white solid which was stored in the dark at 4 
o
C (118 mg, 98%). Rf  
= 0.43 (3:7 EtOAc:PE); UV λmax (EtOH): 251.5 nm; IR ʋmax 3300 (OH), 2927, 2863, 
2415, 2103 (very strong, N3), 1505 cm
-1
; δH (500 MHz CDCl3): 1.84 (1H, s, OH), 
4.58 (2H, s, CH2), 6.94 (2H, d, J = 8.5 Hz, CHCN3), 7.27 (2H, d, J = 8.5 Hz, 
CHCCH2); δC (125 MHz CDCl3): 64.7 (CH2), 119.1 (CHCCH2), 128.5 (CHCN3), 
137.6 (CN3), 139.4 (CCH2) 
 
4-Azidobenzyl bromide (300) 
 
To a solution of 4-azidobenzyl alcohol (334 mg, 2.24 mmol, 1 eq) in diethyl ether 
(2mL) at 0
o
C was added PBr3 (168 µL, 1.79 mmol, 0.8 eq) in diethyl ether (2 mL) 
over 30 min. The reaction was stirred for 15 min at 0 
o
C, then room temperature for 
30 min, diluted with water (10 mL) and extracted with EtOAc (3 x 15 mL). The 
combined organic extracts were washed with sat. NaHCO3 (30 mL) and brine (30 
mL), dried over MgSO4 and concentrated in vacuo. Chromatography (SP4, silica, 1-
10% EtOAc, PE) gave 300 as a colourless oil (363 mg, 76%). Rf  = 0.75 (1:9 
EtOAc:PE); UV λmax (EtOH): 379.0, 262.0, 209.0 nm; IR ʋmax 2104 (very strong, N3), 
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1606, 1504 cm
-1
; δH (500 MHz CDCl3): 4.40 (2H, s, CH2), 6.92 (2H, d, J = 8.5 Hz, 
CHCN3), 7.30 (2H, d, J = 8.5 Hz, CHCCH2); δC (125 MHz CDCl3): 32.9 (CH2), 119.4 
(CHCCH2), 130.6 (CHCN3), 134.5 (CN3), 140.2 (CCH2)  
 
4-Azidobenzylamine (295) 
 
To benzyl bromide 289 (91 mg, 0.43 mmol, 1 eq) in acetonitrile (4 mL) was added 
18-crown-6 (14 mg, 0.05 mmol, 1 eq) and the reaction was stirred at room 
temperature for 30 min, then sodium diformylamide (110 mg, 1.16 mmol, 2.7 eq) was 
added and the reaction heated to 95 
o
C for 24 h before cooling to room temperature. 
5% HCl in EtOH (3 mL) was added and the reaction stirred for 3 days, then 
concentrated in vacuo. The residues were diluted with sat. NaHCO3 (15 mL) and 
extraction with EtOAc (3 x 25 mL). The combined organic extracts were dried 
(MgSO4) and concentrated in vacuo. Chromatography (SP4, silica, 7-60% EtOAc, 
PE) gave 295 as a white oily solid (61 mg, 96%). Rf  = 0.41 (3:7 EtOAc:PE); UV λmax 
(EtOH): 251.5 nm; IR ʋmax 3307 (NH), 2101 (very strong, N3), 1506, 1279 cm
-1
; δH 
(500 MHz CDCl3): 4.66 (2H, s, CH2), 7.03 (2H, d, J = 8.5 Hz, CHCN3), 7.36 (2H, d, J 
= 8.5 Hz, CHCCH2); δC (125 MHz CDCl3): 64.7 (CH2), 119.1 (CHCCH2), 128.6 
(CHCN3), 137.6 (CN3), 139.4 (CCH2) 
 
2-(4-Azidobenzyl)-3-(4-chlorophenyl)-3-hydroxyisoindolinone (301) 
 
General procedure B: 2-(4-chlorobenzoyl)benzoic acid (185 mg,0.71 mmol, 1 eq) 
and 4-azidobenzyl amine (116 mg, 0.78 mmol). The reaction was undertaken in the 
dark. Chromatography (SP4, silica, 7-60% EtOAc, PE) gave the title compound as a 
yellow oil (216 mg, 78%). Rf  = 0.79 (3:7 EtOAc:PE); UV λmax (EtOH): 252.5, 225.5 
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nm; IR ʋmax  2110 (very strong, N3), 1775 (C=O), 1606 (Amide C-N), 1092 cm
-1
; δH 
(500 MHz CDCl3): 4.28 (1H, d, J = 11.1 Hz, NCH2), 4.45 (1H, d, J = 11.1 Hz, 
NCH2), 4.45 (1H, d, J = 11.1 Hz, NCH2), 6.89 (2H, d, J = 8.6 Hz, CHCN3), 7.19 (2H, 
dt, J = 2.5 and 8.6 Hz, benzyl Ar-H), 7.28 (2H, dt, J = 2.0 and 8.8 Hz, Ar-H),  7.39 
(1H, d, J =7.7 Hz, H
4
), 7.46 (2H, dt, J = 2.0 and 8.8 Hz, Ar-H), 7.52 (1H, ap. td, J = 
0.9 and 7.5 Hz, H
5
), 7.60 (1H, ap. td, J = 1.1 and 7.5 Hz, H
6
), 7.86 (1H, ap. td, J = 0.8 
and 7.6 Hz, H
7
); δC (125 MHz CDCl3): 108.1 (hemi-aminal), 119.1, 123.3, 125.8, 
126.3, 127.3, 129.0, 129.5, 130.9, 133.3, 135.5, 136.3, 139.8 (C-N3), 147.9, 168.1 
(C=O)  
 
3-(4-Chlorophenyl)-3-hydroxy-2-(4-nitrobenzyl)isoindolin-1-one (304) 
 
General procedure B: 2-(4-chlorobenzoyl)benzoic acid (750 mg, 2.88 mmol) and 4-
nitrobenzylamine hydrochloride (597 mg, 3.16 mmol). Chromatography (silica, 1:1 
EtOAc:PE) gave 304 as a white solid (714 mg, 63%). Rf  =  0.66 (1:1 EtOAc:PE); mp 
= 178.3-182.1 
o
C (lit 148-149 
o
C)
192
; UV λmax (EtOH): 257.5 nm; IR ʋmax 3190 (OH), 
2928, 1679 (C=O), 1608 (Amide C-N),1342 (NO2 stretch), 709, 693 (C-Cl) cm
-1
; δH 
(500 MHz CDCl3): 3.40 (1H, s, OH), 4.16 (1H, d, J = 15.4 Hz, NCH2), 4.58 (1H, d, J 
= 15.4 Hz, NCH2), 7.13-7.20 (5H, m, Ar-H), 7.25 (2H, d, J = 8.7 Hz, benzyl Ar-H), 
7.43 (2H, ap. dtd, J = 1.3, 7.4 and 18.2 Hz, H
5
 and H
6
), 7.71 (1H, d, J = 6.9 Hz, H
7
), 
7.91 (2H, d, J = 8.7 Hz, CHCNO2); δC (125 MHz CDCl3): 42.3 (NCH2), 91.1 (hemi-
aminal), 122.8, 123.4 (CHCNO2), 123.7 (H
7
), 127.8, 128.8, 129.5, 129.8 (benzyl Ar-
H), 130.1, 133.4, 134.9, 136.4, 145.2, 147.0, 148.3, 167.8 (C=O); LCMS Rt = 1.52 
min, (3); MS (ESI+) m/z 395.3 [M+H]
+
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3-(4-Chlorophenyl)-3-((1-(hydroxymethyl)cyclopropyl)methoxy)-2-(4-
nitrobenzyl)isoindolin-1-one (195) 
 
Using commercial Vilsmeier reagent 
 
To a solution of 304 (100 mg, 0.25 mmol, 1 eq) in THF (3 mL) was added 
(chloromethylene)dimethyliminium chloride (44 mg, 0.38 mmol, 1.5 eq) and the 
reaction stirred for 4 h at room temperature, then concentrated in vacuo. The residue 
was dissolved in THF (3 mL) and K2CO3 (74 mg, 0.54 mmol, 2.1 eq) and 1,1-
bis(hydroxymethyl)cyclopropane (0.05 mL, 0.51 mmol, 2 eq) added. The reaction 
was stirred for 16 h then concentrated in vacuo. The residue was suspended in water 
(30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were 
washed with brine and dried (Na2SO4) and concentrated in vacuo. Chromatography 
(SP4, silica, 12-100% EtOAc, PE) gave 195 as a white oily solid (26 mg, 22%). 
 
Using oxalyl chloride 
 
To a solution of 304 (100 mg, 0.25 mmol, 2 eq) in DCM (2 mL) was added (COCl)2 
(0.11 mL, 1.27 mmol, 5 eq) dropwise, and the mixture was stirred for 2 h, then 
concentrated in vacuo. The residue was redissolved in DCM (2 mL), K2CO3 (73 mg, 
0.55 mmol, 2.2 eq) and 1,1-bis(hydroxymethyl)cyclopropane (0.05 mL, 0.51 mmol, 2 
eq) was added and the reaction stirred for 15 h, then concentrated in vacuo. The 
residue was suspended in water (30 mL) before extracting with EtOAc (3 x 30 mL). 
The combined organic extracts were washed with Na2SO4, and concentrated in vacuo. 
Chromatography (SP4, silica, 12-100% EtOAc, PE) gave 195 as an oily solid (74 mg, 
62%). 
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Rf  = 0.56 (1:1 EtOAc:PE); UV λmax (EtOH): 267.5 nm; IR ʋmax 3445 (OH), 2923, 
2875, 1689 (C=O), 1605 (Amide C-N), 1341 (NO2) cm
-1
; δH (500 MHz CDCl3): 014-
0.16 (1H, m, cyclopropyl), 0.19-0.21 (1H, m, cyclopropyl), 0.41-0.46 (2H, m, 
cyclopropyl), 1.57 (1H, t, J = 2.4 Hz OH), 2.80 (1H, d, J = 9.5 Hz, OCH2), 2.82 (1H. 
d. J = 9.5 Hz, OCH2), 3.45 (1H, dd, J = 2.4 and 11.2 Hz, CH2OH), 3.50 (1H, dd, J = 
2.4 and 11.2 Hz, CH2OH), 4.47 (1H, d, J = 15.2 Hz, NCH2), 4.52 (1H, d, J = 15.2 Hz, 
NCH2), 7.15-7.17 (4H, m, Ar-H), 7.32 (2H, d, J = 6.9 Hz, Ar-H), 7.53-7.57 (2H, m, 
Ar-H), 7.91-7.93 (1H, m, H
7
), 8.01 (1H, d, J = 8.8 Hz, CHCNO2); δC (125 MHz 
CDCl3): 8.6 (cyclopropyl), 8.7 (cyclopropyl), 22.3 (cyclopropyl), 42.3 (cyclopropyl), 
67.5 (CH2OH), 67.7 (OCH2), 94.5 (hemi-aminal), 123.1, 123.4, 123.9, 127.9, 128.7, 
129.8, 130.2, 131.2, 133.3, 134.8, 136.8, 144.7, 145.0 (C-NO2), 147.1, 168.3; LCMS 
Rt = 1.59 min, (3); MS (ESI+) m/z 479.2 [M+H]
+
   
 
4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(3-iodobenzyl)isoindolin-1-one (307) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (440 mg, 1.39 
mmol) and 3-iodobenzylamine hydrochloride (750 mg, 2.78 mmol). Chromatography 
(SP4, silica, 7-60 % EtOAc, PE) gave 307 as a white solid (263 mg, 37%). Rf  = 0.5 
(3:7 EtOAc:PE); mp = 183.9-185.3 
o
C; UV λmax (EtOH): 225.0 nm; IR ʋmax 3278 
(OH), 1679 (C=O), 1587 (Amide C-N), 813, 764 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 
3.56 (1H, s, OH), 4.10 (1H, d, J = 15.1 Hz, NCH2), 4.31 (1H, d, J = 15.1 Hz, NCH2), 
7.07 (1H, d, J = 7.8, benzyl Ar-H), 7.13-7.19 (4H, m, Ar-H), 7.22-7.23 (1H, m, Ar-
H), 7.36-7.40 (3H, m, Ar-H), 7.61-7.65 (1H, m, H
7); δC (125 MHz CDCl3): 42.0 
(NCH2), 90.8 (CI), 95.1 (hemi-aminal), 122.2, 128.1, 128.2, 128.5, 129.7, 129.9, 
131.6, 132.8, 134.1, 134.7, 134.8, 136.2, 137.6, 139.6, 143.8, 166.2 (C=O); LCMS Rt 
= 1.72 min, (5); MS (ESI+) m/z 510.1 [M+H]
+
; HRMS m/z: Calc. for 
C21H15
35
Cl2INO2: 509.9519 [M+H]
+
. Found 509.9515 [M+H]
+
. 
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4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(3-((triisopropylsilyl)ethynyl)benzyl) 
isoindolinone (308) 
 
General procedure F: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(3-iodobenzyl) 
isoindolin-1-one (263 mg, 0.52 mmol, 1 eq) and triisopropylsilylacetylene (150 µL, 
0.67 mmol). Chromatography (SP4, silica, 7-60% EtOAc, PE) gave the title 
compound as a white solid (234 mg, 80%). Rf = 0.51 (3:7 EtOAc:PE); mp = 206.9-
208.8 
o
C; UV λmax (EtOH): 262.0, 250.5 nm; IR ʋmax 3373 (C=O), 2943, 2864, 2159 
(Ethynyl), 1695 (C=O), 1587 (Amide C-N), 760 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 
1.05 (18H, s, CH3), 3.59 (1H, s, OH), 4.05 (1H, d, J = 15.1 Hz, NCH2), 4.39 (1H, d, J 
= 15.1 Hz, NCH2), 6.78-7.05 (3H, m, Ar-H), 7.09-7.18 (5H, m, Ar-H), 7.34-7.35 (2H, 
m, H
5
 and H
6
), 7.60-7.62 (1H, m, H
7); δC (125 MHz CDCl3): 11.3 (CH3), 18.7 (CH), 
42.4 (NCH2), 90.6 (ethynyl), 90.9 (ethynyl), 106.7 (hemi-aminal), 122.0 (C-ethynyl), 
123.5, 128.1, 128.2, 128.4, 129.7, 131.0, 131.5, 132.0, 132.9, 134.0, 134.7, 134.8, 
137.5, 143.9, 166.2 (C=O); LCMS Rt = 2.26 min, (5); MS (ESI+) m/z 564.4 [M+H]
+
; 
HRMS m/z: Calc. for C32H36
35
Cl2NO2Si: 564.1887 [M+H]
+
. Found 562.1883 [M+H]
+
.  
 
4-Chloro-3-(4-chlorophenyl)-3-(1((hydroxymethyl)cyclopropane)methoxy)-2-(3-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (309) 
 
General procedure C: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(3-
((triisopropylsilyl)ethynyl)benzyl)isoindolinone (167 mg, 0.30 mmol) and 1,1-
bis(hydroxymethyl)cyclopropane (0.06 mL, 0.59 mmol). Chromatography (SP4, 
silica, 7-60% EtOAc, PE) gave the title compound as a colourless oil (67mg, 37%). Rf  
= 0.29 (3:7 EtOAc:PE); UV λmax (EtOH): 262.0, 250.5 nm; IR ʋmax 2942, 2864, 2158 
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(Ethynyl), 1708 (C=O), 763 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 0.11-0.14 (1H, m, 
cyclopropyl), 0.26-0.28 (1H, m, cyclopropyl), 0.38-0.45 (2H, m, cyclopropyl), 1.74 
(1H, s, OH), 2.78 (1H, d, J = 9.2 Hz, OCH2), 2.94 (1H, d, J = 9.2 Hz, OCH2), 3.42 
(1H, d, J = 11.4 Hz, CH2OH), 3.54 (1H, d, J = 11.4 Hz, CH2OH), 4.14 (1H, d, J = 
15.0 Hz, NCH2), 4.48 (1H, d, J = 15.0 Hz, NCH2), 7.09-7.19 (6H, m, Ar-H), 7.29 
(1H, d, J = 7.5 Hz, benzyl Ar-H), 7.44 (1H, d, J = 7.9 Hz, H
5
), 7.48-7.51 (1H, m, H
6
), 
7.86 (1H, d, J = 7.3 Hz, H
7); δC (125 MHz CDCl3): 8.5 (cyclopropyl), 8.5 
(cyclopropyl), 11.3 (CH3), 18.7 (CH(CH3)2), 22.1 (cyclopropyl), 42.6 (NCH2), 67.8 
(CH2OH), 67.9 (OCH2), 90.8 (ethynyl), 94.7 (ethynyl), 106.6 (hemi-aminal), 122.3, 
123.5, 128.2, 128.3, 128.4, 129.1, 129.7, 131.2, 131.8, 132.2, 133.9, 134.2, 134.7, 
135.0, 137.1, 140.8, 166.7 (C=O); LCMS Rt = 2.36 min, (5); HRMS m/z: Calc. for 
C37H44
35
Cl2NO3Si: 648.2462 [M+H]
+
. Found 648.2463 [M+H]
+
. 
 
4-Chloro-3-(4-chlorophenyl)-2-(3-ethynylbenzyl)-(1-((hydroxymethyl)cyclopropane) 
methoxy)isoindolin-2-one (310) 
 
General procedure G: 4-chloro-3-(4-chlorophenyl)-3-(1((hydroxymethyl) 
cyclopropane)methoxy)-2-(3-((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (76 
mg, 0.12 mmol). Chromatography (SP4, silica, 7-60% EtOAc, PE) gave 310 as a 
colourless oil (36 mg, 61%). Rf  = 0.2 (3:7 EtOAc:PE); UV λmax (EtOH): 246.0, 225.0, 
211.0 nm; IR ʋmax 3300 (OH), 2927, 2874, 2361, 2160 (Ethynyl), 1695 (C=O), 1587 
(Amide C-N), 1074 cm
-1
; δH (500 MHz CDCl3): 0.10-0.12 (1H, m, cyclopropyl), 
0.26-0.29 (1H, m, cyclopropyl), 0.39-0.45 (2H, m, cyclopropyl), 1.70 (1H, t, J = 5.6, 
OH), 2.80 (1H, d, J = 9.2 Hz, OCH2), 2.93 (1H, d, J = 9.2 Hz, OCH2), 3.04 (1H, s, 
ethynyl), 3.43 (1H, dd, J = 4.2 and 11.4 Hz, CH2OH), 4.43 (1H, dd, J = 4.2 and 11.4 
Hz, CH2OH), 4.18 (1H, d, J = 14.9 Hz, NCH2), 4.46 (1H, d, J = 14.9 Hz, NCH2), 
7.11-7.19 (7H, m, Ar-H), 7.30 (1H, d, J = 7.6 Hz, Ar-H), 7.45 (1H, dd, J = 0.9 and 
7.9, H
5
), 7.49-7.52 (1H, m, H
6
), 7.85 (1H, dd, J = 0.8 and 7.4 Hz, H
7
); δC (125 MHz 
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CDCl3): 8.5 (cyclopropyl), 22.1 (cyclopropyl), 42.5 (NCH2), 67.8 (CH2OH), 67.9 
(OCH2), 77.4 (ethynyl), 83.1 (ethynyl), 96.6 (hemi-aminal), 122.1, 122.3, 128.3, 
128.3 128.5, 129.6, 129.7. 131.0, 131.8, 132.6, 133.9, 134.1, 134.7, 135.0, 137.3, 
140.8, 166.7 (carbonyl); LCMS Rt = 1.67 min, (4); HRMS m/z: Calc. for 
C28H24
35
Cl2NO3
:
 492.1128 [M+H]
+
. Found 492.1123 [M+H]
+
.; Analytical HPLC: 
98.7% purity 
 
4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-(prop-1-ynyl)benzyl)isoindolin-1-one 
(313) 
 
To a solution of 252 (383 mg, 0.75 mmol, 1 eq) in THF (4 mL) was added CuI (9 mg, 
0.05 mmol, 0.06 eq) and Pd(PPh3)2Cl2 (16 mg, 0.02 mmol, 0.03 eq) and the solution 
degassed for 5 min. Et3N (0.26 mL, 1.88 mmol, 2.5 eq) was added and the solution 
degassed for a further 15 min and the reaction flack sealed. The reaction mixture was 
cooled to -78 
o
C and propyne (in excess) was added via cannula, then gradually 
warmed to room temperature and stirred for 18 h, filtered through Celite, washed with 
methanol (2 x 10 mL) and concentrated in vacuo. Chromatography (SP4, silica, 7-
60% EtOAc, PE) gave 313 as an off-white solid (294 mg, 94%). Rf  = 0.5 (3:7 
EtOAc:PE); mp = 224.0-225.7 
o
C; UV λmax (EtOH): 232.0 nm;  IR ʋmax 3178 (OH), 
2159 (Ethynyl), 1979, 1676 (C=O), 1658 (Amide C-N), 1406, 815, 770 (C-Cl) cm
-1
; 
δH (500 MHz CDCl3): 2.05 (3H, s, CH3), 3.30 (1H, s, OH), 4.05 (1H, d, J = 15.1 Hz, 
NCH2), 4.62 (1H, d, J = 15.1 Hz, NCH2), 7.11 (2H, d, J = 8.3 Hz, benzyl Ar-H), 7.19 
(2H, d, J = 8.3 Hz, benzyl Ar-H), 7.27-7.28 (4H, m, Ar-H), 7.45-7.47 (2H, m, H
5
 and 
H
6
), 7.76 (1H, dd, J = 1.8 and 6.7 Hz, H
7); δC (125 MHz CDCl3): 4.4 (CH3), 42.6 
(NCH2), 79.5 (ethynyl), 86.0 (ethynyl), 91.0 (hemi-aminal), 122.1, 122.9, 128.3, 
128,5, 128.6, 129.6, 131.4, 131.6, 133.0, 134.0, 134.7, 134.9, 137.0, 143.8, 166.1; 
LCMS Rt = 1.68 min, (4); MS (ESI+) m/z 422.2 [M+H]
+
; HRMS m/z: Calc. for 
C24H18
35
Cl2NO2: 422.0709 [M+H]
+
. Found: 422.0711 [M+H]
+
.       
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4-Chloro-3-(4-chlorophenyl)-3-(1-((hydroxymethyl)cyclopropane)methoxy)-2-(4-
(prop-1-ynyl)benzyl)isoindolin-1-one (311) 
 
General procedure C: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-(prop-1-
ynyl)benzyl)isoindolin-1-one (294 mg, 0.70 mmol) and 1,1-bis(hydroxymethyl) 
cyclopropane (0.14 mL, 1.39 mmol). Chromatography (SP4, silica, 6-70% EtOAc, 
PE) followed by (SP4, silica, 12-100% EtOAc, PE) gave 311 as a colourless oil (72 
mg, 20%). Rf  =  0.21 (3:7 EtOAc:PE); UV λmax (EtOH): 229.0 nm; IR ʋmax 3423 
(OH), 2920, 2159 (Ethynyl), 1703 (C=O), 1587 (Amide C-N), 760 (C-Cl) cm
-1
; δH 
(500 MHz CDCl3): 0.02-0.08 (1H, m cyclopropyl), 0.22-0.28 (1H, m, cyclopropyl), 
0.38-0.42 (2H, m, cyclopropyl), 1.67 (1H, s, OH), 2.02 (3H, s, CH3), 2.77 (1H, d, J = 
9.1 Hz, OCH2), 2.87 (1H, d, J = 9.1 Hz, OCH2). 3.38 (1H, dd, J = 3.5 and 11.4 Hz, 
CH2OH), 3.47 (1H, dd, J = 4.8 Hz and 11.4 Hz, CH2OH), 4.06 (1H, d, J = 15.0 Hz, 
NCH2), 4.53 (1H, d, J = 15.0 Hz, NCH2), 7.09 (2H, d, J = 8.2 Hz, benzyl Ar-H), 7.19-
7.26 (6H, m, Ar-H), 7.44 (1H, dd, J = 1.0 and 8.0 Hz, H
5
), 7.48-7.51 (1H, m, H
6
), 
7.90 (1H, dd, J = 1.0 and 7.4 Hz, H
7
); δC (125 MHz CDCl3): 4.4 (CH3), 8.5 
(cyclopropyl), 8.6 (cyclopropyl), 22.1 (cyclopropyl), 42.7 (NCH2), 67.8 (CH2OH), 
68.0 (OCH2), 79.4 (CCCH3), 86.1 (CCCH3), 94.8 (hemi-aminal), 122.3, 123.3, 128.4, 
128.9, 129.1, 129.7, 131.3, 133.9, 134.7, 135.0, 136.4, 140.8, 166.8 (C=O); LCMS Rt 
= 1.73 min, (3); MS (ESI+) m/z 506.2 [M+H]
+
; HRMS m/z: Calc. for 
C29H26
35
Cl2NO3: 506.1284 [M+H]
+
. Found: 506.1285 [M+H]
+
.; Analytical HPLC: 
95.3% purity 
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4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-(phenylethynyl)benzyl)isoindolin-1-one 
(314) 
 
General procedure F: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-iodobenzyl)-
isoindolin-1-one (241 mg, 0.47 mmol) and phenylacetylene (67 µL, 0.61 mmol). 
Chromatography (SP4, silica, 7-60% PE, EtOAc) and (silica, 3:7 EtOAc:PE) gave 
314 as a white solid (208 mg, 91%). Rf  = 0.43 (3:7 EtOAc:PE); mp = 210.2-214.0 
o
C; 
UV λmax (EtOH): 302.0, 284.0 nm; IR ʋmax 3186 (OH), 2158 (Ethynyl), 1657 (CO),  
1589 (Amide C-N), 1406, 751 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 3.22 (1H, s, OH), 
4.02 (1H, d, J = 15.1 Hz, NCH2), 4.54 (1H, d, J = 15.1 Hz, NCH2), 7.08 (2H, d, J = 
8.2 Hz, benzyl Ar-H), 7.18-7.28 (9H, m, Ar-H), 7.35-7.740 (2H, m, H
5
 and H
6
), 7.41-
7.44 (2H, m, Ar-H), 7.66 (1H, dd, J = 1.7 and 6.7 Hz, H
7); δC (125 MHz CDCl3): 42.7 
(NCH2), 89.1 (alkyne), 89.5 (alkyne), 100.0 (hemi-aminal), 122.1 (C-alkyne), 122.2 
(C-alkyne), 123.2, 128.3, 128.3, 128.3, 128.6, 128.7, 129.6, 131.5, 131.6, 131.6, 
133.0, 134.0, 134.8, 134.9, 137.8, 143.8, 166.1 (C=O); LCMS Rt = 1.82 min, (3); MS 
(ESI+) m/z 484.2 [M+H]
+
; HRMS m/z: Calc. for C29H20
35
Cl2NO2 484.0866 [M+H]
+
. 
Found 484.0861 [M+H]
+
. 
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4-Chloro-3-(4-chlorophenyl)-3-(1-((hydroxymethyl)cyclopropane)methoxy)-2-(4-
(phenylethynyl)benzyl)isoindolin-1-one (312) 
 
General procedure C: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-
(phenylethynyl)benzyl)isoindolin-1-one (208  mg, 0.43 mmol) and 1,1-
bis(hydroxymethyl)cyclopropane (0.08 mL, 0.86 mmol). Chromatography (SP4, 
silica, 7-60 % EtOAc, PE) followed by (SP4, silica, 12-100 % EtOAc, PE) gave 312 
as a colourless oil (89 mg, 36%). Rf   = 0.21 (3:7 EtOAc:PE); UV λmax (EtOH): 302.0, 
284.0 nm; IR ʋmax 3465 (OH), 2919, 1704 (C=O), 1587 (Amide C-N), 755 (C-Cl)   
cm
-1
; δH (500 MHz): 0.09-0.13 (1H, m, cyclopropyl), 0.27-0.29 (1H, m, cyclopropyl), 
0.40-0.45 (2H, m, cyclopropyl), 1.70 (1H, s, OH), 2.82 (1H, d, J = 9.1 Hz, OCH2), 
2.90 (1H, d, J = 9.1 Hz, OCH2), 3.40-3.41 (1H, m, CH2OH), 3.50 (1H, dd, J = 3.9 and 
11.4 Hz, CH2OH), 4.14 (1H, d, J = 15.1 Hz, NCH2), 4.54 (1H, d, J = 15.1 Hz, NCH2), 
7.15 (2H, d, J = 8.2 Hz, Ar-H), 7.22-7.7.35 (9H, m, Ar-H), 7.45 (1H, dd, J = 1.0 and 
8.0 Hz, H
5
), 7.49-7.52 (3H, m, Ar-H), 7.86 (1H, dd, J = 1.0 and 7.4 Hz, H
7); δC (125 
MHz): 8.6 (cyclopropyl), 8.6 (cyclopropyl), 22.1 (cyclopropyl), 42.8 (NCH2), 67.9 
(CH2OH), 68.2 (OCH2), 89.0 (ethynyl), 89.6 (ethynyl), 95.8 (hemi-aminal), 122.3, 
122.4, 123.2, 128.3, 128.3, 128.5, 129.0, 129.7, 131.5, 131.6, 131.9, 133.9, 134.4, 
134.7, 135.0, 137.2, 140.8, 156.8, 166.8 (C=O); LCMS Rt = 1.91 min, (4); MS (ESI+) 
m/z 568.3 [M+H]
+
; HRMS m/z: Calc. for C34H28
35
Cl2NO3: 568.1441 [M+H]
+
. Found 
568.1440 [M+H]
+
.; Analytical HPLC: 94.8% purity 
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4-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-nitrobenzyl)isoindolin-2-one (321) 
 
General procedure B: sodium 3-chloro-2-(4-chlorobenzoyl)benzoate (500 mg, 1.58 
mmol) and 4-nitrobenzylamine hydrochloride (328 mg, 1.74 mmol). Chromatography 
(SP4, silica, 12-100% EtOAc, petrol) gave 321 as a white solid (187 mg, 28%). Rf = 
0.59 (1:1 EtOAc:PE); mp. = 202.2-202.9 
o
C (lit. 202-203 
o
C)
240
; UV λmax (EtOH): 
272.0 nm; IR ʋmax 1686 (C=O), 1589 (Amide C-N), 1515 cm
-1
; δH (500 MHz d6-
DMSO): 4.41 (1H, d, J = 16.2 Hz, NCH2), 4.54 (1H, d, J = 16.2 Hz, NCH2), 7.28-7.33 
(4H, m, Ar-H), 7.40 (2H, d, J = 8.2 Hz, Ar-H), 7.55 (1H, s, OH), 7.63-7.66 (2H, m, 
Ar-H), 7.72 (1H, d, J = 5.5 Hz, H
7
), 8.04 (2H, d, J = 8.2 Hz, Ar-H); δC (125 MHz d3-
MeCN): 41.3 (NCH2), 89.9 (hemi-aminal), 121.4, 122.7, 127.8, 128.2, 128.7, 128.9, 
131.6, 133.0, 135.5, 135.8, 143.5(CCCl), 145.4 (CH2C), 146.5 (Ar-NO2), 165.6 
(carbonyl carbon); LCMS Rt = 3.63 min (1); MS (ESI+) m/z 429.07 [M+H]
+
   
 
(3-Hydroxymethyloxetan-3-yl)-methanol (318) 
 
A mixture of 3-bromo-2,2-bis-hydroxymethylpropan-1-ol (100 mg, 0.50 mmol, 1 eq), 
ethanol (0.9 mL) and potassium hydroxide (32 mg,0.60 mmol, 1.15 eq) was stirred for 
2h at room temperature then reflux for 15 min, cooled to room temperature and 
filtered . The solid was washed with methanol (10 mL). The filtrate was evaporated in 
vacuo and residue purified by chromatography (silica, 10:90 MeOH:EtOAc) to give 
318 as a colourless liquid (46 mg, 78%). Rf = 0.3 (1:9 MeOH:EtOAc); IR ʋmax 3280 
(OH), 2954, 2881 cm
-1
; δH (500 MHz CDCl3): 2.20 (2H, s, OH), 3.95 (4H, s, 
CH2OH), 4.41 (4H, s, CH2O); δC (125 MHz CDCl3): 44.6, (quaternary carbon), 66.7 ( 
CH2OH), 76.3 (CH2O)  
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3-(2-Bromomethyl-3-hydroxy-2-hydroxymethyl-propoxy)-4-chloro-3-(4-
chlorophenyl)-2-(4-nitrobenzyl)isoindolin-1-one (322) 
 
General procedure C: 4-chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-
nitrobenzyl)isoindolin-2-one (382 mg, 0.89 mmol, 1 eq) and 2-(bromomethyl)-2-
(hydroxymethyl)propan-1,2-diol (354 mg ,1.78 mmol, 2 eq). Chromatography (SP4, 
silica, 17-100 % EtOAc, petrol) gave 322 as a white solid (227 mg, 42%). Rf  = 0.45 
(3:7 EtOAc:PE); mp = 185.7-185.4 
o
C; UV λmax (EtOH): 262.0, 250.0 nm; IR ʋmax 
3376 (C=O), 2942, 2160 (Ethynyl), 1695 (C=O), 1588 (Amide C-N), 757 (C-Cl), 655 
cm
-1
; δH (500 MHz d6): 2.86 (1H, d, J = 8.5 Hz, OCH2), 3.24 (1H, d, J = 8.5 Hz 
OCH2), 3.52-3.60 (4H, m, CH2OH), 3.67 (1H, s, CH2Br), 4.37 (1h, d, J = 16.0 Hz, 
NCH2), 4.70 (1H, J = 4.9 Hz, OH), 4.76 (1H, t, J = 4.8 Hz, OH), 4.90 (1H, d, J = 16.0 
Hz, NCH2), 7.20-7.24 (6H, m, Ar-H), 7.76 (2H, d, J = 4.1 Hz, Ar-H), 7.94-7.98 (3H, 
m, Ar-H); δC (125 MHz d6 DMSO): 36.7 (CBr), 41.1 (C(CH2)4), 44.6 (NCH2), 60.4 
(CH2OH), 60.4 (CH2OH), 62.0 (OCH2), 93.0 (hemi-aminal carbon), 122.1, 122.8, 
127.9, 128.4, 129.2, 129.2, 132.9, 133.2, 133.8, 134.1, 135.3, 139.8, 144.8, 146.0 
(CNO2), 165.8 (C=O) ; LCMS Rt = 1.56 min, (3); MS (ES-) m/z 655 [M+HCOO]
-
; 
HMRS: Calculated for C26H27
79
Br
35
Cl2N3O6 626.0455 [M+NH4]
+
 Found 626.0437 
[M+NH4]
+ 
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4-Chloro-3-(4-chlorophenyl)-3-hydroxymethyloxetan-3-ylmethoxy)-2-(4-
nitrobenzyl)isoindolin-2-one (317) 
 
General procedure H: 3-(2-bromomethyl-3-hydroxy-2-hydroxymethyl-propoxy)-4-
chloro-3-(4-chlorophenyl)-2-(4-nitrobenzyl)isoindolin-1-one (63 mg, 0.10 mmol). 
Chromatography (SP4, silica, 17-100% EtOAc, PE) gave the title compound as 
colourless oil (36 mg, 68%). Rf  = 0.27 (3:7 EtOAc:PE); mp = 207.8-208.3 
o
C; UV 
λmax (EtOH): 267.0 nm; IR ʋmax 3408 (OH), 2875, 2163, 1687 (C=O), 1518 (Amide 
C-N), 1339 (NO2) cm
-1
; δH (500 MHz CDCl3): 1.72 (1H, s, OH), 3.07 (1H, d, J = 9.0 
Hz, OCH2), 3.31 (1H, d, J = 9.0 Hz, OCH2), 3.86 (2H, s, CH2OH), 4.36-4.44 (4H, m, 
oxetane CH2), 4.42 (1H, d, J = 15.0 Hz, NCH2), 4.52 (1H, d, J = 15.0 Hz, NCH2), 
7.16-7.26 (6H, m, Ar-H), 7.50-7.51 (1H, m, H
5
), 7.55-7.58 (1H, m, H
6
), 7.90 (1H, dd, 
J = 3.5 and 7.5 Hz, H
7
), 7.98 (2H, d, 8.5 Hz, CHCNO2); δC (125 MHz CDCl3): 42.2 
(NCH2), 44.0 (oxetane OCH2C), 64.4 (OCH2), 64.8 (CH2OH), 75.6 (oxetane CH2), 
75.6 (oxetane CH2), 94.4 (hemi-aminal), 122.6, 123.4, 128.8, 128.6, 129.6, 129.8, 
132.3, 133.9, 134.3, 134.6, 135.1, 140.3, 144.1, 147.1 (C-NO2), 166.8 (C=O); LCMS 
Rt = 1.48 min, (3); MS (ESI+) m/z 573 [M+HCOOH]
+
; HRMS m/z: Calc. for 
C26H26Cl22N3O6 546.1193 [M+NH4]
+
. Found: 546.1190 [M+NH4]
+
.; Analytical 
HPLC: 97.9% purity 
 
Chiral Separation mobile phase hexane:ethanol 85:15:  
326 Peak 1: (50 mg, 49%); Specific rotation [α] = -10.7 o (at 24.4 oC, wavelength = 
589 nm, tube length = 0.1 dm, concentration = 0.560 g per 100 mL);  
327 Peak 2: (50 mg, 49%); Specific rotation [α] = +30.3 o (at 24.5 oC, wavelength = 
589 nm tube length = 0.1 dm, concentration = 0.462 g per 100 mL) 
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3-(2-Bromomethyl-3-hydroxy-2-hydroxymethyl-propoxy)-4-chloro-3-(4-
chlorophenyl)-2-((4-triisopropylsilyl)ethynyl)benzyl)isoindolin-2-one (323) 
 
General procedure C: 3-Chloro-3-(4-chlorophenyl)-3-hydroxy-2-(4-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (334 mg, 0.59 mmol) and 2-
(bromomethyl)-2-(hydroxymethyl)-1,3-propan-diol (236 mg, 1.19 mmol). 
Chromatography (SP4, silica, 10-80% EtOAc, PE) gave 323 as a colourless oil (135 
mg, 31%). Rf  = 0.12 (3:7 EtOAc:PE); UV λmax (EtOH): 267.0, 255.0 nm; IR ʋmax 
3342 (OH), 2942, 2865, 2361, 2156 (Ethynyl), 1685 (C=O), 1589 (Amide C-N), 
1041, 761 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 1.04 (18H, s, CH3), 2.13 (1H, s, OH), 
2.18 (1H, s, OH), 2.73 (1H, s, J = 8.9 Hz, CH2Br), 3.10 (1H, d, J = 8.9 Hz, CH2Br), 
3.42 (1H, d, J = 10.5 Hz, OCH2), 3.46 (1H, d, J = 10.5 Hz, OCH2), 3.57-3.66 (4H, m, 
CH2OH), 4.24 (1H, d, J = 15.1 Hz, NCH2), 4.45 (1H, d, J = 15.1 Hz, NCH2), 6.86 
(2H, d, J = 8.2 Hz, benzyl Ar-H), 7.05-7.14 (6H, m, Ar-H), 7.40 (1H, dd, J = 1.0 and 
8.0 Hz, H
5
), 7.44-7.47 (1H, m, H
6
), 7.79 (1H, dd, J = 1.0 and 7.4 Hz, H
7); δC (125 
MHz CDCl3): 11.3 (CH3), 18.7 (CH(CH3)2), 34.7 (CH2Br), 42.8 (C(CH2)4), 44.5 
(NCH2), 63.05 (OCH2), 64.2 (CH2OH), 64.5 (CH2OH), 90.9 (ethynyl), 94.4 (ethynyl), 
106.7 (hemi-aminal), 122.4, 122.5, 128.1, 128.4, 128.7, 129.7, 131.8,  132.2, 134.1, 
134.2, 134.6, 134.9, 136.9, 140.2, 166.8 (C=O); LCMS Rt = 2.26 min, (4); HRMS 
m/z: Calc. for C37H48
79
Br
35
Cl2NO4Si: 761.1938 [M+NH4]
+
. Found 761.1934 
[M+NH4]
+
. 
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4-Chloro-3-(4-chlorophenyl)-3-(3-hydroxymethyl-oxetan-3-ylmethoxy)-2-
(((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (324) 
 
General procedure H: 3-(2-bromomethyl-3-hydroxy-2-hydroxymethyl-propoxy)-4-
chloro-3-(4-chlorophenyl)-2-((4-triisopropylsilyl)ethynyl)benzyl)isoindolin-2-one 
(750 mg, 2.88 mmol). Chromatography (SP4, silica, 12-100% EtOAc, PE) gave 324 
as a colourless oil (142 mg, 63%). Rf  = 0.18 (1:1 EtOAc:PE); UV λmax (EtOH): 262.0, 
250.5 nm; IR ʋmax 3362 (OH), 2842, 2865, 2156 (Ethynyl), 1694 (C=O), 1590 (Amide 
C-N), 815, 761 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 1.10 (18H, s, CH3), 1.76 (1H, t, 
4.5 Hz, OH), 2.99 (1H, d, J = 9.0 Hz, OCH2), 3.17 (1H, d, J = 9.0Hz, OCH2), 3.71 
(1H, dd, J = 4.5 and 10.8 Hz, CH2OH), 3.79 (1H, dd, J = 4.5 and 10.8 Hz, CH2OH), 
4.20 (1H, d, J = 15.0 Hz, NCH2), 4.29 (1H, d, J = 6.25 Hz, oxetane CH2), 4.37-4.41 
(3H, m, oxetane CH2), 4.49 (1H, d, J = 15.0 Hz, NCH2), 7.04 (2H, d, J = 8.2 Hz, 
benzyl Ar-H), 7.19-7.20 (4H, m, Ar-H), 7.25 (2H, d, J = 8.2 Hz, benzyl Ar-H), 7.46 
(1H, dd, J = 0.8 and 8.0 Hz, H
5
), 7.51-7.54 (1H, m, H
6
), 7.87 (1H, dd, J = 0.8 and 7.4 
Hz, H
7); δC (125 MHz CDCl3): 11.3 (CH3), 18.7 (CH(CH3)2), 42.8 (NCH2), 43.9 
(oxetane quat. C), 64.3 (OCH2), 65.0 (CH2OH), 75.4 (oxetane CH2), 75.6 (oxetane 
CH2), 91.1 (CC-Si), 94.7 (CC-Si), 106.6 (hemi-aminal), 122.5 (C-CC-Si), 122.7, 
128.3, 128.6, 128.8, 129.6, 131.7, 132.1, 134.1, 134.1, 134.6, 134.9, 137.0, 140.0, 
166.7 (C=O); LCMS Rt = 2.20 min, (5); MS (ESI+) m/z 664.5 [M+H]
+
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4-Chloro-3-(4-chlorophenyl)-2-(4-ethynylbenzyl)-3-(3-hydroxymethyl-oxetan-3-
ylmethoxy)isoindolin-1-one (325) 
 
General procedure G: 4-chloro-3-(4-chlorophenyl)-3-(3-hydroxymethyl-oxetan-3-
ylmethoxy)-2-(((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (142 mg, 0.21 
mmol. Chromatography (SP4, silica, 12-100% EtOAc, PE) gave 325 as a colourless 
oil (95 mg, 89%). Rf = 0.18 (1:1, EtOAc:PE); mp = 182.2-182.9 
o
C; UV λmax (EtOH): 
229.0 nm; IR ʋmax 3447 (OH), 3296, 2924, 2872, 2360, 2162 (Ethynyl), 2026, 1709, 
1683 (C=O), 1587 (Amide C-N), 762 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 1.58 (1H, t, 
J = 5.3 Hz, OH), 3.02 (1H, d, J = 8.9 , OCH2), 3.07 (1H, s, CCH), 3.21 (1H, d, J = 8.9 
Hz, OCH2), 3.74 (1H, dd, J = 5.3 and 10.9 Hz, CH2OH), 3.80 (1H, dd, J = 5.3 and 
10.9 Hz, CH2OH), 4.17 (1H, d, J = 15.1 Hz, NCH2), 4.31-4.40 (4H, m, oxetane CH2), 
4.58 (1H, d, J = 15.1 Hz, NCH2), 7.13 (2H, d, J = 8.2 Hz, benzyl Ar-H), 7.24-7.43 
(6H, m, Ar-H), 7.50 (1H, dd, J = 0.9 and 7.9 Hz, H
5
), 7.55-7.59 (1H, m, H
6
), 7.92 
(1H, dd, J = 0.9 and 7.4 Hz, H
7); δC (125 MHz CDCl3): 42.8 (NCH2), 43.9 (oxetane 
OCH2C), 64.4 (OCH2), 65.0 (CH2OH), 75.4 (oxetane CH2), 75.6 (oxetane CH2), 77.6 
(CCH), 83.1 (CCH), 94.8 (hemi-aminal), 121.3, 122.5, 128.6, 128.9, 129.6, 132.1, 
132.1, 134.1, 134.1, 134.6, 134.9, 137.7, 140.4, 166.8 (C=O); LCMS Rt =1.53 min, 
(3); MS (ESI+) m/z 552 [M+HCOO]
+
; HRMS m/z: Calc. for C28H23
35
Cl2NO4 
508.1077 [M+H]
+
. Found 508.1074 [M+H]
+
.; Analytical HPLC: 99.2% purity 
 
Chiral Separation mobile phase tert butyl methyl ether:isopropanol 95:5:  
328 Peak 1: (38 mg, 42%); Specific rotation [α] = -7.74 o (at 25.6 oC, wavelength = 
589 nm, tube length = 0.1 dm, concentration = 0.517 g per 100 mL);  
329 Peak 2: (37 mg, 41%); Specific rotation [α] = +4.65 o (at 25.6 oC, wavelength = 
589 nm tube length = 0.1 dm, concentration = 0.43 g per 100 mL) 
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5-tert-Butyl-2-hydroxybenzaldehyde (340) 
 
To a solution of 4-tertbutylphenol (2.00 g, 13.3 mmol, 1 eq) in TFA (20 mL) was 
added hexamethylenetetramine (1.86 g, 13.3 mmol, 1 eq) and the reaction was heated 
to 120 
o
C for 30 min with microwave heating, cooled in an ice-bath, diluted with 
water (40 mL) and neutralised using K2CO3. The resulting aqueous solution was 
extracted with EtOAc (3 x 60 mL) and combined organic extracts dried over MgSO4 
and concentrated in vacuo. Chromatography (SP4, silica, 1-10% EtOAc, PE) gave 
340 as a white oily solid (1.09 g, 46%). Rf  = 0.57 (5:95 EtOAc:PE); UV λmax (EtOH): 
335.0, 258.5, 220.0 nm; IR ʋmax 2963 (OH), 2160, 1652 (C=O), 1483 cm
-1
; δH (500 
MHz CDCl3): 1.25 (9H, s, CH3), 6.86 (1H, d, J = 8.8 Hz, H
3
), 7.44 (1H, d, J = 2.5 Hz, 
H
6
), 7.51 (1H, dd, J = 2.5 and 8.8 Hz, H
4), 9.81 (1H, s, OH), 10.80 (1H, s, CHO); δC 
(125 MHz CDCl3): 31.4 (CH3), 34.1 (C(CH3)3), 117.2 (C
3
), 120.0, 129.8, 134.8, 142.8 
(CC(CH3)3), 157.8 (COH), 196.9 (C=O); LCMS Rt = 1.52 min, (3), MS (ESI+) m/z 
179.2 [M+H]
+
      
 
4-Chlorobenzoic acid (4-tert-butyl-2-hydroxy-benzylidene)hydrazine (341) 
 
To a solution of 340 (1.06 g, 5.96 mmol, 1 eq) in AcOH (20 mL) was added 4-
chlorobenzhydrazide (1.02 g , 5.96 mmol, 1 eq) and the reaction stirred at room 
temperature for 15 min, then added dropwise to ice-cold water (20 mL). The 
precipitate was collected by filtration, washed with ice-cold water (20 mL) and petrol, 
(10 mL) and dried over P2O5 to give 341 as a white solid (1.85 g, 94%). Rf  = 0.26 (1:4 
EtOAc:PE); mp = 225.2-228.0 
o
C; UV λmax (EtOH): 338.5, 290.5, 241.0 nm; IR ʋmax 
2953 (OH), 2159 (C=N), 1642 (C=O), 826, 750 (C-Cl) cm
-1
; δH (500 MHz d6 
DMSO): 1.29 (9H, s, CH3), 6.89 (1H, dd, J = 8.6 Hz, H
6
), 7.36 (1H, dd, J = 2.2 and 
8.6 Hz, H
5
), 7.53 (1H, d, J = 2.2 Hz, H
3
), 7.64 (2H, d, J = 8.1 Hz, CHCCl), 7.98 (2H, 
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d, J = 8.1 Hz, CHCCO), 8.66 (1H, s, CHN), 11.02 (1H, s,  OH), 12.12 (1H, s, NH); δC 
(125 MHz d6 DMSO): 31.2 (CH3), 33.8 (C(CH3)3), 116.1 (C
6
), 17.9, 125.4 (C
3
), 
128.6, 128.7, 129.6 (CHCCl), 131.6 (CHCCO), 136.7, 141.5, 148.8 (C=N), 155.3 
(CO), 161.8 (C=O); LCMS Rt = 1.60 min, (3); MS (ESI+) m/z 331.2 [M+H]
+
; HRMS 
m/z: Calc. for C18H20
35
ClN2O2: 331.1208 [M+H]
+
. Found 331.1207 [M+H]
+
.      
 
5-tert-Butyl-2-(4-chlorobenzoyl)benzaldehyde (342) 
 
To 341 (500 mg, 1.51 mmol, 1 eq) in THF (11 mL) at 0 
o
C was added Pb(OAc)4 (670 
mg, 1.51 mmol, 1 eq) portionwise and stirred for 2 h at 0 
o
C, then concentrated in 
vacuo. The residue was dissolved in EtOAc (30 mL), filtered through Celite and 
washed with EtOAc (20 mL). The filtrate was washed with sat. NaHCO3 solution (30 
mL) and brine (30 mL), dried over Na2SO4 and concentrated in vacuo. 
Chromatography (SP4, silica, 2-20% EtOAc, PE) gave 342 as a white solid (331 mg, 
73%). Rf  = 0.51 (1:9 EtOAc:PE); mp = 116.3-117.1 
o
C; UV λmax (EtOH): 261.0 nm; 
IR ʋmax 2963 (Aldehyde C-H), 2160, 1688 (Ketone C=O), 1657 (Aldehyde C=O), 
1583 cm
-1
; δH (500 MHz CDCl3): 1.34 (9H, s, CH3), 7.35-7.38 (3H, m, Ar-H), 7.64 
(1H, dd, J = 2.0 and 8.0 Hz, H
5
), 7.68 (2H, d, J = 8.7 Hz, Ar-H), 7.97 (1H, d, J = 2.0 
Hz, H
7), 9.96 (1H, s, CHO); δC (125 MHz CDCl3): 31.1 (CH3), 35.2 (C(CH3)3), 127.4, 
129.0, 129.0, 130.5, 131.3, 135.5, 135.7, 138.0, 140.0 (CCl), 154.7 (CC(CH3)3), 191.0 
(CHO), 195.4 (CO); LCMS Rt = 1.80 min, (3); MS (ESI+) m/z 301.2 [M+H]
+
; HRMS 
m/z: Calc. for C18H18
35
ClO2: 301.0990 [M+H]
+
. Found 301.0997 [M+H]
+
. 
 
6-tert-Butyl-2-(4-chlorobenzoyl)benzoic acid (343) 
 
To a solution of 5-tert-butyl-2-(4-chlorobenzoyl)-benzaldehyde (606 mg, 2.01 mmol, 
1 eq) in MeCN (12 mL) was added sulfamic acid (364 mg, 2.62 mmol, 1.3 eq) in 
water (2 mL) and the reaction was stirred for 10 min before NaClO2 (254 mg, 4.03 
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mmol, 2 eq) in water (2 mL) was added dropwise, and stirred 1.5 h, then concentrated 
in vacuo. The residue was suspended in water (30 mL) and extracted with EtOAc (3 x 
40 mL). The combined organic layers were dried over Na2SO4 and evaporated in 
vacuo. Recrystallisation (EtOAc and petrol) gave 343 as a white fluffy solid (529 mg, 
83%). Rf  =  0.06 (3:7 EtOAc:PE); mp = 218.1-219.6 
o
C; UV λmax (EtOH): 254.5 nm; 
IR ʋmax (cm
-1
) 2965 (OH), 2161, 2032, 1679 (Ketone C=O), 1584 (Acid C=O), 757 
(C-Cl) cm
-1
; δH (500 MHz d6 DMSO): 1.36 (9H, s, CH3), 7.39 (1H, d, J = 8.0 Hz, H
3
), 
7.58 (2H, d, J = 8.5 Hz, CHCCl), 7.63 (2H, d, J = 8.5 Hz, CHCCO), 7.78 (1H, d, J = 
8.0 Hz, H
4
), 7.98 (1H, s, H
6), 13.2 (1H, s, OH); δC (125 MHz CDCl3): 30.8 (CH3), 
34.6 (C(CH3)3), 126.2 (C
6
), 127.5 (C
3
), 128.8, 129.4 (CHCCl), 129.9 (C
4
), 130.5 
(CHCCO), 135.9 (CCOOH), 137.9 (CCO), 138.2 (CCl), 152.7 (CC(CH3)3), 167.1 
(COOH), 195.3 (CO); LCMS Rt = 1.58 min, (3); MS (ESI+) m/z 317.2 [M+H]
+
; 
HRMS m/z: Calc. for C18H18
35
ClO3: 317.0939 [M+H]
+
. Found 317.0942 [M+H]
+
. 
 
6-tert-Butyl-3-(chlorophenyl)-3-hydroxy-2-(4-iodobenzyl)isoindolin-2-one (334) 
 
General procedure B: 6-tert-butyl-2-(4-chlorobenzoyl)-benzoic acid (500 mg, 1.58 
mmol) and 4-iodobenzylamine hydrochloride (468 mg. 1.74 mmol). Chromatography 
(SP4, silica, 7-60 % EtOAc, PE) gave 334 as a white solid (724 mg, 86%). Rf  = 0.68 
(3:7 EtOAc:PE); mp =223.6-226.1 
o
C; UV λmax (EtOH): 228.5 nm; IR ʋmax 3253 
(OH), 2970, 2159, 1664 (C=O), 1623, 835, 695 (C-Cl) cm
-1
; δH (500 MHz CDCl3): 
1.26 (9H, s, CH3), 3.25 (1H, s, OH), 3.88 (1H, d, J = 15.1 Hz, NCH2), 4.38 (1H, d, J = 
15.1 Hz, NCH2), 6.80 (2H, d, J = 8.3 Hz, benzyl Ar-H), 7.09-7.13 (5H, m, Ar-H), 
7.37 (2H, d, J = 8.3 Hz, benzyl Ar-H), 7.47 (1H, dd, J = 1.8 and 8.1 Hz, H
5
), 7.81 
(1H, d, J = 1.8 Hz, H
7); δC (125 MHz CDCl3): 31.4 (CH3), 35.2 (C(CH3)3), 42.4 
(NCH2), 91.0 (CI), 92.6 (hemi-aminal), 120.5, 122.3, 127.9, 128.6, 129.7, 130.5, 
130.7, 134.5, 136.8, 137.3, 137.6, 145.7, 153.7 (CC(CH3)3), 168.1 (C=O);  LCMS Rt 
= 1.87 min, (5); MS (ESI+) m/z 532.2 [M+H]
+
; HRMS m/z: Calc. for C25H23
35
ClINO2  
532.0535 [M+H]
+
. Found 532.0532 [M+H]
+
. 
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6-tert-Butyl-3-(4-chlorophenyl)-3-hydroxy-2-(4-((triisopropylsilyl)ethynyl) 
benzyl)isoindolin-1-one (335) 
 
General procedure F: 334 (700 mg, 1.32 mmol, 1 eq) and triisopropylsiliylacetylene 
(384 µL, 1.71 mmol, 1.3 eq). Chromatography (SP4, silica, 3-30% EtOAc, PE) gave 
335 as a white solid (708 mg, 91%). Rf  = 0.34 (15:85 EtOAc:PE); mp = 165.8-167.7 
o
C; UV λmax (EtOH): 266.0, 254.5 nm; IR ʋmax 3285 (OH), 2945, 2866, 2153 
(Ethynyl), 1677 (C=O), 838 cm
-1
; δH (500 MHz CDCl3): 1.01 (18H, s, 
Si(CH(CH3)2)3), 1.23 (9H, s, C(CH3)3), 3.78 (1H, d, J = 15.1 Hz, NCH2), 4.16 (1H, d, 
J = 15.1 Hz, NCH2), 4.55 (1H, s, OH), 6.80 (2H, d, J = 8.2 Hz, benzyl Ar-H), 7.02-
7.09 (6H, m, Ar-H), 7.42 (1H, dd, J = 1.6 and 8.1 Hz, H
5
), 7.76 (1H, d, 1.6 Hz, H
7
); 
δC (125 MHz CDCl3): 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 31.4 (C(CH3)3), 
35.1 (C(CH3)3), 42.6 (NCH2), 90.4 (ethynyl), 90.9 (ethynyl), 107.0 (hemi-aminal), 
120.4 (C-ethynyl), 122.1, 127.9, 128.4, 128.6, 129.8, 130.4, 131.7, 134.4, 137.1, 
137.9146.1, 153.3 (CC(CH3)3), 168.5 (C=O); LCMS Rt = 2.50 min, (5); MS (ESI+) 
m/z 586.4 [M+H]
+
; HRMS m/z: Calc. for C36H45
35
ClNO2Si: 586.2903 [M+H]
+
. Found 
586.2901 [M+H]
+
.     
 
6-tert-Butyl-3-(4-chlorophenyl)-3-(1-((hydroxymethyl)cyclopropane)methoxy)-2-(4-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (336) 
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General procedure C: 6-tert-butyl-3-(4-chlorophenyl)-3-hydroxy-2-(4-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (354 mg, 0.60 mmol, 1 eq) and 
bis(hydroxymethyl)cyclopropane (0.12 mL, 1.21 mmol). Chromatography (SP4, 
silica, 7-60 % EtOAc, PE) gave 336 as a colourless oil (200 mg, 50%). Rf  = 0.53 (3:7 
EtOAc:PE); UV λmax (EtOH): 266.5, 254.5 nm; IR ʋmax 2942, 2865, 2158 (Ethynyl), 
1685 (C=O) cm
-1
; δH (500 MHz CDCl3): 0.11-0.15 (2H, m, cyclopropyl), 0.35-0.41 
(2H, m, cyclopropyl), 1.09 (18H, s, Si(CH(CH3)2)3), 1.33 (9H, s, C(CH3)3), 1.61 (1H, 
t, J =  5.5 Hz, OH), 2.63 (1H, d, J = 9.5 Hz, OCH2), 2.82 (1H, d, J = 9.5 Hz, OCH2), 
3.34 (1H, dd, J = 5.5 and 11.3 Hz, CH2OH), 3.46 (1H, dd, J = 5.5 and 11.3 Hz, 
CH2OH), 4.16 (1H, d, J = 15.0 Hz, NCH2), 4.55 (1H, d, J = 15.0 Hz, NCH2), 7.03 
(1H, d, J = 8.0 Hz, H
4
), 7.11 (2H, d, J = 8.2 Hz, benzyl Ar-H), 7.15-7.19 (4H, m, Ar-
H), 7.24 (2H, d, J = 1.6 Hz, Ar-H), 7.52 (1H, dd, J = 1.8 and 8.0 Hz, H
5
), 7.90 (1H, d, 
J = 1.8 Hz, H
7); δC (125 MHz CDCl3): 8.6 (cyclopropyl), 8.7 (cyclopropyl), 11.3 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 22.1 (cyclopropyl), 31.4 (C(CH3)3), 35.2 
(C(CH3)3), 42.8 (NCH2), 67.8 (CH2OH), 68.1 (OCH2), 90.7 (ethynyl), 94.7 (ethynyl), 
106.8 (hemi-aminal), 120.6, 122.4, 122.5, 127.9, 128.6, 129.0, 130.3 ,131.3 ,131.8, 
137.3 ,137.7, 142.3, 153.8 (CC(CH3)3), 168.7 (C=O); LCMS Rt = 2.66 min, (5); MS 
(ESI+) m/z 670.5 [M+H]
+
; HRMS m/z: Calc. for C41H53
35
ClNO3Si: 670.3478 
[M+H]
+
. Found 670.3477 [M+H]
+
.      
 
6-tert-Butyl-3-(4-chlorophenyl)-2-(4-ethynylbenzyl)-3-(1-((hydroxymethyl) 
cyclopropyl)methoxy)isoindolin-1-one (330) 
 
General procedure G: 6-tert-butyl-3-(4-chlorophenyl)-3-(1-((hydroxymethyl) 
cyclopropane)methoxy)-2-(4-((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (150 
mg, 0.22 mmol). Chromatography (SP4, silica, 7-60% EtOAc, PE) gave 330 as a 
colourless oil (91 mg, 80%). Rf  = 0.36 (3:7 EtOAc:PE); UV λmax (EtOH): 230.0 nm; 
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IR ʋmax 3494 (OH), 3295, 2962, 2869, 2158 (Ethynyl), 2030, 1686 (C=O), 1489 cm
-1
; 
δH (500 MHz CDCl3): 0.08-0.11 (1H, m, cyclopropyl), 0.12-0.15 (1H, m, 
cyclopropyl), 0.36-0.42 (2H, m, cyclopropyl), 1.35 (9H, s, C(CH3)3), 1.67 (1H, s, 
OH), 2.63 (1H, d, J = 9.5 Hz, OCH2), 2.84 (1H, d, J = 9.5 Hz, OCH2), 3.04 (1H, s, 
CCH), 3.35 (1H, d, J =11.0 Hz, CH2OH), 3.47 (1H, d, J = 11.0 Hz, CH2OH), 4.16 
(1H, d, J = 15.0 Hz, NCH2), 4.59 (1H, d, J = 15.0 Hz, NCH2), 7.05 (1H, d, J = 8.0 Hz, 
H
4
), 7.16-7.20 (6H, m, Ar-H), 7.30 (2H, d, J = 8.2 Hz, Ar-H), 7.54 (1H, dd, J = 1.7 
and 8.0 Hz, H
5
), 7.92 (1H, d, J = 1.3 Hz, H
7); δC (125 MHz CDCl3): 8.6 
(cyclopropyl), 8.6 (cyclopropyl), 22.1 (cyclopropyl), 31.4 (C(CH3)3), 35.2 (C(CH3)3), 
42.8, (NCH2), 67.8 (CH2OH), 68.0 (OCH2), 83.4 (ethynyl), 94.8 (hemi-aminal) 120.6 
(C-CCH), 121.0, 122.4, 127.9, 128.6, 129.1, 130.3, 131.3, 131.9, 134.5, 137.3, 138.4, 
142.3, 153.8 (C-
t
Bu), 168.7 (C=O); LCMS Rt = 2.66 min, (5); HRMS m/z: Calc. for 
C32H32
35
ClNO3: 514.2143 [M+H]
+
. Found: 514.2140 [M+H]
+
.; Analytical HPLC: 
95.6% purity 
 
3-(2-Bromomethyl-2-hydroxymethyl-propoxy)-6-tert-butyl-3-(4-chlorophenyl)-2-(4-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (349) 
 
General procedure D: 334 (266 mg, 0.45 mmol), 2-(bromomethyl)-2-
(hydroxymethyl)propan-1,3-diol (902 mg, 4.34 mmol) in THF (5 mL). Reaction 
quenched after 3.5 h at 0 
o
C and 1 h at RT. Chromatography (SP4, silica, 7-60% 
EtOAc, PE) gave 349 as a colourless oil (300 mg, 87%). Rf  = 0.26 (3:7 EtOAc:PE); 
UV λmax (EtOH): 267.0, 255.0 nm; IR ʋmax 3567 (OH), 2941, 2865, 2365, 2157 
(Ethynyl), 1685 (C=O), 839 cm
-1
; δH (500 MHz CDCl3): 1.04 (18H, s, 
Si(CH(CH3)2)3), 1.29 (9H, s, C(CH3)3), 1.96 (2H, s, OH), 2.74 (1H, d, J = 9.1 Hz, 
CH2Br), 2.88 (1H, d, J = 9.1 Hz, CH2Br), 3.40 (1H, d, J = 10.4 Hz, OCH2), 3.44 (1H, 
7. MDM2/p53 Experimental Procedures 
 
307 
 
d, J = 10.4 Hz, OCH2), 3.49-3.52 (4H, m, CH2OH), 4.28 (1H, d, J = 15.1 Hz, NCH2), 
4.40 (1H, d, J = 15.1 Hz, NCH2), 6.98-7.00 (3H, m, Ar-H), 7.02 (2H, d, J = 8.6 Hz, 
Ar-H), 7.09 (2H, d, J = 8.9 Hz, Ar-H), 7.17-7.19 (2H, m , Ar-H), 7.48 (1H, dd, J = 1.8 
and 8.0 Hz, H
5
), 7.82 (1H, d, J = 1.8 Hz, H
7); δC (125 MHz CDCl3): 11.3 
(Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 31.3 (C(CH3)3), 34.6 (CH2Br), 35.2 
(C(CH3)3), 42.9 (NCH2), 44.4 (OCH2C(CH2)3), 62.7 (OCH2), 64.6 (CH2OH), 64.7 
(CH2OH), 90.9 (ethynyl), 94.7 (ethynyl), 106.7 (hemi-aminal), 120.6 (C
7
), 122.6, 
122.6, 127.8, 128.6, 128.8, 130.4, 131.3, 131.8, 134.6, 137.0, 137.5, 141.6, 154.1 
(C(CH3)3), 168.8 (C=O); LCMS Rt = 2.50 min, (5); HRMS m/z: Calc. for 
C41H54
79
Br
35
ClNO4Si: 766.2689 [M+H]
+
. Found 766.2690 [M+H]
+
. 
 
6-tert-Butyl-3-(4-chlorophenyl)-3-(3-hydroxymethyl-oxetan-3-ylmethoxy)-2-(4-
((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (350) 
 
General procedure H: 349 (250 mg, 0.33 mmol). Chromatography (SP4, silica, 7-
60% EtOAc, PE) gave 350 as a colourless oil (176 mg, 78%). Rf  = 0.13 (3:7 
EtOAc:PE); UV λmax (EtOH): 266.5, 254.5 nm; IR ʋmax  2944, 2866, 1689 (C=O), 728 
C-Cl) cm
-1
; δH (500 MHz CDCl3): 1.04 (18H, s, Si(CH(CH3)2)3), 1.29 (9H, s, 
C(CH3)3), 1.62 (1H, s, OH), 2.94 (2H, s, OCH2), 3.60 (1H, d, J = 10.8 Hz, CH2OH), 
4.13 (1H, d, J = 15.0 Hz, NCH2), 4.22-4.30 (4H, m, oxetane CH2), 4.50 (1H, d, J = 
15.0 Hz), 6.94 (1H, d, J = 8.0 Hz, H
4
), 7.03 (2H, d, J = 8.0 Hz, benzyl Ar-H), 7.08 
(2H, d, J = 8.4 Hz, Ar-H), 7.13 (2H, d, J = 8.4 Hz, Ar-H), 7.14 (2H, d, J = 8.0 benzyl 
Ar-H), 7.48 (1H, dd, J = 1.3 and 7.9 Hz, H
5
), 7.89 (1H, d, J = 1.3 Hz, H
7); δC (125 
MHz CDCl3): 11.3 (Si(CH(CH3)2)3), 18.7 (Si(CH(CH3)2)3), 31.3 (C(CH3)3), 35.2 
(C(CH3)3, 42.9 (NCH2), 44.0 (oxetane quat. C), 64.1 (OCH2), 65.0 (CH2OH), 75.6 
(oxetane CH2), 75.6 (oxetane CH2), 91.0 (ethynyl), 94.8 (ethynyl), 106.7 (hemi-
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aminal), 120.8 (C-ethynyl), 122.3, 122.6, 127.8, 128.7, 128.9, 130.5, 131.3, 131.8, 
134.6, 136.9, 137.5, 142.0, 154.0 (CC(CH3)3), 168.7 (C=O); LCMS Rt = 2.40 min, 
(5); MS (ESI+) m/z 686.6 [M+H]
+
; HRMS m/z: Calc. for C41H53
35
ClNO4Si: 686.3427 
[M+H]
+
. Found 686.3427 [M+H]
+
.     
 
6-tert-Butyl-3-(4-chlorophenyl)-2-(4-ethynylbenzyl)-3-(3-hydroxymethyloxetan-3-
ylmethoxy)isoindolin-1-one (351) 
 
General procedure G: 6-tert-butyl-3-(4-chlorophenyl)-3-(3-hydroxymethyl-oxetan-
3-ylmethoxy)-2-(4-((triisopropylsilyl)ethynyl)benzyl)isoindolin-1-one (141 mg, 0.20 
mmol). Chromatography (SP4, silica, 12-100 % EtOAc, PE) gave 351 as a colourless 
oil (62 mg, 59%). Rf  = 0.28 (1:1 EtOAc:PE); UV λmax (EtOH): 229.5 nm; IR ʋmax 
3300 (OH), 2963, 2874, 2160 (Ethynyl), 1687 (C=O), 1091, 907, 727 (C-Cl) cm
-1
; δH 
(500 MHz CDCl3): 1.30 (9H, s, 
t
Bu), 1.63 (1H, s, OH), 2.92 (2H, s, OCH2), 2.97 (1H, 
s, ethynyl), 3.59 (1H, d, J = 11.0 Hz, CH2OH), 3.62 (1H,d, J = 11.0 Hz, CH2OH), 
4.08 (1H, d, J = 15.0 Hz, NCH2), 4.16 (1H, d, J = 6.2 Hz, oxetane CH2), 4.23 (1H, d, 
J = 6.2 Hz, oxetane CH2), 4.25 (1H, d, J = 6.2 Hz, oxetane CH2), 4.28 (1H, d, 6.2 Hz, 
oxetane CH2), 4.56 (1H, d, 15.0 Hz, NCH2), 6.95 (1H, d, J = 8.0 Hz, H
4
), 7.08-7.10 
(4H, m, Ar-H), 7.15 (2H, d, J = 8.9 Hz, Ar-H), 7.24 (2H, d, J = 8.2 Hz, Ar-H), 7.49 
(1H, dd, J = 1.8 and 8.0 Hz, H
5
), 7.89 (1H, d, J = 1.8 Hz, H
7); δC (125 MHz CDCl3): 
31.3 (C(CH3)3), 35.2 (C(CH3)3), 42.9 (NCH2), 43.9 (oxetane OCH2C), 64.1 (OCH2), 
64.9 (CH2OH), 75.5 (oxetane CH2), 75.6 (oxetane CH2), 77.5 (CCH), 83.2 (CCH), 
94.8 (hemi-aminal), 120.8, 121.2, 122.4, 127.8, 128.7, 129.0, 130.6, 131.3, 132.0, 
134.7, 136.9, 138.2, 141.9, 154.1, 168.7 (C=O); LCMS Rt = 1.73 min, 2.(1); MS 
(ESI+) m/z 530.3 [M+H]
+
; HRMS m/z: Calc. for C32H33
35
ClNO4: 530.2093 [M+H]
+
. 
Found 530.2090 [M+H]
+
.; Analytical HPLC: 100.0% purity
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Appendix 1- Protein Crystallography 
 
Methodology 
 
MDM2 residues 17-109 or 17-125 expressed as a GST fusion. To a pellet equivalent 
to 1 L of culture was added DNAase (2 µL) and lysozme. After 20 min rotation at 4 
o
C, sample was lysated on ice for 3 min using sonication in 20 sec cycles with 40 sec 
rest. Sample centrifuged at 4 
o
C for 1 h at 20 000 rpm. Supernatent was loaded into 
gravity flow glutathione Sepharose column containing 2 mL of resin washed before 
use with PBS buffer. Column was washed with PBS buffer (20 mL) and protein 
eluded using 10 mL of glutathione buffer (PBS buffer with 20 mM glutathione). 
Cleavage was achieved using 1/20
th
 (w/w) 3C protease (prepared in-house as a GST-
fusion) overnight at 4 
o
C. Further purification achieved using size exclusion 
chromatography using highload 20/60 Superdex 200 column equilibrated with Hepes 
buffer. 
 
Table 32 Conditions for crystallisation for each mutant 
Mutant Purchased trays Custom Trays Comments 
K94A 
Molecular Dimension 
1+ 2, Wizard EDL, 
ST, Proplex 
- - 
K94E95A Insufficient protein - - 
Wild type 
AMD, Wizard EDL, 
ST, JCS6 
PEG4000, PEG5000, 
PEG8000 
- 
E69K70A - 
PEG4000, 0.2 M 
(NH4)2SO4, 0.1 M NaOAc 
(pH adjusted to 4.6) and 
PEG4000, 0.2 M 
(NH4)2SO4 
Only with 
inhibitors NCL-
00018225 and 
NCL-00013774 
Seeded 
E69A 
(17-109) 
1
st
 Morpheus, 
PEG/ION 
PEG4000, 0.2 M 
(NH4)2SO4, 0.1 M NaOAc 
and PEG4000, 0.2 M 
(NH4)2SO4 
- 
9. Appendix 1 
 
336 
 
E69A 
(17-125) 
- 
PEG4000, 0.2 M 
(NH4)2SO4, 0.1 M NaOAc 
(adjusted to pH 4.6) 
- 
E69K70E9
4A 
- 
PEG5000, 0.5-2.0 M 
(NH4)2SO4 and      
PEG8000, 0.2-0.35 M 
(NH4)2SO4 
- 
 
Table 33 Conditions for crystallisation tray set-up 
52% 
PEG5000, 
0.05 M 
(NH4)2SO4, 
215 µL 
water 
54% 
PEG5000, 
0.05 M 
(NH4)2SO4, 
205 µL 
water 
56% 
PEG5000, 
0.05 M 
(NH4)2SO4, 
195 µL 
water 
58% 
PEG5000, 
0.05 M 
(NH4)2SO4, 
185 µL 
water 
60% 
PEG5000, 
0.05 M 
(NH4)2SO4, 
175 µL 
water 
62% 
PEG5000, 
0.05 M 
(NH4)2SO4, 
165 µL 
water 
52% 
PEG5000, 
0.1 M 
(NH4)2SO4, 
190 µL 
water 
54% 
PEG5000, 
0.1 M 
(NH4)2SO4, 
180 µL 
water 
56% 
PEG5000, 
0.1 M 
(NH4)2SO4, 
170 µL 
water 
58% 
PEG5000, 
0.1 M 
(NH4)2SO4, 
160 µL 
water 
60% 
PEG5000, 
0.1 M 
(NH4)2SO4, 
150 µL 
water 
62% 
PEG5000, 
0.1 M 
(NH4)2SO4, 
140 µL 
water 
52% 
PEG5000, 
0.15 M 
(NH4)2SO4, 
165 µL 
water 
54% 
PEG5000, 
0.15 M 
(NH4)2SO4, 
155 µL 
water 
56% 
PEG5000, 
0.15 M 
(NH4)2SO4, 
145 µL 
water 
58% 
PEG5000, 
0.15 M 
(NH4)2SO4, 
135 µL 
water 
60% 
PEG5000, 
0.15 M 
(NH4)2SO4, 
125 µL 
water 
62% 
PEG5000, 
0.15 M 
(NH4)2SO4, 
115 µL 
water 
52% 
PEG5000, 
0.2 M 
(NH4)2SO4, 
140 µL 
water 
54% 
PEG5000, 
0.2 M 
(NH4)2SO4, 
130 µL 
water 
56% 
PEG5000, 
0.2 M 
(NH4)2SO4, 
120 µL 
water 
58% 
PEG5000, 
0.2 M 
(NH4)2SO4, 
110 µL 
water 
60% 
PEG5000, 
0.2 M 
(NH4)2SO4, 
100 µL 
water 
62% 
PEG5000, 
0.2 M 
(NH4)2SO4, 
90 µL water 
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Table 34 Thermofluor plate set-up for identification of the optimal dye concentrations 
7.5 µL 5 x 
dye,           
7.5 µL 3 µM 
protein 
7.5 µL 5 x 
dye,           
7.5 µL buffer 
7.5 µL 10 x 
dye,           
7.5 µL 3 µM 
protein 
7.5 µL 15 x 
dye,           
7.5 µL 3 µM 
protein 
7.5 µL 20 x 
dye,           
7.5 µL 3 µM 
protein 
7.5 µL 5 x 
dye,           
7.5 µL 4 µM 
protein 
7.5 µL 10 x 
dye,           
7.5 µL buffer 
7.5 µL 10 x 
dye,           
7.5 µL 4 µM 
protein 
7.5 µL 15 x 
dye,           
7.5 µL 4 µM 
protein 
7.5 µL 20 x 
dye,           
7.5 µL 4 µM 
protein 
7.5 µL 5 x 
dye,           
7.5 µL 5 µM 
protein 
7.5 µL 15 x 
dye,           
7.5 µL buffer 
7.5 µL 10 x 
dye,           
7.5 µL 5 µM 
protein 
7.5 µL 15 x 
dye,           
7.5 µL 5 µM 
protein 
7.5 µL 20 x 
dye,           
7.5 µL 5 µM 
protein 
7.5 µL 5 x 
dye,           
7.5 µL 6 µM 
protein 
7.5 µL 20 x 
dye,           
7.5 µL buffer 
7.5 µL 10 x 
dye,           
7.5 µL 6 µM 
protein 
7.5 µL 15 x 
dye,           
7.5 µL 6 µM 
protein 
7.5 µL 20 x 
dye,           
7.5 µL 6 µM 
protein 
 
Table 35 MDM2 and p53 concentrations to identify optimal conditions for 
fluorescence 
[MDM2]  
(nM) 
Fluorescently labelled p53 concentration (nM) 
5 1 4 7 10 13 16 19 22 25 28 31 34 
10 2 8 14 20 26 32 38 44 50 56 62 68 
15 4 16 28 40 52 64 76 88 100 112 124 136 
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Appendix 2 Crystallography of 127 
 
Table 1.  Crystal data and structure refinement for 127. 
 
Identification code  127 
Chemical formula (moiety) C12H17NO 
Chemical formula (total) C12H17NO 
Formula weight  191.27 
Temperature  293(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  monoclinic, P121/c1 
Unit cell parameters a = 9.4720(4) Å  = 90° 
 b = 10.8606(4) Å  = 102.654(4)° 
 c = 10.5802(4) Å  = 90° 
Cell volume 1061.97(7) Å
3
 
Z 4 
Calculated density  1.196 g/cm
3
 
Absorption coefficient  0.076 mm1 
F(000) 416 
Crystal colour and size colourless, 0.50  0.40  0.40 mm3 
Reflections for cell refinement 3781 ( range 3.2 to 27.1°) 
Data collection method Oxford Diffraction Gemini A Ultra 
diffractometer 
 thin-slice  scans 
 range for data collection 3.2 to 27.1° 
Index ranges h 11 to 9, k 10 to 13, l 13 to 11 
Completeness to  = 26.0° 87.8 %  
Reflections collected 6016 
Independent reflections 1880 (Rint = 0.0172) 
Reflections with F
2
>2 1503 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9632 and 0.9704 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0456, 0.0840 
Data / restraints / parameters 1880 / 0 / 128 
Final R indices [F
2
>2] R1 = 0.0310, wR2 = 0.0809 
R indices (all data) R1 = 0.0422, wR2 = 0.0839 
Goodness-of-fit on F
2
 1.087 
Extinction coefficient 0.022(5) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.16 and 0.14 e Å3 
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Table 2.  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) 
for 127.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
 
O(1) 0.28781(8) 0.03042(7) 0.06200(6) 0.0252(2) 
N(1) 0.42847(10)  0.18797(9) 0.38777(8) 0.0271(3) 
C(1) 0.37117(11)  0.07559(10) 0.39158(10) 0.0243(3) 
C(2) 0.32505(11)  0.00161(10) 0.28520(10) 0.0220(3) 
C(3) 0.33582(11)  0.04560(10) 0.16406(9) 0.0193(3) 
C(4) 0.39456(11)  0.16148(10) 0.15631(10) 0.0211(3) 
C(5) 0.43863(11)  0.22702(10) 0.27032(10) 0.0255(3) 
C(6) 0.28700(12)  0.01564(10)  0.06602(9) 0.0219(3) 
C(7) 0.21730(11) 0.08138(10)  0.16215(9) 0.0207(3) 
C(8) 0.05925(11) 0.10332(10)  0.15656(10) 0.0236(3) 
C(9)  0.01086(12) 0.20023(10)  0.25453(10) 0.0264(3) 
C(10) 0.00011(12) 0.16367(11)  0.39072(10) 0.0282(3) 
C(11) 0.15706(12) 0.14177(11)  0.39835(10) 0.0265(3) 
C(12) 0.22849(12) 0.04559(10)  0.29933(10) 0.0227(3) 
 
Table 3.   Bond lengths [Å] and angles [°] for 127. 
 
O(1)–C(3)  1.3561(12) O(1)–C(6)  1.4423(12) 
N(1)–C(1)  1.3399(15) N(1)–C(5)  1.3362(14) 
C(1)–H(1A)  0.930 C(1)–C(2)  1.3740(15) 
C(2)–H(2A)  0.930 C(2)–C(3)  1.3924(14) 
C(3)–C(4)  1.3857(15) C(4)–H(4A)  0.930 
C(4)–C(5)  1.3840(15) C(5)–H(5A)  0.930 
C(6)–H(6A)  0.970 C(6)–H(6B)  0.970 
C(6)–C(7)  1.5121(14) C(7)–H(7A)  0.980 
C(7)–C(8)  1.5298(15) C(7)–C(12)  1.5286(14) 
C(8)–H(8A)  0.970 C(8)–H(8B)  0.970 
C(8)–C(9)  1.5237(15) C(9)–H(9A)  0.970 
C(9)–H(9B)  0.970 C(9)–C(10)  1.5200(15) 
C(10)–H(10A)  0.970 C(10)–H(10B)  0.970 
C(10)–C(11)  1.5251(16) C(11)–H(11A)  0.970 
C(11)–H(11B)  0.970 C(11)–C(12)  1.5284(15) 
C(12)–H(12A)  0.970 C(12)–H(12B)  0.970 
 
C(3)–O(1)–C(6) 117.93(8) C(1)–N(1)–C(5) 115.42(9) 
N(1)–C(1)–H(1A) 117.8 N(1)–C(1)–C(2) 124.48(10) 
H(1A)–C(1)–C(2) 117.8 C(1)–C(2)–H(2A) 120.7 
C(1)–C(2)–C(3) 118.63(10) H(2A)–C(2)–C(3) 120.7 
O(1)–C(3)–C(2) 116.40(9) O(1)–C(3)–C(4) 125.08(9) 
C(2)–C(3)–C(4) 118.51(9) C(3)–C(4)–H(4A) 121.2 
C(3)–C(4)–C(5) 117.64(10) H(4A)–C(4)–C(5) 121.2 
N(1)–C(5)–C(4) 125.30(10) N(1)–C(5)–H(5A) 117.4 
C(4)–C(5)–H(5A) 117.4 O(1)–C(6)–H(6A) 110.2 
O(1)–C(6)–H(6B) 110.2 O(1)–C(6)–C(7) 107.56(8) 
H(6A)–C(6)–H(6B) 108.5 H(6A)–C(6)–C(7) 110.2 
H(6B)–C(6)–C(7) 110.2 C(6)–C(7)–H(7A) 108.0 
C(6)–C(7)–C(8) 111.68(9) C(6)–C(7)–C(12) 110.52(8) 
H(7A)–C(7)–C(8) 108.0 H(7A)–C(7)–C(12) 108.0 
C(8)–C(7)–C(12) 110.39(8) C(7)–C(8)–H(8A) 109.3 
10. Appendix 2 
 
340 
 
C(7)–C(8)–H(8B) 109.3 C(7)–C(8)–C(9) 111.45(9) 
H(8A)–C(8)–H(8B) 108.0 H(8A)–C(8)–C(9) 109.3 
H(8B)–C(8)–C(9) 109.3 C(8)–C(9)–H(9A) 109.5 
C(8)–C(9)–H(9B) 109.5 C(8)–C(9)–C(10) 110.75(9) 
H(9A)–C(9)–H(9B) 108.1 H(9A)–C(9)–C(10) 109.5 
H(9B)–C(9)–C(10) 109.5 C(9)–C(10)–H(10A) 109.4 
C(9)–C(10)–H(10B) 109.4 C(9)–C(10)–C(11) 111.15(9) 
H(10A)–C(10)–H(10B) 108.0 H(10A)–C(10)–C(11) 109.4 
H(10B)–C(10)–C(11) 109.4 C(10)–C(11)–H(11A) 109.4 
C(10)–C(11)–H(11B) 109.4 C(10)–C(11)–C(12) 111.14(9) 
H(11A)–C(11)–H(11B) 108.0 H(11A)–C(11)–C(12) 109.4 
H(11B)–C(11)–C(12) 109.4 C(7)–C(12)–C(11) 111.39(9) 
C(7)–C(12)–H(12A) 109.3 C(7)–C(12)–H(12B) 109.4 
C(11)–C(12)–H(12A) 109.4 C(11)–C(12)–H(12B) 109.3 
H(12A)–C(12)–H(12B) 108.0  
 
Table 4.   Anisotropic displacement parameters (Å
2
) for 127.  The anisotropic 
displacement factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U
11
      U
22
      U
33
      U
23
      U
13
      U
12
 
 
O(1) 0.0367(5)  0.0225(4) 0.0158(4)  0.0002(3) 0.0048(3) 
 0.0051(3) 
N(1) 0.0280(5)  0.0319(6) 0.0220(5)  0.0046(4) 0.0067(4)   
0.0001(4) 
C(1) 0.0232(6)  0.0335(7) 0.0175(5)   0.0027(5) 0.0070(4)   
0.0051(5) 
C(2) 0.0218(6)  0.0226(6) 0.0220(6)   0.0034(5) 0.0059(4)   
0.0010(5) 
C(3) 0.0176(5)  0.0214(6) 0.0186(5)  0.0010(4) 0.0032(4)   
0.0036(4) 
C(4) 0.0231(6)  0.0234(6) 0.0182(5)   0.0023(4) 0.0074(4)   
0.0025(5) 
C(5) 0.0266(6)  0.0236(6) 0.0275(6)  0.0026(5) 0.0084(5) 
 0.0012(5) 
C(6) 0.0260(6)  0.0235(6) 0.0164(5)   0.0022(5) 0.0052(4) 
 0.0005(5) 
C(7) 0.0228(6)  0.0196(6) 0.0196(5)   0.0002(4) 0.0044(4)   
0.0020(4) 
C(8) 0.0257(6)  0.0255(6) 0.0208(5)   0.0012(5) 0.0079(4)   
0.0008(5) 
C(9) 0.0221(6)  0.0242(6) 0.0327(6)  0.0019(5) 0.0057(5) 
 0.0008(5) 
C(10) 0.0267(6)  0.0294(6) 0.0265(6)  0.0081(5) 0.0015(5) 
 0.0003(5) 
C(11) 0.0309(7)  0.0292(6) 0.0201(6)  0.0035(5) 0.0068(5)   
0.0021(5) 
C(12) 0.0231(6)  0.0251(6) 0.0206(6)  0.0006(5) 0.0064(4)   
0.0007(5) 
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Table 5.   Hydrogen coordinates and isotropic displacement parameters (Å
2
) 
for 127. 
 
      x       y       z       U 
 
H(1A) 0.3620  0.0456 0.4717 0.029 
H(2A) 0.2874 0.0762 0.2939 0.026 
H(4A) 0.4040  0.1941 0.0773 0.025 
H(5A) 0.4786  0.3045 0.2647 0.031 
H(6A) 0.2326  0.0919  0.0812 0.026 
H(6B) 0.3851  0.0316  0.0750 0.026 
H(7A) 0.2702 0.1587  0.1397 0.025 
H(8A) 0.0060 0.0267  0.1742 0.028 
H(8B) 0.0545 0.1301  0.0701 0.028 
H(9A)  0.1118 0.2095  0.2512 0.032 
H(9B) 0.0368 0.2788  0.2324 0.032 
H(10A)  0.0408 0.2284  0.4509 0.034 
H(10B)  0.0555 0.0892  0.4159 0.034 
H(11A) 0.2103 0.2185  0.3823 0.032 
H(11B) 0.1604 0.1140  0.4848 0.032 
H(12A) 0.3296 0.0373  0.3026 0.027 
H(12B) 0.1821  0.0335  0.3214 0.027 
 
Table 6.  Torsion angles [°] for 127. 
 
C(5)–N(1)–C(1)–C(2)  0.33(16) N(1)–C(1)–C(2)–C(3) 0.98(16) 
C(6)–O(1)–C(3)–C(2)  175.36(9) C(6)–O(1)–C(3)–C(4) 5.05(15) 
C(1)–C(2)–C(3)–O(1) 179.48(9) C(1)–C(2)–C(3)–C(4)  0.91(15) 
O(1)–C(3)–C(4)–C(5) 179.85(9) C(2)–C(3)–C(4)–C(5) 0.28(15) 
C(1)–N(1)–C(5)–C(4)  0.38(16) C(3)–C(4)–C(5)–N(1) 0.40(16) 
C(3)–O(1)–C(6)–C(7) 175.13(8) O(1)–C(6)–C(7)–C(8)  63.32(11) 
O(1)–C(6)–C(7)–C(12) 173.38(8) C(6)–C(7)–C(8)–C(9)  179.44(8) 
C(12)–C(7)–C(8)–C(9)  56.06(12) C(7)–C(8)–C(9)–C(10) 56.72(12) 
C(8)–C(9)–C(10)–C(11)  56.28(12) C(9)–C(10)–C(11)–C(12) 55.76(12) 
C(10)–C(11)–C(12)–C(7)  55.44(12) C(6)–C(7)–C(12)–C(11) 179.33(8) 
C(8)–C(7)–C(12)–C(11) 55.29(12)  
 
